
@article{ WOS:000968289000001,
Author = {Wolfson, Philip E. and Andries, Julane and Ahlers, Daniel and Whippo,
   Melissa},
Title = {Ketamine-assisted psychotherapy in adolescents with multiple psychiatric
   diagnoses},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2023},
Volume = {14},
Month = {MAR 30},
Abstract = {Ketamine-assisted psychotherapy is a promising new treatment for a
   variety of mental disorders of adolescence. There is currently an
   adolescent mental health crisis, with a high prevalence of disorders,
   diagnostic complexity, and many adolescents failing to respond to
   conventional treatments. While there is strong evidence for the use of
   ketamine in adults for a variety of treatment-refractory mental
   illnesses, research in adolescents is in its early stages.
   Ketamine-assisted psychotherapy (KAP) has been described in adults with
   promising results and here we present the first published cases of the
   use of KAP in adolescents. The four cases include adolescents aged 14-19
   at the initiation of treatment, each with a variety of comorbid
   diagnoses including treatment-resistant depression, bipolar disorder,
   eating disorders, anxiety, panic, and trauma-related symptoms. They each
   initially received sublingual ketamine, followed by sessions with
   intramuscular ketamine. Their courses varied, but each had symptomatic
   and functional improvements, and the treatment was well-tolerated.
   Subjective patient reports are included. Rapid resolution of
   symptomatology and suffering often occurs within months as the result of
   the application of KAP to adolescent psychiatric care but is not
   inevitable. Family involvement in the treatment process appears to be
   essential to success. The development of this modality may have a
   singularly positive impact that will expand the psychiatric toolbox and
   its healing potency.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Wolfson, PE (Corresponding Author), Ctr Transformat Psychotherapy, San Anselmo, CA 94960 USA.
   Wolfson, PE (Corresponding Author), Ketamine Res Fdn, San Anselmo, CA 94960 USA.
   Wolfson, Philip E.; Andries, Julane; Ahlers, Daniel; Whippo, Melissa, Ctr Transformat Psychotherapy, San Anselmo, CA 94960 USA.
   Wolfson, Philip E.; Andries, Julane; Ahlers, Daniel; Whippo, Melissa, Ketamine Res Fdn, San Anselmo, CA 94960 USA.},
DOI = {10.3389/fpsyt.2023.1141988},
Article-Number = {1141988},
ISSN = {1664-0640},
Keywords = {adolescent psychiatry; major depressive disorder; bipolar disorder;
   ketamine-assisted psychotherapy; ketamine; psychedelic psychotherapy;
   eating disorders; adolescent mental health crisis},
Keywords-Plus = {TREATMENT-RESISTANT DEPRESSION; INTRAVENOUS KETAMINE; MOOD DISORDERS;
   EFFICACY; CHILDREN; SAFETY; NEUROTOXICITY; METAANALYSIS; ANESTHESIA;
   INFUSION},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {ketamine.research@gmail.com},
Funding-Acknowledgement = {Ketamine Research Foundation},
Funding-Text = {This work was supported by the Ketamine Research Foundation.},
Cited-References = {Abbar M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067194.
   Alam F., 2016, INT J DISABIL HUM DE, V15, P121, DOI {[}10.1515/ijdhd-2015-0003, DOI 10.1515/IJDHD-2015-0003].
   An DJ, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.648691.
   Baldessarini RJ, 2012, WORLD PSYCHIATRY, V11, P40, DOI 10.1016/j.wpsyc.2012.01.006.
   Benton TD, 2021, JAMA PEDIATR, V175, P1108, DOI 10.1001/jamapediatrics.2021.2479.
   Bodden DHM, 2018, J AFFECT DISORDERS, V241, P256, DOI 10.1016/j.jad.2018.06.015.
   Boric K, 2017, PEDIATR ANESTH, V27, P893, DOI 10.1111/pan.13203.
   Branje S., 2022, CURR OPIN PSYCHOL.
   Bridge JA, 2006, J CHILD PSYCHOL PSYC, V47, P372, DOI 10.1111/j.1469-7610.2006.01615.x.
   Cuijpers P, 2014, WORLD PSYCHIATRY, V13, P56, DOI 10.1002/wps.20089.
   Cullen KR, 2018, J CHILD ADOL PSYCHOP, V28, P437, DOI 10.1089/cap.2018.0030.
   Di Vincenzo JD, 2021, J PSYCHIATR RES, V137, P232, DOI 10.1016/j.jpsychires.2021.02.058.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Dunn V, 2006, BRIT J PSYCHIAT, V188, P216, DOI 10.1192/bjp.188.3.216.
   Dwyer JB, 2021, AM J PSYCHIAT, V178, P352, DOI 10.1176/appi.ajp.2020.20010018.
   Dwyer JB, 2020, J CHILD PSYCHOL PSYC, V61, P312, DOI 10.1111/jcpp.13202.
   Dwyer JB, 2017, J AM ACAD CHILD PSY, V56, P352, DOI 10.1016/j.jaac.2017.01.006.
   Faria-Guimaraes D, 2022, J CHILD ADOL PSYCHOP, V32, P366, DOI 10.1089/cap.2022.0013.
   Gardner R. A., 2001, ACAD FORUM, V45, P10.
   Ghandour RM, 2019, J PEDIATR-US, V206, P256, DOI 10.1016/j.jpeds.2018.09.021.
   Green SM, 1999, ANN EMERG MED, V34, P492, DOI 10.1016/S0196-0644(99)80051-1.
   Gunnell D, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2608.
   Hartogsohn Ido, 2017, DRUG SCI POLICY LAW, V3, P1, DOI DOI 10.1177/2050324516683325.
   Hassan K, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.992624.
   Hull TD, 2022, J AFFECT DISORDERS, V314, P59, DOI 10.1016/j.jad.2022.07.004.
   Hyde S., KETAMINE DEPRESSION.
   Iorfino F, 2019, JAMA PSYCHIAT, V76, P1167, DOI 10.1001/jamapsychiatry.2019.2360.
   Jonsson U, 2011, J AFFECT DISORDERS, V130, P395, DOI 10.1016/j.jad.2010.10.046.
   Kahn N., 2019, PROMOTING POSITIVE A, P53.
   Kessler RC, 2001, BIOL PSYCHIAT, V49, P1002, DOI 10.1016/S0006-3223(01)01129-5.
   Kim S, 2021, EUR CHILD ADOLES PSY, V30, P1485, DOI 10.1007/s00787-020-01542-3.
   Kishimoto T, 2016, PSYCHOL MED, V46, P1459, DOI 10.1017/S0033291716000064.
   Krystal JH, 2019, NEURON, V101, P774, DOI 10.1016/j.neuron.2019.02.005.
   Lee JH, 2015, EXP NEUROL, V272, P50, DOI 10.1016/j.expneurol.2015.03.028.
   LITTLE B, 1972, AM J OBSTET GYNECOL, V113, P247, DOI 10.1016/0002-9378(72)90774-0.
   Lorenzo-Luaces L, 2020, BEHAV RES THER, V131, DOI 10.1016/j.brat.2020.103637.
   Marcantoni WS, 2020, J AFFECT DISORDERS, V277, P831, DOI 10.1016/j.jad.2020.09.007.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Mathai DS, 2021, J CHILD ADOL PSYCHOP, V31, P553, DOI 10.1089/cap.2021.0078.
   McCann ME, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6459.
   McInnes LA, 2022, J AFFECT DISORDERS, V301, P486, DOI 10.1016/j.jad.2021.12.097.
   Metzner R., 1967, PSYCHEDELIC REV, V9, P5.
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371.
   Niesters M, 2014, BRIT J CLIN PHARMACO, V77, P357, DOI 10.1111/bcp.12094.
   Nock MK, 2013, JAMA PSYCHIAT, V70, P300, DOI 10.1001/2013.jamapsychiatry.55.
   Papolos DF, 2013, J AFFECT DISORDERS, V147, P431, DOI 10.1016/j.jad.2012.08.040.
   Price RB, 2022, MOL PSYCHIATR, V27, P5096, DOI 10.1038/s41380-022-01757-7.
   Rachtel M., 2022, JAMA-J AM MED ASSOC.
   Racine N, 2021, JAMA PEDIATR, V175, P1142, DOI 10.1001/jamapediatrics.2021.2482.
   Rolan P, 2014, BRIT J CLIN PHARMACO, V77, P1011, DOI 10.1111/bcp.12264.
   Roy AV, 2021, J PSYCHOPHARMACOL, V35, P168, DOI 10.1177/0269881120928203.
   Silva LOJE, 2020, AM J EMERG MED, V38, P1860, DOI 10.1016/j.ajem.2020.05.094.
   Slikker W, 2007, TOXICOL SCI, V98, P145, DOI 10.1093/toxsci/kfm084.
   Soriano SG, 2012, CRIT CARE MED, V40, P2518, DOI 10.1097/CCM.0b013e31825ae442.
   Steiner RJ, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-3766.
   Sultan RS, 2018, J CHILD ADOL PSYCHOP, V28, P158, DOI 10.1089/cap.2017.0077.
   Wallach J, 2018, HANDB EXP PHARMACOL, V252, P305, DOI 10.1007/164\_2018\_148.
   Walsh Z, 2021, BJPSYCH OPEN, V8, DOI 10.1192/bjo.2021.1061.
   Weber Garret, 2018, Case Rep Anesthesiol, V2018, P9375910, DOI 10.1155/2018/9375910.
   Wilkinson ST, 2022, J AFFECT DISORDERS, V318, P150, DOI 10.1016/j.jad.2022.08.090.
   Wink LK, 2021, J AUTISM DEV DISORD, V51, P1392, DOI 10.1007/s10803-020-04542-z.
   Wolfson P., KETAMINE PAPERS 2016.
   Yan J, 2014, J NEUROSURG ANESTH, V26, P155, DOI 10.1097/ANA.0000000000000027.
   Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336.
   Yard E, 2021, MMWR-MORBID MORTAL W, V70, P888, DOI 10.15585/mmwr.mm7024e1.
   Zarrinnegar P, 2019, J CHILD ADOL PSYCHOP, V29, P472, DOI 10.1089/cap.2019.0028.},
Number-of-Cited-References = {66},
Times-Cited = {0},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {D4EX3},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000968289000001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000246057000002,
Author = {Krupitsky, Evgeny M. and Burakov, Andrei M. and Dunaevsky, Igor V. and
   Romanova, Tatyana N. and Slavina, Tatyana Y. and Grinenko, Alexander Y.},
Title = {Single versus repeated sessions of ketamine-assisted psychotherapy for
   people with heroin dependence},
Journal = {JOURNAL OF PSYCHOACTIVE DRUGS},
Year = {2007},
Volume = {39},
Number = {1},
Pages = {13-19},
Month = {MAR},
Abstract = {A prior study found that one ketamine-assisted psychotherapy session was
   significantly more effective than active placebo in promoting abstinence
   (Krupitsky et al. 2002). In this study of the efficacy of single versus
   repeated sessions of ketamine-assisted psychotherapy in promoting
   abstinence in people with heroin dependence, 59 detoxified inpatients
   with heroin dependence received a ketamine-assisted psychotherapy (KPF)
   session prior to their discharge from an addiction treatment hospital,
   and were then randomized into two treatment groups. Participants in the
   first group received two addiction counseling sessions followed by two
   KPT sessions, with sessions scheduled on a monthly interval (multiple
   KPT group). Participants in the second group received two addiction
   counseling sessions on a monthly interval, but no additional ketamine
   therapy sessions (single KPT group). At one-year follow-up, survival
   analysis demonstrated a significantly higher rate of abstinence in the
   multiple KPT group. Thirteen out of 26 subjects (50\%) in the multiple
   KPT group remained abstinent, compared to 6 out of 27 subjects (22.2\%)
   in the single KPT group (p < 0.05). No differences between groups were
   found in depression, anxiety, craving for heroin, or their understanding
   of the meaning of their lives. It was concluded that three sessions of
   ketamine-assisted psychotherapy are more effective than a single session
   for the treatment of heroin addiction.},
Publisher = {ROUTLEDGE JOURNALS, TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Krupitsky, EM (Corresponding Author), Pavlov State Med Univ St Petersburg, Res Lab, St Petersburg Reg Ctr Addict \& Psychopharmacol, Novo Deviatkino 19-1, St Petersburg 188661, Leningrad Reg, Russia.
   Pavlov State Med Univ St Petersburg, Res Lab, St Petersburg Reg Ctr Addict \& Psychopharmacol, St Petersburg 188661, Leningrad Reg, Russia.},
DOI = {10.1080/02791072.2007.10399860},
ISSN = {0279-1072},
EISSN = {2159-9777},
Keywords = {hallucinogens; heroin addiction; ketamine; psychedelics; psychotherapy;
   treatment},
Keywords-Plus = {ADDICTION},
Research-Areas = {Psychology; Substance Abuse},
Web-of-Science-Categories  = {Psychology, Clinical; Substance Abuse},
Author-Email = {kru@ek3506.spb.edu},
Affiliations = {Pavlov First Saint Petersburg State Medical University},
ResearcherID-Numbers = {Krupitsky, Evgeny/M-5935-2016},
ORCID-Numbers = {Krupitsky, Evgeny/0000-0002-0529-4525},
Cited-References = {{[}Anonymous], 2001, KETAMINE DREAMS REAL.
   {[}Anonymous], 1978, UNHEARD CRY MEANING.
   {[}Anonymous], 1992, MEASURING ALCOHOL CO.
   {[}Anonymous], 1979, PSYCHEDELIC DRUGS RE.
   CRUMBAUGH JC, 1968, J INDIV PSYCHOL, V24, P74.
   Halpern JH, 1996, ADDICT RES, V4, P177, DOI 10.3109/16066359609010756.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 2004, J SUBST ABUSE TREAT, V26, P285, DOI 10.1016/j.jsat.2004.02.002.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krystal JH, 1998, ARCH GEN PSYCHIAT, V55, P354, DOI 10.1001/archpsyc.55.4.354.
   PAHNKE WN, 1970, J AMER MED ASSOC, V212, P1856, DOI 10.1001/jama.212.11.1856.
   SPIELBERGER CS, 1976, MANUAL STATE TRAIT A.
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008.},
Number-of-Cited-References = {13},
Times-Cited = {78},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {J. Psychoact. Drugs},
Doc-Delivery-Number = {161ZX},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000246057000002},
DA = {2023-07-30},
}

@article{ WOS:000725738800001,
Author = {Ragnhildstveit, Anya and Jackson, Laura Kate and Cunningham, Sarah and
   Good, Linda and Tanner, Quinn and Roughan, Matthew and Henrie-Barrus,
   Patricia},
Title = {Case Report: Unexpected Remission From Extreme and Enduring Bulimia
   Nervosa With Repeated Ketamine Assisted Psychotherapy},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2021},
Volume = {12},
Month = {NOV 17},
Abstract = {Background: Bulimia nervosa is a disabling psychiatric disorder that
   considerably impairs physical health, disrupts psychosocial functioning,
   and reduces overall quality of life. Despite available treatment, less
   than half of sufferers achieve recovery and approximately a third become
   chronically ill. Extreme and enduring cases are particularly resistant
   to first-line treatment, namely antidepressants and cognitive behavioral
   therapy, and have the highest rate of premature mortality. Here, we
   demonstrate that in such cases, repeated sessions of ketamine assisted
   psychotherapy (KAP) is an effective treatment alternative for improving
   symptoms.Case Presentation: A 21-year-old woman presented with extreme
   and enduring bulimia nervosa. She reported recurrent binge-eating and
   purging by self-induced vomiting 40 episodes per day, which proved
   refractory to both pharmacological and behavioral treatment at the
   outpatient, residential, and inpatient level. Provided this, her
   physician recommended repeated KAP as an exploratory and off-label
   intervention for her eating disorder. The patient underwent three
   courses of KAP over 3 months, with each course consisting of six
   sessions scheduled twice weekly. She showed dramatic reductions in
   binge-eating and purging following the first course of treatment that
   continued with the second and third. Complete cessation of behavioral
   symptoms was achieved 3 months post-treatment. Her remission has
   sustained for over 1 year to date.Conclusions: To our knowledge, this is
   the first report of repeated KAP used to treat bulimia nervosa that led
   to complete and sustained remission, a rare outcome for severe and
   enduring cases, let alone extreme ones. Additionally, it highlights the
   degree to which KAP can be tailored at the individual level based on
   symptom severity and treatment response. While its mechanism of action
   is unclear, repeated KAP is a promising intervention for bulimia nervosa
   that warrants future research and clinical practice consideration.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ragnhildstveit, A (Corresponding Author), Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA.
   Ragnhildstveit, Anya; Jackson, Laura Kate; Cunningham, Sarah, Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA.
   Good, Linda, Utah Valley Univ, Behav Sci Dept, Orem, UT USA.
   Tanner, Quinn, Univ Utah, Div Publ Hlth, Sch Med, Salt Lake City, UT USA.
   Roughan, Matthew, Capella Univ, Marriage \& Family Therapy Program, Minneapolis, MN USA.
   Roughan, Matthew; Henrie-Barrus, Patricia, Riverwoods Behav Hlth, Provo, UT USA.
   Henrie-Barrus, Patricia, Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.},
DOI = {10.3389/fpsyt.2021.764112},
Article-Number = {764112},
ISSN = {1664-0640},
Keywords = {bulimia nervosa; eating disorder; binge-eating; purging; ketamine;
   ketamine assisted psychotherapy; psychopharmacology; case report},
Keywords-Plus = {POSTTRAUMATIC-STRESS-DISORDER; D-ASPARTATE ANTAGONIST; EATING-DISORDERS;
   ANOREXIA-NERVOSA; ANTIDEPRESSANT EFFICACY; INTRAVENOUS KETAMINE;
   CLINICAL-TRIALS; DEPRESSION; MORTALITY; METAANALYSIS},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {anya.ragnhildstveit@utah.edu},
Affiliations = {Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; Utah Valley University; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah},
ORCID-Numbers = {Ragnhildstveit, Anya/0000-0002-5796-3428},
Cited-References = {aan het Rot M, 2010, BIOL PSYCHIAT, V67, P139, DOI 10.1016/j.biopsych.2009.08.038.
   Albott CS, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11634.
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI {[}DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596].
   Andrade C, 2017, J CLIN PSYCHIAT, V78, pE852, DOI 10.4088/JCP.17f11738.
   Arcelus J, 2011, ARCH GEN PSYCHIAT, V68, P724, DOI 10.1001/archgenpsychiatry.2011.74.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Calabrese L., 2019, INT J PSYCHIATR RES, V2, P1.
   Cucchi A, 2016, PSYCHOL MED, V46, P1345, DOI 10.1017/S0033291716000027.
   Dalle Grave R., 2021, COMPLEX CASES COMORB, P79, DOI {[}10.1007/978-3-030-69341-1, DOI 10.1007/978-3-030-69341-1].
   Dechant E., 2020, J WOMENS HLTH DEV, V3, P373, DOI 10.26502/fjwhd.2644-28840044.
   Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Eddy KT, 2017, J CLIN PSYCHIAT, V78, P184, DOI 10.4088/JCP.15m10393.
   Fairburn C.G., 2008, COGN BEHAV THER EAT, V16th ed., P265.
   Fairburn Christopher G., 1993, P317.
   Feder Adriana, 2020, Adv Pharmacol, V89, P261, DOI 10.1016/bs.apha.2020.05.004.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Franko DL, 2018, J PSYCHIATR RES, V96, P183, DOI 10.1016/j.jpsychires.2017.10.008.
   Gagnier JJ, 2014, J CLIN EPIDEMIOL, V67, P46, DOI 10.1016/j.jclinepi.2013.08.003.
   Grilo CM, 2015, BEHAV RES THER, V67, P41, DOI 10.1016/j.brat.2015.02.002.
   Halstead M, 2021, CLIN CASE STUD, V20, P310, DOI 10.1177/1534650121990894.
   Himmerich H, 2019, SOC PSYCH PSYCH EPID, V54, P813, DOI 10.1007/s00127-019-01667-0.
   Huas C, 2013, EUR EAT DISORD REV, V21, P15, DOI 10.1002/erv.2178.
   Kolp E., 2007, INT J TRANSPERSONAL, V26, P1, DOI DOI 10.24972/IJTS.2007.26.1.1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krystal JH, 2019, NEURON, V101, P774, DOI 10.1016/j.neuron.2019.02.005.
   Lai R, 2014, WORLD J BIOL PSYCHIA, V15, P579, DOI 10.3109/15622975.2014.922697.
   Lapidus KAB, 2014, BIOL PSYCHIAT, V76, P970, DOI 10.1016/j.biopsych.2014.03.026.
   Marcantoni WS, 2020, J AFFECT DISORDERS, V277, P831, DOI 10.1016/j.jad.2020.09.007.
   McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d.
   Mills IH, 1998, QJM-MON J ASSOC PHYS, V91, P493, DOI 10.1093/qjmed/91.7.493.
   Mitchell JE, 2007, INT J EAT DISORDER, V40, P95, DOI 10.1002/eat.20343.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   Murrough JW, 2013, BIOL PSYCHIAT, V74, P250, DOI 10.1016/j.biopsych.2012.06.022.
   Newport DJ, 2015, AM J PSYCHIAT, V172, P950, DOI 10.1176/appi.ajp.2015.15040465.
   Nitsch A, 2021, CLEV CLIN J MED, V88, P333, DOI 10.3949/ccjm.88a.20168.
   Park Lawrence T, 2019, Focus (Am Psychiatr Publ), V17, P8, DOI 10.1176/appi.focus.20180030.
   Peyrovian B, 2020, J PSYCHIATR RES, V127, P1, DOI 10.1016/j.jpsychires.2020.03.020.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Preti A, 2011, ACTA PSYCHIAT SCAND, V124, P6, DOI 10.1111/j.1600-0447.2010.01641.x.
   Qian J, 2022, EAT WEIGHT DISORD-ST, V27, P415, DOI 10.1007/s40519-021-01162-z.
   Schwartz T, 2021, CLIN CASE REP, V9, DOI 10.1002/ccr3.3869.
   Scolnick B, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00763.
   Steinhausen HC, 2009, AM J PSYCHIAT, V166, P1331, DOI 10.1176/appi.ajp.2009.09040582.
   Strand M, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00472-8.
   van Hoeken D, 2020, CURR OPIN PSYCHIATR, V33, P521, DOI 10.1097/YCO.0000000000000641.
   Vocks S, 2010, INT J EAT DISORDER, V43, P205, DOI 10.1002/eat.20696.
   Westmoreland P, 2016, J PSYCHIATR PRACT, V22, P313, DOI 10.1097/PRA.0000000000000160.
   Wheeler SW, 2020, PSYCHOL CONSCIOUS, V7, P279, DOI 10.1037/cns0000237.
   Wilkinson ST, 2019, DRUG DISCOV TODAY, V24, P606, DOI 10.1016/j.drudis.2018.11.007.
   Wonderlich S, 2012, INT J EAT DISORDER, V45, P467, DOI 10.1002/eat.20978.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zarate CA, 2012, BIOL PSYCHIAT, V71, P939, DOI 10.1016/j.biopsych.2011.12.010.},
Number-of-Cited-References = {53},
Times-Cited = {9},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {XH9IH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000725738800001},
OA = {gold, Green Published},
DA = {2023-07-30},
}

@article{ WOS:000618484000001,
Author = {Halstead, Mailae and Reed, Sara and Krause, Robert and Williams, Monnica
   T.},
Title = {Ketamine-Assisted Psychotherapy for PTSD Related to Racial
   Discrimination},
Journal = {CLINICAL CASE STUDIES},
Year = {2021},
Volume = {20},
Number = {4},
Pages = {310-330},
Month = {AUG},
Abstract = {Current research suggests that ketamine-assisted psychotherapy has
   benefit for the treatment of mental disorders. We report on the results
   of ketamine-assisted intensive outpatient psychotherapeutic treatment of
   a client with treatment-resistant, posttraumatic stress disorder (PTSD)
   as a result of experiences of racism and childhood sexual abuse. The
   client's presenting symptoms included hypervigilance, social avoidance,
   feelings of hopelessness, and intense recollections. These symptoms
   impacted all areas of daily functioning. Psychoeducation was provided on
   how untreated intergenerational trauma, compounded by additional
   traumatic experiences, potentiated the client's experience of PTSD and
   subsequent maladaptive coping mechanisms. Ketamine was administered four
   times over a 13-day span as an off-label, adjunct to psychotherapy.
   Therapeutic interventions and orientations utilized were
   mindfulness-based cognitive therapy (MBCT) and functional analytic
   psychotherapy (FAP). New skills were obtained in helping the client
   respond effectively to negative self-talk, catastrophic thinking, and
   feelings of helplessness. Treatment led to a significant reduction in
   symptoms after completion of the program, with gains maintained 4 months
   post-treatment. This case study demonstrates the effective use of
   ketamine as an adjunct to psychotherapy in treatment-resistant PTSD.},
Publisher = {SAGE PUBLICATIONS INC},
Address = {2455 TELLER RD, THOUSAND OAKS, CA 91320 USA},
Type = {Article},
Language = {English},
Affiliation = {Williams, MT (Corresponding Author), Univ Ottawa, Sch Psychol, 136 Jean Jacques Lussier,Vanier Hall, Ottawa, ON K1N 6N5, Canada.
   Halstead, Mailae; Reed, Sara; Williams, Monnica T., Behav Wellness Clin, Tolland, CT USA.
   Krause, Robert, Grad Inst, Bethany, CT USA.
   Williams, Monnica T., Univ Ottawa, Mental Hlth Dispar, Sch Psychol, Ottawa, ON, Canada.},
DOI = {10.1177/1534650121990894},
EarlyAccessDate = {FEB 2021},
Article-Number = {1534650121990894},
ISSN = {1534-6501},
EISSN = {1552-3802},
Keywords = {ketamine; racial trauma; posttraumatic stress disorder; psychedelics;
   cognitive behavioral therapy; functional analytic psychotherapy},
Keywords-Plus = {POSTTRAUMATIC-STRESS-DISORDER; INTRAVENOUS KETAMINE; ANTIDEPRESSANT;
   EXPOSURE; EFFICACY; TRAUMA},
Research-Areas = {Psychology; Psychiatry},
Web-of-Science-Categories  = {Psychology, Clinical; Psychiatry},
Author-Email = {Monnica.Williams@uOttawa.ca},
Affiliations = {University of Ottawa},
ResearcherID-Numbers = {Williams, Monnica/O-8209-2017},
ORCID-Numbers = {Williams, Monnica/0000-0003-0095-3277},
Funding-Acknowledgement = {Canada Research Chairs Program},
Funding-Text = {The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   project was undertaken, in part, thanks to funding from the Canada
   Research Chairs Program.},
Cited-References = {Al-Mateen C. S., 2016, HDB MENTAL HLTH AFRI, P63, DOI {[}10.1007/978-3-319-25501-9\_4, DOI 10.1007/978-3-319-25501-9\_4].
   Albott CS, 2017, J CLIN PSYCHIAT, V78, pE308, DOI 10.4088/JCP.16l11277.
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU.
   {[}Anonymous], 2002, MINDFULNESS BASED CO.
   Beck A.T., 1996, BECK DEPRESSION INVE.
   Bennett R., 2020, JPSYCHEDEL PSYCHIAT, V2, P19.
   Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Brom D, 2017, J TRAUMA STRESS, V30, P304, DOI 10.1002/jts.22189.
   Calabrese L., 2019, INT J PSYCHIATR RES, V2, P1.
   Carbonaro TM, 2016, J PSYCHOPHARMACOL, V30, P1268, DOI 10.1177/0269881116662634.
   Chae DH, 2011, AM J ORTHOPSYCHIAT, V81, P498, DOI 10.1111/j.1939-0025.2011.01122.x.
   Chong C., 2006, PAIN MED, V7, P469, DOI {[}10.1111/j.1526-4637.2006.00208\_8.x, DOI 10.1111/J.1526-4637.2006.00208\_8.X].
   Collo G, 2018, NEURAL REGEN RES, V13, P645, DOI 10.4103/1673-5374.230288.
   Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   D┬u┬iaz-Mart┬u┬inez A.M., 2003, CLIN CASE STUD, V2, P211, DOI {[}10.1177/1534650103002003004, DOI 10.1177/1534650103002003004].
   Ellis A., 1991, J RATIONAL EMOTIVE C, V9, P139, DOI {[}DOI 10.1007/BF01061227, https://doi.org/10.1007/BF01061227].
   English D, 2020, J APPL DEV PSYCHOL, V66, DOI 10.1016/j.appdev.2019.101068.
   FEDER A, 2021, AM J PSYCHIAT ADV ON.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Federal Drug Administration, 2018, BREAKTHROUGH THERAPY.
   Foa EB, 1999, PSYCHOL ASSESSMENT, V11, P303, DOI 10.1037/1040-3590.11.3.303.
   Frye LA, 2012, CLIN CASE STUD, V11, P184, DOI 10.1177/1534650112446850.
   Gonz┬u├lez-Prendes A.A., 2009, CLIN CASE STUD, V8, P383, DOI DOI 10.1177/1534650109345004.
   Goosby BJ, 2013, SOCIOL COMPASS, V7, P630, DOI 10.1111/soc4.12054.
   HARDY KV, 1995, J MARITAL FAM THER, V21, P227, DOI 10.1111/j.1752-0606.1995.tb00158.x.
   Hemmings C, 2018, J MULTICULT COUNS D, V46, P20, DOI 10.1002/jmcd.12090.
   Holmes SC., 2016, TRAUMATOLOGY, V22, P314, DOI {[}DOI 10.1037/TRM0000104, 10.1037/trm0000104].
   Hook JN, 2016, J COUNS PSYCHOL, V63, P269, DOI 10.1037/cou0000114.
   Kabat-Zinn J, 1990, FULL CATASTROPHE LIV, V1st ed..
   Kolp E., 2014, INT J TRANSPERS STUD, V33, P84, DOI {[}DOI 10.24972/IJTS.2014.33.2.84, https://doi.org/10.24972/ijts.2014.33.2.84].
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   Lucero R, 2018, CONTEMP FAM THER, V40, P266, DOI 10.1007/s10591-017-9424-z.
   Luoma JB, 2020, J PSYCHOACTIVE DRUGS, V52, P289, DOI 10.1080/02791072.2020.1769878.
   Menakem R., 2017, MY GRANDMOTHERS HAND.
   Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6.
   Miller A., 2015, BEHAV THERAPIST, V38, P150.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Nair J, 2008, CNS SPECTRUMS, V13, P585, DOI 10.1017/S1092852900016862.
   Popova V, 2019, AM J PSYCHIAT, V176, P428, DOI 10.1176/appi.ajp.2019.19020172.
   Roberts AL, 2011, PSYCHOL MED, V41, P71, DOI 10.1017/S0033291710000401.
   ROSENBERG DE, 1963, PSYCHOPHARMACOLOGIA, V5, P1, DOI 10.1007/BF00405570.
   Ruzek, 2006, COGN BEH THER, P173.
   Saleem FT, 2020, CLIN CHILD FAM PSYCH, V23, P1, DOI 10.1007/s10567-019-00304-1.
   Schwartz R.C., 2009, TREATING COMPLEX TRA, P82.
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09m05305whi.
   Sholt M, 2006, ART THER, V23, P66, DOI 10.1080/07421656.2006.10129647.
   Sloshower J, 2020, J CONTEXT BEHAV SCI, V15, P12, DOI 10.1016/j.jcbs.2019.11.002.
   Thomas R, 2016, KLIN PSIKOFARMAKOL B, V26, P329, DOI 10.5455/bcp.20161027122045.
   Thompson RW, 2011, TRAUMA VIOLENCE ABUS, V12, P220, DOI 10.1177/1524838011416375.
   Tsai M, 2009, GUIDE TO FUNCTIONAL ANALYTIC PSYCHOTHERAPY: AWARENESS, COURAGE, LOVE, AND BEHAVIORISM, P1, DOI 10.1007/978-0-387-09787-9.
   Walsh Z, 2018, INT REV PSYCHIATR, V30, P343, DOI 10.1080/09540261.2018.1474088.
   Washington Harriet A., 2007, MEDICAL APARTHEID DA.
   Wetterneck C. T., 2012, INT J BEHAV CONSULTA, V7, P167.
   Williams M., 2019, DIRECTIONS PSYCHIAT, V39, P265.
   WILLIAMS M, 2020, DRUGS ED PREVENTION.
   Williams M. T., 2018, DIRECTIONS PSYCHIAT, V38, P179.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P1, DOI 10.1556/2054.2019.032.
   Williams MT, 2018, PSYCHOL VIOLENCE, V8, P735, DOI 10.1037/vio0000212.
   Williams MT., 2018, PRACTICE INNOVATIONS, V3, P1, DOI {[}10.1037/pri0000076, DOI 10.1037/PRI0000076].
   WILLIAMS MT, 2020, J PSYCHEDELIC STUDIE, V4.},
Number-of-Cited-References = {62},
Times-Cited = {10},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Clin. Case Stud.},
Doc-Delivery-Number = {SS7MK},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000618484000001},
OA = {hybrid},
DA = {2023-07-30},
}

@article{ WOS:000848145600013,
Author = {Joneborg, Isak and Lee, Yena and Di Vincenzo, Joshua D. and Ceban,
   Felicia and Meshkat, Shakila and Lui, Leanna M. W. and Fancy, Farhan and
   Rosenblat, Joshua D. and McIntyre, Roger S.},
Title = {Active mechanisms of ketamine-assisted psychotherapy: A systematic
   review},
Journal = {JOURNAL OF AFFECTIVE DISORDERS},
Year = {2022},
Volume = {315},
Pages = {105-112},
Month = {OCT 15},
Abstract = {Background: Few studies have evaluated the efficacy of ketamine-assisted
   psychotherapy (KAP) in the treatment of treatment-resistant depression
   (TRD) and substance use disorders (SUD). Methods: A systematic review of
   clinical trials reporting on the efficacy of KAP and discussing
   mechanisms of action, identified on PubMed and PsycInfo. Results: Five
   randomized-controlled trials reported on the efficacy of KAP treatment
   and discussed active mechanisms. Four of the studies treated adults with
   SUD and a single study treated adults with TRD. Overall, KAP had a
   significant positive effect on primary outcome measures compared to
   controls, however, the data is mixed. The study examining KAP for TRD
   found no benefit. Limitations: Lack of large, replicated clinical
   trials. No studies actively examining mechanisms of action. Conclusion:
   Evidence suggests that temporary neural changes caused by ketamine such
   as n-methyl-D-aspartate receptor (NMDAR) inhibition and increase of
   synaptic neuroplasticity affect treatment outcomes of KAP. Based on
   reports of preliminary findings, we speculate that adjunct
   psychotherapy, changes in perspective, and spir-ituality may also play a
   role.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Review},
Language = {English},
Affiliation = {McIntyre, RS (Corresponding Author), Univ Hlth Network, 399 Bathurst St,MP 9-325, Toronto, ON M5T 2S8, Canada.
   Joneborg, Isak, Lund Univ, Dept Psychol, Lund, Sweden.
   Joneborg, Isak; Lee, Yena; Di Vincenzo, Joshua D.; Ceban, Felicia; Rosenblat, Joshua D.; McIntyre, Roger S., Brain \& Cognit Discovery Fdn, Toronto, ON, Canada.
   Lee, Yena; Di Vincenzo, Joshua D.; Fancy, Farhan; Rosenblat, Joshua D.; McIntyre, Roger S., Canadian Rapid Treatment Ctr Excellence, Mississauga, ON, Canada.
   Lee, Yena; Di Vincenzo, Joshua D.; Ceban, Felicia; Meshkat, Shakila; Lui, Leanna M. W.; Fancy, Farhan; Rosenblat, Joshua D.; McIntyre, Roger S., Univ Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada.
   Rosenblat, Joshua D.; McIntyre, Roger S., Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   McIntyre, Roger S., Univ Toronto, Dept Pharmacol, Toronto, ON, Canada.
   Lui, Leanna M. W.; Fancy, Farhan; McIntyre, Roger S., Univ Toronto, Inst Med Studies, Toronto, ON, Canada.
   McIntyre, Roger S., Univ Hlth Network, 399 Bathurst St,MP 9-325, Toronto, ON M5T 2S8, Canada.},
DOI = {10.1016/j.jad.2022.07.030},
EarlyAccessDate = {AUG 2022},
ISSN = {0165-0327},
EISSN = {1573-2517},
Keywords = {Ketamine; Psychotherapy; Substance -use; Mood disorders; Psychedelics;
   Rapid acting antidepressants},
Keywords-Plus = {INTRAVENOUS KETAMINE; DEPRESSION; INFUSION; THERAPY; SINGLE},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Psychiatry},
Author-Email = {roger.mcintyre@uhn.ca},
Affiliations = {Lund University; University of Toronto; University Health Network
   Toronto; University of Toronto; University of Toronto; University of
   Toronto; University of Toronto; University Health Network Toronto},
ResearcherID-Numbers = {McIntyre, Roger/AAU-1000-2020
   Meshkat, Shakila/HHZ-1030-2022
   Di Vincenzo, Joshua/HHS-7099-2022},
ORCID-Numbers = {McIntyre, Roger/0000-0003-4733-2523
   },
Cited-References = {Ballard ED, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20190-4.
   Cuijpers P, 2014, WORLD PSYCHIATRY, V13, P56, DOI 10.1002/wps.20089.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Dakwar E, 2020, AM J PSYCHIAT, V177, P125, DOI 10.1176/appi.ajp.2019.19070684.
   Dakwar E, 2019, AM J PSYCHIAT, V176, P923, DOI 10.1176/appi.ajp.2019.18101123.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Ezquerra-Romano II, 2018, NEUROPHARMACOLOGY, V142, P72, DOI 10.1016/j.neuropharm.2018.01.017.
   Fava M, 2020, MOL PSYCHIATR, V25, P1592, DOI 10.1038/s41380-018-0256-5.
   Food and Drug Administration, 2019, FDA APPR NEW NAS SPR.
   Grabski M, 2022, AM J PSYCHIAT, V179, P152, DOI 10.1176/appi.ajp.2021.21030277.
   Jones JL, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00277.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Marcantoni WS, 2020, J AFFECT DISORDERS, V277, P831, DOI 10.1016/j.jad.2020.09.007.
   McIntyre RS, 2021, AM J PSYCHIAT, V178, P383, DOI 10.1176/appi.ajp.2020.20081251.
   McMullen EP, 2021, ADV THER, V38, P2795, DOI 10.1007/s12325-021-01732-8.
   Podrebarac SK, 2021, SPIRITUAL CLIN PRACT, V8, P177, DOI 10.1037/scp0000242.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898.
   Voort JLV, 2016, J AFFECT DISORDERS, V206, P300, DOI 10.1016/j.jad.2016.09.008.
   Wilkinson ST, 2021, PSYCHOTHER PSYCHOSOM, V90, P318, DOI 10.1159/000517074.
   Worrell SD, 2021, NEUROSCI BIOBEHAV R, V126, P573, DOI 10.1016/j.neubiorev.2021.05.006.},
Number-of-Cited-References = {24},
Times-Cited = {4},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {13},
Journal-ISO = {J. Affect. Disord.},
Doc-Delivery-Number = {4E9NQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000848145600013},
DA = {2023-07-30},
}

@article{ WOS:000465671500001,
Author = {Dore, Jennifer and Turnipseed, Brent and Dwyer, Shannon and Turnipseed,
   Andrea and Andries, Julane and Ascani, German and Monnette, Celeste and
   Huidekoper, Angela and Strauss, Nicole and Wolfson, Phil},
Title = {Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical
   Data and Outcomes in Three Large Practices Administering Ketamine with
   Psychotherapy},
Journal = {JOURNAL OF PSYCHOACTIVE DRUGS},
Year = {2019},
Volume = {51},
Number = {2, SI},
Pages = {189-198},
Abstract = {Currently, ketamine is the only legal psychedelic medicine available to
   mental health providers for the treatment of emotional suffering. Over
   the past several years, ketamine has come into psychiatric use as an
   intervention for treatment resistant depression (TRD), administered
   intravenously without a psychotherapeutic component. In these settings,
   ketamine's psychedelic effects are viewed as undesirable ``side
   effects.{''} In contrast, we believe ketamine can benefit patients with
   a wide variety of diagnoses when administered with psychotherapy and
   using its psychedelic properties without need for intravenous (IV)
   access. Its proven safety over decades of use makes it ideal for office
   and supervised at-home use. The unique experience that ketamine
   facilitates with its biological, experiential, and psychological impacts
   has been tailored to optimize office-based treatment evolving into a
   method that we call Ketamine Assisted Psychotherapy (KAP). This article
   is the first to explore KAP within an analytical framework examining
   three distinct practices that use similar methods. Here, we present
   demographic and outcome data from 235 patients. Our findings suggest
   that KAP is an effective method for decreasing depression and anxiety in
   a private practice setting, especially for older patients and those with
   severe symptom burden.},
Publisher = {ROUTLEDGE JOURNALS, TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wolfson, P (Corresponding Author), Ketamine Res Fdn, 6 Crest Ave San Anselmo, San Anselmo, CA 94960 USA.
   Dore, Jennifer; Dwyer, Shannon, Helios Psychiat, Woodside, CA USA.
   Turnipseed, Brent; Turnipseed, Andrea, Roots Behav Hlth, Austin, TX USA.
   Andries, Julane; Ascani, German; Monnette, Celeste; Wolfson, Phil, Ctr Transformat Psychotherapy, San Anselmo, CA USA.
   Huidekoper, Angela; Strauss, Nicole; Wolfson, Phil, Ketamine Res Fdn, 6 Crest Ave San Anselmo, San Anselmo, CA 94960 USA.},
DOI = {10.1080/02791072.2019.1587556},
EarlyAccessDate = {MAR 2019},
ISSN = {0279-1072},
EISSN = {2159-9777},
Keywords = {Depression; ketamine; psychedelic psychotherapy; psychedelics;
   psychotherapy; PTSD},
Keywords-Plus = {ANTIDEPRESSANT; PSYCHEDELICS; THERAPY},
Research-Areas = {Psychology; Substance Abuse},
Web-of-Science-Categories  = {Psychology, Clinical; Substance Abuse},
Author-Email = {ketamine.research@gmail.com},
Cited-References = {aan het Rot M, 2010, BIOL PSYCHIAT, V67, P139, DOI 10.1016/j.biopsych.2009.08.038.
   {[}Anonymous], 2020, INTERNAL FAMILY SYST.
   {[}Anonymous], 2014, BODY KEEPS SCORE BRA.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Brown D. A., 2016, ATTACHMENT DISORDER.
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710.
   Chilukuri Harihar, 2014, Indian J Psychol Med, V36, P71, DOI 10.4103/0253-7176.127258.
   Cusin C, 2012, AM J PSYCHIAT, V169, P868, DOI 10.1176/appi.ajp.2012.12020219.
   Early T., 2016, KETAMINE PAPERS SCI, P305.
   Feduccia AA, 2018, PSYCHOPHARMACOLOGY, V235, P561, DOI 10.1007/s00213-017-4779-2.
   FONTANA AE, 1974, ACTA PSIQUIAT PSICOL, V20, P32.
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5.
   Hyde S. J., 2015, KETAMINE DEPRESSION.
   Jaitly V., 2013, J OBSERVATIONAL PAIN, V1/2.
   Jansen K, 2001, KETAMINE DREAMS REAL.
   KHORRAMZADEH E, 1973, PSYCHOSOMATICS, V14, P344.
   Kolp E., 2007, INT J TRANSPERSONAL, V26, P1, DOI DOI 10.24972/IJTS.2007.26.1.1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Krystal JH, 2007, SWISS MED WKLY, V137, P215.
   Krystal JH, 2006, NEUROPSYCHOPHARMACOL, V31, P1793, DOI 10.1038/sj.npp.1300994.
   Lara DR, 2013, INT J NEUROPSYCHOPH, V16, P2111, DOI 10.1017/S1461145713000485.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Matthew S., 2016, KETAMINE TREATMENT R.
   McGirr A, 2015, PSYCHOL MED, V45, P693, DOI 10.1017/S0033291714001603.
   Milliere R, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01475.
   Mithoefer MC, 2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3.
   Nour MM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00269.
   Ryan W., 2016, THE KETAMINE PAPERS, P199.
   Sullivan P., 2018, KRIYA C NUEV SCH HIL.
   Wallach J., 2018, KRIYA C NUEV SCH HIL.
   Weber F, 2004, PEDIATR ANESTH, V14, P983, DOI 10.1111/j.1460-9592.2004.01358.x.
   WIEBER J, 1975, ANAESTHESIST, V24, P260.
   Williams NR, 2018, AM J PSYCHIAT, V175, P1205, DOI 10.1176/appi.ajp.2018.18020138.
   Wolfson P., 2016, THE KETAMINE PAPERS.
   Yensen R., 2016, THE KETAMINE PAPERS, P69.
   Zarate C, 2013, ANN NY ACAD SCI, V1292, P21, DOI 10.1111/nyas.12223.},
Number-of-Cited-References = {37},
Times-Cited = {79},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {19},
Journal-ISO = {J. Psychoact. Drugs},
Doc-Delivery-Number = {IC5EA},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000465671500001},
OA = {hybrid},
DA = {2023-07-30},
}

@article{ WOS:000903278800005,
Author = {Davis, Alan K. and Mangini, Pratheek and Xin, Yitong},
Title = {Ketamine-assisted psychotherapy for trauma-exposed patients in an
   outpatient setting: A clinical chart review study},
Journal = {JOURNAL OF PSYCHEDELIC STUDIES},
Year = {2021},
Volume = {5},
Number = {2},
Pages = {94-102},
Month = {SEP},
Abstract = {Trauma exposure across the lifespan produces risks for posttraumatic
   stress disorder (PTSD), depression, anxiety, as well as global
   disability in functioning. This retrospective clinical chart review is
   the first of its kind to assess the utility of sublingual
   ketamine-assisted body-centered psychotherapy in trauma-exposed patients
   in a real world clinic setting. De-identified clinical records data on
   self -re-ported symptom measures were retrospectively analyzed for
   patients (N = 18; Mage = 45.22, SD = 12.90) entering ketamine-assisted
   psychotherapy treatment in an outpatient clinic between 2018 and 2020.
   Patients who completed six sessions of ketamine therapy reported
   meaningful (e.g., medium effect size) improvements in PTSD symptoms (P =
   0.058; d = -0.48) and global disability in functioning (P = 0.050; d =
   -0.52) and statistically significant and meaningful improvements in
   depression (P = 0.019; d = -0.53). There were no improvements in anxiety
   symptoms. Sublingual ketamine-assisted psychotherapy was associated with
   heterogenous clinical utility among patients with trauma-exposure in an
   outpatient setting. This study was underpowered and unrepresentative of
   the population of ke-tamine patients in the United States. Replication
   of these findings is needed with larger and more diverse patient
   samples.},
Publisher = {AKADEMIAI KIADO ZRT},
Address = {BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY},
Type = {Review},
Language = {English},
Affiliation = {Davis, AK (Corresponding Author), Ohio State Univ, Coll Social Work, Columbus, OH 43210 USA.
   Davis, AK (Corresponding Author), Johns Hopkins Univ, Ctr Psychedel \& Consciousness Res, Baltimore, MD 21218 USA.
   Davis, Alan K.; Xin, Yitong, Ohio State Univ, Coll Social Work, Columbus, OH 43210 USA.
   Davis, Alan K., Johns Hopkins Univ, Ctr Psychedel \& Consciousness Res, Baltimore, MD 21218 USA.
   Mangini, Pratheek, Rutgers Robert Wood Johnson Med Sch, Dept Psychiat, New Brunswick, NJ USA.},
DOI = {10.1556/2054.2021.00179},
EISSN = {2559-9283},
Keywords = {trauma; PTSD; depression; ketamine; mindfulness; psychotherapy},
Keywords-Plus = {POSTTRAUMATIC-STRESS-DISORDER; ADVERSE CHILDHOOD EXPERIENCES; FUNCTIONAL
   IMPAIRMENT; SLEEP DISTURBANCES; ANXIETY DISORDERS; ADULTS; PREVALENCE;
   DEPRESSION; SERTRALINE; EFFICACY},
Research-Areas = {Pharmacology \& Pharmacy; Psychiatry; Psychology},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy; Psychiatry; Psychology, Multidisciplinary},
Author-Email = {davis.5996@osu.edu},
Affiliations = {University System of Ohio; Ohio State University; Johns Hopkins
   University; Rutgers State University New Brunswick; Rutgers State
   University Medical Center},
ResearcherID-Numbers = {Xin, Yitong/HPD-5972-2023
   },
ORCID-Numbers = {Xin, Yitong/0000-0001-5871-1137
   Davis, Alan/0000-0003-4770-8893},
Cited-References = {Allem JP, 2015, ADDICT BEHAV, V50, P199, DOI 10.1016/j.addbeh.2015.06.038.
   {[}Anonymous], 2020, REL 2020 IBM SPSS ST.
   {[}Anonymous], 2016, IBM SPSS STAT WINDOW.
   Bader K, 2007, J SLEEP RES, V16, P285, DOI 10.1111/j.1365-2869.2007.00608.x.
   Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402.
   Bisson JI, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub4.
   Brady F, 2015, BEHAV RES THER, V75, P40, DOI 10.1016/j.brat.2015.10.001.
   Brady K, 2000, JAMA-J AM MED ASSOC, V283, P1837, DOI 10.1001/jama.283.14.1837.
   Brom D, 2017, J TRAUMA STRESS, V30, P304, DOI 10.1002/jts.22189.
   Brown TSH, 2015, J CLIN SLEEP MED, V11, P735, DOI 10.5664/jcsm.4846.
   Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913.
   Crouch E, 2019, CHILD ABUSE NEGLECT, V92, P209, DOI 10.1016/j.chiabu.2019.04.010.
   D'Andrea D, 2013, BIOL PSYCHIAT, V74, pE13, DOI 10.1016/j.biopsych.2013.04.019.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Feder A, 2021, AM J PSYCHIAT, V178, P193, DOI 10.1176/appi.ajp.2020.20050596.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8.
   Friedman MJ, 2007, J CLIN PSYCHIAT, V68, P711, DOI 10.4088/JCP.v68n0508.
   Glue P, 2018, J PSYCHOPHARMACOL, V32, P663, DOI 10.1177/0269881118762073.
   Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954.
   Hughes K, 2019, EUR J PUBLIC HEALTH, V29, P741, DOI 10.1093/eurpub/ckz037.
   Imel ZE, 2013, J CONSULT CLIN PSYCH, V81, P394, DOI 10.1037/a0031474.
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012.
   Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4.
   Koenen KC, 2017, PSYCHOL MED, V47, P2260, DOI 10.1017/S0033291717000708.
   Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C.
   Maercker A, 2004, BRIT J PSYCHIAT, V184, P482, DOI 10.1192/bjp.184.6.482.
   Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003.
   McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d.
   Memon RI, 2020, PSYCHIAT QUART, V91, P1147, DOI 10.1007/s11126-020-09830-6.
   Milanak ME, 2013, PSYCHIAT RES, V209, P173, DOI 10.1016/j.psychres.2013.03.031.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929.
   Panahi Y, 2011, PSYCHOL MED, V41, P2159, DOI 10.1017/S0033291711000201.
   Pietrzak RH, 2012, AM J GERIAT PSYCHIAT, V20, P380, DOI 10.1097/JGP.0b013e31820d92e7.
   Plummer F, 2016, GEN HOSP PSYCHIAT, V39, P24, DOI 10.1016/j.genhosppsych.2015.11.005.
   Prins A, 2016, J GEN INTERN MED, V31, P1206, DOI 10.1007/s11606-016-3703-5.
   Rodriguez P, 2012, J REHABIL RES DEV, V49, P649, DOI 10.1682/JRRD.2011.09.0162.
   Rosenblat JD, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18r12475.
   Shadli SM, 2018, INT J NEUROPSYCHOPH, V21, P717, DOI 10.1093/ijnp/pyy032.
   Sheehan KH, 2008, INT CLIN PSYCHOPHARM, V23, P70, DOI 10.1097/YIC.0b013e3282f2b4d6.
   Stein MB, 1996, AM J PSYCHIAT, V153, P275.
   Terrill Alexandra L, 2015, Int J MS Care, V17, P49, DOI 10.7224/1537-2073.2014-008.
   van der Kolk BA, 2014, J CLIN PSYCHIAT, V75, pE559, DOI 10.4088/JCP.13m08561.
   Warner CH, 2013, AM FAM PHYSICIAN, V88, P827.
   Watkins LE, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00258.
   Westphal M, 2011, DEPRESS ANXIETY, V28, P686, DOI 10.1002/da.20842.},
Number-of-Cited-References = {47},
Times-Cited = {5},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {1},
Journal-ISO = {J. Psychedelic Stud.},
Doc-Delivery-Number = {7H5YN},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000903278800005},
OA = {gold},
DA = {2023-07-30},
}

@article{ WOS:000812398000001,
Author = {Drozdz, Sandra J. and Goel, Akash and McGarr, Matthew W. and Katz, Joel
   and Ritvo, Paul and Mattina, Gabriella F. and Bhat, Venkat and Diep,
   Calvin and Ladha, Karim S.},
Title = {Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the
   Literature},
Journal = {JOURNAL OF PAIN RESEARCH},
Year = {2022},
Volume = {15},
Pages = {1691-1706},
Abstract = {Currently, ketamine is used in treating multiple pain, mental health,
   and substance abuse disorders due to rapid-acting analgesic and
   antidepressant effects. Its limited short-term durability has motivated
   research into the potential synergistic actions between ketamine and
   psychotherapy to sustain benefits. This systematic review on
   ketamine-assisted psychotherapy (KAP) sum-marizes existing evidence
   regarding present-day practices. Through rigorous review, seventeen
   articles that included 603 participants were identified. From available
   KAP publications, it is apparent that combined treatments can, in
   specific circumstances, initiate and prolong clinically significant
   reductions in pain, anxiety, and depressive symptoms, while encouraging
   rapport and treatment engagement, and promoting abstinence in patients
   addicted to other substances. Despite much variance in how KAP is
   applied (route of ketamine administration, ketamine dosage/frequency,
   psychotherapy modality, overall treatment length), these findings
   suggest psychotherapy, provided before, during, and following ketamine
   sessions, can maximize and prolong benefits. Additional large-scale
   randomized control trials are warranted to understand better the
   mutually influential relationships between psychotherapy and ketamine in
   optimizing responsiveness and sustaining long-term benefits in patients
   with chronic pain. Such investigations will assist in developing
   standardized practices and maintenance programs.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Review},
Language = {English},
Affiliation = {Ladha, KS (Corresponding Author), St Michaels Hosp, 30 Bond St,6th Floor,Donnelly Wing, Toronto, ON, Canada.
   Drozdz, Sandra J.; Goel, Akash; Mattina, Gabriella F.; Ladha, Karim S., St Michaels Hosp, Dept Anesthesia, Toronto, ON, Canada.
   Goel, Akash, Stanford Univ, Dept Anesthesiol Pain \& Perioperat Med, Stanford, CA 94305 USA.
   Goel, Akash; Katz, Joel; Diep, Calvin; Ladha, Karim S., Univ Toronto, Dept Anesthesiol \& Pain Med, Toronto, ON, Canada.
   McGarr, Matthew W., Univ Toronto, Temerty Fac Med, Toronto, ON, Canada.
   Katz, Joel; Ritvo, Paul, York Univ, Dept Psychol, Toronto, ON, Canada.
   Katz, Joel, Univ Hlth Network, Dept Anesthesia \& Pain Management, Toronto, ON, Canada.
   Katz, Joel; Ritvo, Paul, York Univ, Sch Kinesiol \& Hlth Sci, Toronto, ON, Canada.
   Bhat, Venkat, St Michaels Hosp, Intervent Psychiat Program, Toronto, ON, Canada.
   Bhat, Venkat, Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   Bhat, Venkat; Ladha, Karim S., St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.},
DOI = {10.2147/JPR.S360733},
ISSN = {1178-7090},
Keywords = {addiction; alternative treatment; anesthesia; chronic pain; mental
   health; novel therapeutic},
Keywords-Plus = {COGNITIVE-BEHAVIOR THERAPY; LOW-BACK-PAIN; INTRAVENOUS KETAMINE;
   COMORBID DEPRESSION; MECHANISMS; EFFICACY; DISORDERS; ANTIDEPRESSANTS;
   INFUSIONS; ANXIETY},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Clinical Neurology},
Author-Email = {Karim.Ladha@mail.utoronto.ca},
Affiliations = {University of Toronto; Saint Michaels Hospital Toronto; Stanford
   University; University of Toronto; University of Toronto; York
   University - Canada; University of Toronto; University Health Network
   Toronto; York University - Canada; University of Toronto; Saint Michaels
   Hospital Toronto; University of Toronto; University of Toronto; Li Ka
   Shing Knowledge Institute; Saint Michaels Hospital Toronto},
ResearcherID-Numbers = {Diep, Calvin/HSH-8413-2023
   Katz, Joel/HDO-1635-2022
   Ladha, Karim/K-7170-2015
   Katz, Joel/J-7015-2014},
ORCID-Numbers = {Ladha, Karim/0000-0001-7303-2458
   Drozdz, Sandra/0000-0001-7601-3295
   Katz, Joel/0000-0002-8686-447X},
Cited-References = {Adams TG, 2017, J CLIN PSYCHOPHARM, V37, P269, DOI 10.1097/JCP.0000000000000659.
   Aderka IM, 2012, J CONSULT CLIN PSYCH, V80, P93, DOI 10.1037/a0026455.
   Arnow BA, 2006, PSYCHOSOM MED, V68, P262, DOI 10.1097/01.psy.0000204851.15499.fc.
   Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600.
   Azhari N, 2021, AM J DRUG ALCOHOL AB, V47, P92, DOI 10.1080/00952990.2020.1808982.
   Becker J., 2014, INT J TRANSPERSONAL, V33, P151, DOI {[}10.24972/ijts.2014.33.2.151, DOI 10.24972/IJTS.2014.33.2.151].
   Belmaker RH, 2008, CNS SPECTRUMS, V13, P682, DOI 10.1017/S1092852900013766.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Bhamb B, 2006, CURR MED RES OPIN, V22, P1859, DOI 10.1185/030079906X132398.
   Blier P, 2001, J PSYCHIATR NEUROSCI, V26, P37.
   BOGAARDS MC, 1994, CLIN J PAIN, V10, P174, DOI 10.1097/00002508-199409000-00003.
   Carroll KM, 1997, ADDICT BEHAV, V22, P233, DOI 10.1016/S0306-4603(96)00038-X.
   Castelnuovo G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00115.
   Collo G, 2018, NEURAL REGEN RES, V13, P645, DOI 10.4103/1673-5374.230288.
   CORSSEN G, 1966, ANESTH ANAL CURR RES, V45, P29.
   Croft PR, 1995, SPINE, V20, P2731, DOI 10.1097/00007632-199512150-00015.
   Cuijpers P, 2017, CAN PSYCHOL, V58, P7, DOI 10.1037/cap0000096.
   Cuijpers P, 2011, AM J PSYCHIAT, V168, P581, DOI 10.1176/appi.ajp.2010.10101411.
   Dahan A, 2011, EUR J PAIN, V15, P258, DOI 10.1016/j.ejpain.2010.06.016.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Dakwar E, 2020, AM J PSYCHIAT, V177, P125, DOI 10.1176/appi.ajp.2019.19070684.
   Dakwar E, 2019, AM J PSYCHIAT, V176, P923, DOI 10.1176/appi.ajp.2019.18101123.
   Dakwar E, 2014, BIOL PSYCHIAT, V76, P40, DOI 10.1016/j.biopsych.2013.08.009.
   Daly EJ, 2019, JAMA PSYCHIAT, V76, P893, DOI 10.1001/jamapsychiatry.2019.1189.
   Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022.
   Domino EF, 2010, ANESTHESIOLOGY, V113, P678, DOI 10.1097/ALN.0b013e3181ed09a2.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Duek O., 2019, CURR TREAT OPT PSYCH, V6, P143, DOI 10.1007/s40501-019-00172-0.
   Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033.
   Ezquerra-Romano II, 2018, NEUROPHARMACOLOGY, V142, P72, DOI 10.1016/j.neuropharm.2018.01.017.
   FAWCETT J, 1994, BRIT J PSYCHIAT, V165, P37, DOI 10.1192/S0007125000293276.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   FONTANA AE, 1974, ACTA PSIQUIAT PSICOL, V20, P32.
   Gallagher R M, 1999, Semin Clin Neuropsychiatry, V4, P203.
   Halstead M, 2021, CLIN CASE STUD, V20, P310, DOI 10.1177/1534650121990894.
   Iadarola ND, 2015, THER ADV CHRONIC DIS, V6, P97, DOI 10.1177/2040622315579059.
   IsHak WW, 2018, HARVARD REV PSYCHIAT, V26, P352, DOI 10.1097/HRP.0000000000000198.
   Jacobsen Ramune, 2007, J Opioid Manag, V3, P207.
   Katz J, 2014, MENTAL HLTH PAIN, P119, DOI DOI 10.1007/978-2-8178-0414-9\_8.
   Kavalaii ET, 2012, AM J PSYCHIAT, V169, P1150, DOI 10.1176/appi.ajp.2012.12040531.
   Keizer BM, 2020, PSYCHOTHER PSYCHOSOM, V89, P326, DOI 10.1159/000507095.
   KHORRAMZADEH E, 1973, PSYCHOSOMATICS, V14, P344.
   Kroenke K, 2011, J PAIN, V12, P964, DOI 10.1016/j.jpain.2011.03.003.
   Kroenke Kurt, 2005, Prim Care Companion J Clin Psychiatry, V7, P148.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028.
   Maisto SA, 2003, ADDICT BEHAV, V28, P449, DOI 10.1016/S0306-4603(01)00267-2.
   Majeed MH, 2019, INT J PSYCHIAT MED, V54, P140, DOI 10.1177/0091217418791447.
   Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006.
   Miller LR, 2009, J PAIN, V10, P619, DOI 10.1016/j.jpain.2008.12.007.
   Moher D, 2015, SYST REV-LONDON, V4, DOI {[}10.1186/s13643-015-0087-2, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299].
   Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   Myers KM, 2011, NEUROPSYCHOPHARMACOL, V36, P274, DOI 10.1038/npp.2010.88.
   Noppers I, 2010, EXPERT OPIN PHARMACO, V11, P2417, DOI 10.1517/14656566.2010.515978.
   Ocker AC, 2020, PAIN PRACT, V20, P95, DOI 10.1111/papr.12829.
   Ohayon MM, 2003, ARCH GEN PSYCHIAT, V60, P39, DOI 10.1001/archpsyc.60.1.39.
   Patetsos E, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/2020915.
   Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15.
   Pradhan B, 2018, BBA-PROTEINS PROTEOM, V1866, P831, DOI 10.1016/j.bbapap.2018.03.006.
   Rodriguez CI, 2016, J CLIN PSYCHIAT, V77, P408, DOI 10.4088/JCP.15l10138.
   Rush AJ, 2004, CONTROL CLIN TRIALS, V25, P119, DOI 10.1016/S0197-2456(03)00112-0.
   Samwel HJA, 2009, BRIT J HEALTH PSYCH, V14, P405, DOI 10.1348/135910708X337760.
   Sanacora G, 2015, NEUROPSYCHOPHARMACOL, V40, P259, DOI 10.1038/npp.2014.261.
   Shiroma PR, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20l13406.
   Sigtermans MJ, 2009, PAIN, V145, P304, DOI 10.1016/j.pain.2009.06.023.
   SPRAVATO<(R), 2020, PRESCR INF.
   Torrens M, 2005, DRUG ALCOHOL DEPEN, V78, P1, DOI 10.1016/j.drugalcdep.2004.09.004.
   TURK DC, 1990, PAIN, V43, P7, DOI 10.1016/0304-3959(90)90046-G.
   van Tulder MW, 2001, SPINE, V26, P270, DOI 10.1097/00007632-200102010-00012.
   Wilkinson ST, 2021, PSYCHOTHER PSYCHOSOM, V90, P318, DOI 10.1159/000517074.
   Wilkinson ST, 2019, JAMA-J AM MED ASSOC, V322, P1039, DOI 10.1001/jama.2019.10728.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Witkiewitz K, 2008, PSYCHOL ADDICT BEHAV, V22, P157, DOI 10.1037/0893-164X.22.2.157.
   Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998.
   Zunszain PA, 2013, MOL PSYCHIATR, V18, P1236, DOI 10.1038/mp.2013.87.},
Number-of-Cited-References = {82},
Times-Cited = {7},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {12},
Journal-ISO = {J. Pain Res.},
Doc-Delivery-Number = {2E7ID},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000812398000001},
OA = {gold, Green Published},
DA = {2023-07-30},
}

@article{ WOS:000907195300001,
Author = {Willms, Joshua and McCauley, Ben and Kerr, Lindsay and Presto, Peyton
   and Arun, Ankith and Shah, Nazeen and Irby, Kierra and Strawn, Megan and
   Kopel, Jonathan},
Title = {Case report: Medical student types journals during ketamine infusions
   for suicidal ideation, treatment-resistant depression, post-traumatic
   stress disorder, and generalized anxiety disorder},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2022},
Volume = {13},
Month = {DEC 21},
Abstract = {Suicide is the most common cause of death in male resident physicians
   and the second most common cause of death in resident physicians
   overall. Physicians also experience high rates of major depressive
   disorder (MDD), post-traumatic stress disorder (PTSD), and burnout.
   These conditions frequently develop during medical school, and threaten
   not only physicians but the patients they care for. A 30-year-old
   medical student presented to our clinic with a history of
   treatment-resistant depression (TRD), generalized anxiety disorder
   (GAD), PTSD, and 5 years of daily suicidal ideation. Previous treatments
   included therapy, lifestyle modifications, and various combinations of
   six antidepressants. These interventions had little effect on the
   patient's mental health. The patient was treated at our clinic with an
   8-month regimen of IV ketamine infusions and ketamine-assisted
   psychotherapy (KAP). The patient achieved remission from suicidality and
   PTSD within 1 month; and TRD and GAD within 7 months. The patient's
   Patient Health Questionnaire (PHQ-9) score decreased from 25 (severe
   depression) to 1 (not depressed). These findings suggest that ketamine
   and KAP may represent effective interventions for mental health
   applications in healthcare professionals. The patient made the unique
   decision to attempt to type narrative journals during four of his
   ketamine infusions (doses ranged from 1.8 to 2.1 mg/kg/h IV). The
   patient successfully typed detailed journals throughout each 1-h
   ketamine infusion. To our knowledge, these journals represent the first
   independently typed, first-person, real-time narratives of
   ketamine-induced non ordinary states of consciousness. The transcripts
   of these journals may provide useful insights for clinicians,
   particularly in the context of KAP.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Willms, J (Corresponding Author), Texas Tech Univ, Dept Pharmacol \& Neurosci, Hlth Sci Ctr, Lubbock, TX 79409 USA.
   Willms, J (Corresponding Author), Denovo Therapy, Lubbock, TX 79413 USA.
   Willms, J (Corresponding Author), Researchers Change, Lubbock, TX 79415 USA.
   Willms, Joshua; Presto, Peyton, Texas Tech Univ, Dept Pharmacol \& Neurosci, Hlth Sci Ctr, Lubbock, TX 79409 USA.
   Willms, Joshua; McCauley, Ben; Kerr, Lindsay, Denovo Therapy, Lubbock, TX 79413 USA.
   Willms, Joshua; Arun, Ankith; Shah, Nazeen; Irby, Kierra; Strawn, Megan, Researchers Change, Lubbock, TX 79415 USA.
   Kopel, Jonathan, Texas Tech Univ, Dept Cell Biol \& Biochem, Hlth Sci Ctr, Lubbock, TX USA.},
DOI = {10.3389/fpsyt.2022.1020214},
Article-Number = {1020214},
ISSN = {1664-0640},
Keywords = {ketamine; depression; suicidality; medical school; ketamine assisted
   psychotherapy},
Keywords-Plus = {COGNITIVE-BEHAVIORAL THERAPY; STAR-ASTERISK-D; ASSISTED PSYCHOTHERAPY;
   INTRAVENOUS KETAMINE; PSYCHOLOGICAL DISTRESS; METAANALYSIS; SYMPTOMS;
   EFFICACY; OUTCOMES; PATIENT},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {j.willms@ttuhsc.edu},
Affiliations = {Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; Texas Tech University System; Texas
   Tech University; Texas Tech University Health Science Center},
ResearcherID-Numbers = {Presto, Peyton/GSN-9526-2022
   },
ORCID-Numbers = {Presto, Peyton/0000-0002-2107-1866},
Funding-Acknowledgement = {Denovo Therapy},
Funding-Text = {The funding was provided by JW and Denovo Therapy.},
Cited-References = {AAMC, 2017, AG APPL US MED SCH A.
   Abbar M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067194.
   Alvi T, 2010, JCPSP-J COLL PHYSICI, V20, P122, DOI 02.2010/JCPSP.122126.
   Beard C, 2016, J AFFECT DISORDERS, V193, P267, DOI 10.1016/j.jad.2015.12.075.
   Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1038/nrdp.2016.65.
   Belouin SJ, 2018, NEUROPHARMACOLOGY, V142, P7, DOI 10.1016/j.neuropharm.2018.02.018.
   Benish SG, 2008, CLIN PSYCHOL REV, V28, P746, DOI 10.1016/j.cpr.2007.10.005.
   Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004.
   Berlim MT, 2008, ANN MED, V40, P149, DOI 10.1080/07853890701769728.
   Bisson J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub3.
   Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214.
   Cain RA, 2007, PRIMARY CARE, V34, P505, DOI 10.1016/j.pop.2007.05.006.
   Carney S, 2003, LANCET, V361, P799.
   Coentre R, 2018, ADV MED EDUC PRACT, V9, P873, DOI 10.2147/AMEP.S162626.
   Cusin C, 2017, AUST NZ J PSYCHIAT, V51, P55, DOI 10.1177/0004867416631828.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Davis AK, 2021, J PSYCHEDELIC STUD, V5, P94, DOI 10.1556/2054.2021.00179.
   De Carlo V, 2016, PSYCHIAT RES, V240, P421, DOI 10.1016/j.psychres.2016.04.034.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Driesen NR, 2013, NEUROPSYCHOPHARMACOL, V38, P2613, DOI 10.1038/npp.2013.170.
   Drozdz SJ, 2022, J PAIN RES, V15, P1691, DOI 10.2147/JPR.S360733.
   Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009.
   Feder Adriana, 2020, Adv Pharmacol, V89, P261, DOI 10.1016/bs.apha.2020.05.004.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Fitzgibbon KP, 2020, CAN J PSYCHIAT, V65, P164, DOI 10.1177/0706743719890167.
   Frank E, 2006, BMJ-BRIT MED J, V333, P682, DOI 10.1136/bmj.38924.722037.7C.
   GARFIELD JM, 1972, ANESTHESIOLOGY, V36, P329, DOI 10.1097/00000542-197204000-00006.
   Gibbon, 2004, COMPREHENSIVE HDB PS, V2, P134, DOI DOI 10.1002/9780471726753.
   Giddens Jennifer M, 2014, Innov Clin Neurosci, V11, P66.
   Grof S., 2008, LSD PSYCHOTHERAPY HE.
   Grunder G, 2021, PHARMACOPSYCHIATRY, V54, P191, DOI 10.1055/a-1486-7386.
   Haglund MEM, 2009, ACAD MED, V84, P258, DOI 10.1097/ACM.0b013e31819381b1.
   Halperin SJ, 2021, J MED EDUC CURRIC DE, V8, DOI 10.1177/2382120521991150.
   Hamner MB, 2004, CNS SPECTRUMS, V9, P740, DOI 10.1017/S1092852900022380.
   HARRIS JA, 1975, ANESTH ANALG, V54, P169.
   Hassamal S, 2015, CLIN NEUROPHARMACOL, V38, P212, DOI 10.1097/WNF.0000000000000104.
   Heru A, 2009, ACAD PSYCHIATR, V33, P302, DOI 10.1176/appi.ap.33.4.302.
   Hojat M, 1999, MED EDUC, V33, P342, DOI 10.1046/j.1365-2923.1999.00331.x.
   Honey GD, 2005, PSYCHOPHARMACOLOGY, V181, P445, DOI 10.1007/s00213-005-0001-z.
   Hope V, 2014, MED EDUC, V48, P963, DOI 10.1111/medu.12512.
   IDVALL J, 1979, BRIT J ANAESTH, V51, P1167, DOI 10.1093/bja/51.12.1167.
   Illingworth BJG, 2021, J PSYCHOPHARMACOL, V35, P501, DOI 10.1177/0269881120965915.
   Jackson T, 2017, AM J SURG, V214, P1118, DOI 10.1016/j.amjsurg.2017.08.037.
   Joneborg I, 2022, J AFFECT DISORDERS, V315, P105, DOI 10.1016/j.jad.2022.07.030.
   Kamp J, 2020, ANESTHESIOLOGY, V133, P1192, DOI 10.1097/ALN.0000000000003577.
   Ke XY, 2018, PSYCHIAT RES, V266, P124, DOI 10.1016/j.psychres.2018.05.050.
   Kline AC, 2018, CLIN PSYCHOL REV, V59, P30, DOI 10.1016/j.cpr.2017.10.009.
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Levine P., 2015, TRAUMA MEMORY BRAIN.
   Li CT, 2016, HUM BRAIN MAPP, V37, P1080, DOI 10.1002/hbm.23085.
   Li KX, 2019, INTRAVENOUS KETAMINE.
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   Little A, 2009, AM FAM PHYSICIAN, V80, P167.
   LLOYD C, 1984, COMPR PSYCHIAT, V25, P552, DOI 10.1016/0010-440X(84)90036-1.
   Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3.
   Manea L, 2015, GEN HOSP PSYCHIAT, V37, P67, DOI 10.1016/j.genhosppsych.2014.09.009.
   Matheson KM, 2016, ACAD PSYCHIATR, V40, P63, DOI 10.1007/s40596-015-0395-9.
   MATHISEN LC, 1995, PAIN, V61, P215, DOI 10.1016/0304-3959(94)00170-J.
   McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d.
   Morgan CJA, 2004, NEUROPSYCHOPHARMACOL, V29, P208, DOI 10.1038/sj.npp.1300342.
   Murrough JW, 2015, PSYCHOL MED, V45, P3571, DOI 10.1017/S0033291715001506.
   Muscat SA, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.710338.
   Newcombe R, 2008, ADDICT RES THEORY, V16, P209, DOI 10.1080/16066350801983707.
   OYE I, 1992, J PHARMACOL EXP THER, V260, P1209.
   Peltoniemi MA, 2016, CLIN PHARMACOKINET, V55, P1059, DOI 10.1007/s40262-016-0383-6.
   Pfenninger EG, 2002, ANESTHESIOLOGY, V96, P357, DOI 10.1097/00000542-200202000-00022.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Posner K, 2008, COLUMBIA SUICIDE SEV, DOI {[}10.1037/t52667-000, DOI 10.1037/T52667-000].
   Richards WA, 2017, J HUMANIST PSYCHOL, V57, P323, DOI 10.1177/0022167816670996.
   Rotenstein LS, 2016, JAMA-J AM MED ASSOC, V316, P2214, DOI 10.1001/jama.2016.17324.
   Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905.
   Schenberg EE, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00733.
   Schwenk TL, 2010, JAMA-J AM MED ASSOC, V304, P1181, DOI 10.1001/jama.2010.1300.
   Shapiro R., 2009, EMDR SOLUTIONS 2 DEP, P556.
   Singh JB, 2016, AM J PSYCHIAT, V173, P816, DOI 10.1176/appi.ajp.2016.16010037.
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737.
   Stone M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2880.
   Szarmach Joanna, 2019, Psychiatr Danub, V31, P585.
   Thase ME, 2007, AM J PSYCHIAT, V164, P739, DOI 10.1176/appi.ajp.164.5.739.
   VITALIANO PP, 1989, J NERV MENT DIS, V177, P70, DOI 10.1097/00005053-198902000-00002.
   Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P25, DOI 10.1016/S0924-977X(96)00042-9.
   Weathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486.
   Weitz ES, 2015, JAMA PSYCHIAT, V72, P1102, DOI 10.1001/jamapsychiatry.2015.1516.
   Wheeler SW, 2020, PSYCHOL CONSCIOUS, V7, P279, DOI 10.1037/cns0000237.
   Wiles N, 2013, LANCET, V381, P375, DOI 10.1016/S0140-6736(12)61552-9.
   Wiles NJ, 2016, LANCET PSYCHIAT, V3, P137, DOI 10.1016/S2215-0366(15)00495-2.
   Wilkinson TJ, 2006, MED TEACH, V28, P129, DOI 10.1080/01421590600607195.
   Wlodarczyk Adam, 2019, Psychiatr Danub, V31, P530.
   Wolfson P., 2016, KETAMINE PAPERS SCI.
   Yaghmour NA, 2017, ACAD MED, V92, P976, DOI 10.1097/ACM.0000000000001736.
   Zanos P, 2018, PHARMACOL REV, V70, P621, DOI 10.1124/pr.117.015198.},
Number-of-Cited-References = {93},
Times-Cited = {0},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {7N2ST},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000907195300001},
OA = {gold, Green Published},
DA = {2023-07-30},
}

@article{ WOS:000925131900031,
Author = {Mohamed, Arafath and Touheed, Shehla and Ahmed, Muzammil and Hor, Mosab
   and Fatima, Sara},
Title = {The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic
   Stress Disorder (PTSD): A New Frontier?},
Journal = {CUREUS JOURNAL OF MEDICAL SCIENCE},
Year = {2022},
Volume = {14},
Number = {10},
Month = {OCT 31},
Abstract = {Post-traumatic stress disorder (PTSD) is a significant public health
   concern for which existing therapies are only marginally effective.
   Indisputably, the primary line of treatment for PTSD is psychotherapy,
   according to current treatment guidelines. However, PTSD continues to be
   a chronic condition even after psychotherapy, with high psychiatric and
   medical illness rates. There is a dire need to search for new compounds
   and approaches for managing PTSD. The usage of psychedelic substances is
   a potential new method. This article reviews the efficacy of
   psychedelic-assisted therapy in treating PTSD and improving patient
   outcomes. It will examine current research on the topic and evaluate the
   benefits and drawbacks of different therapies. The current evidence for
   the use of four different types of psychedelics
   (3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics,
   and cannabis) in the treatment of PTSD will be reviewed. It will also
   include an overview of the therapeutic justification, context of use,
   and level of evidence available for each drug. Several questions are
   formulated that could be studied in future research in order to gain a
   better understanding of the topic.},
Publisher = {CUREUS INC},
Address = {PO BOX 61002, PALO ALTO, CA 94306 USA},
Type = {Review},
Language = {English},
Affiliation = {Mohamed, A (Corresponding Author), Asian Inst Gastroenterol AIG Hosp, Crit Care Med, Hyderabad, India.
   Mohamed, Arafath, Asian Inst Gastroenterol AIG Hosp, Crit Care Med, Hyderabad, India.
   Touheed, Shehla, Shadan Inst Med Sci, Med, Hyderabad, India.
   Ahmed, Muzammil, Olive Hosp, Crit Care Med, Hyderabad, India.
   Hor, Mosab, Children Retina Inst, Ophthalmol, Los Angeles, CA USA.
   Fatima, Sara, Asian Inst Gastroenterol AIG Hosp, Emergency Med, Hyderabad, India.},
DOI = {10.7759/cureus.30919},
Article-Number = {e30919},
EISSN = {2168-8184},
Keywords = {post traumatic stress disorder; ptsd; hallucinogens; dmt; cannabinoids;
   psilocybin; ketamine; lsd; psychedelic-assisted therapy; mdma},
Keywords-Plus = {3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; INTRAVENOUS
   KETAMINE; DOUBLE-BLIND; PSILOCYBIN; CANNABIS; NIGHTMARES; SYMPTOMS;
   MDMA; ACTIVATION; DEPRESSION},
Research-Areas = {General \& Internal Medicine},
Web-of-Science-Categories  = {Medicine, General \& Internal},
Author-Email = {arafathm94@gmail.com},
Cited-References = {aan het Rot M, 2010, BIOL PSYCHIAT, V67, P139, DOI 10.1016/j.biopsych.2009.08.038.
   Albott CS, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11634.
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   Averill LA, 2022, EXPERT OPIN INV DRUG, V31, P133, DOI 10.1080/13543784.2022.2035358.
   Berman P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32651-4.
   Black N, 2019, LANCET PSYCHIAT, V6, P995, DOI 10.1016/S2215-0366(19)30401-8.
   Bogenschutz MP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00100.
   Bouso JC, 2008, J PSYCHOACTIVE DRUGS, V40, P225, DOI 10.1080/02791072.2008.10400637.
   Cameron C, 2014, J CLIN PSYCHOPHARM, V34, P559, DOI 10.1097/JCP.0000000000000180.
   Crocq MA, 2020, DIALOGUES CLIN NEURO, V22, P223, DOI 10.31887/DCNS.2020.22.3/mcrocq.
   Dahlgren MK, 2018, PSYCHOL MED, V48, P1128, DOI 10.1017/S003329171700263X.
   Danforth AL, 2018, PSYCHOPHARMACOLOGY, V235, P3137, DOI 10.1007/s00213-018-5010-9.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Feduccia AA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00650.
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5.
   Francati V, 2007, DEPRESS ANXIETY, V24, P202, DOI 10.1002/da.20208.
   Fraser GA, 2009, CNS NEUROSCI THER, V15, P84, DOI 10.1111/j.1755-5949.2008.00071.x.
   Freeman TP, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1141.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Hamilton I, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1044-x.
   Hasin DS, 2016, AM J PSYCHIAT, V173, P588, DOI 10.1176/appi.ajp.2015.15070907.
   Heal DJ, 2018, NEUROPHARMACOLOGY, V142, P89, DOI 10.1016/j.neuropharm.2018.01.049.
   Henner RL, 2022, J NEUROL SCI, V439, DOI 10.1016/j.jns.2022.120302.
   Hill MN, 2018, NEUROPSYCHOPHARMACOL, V43, P80, DOI 10.1038/npp.2017.162.
   Holze F, 2020, NEUROPSYCHOPHARMACOL, V45, P462, DOI 10.1038/s41386-019-0569-3.
   Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161.
   Jetly R, 2015, PSYCHONEUROENDOCRINO, V51, P585, DOI 10.1016/j.psyneuen.2014.11.002.
   Johnson MW, 2018, NEUROPHARMACOLOGY, V142, P143, DOI 10.1016/j.neuropharm.2018.05.012.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kometer M, 2015, PSYCHOPHARMACOLOGY, V232, P3663, DOI 10.1007/s00213-015-4026-7.
   Krediet E, 2020, INT J NEUROPSYCHOPH, V23, P385, DOI 10.1093/ijnp/pyaa018.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Krystal JH, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0829-z.
   Latimer Dustin, 2021, Psychopharmacol Bull, V51, P125.
   Ly C, 2018, CELL REP, V23, P3170, DOI 10.1016/j.celrep.2018.05.022.
   MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004.
   Mayor S, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l574.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mithoefer MC, 2018, LANCET PSYCHIAT, V5, P486, DOI 10.1016/S2215-0366(18)30135-4.
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611.
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371.
   Morena M, 2016, NEUROPSYCHOPHARMACOL, V41, P80, DOI 10.1038/npp.2015.166.
   Mueller F, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.54.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   Ney LJ, 2019, PROG NEURO-PSYCHOPH, V93, P124, DOI 10.1016/j.pnpbp.2019.03.017.
   Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013.
   Passie T, 2018, DRUG SCI POLICY LAW, V4, P1, DOI {[}10.1177/2050324518767442, DOI 10.1177/2050324518767442].
   Passie T, 2012, DRUG TEST ANAL, V4, P649, DOI 10.1002/dta.1377.
   Pokorny T, 2017, INT J NEUROPSYCHOPH, V20, P747, DOI 10.1093/ijnp/pyx047.
   Pradhan B, 2018, BBA-PROTEINS PROTEOM, V1866, P831, DOI 10.1016/j.bbapap.2018.03.006.
   Rabinak CA, 2014, NEUROBIOL LEARN MEM, V113, P125, DOI 10.1016/j.nlm.2013.09.009.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Roitman P, 2014, CLIN DRUG INVEST, V34, P587, DOI 10.1007/s40261-014-0212-3.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Sanz C, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00007.
   Schmid Y, 2014, J PSYCHOPHARMACOL, V28, P847, DOI 10.1177/0269881114542454.
   Sessa B, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-230109.
   Shalev A, 2017, NEW ENGL J MED, V376, P2459, DOI 10.1056/NEJMra1612499.
   Steinkellner T, 2011, BIOL CHEM, V392, P103, DOI 10.1515/BC.2011.016.
   Stern CAJ, 2017, NEUROPHARMACOLOGY, V125, P220, DOI 10.1016/j.neuropharm.2017.07.024.
   Tedesco S, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.15070.
   Thompson GR, 2014, NEW ENGL J MED, V371, P878, DOI {[}10.1056/NEJMra1402309, 10.1056/NEJMc1407928].
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.},
Number-of-Cited-References = {65},
Times-Cited = {1},
Usage-Count-Last-180-days = {12},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Cureus J Med Sci},
Doc-Delivery-Number = {8N4PO},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000925131900031},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000747929500001,
Author = {Dames, Shannon and Kryskow, Pamela and Watler, Crosbie},
Title = {A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy
   Embedded in a Community of Practice Framework for Healthcare Providers
   With PTSD and Depression},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2022},
Volume = {12},
Month = {JAN 12},
Abstract = {Amid an international pandemic and a worsening mental health crisis,
   ketamine-assisted therapy is emerging as a promising solution for those
   deemed ``treatment resistant.{''} Post-traumatic stress disorder (PTSD)
   and depression are on the rise, with accelerating direct (e.g., burden
   of suffering) and indirect (e.g., disability/role impairment and impact
   on family) costs. Psychedelic-assisted therapies show significant
   promise in the treatment of a number of clinically challenging
   conditions, including depression, anxiety, PTSD, addiction, and
   end-of-life distress. Ketamine is currently the only safe, effective and
   legal widely available psychedelic-like medicine. To address the echo
   pandemic of health care provider distress, a multi-disciplinary team was
   charged with developing a ketamine-assisted psychotherapy program,
   delivered in a community of practice (CoP) group model and evaluated in
   a quality improvement framework. Program evaluation occurred through
   mixed methods. Quantitative mental health assessments included the PHQ-9
   for depression, the PCL-5 for PTSD, GAD-7 for generalized anxiety
   disorder (GAD), and B-IPF for work/life functionality. Participant
   narrative feedback was collected to evaluate outcomes and for quality
   improvement purposes. Mean mental health scores were collected across
   three cohorts, totaling 94 patients. The mean aggregate scores of
   participants meeting the mental health assessment cut-off criteria
   (screening positive) were analyzed to assess clinical significance. Mean
   aggregate results comparing baseline vs. outcome measures (measured
   within 1-2 weeks after completion of the 12-week program) were
   clinically significant, demonstrating significant improvements in
   depression, post-traumatic stress disorder, generalized anxiety disorder
   and work/life functionality. In summary, 91\% saw improvements in
   generalized anxiety, 79\% saw improvements in depression, 86\% of those
   who screened positive for PTSD now screen negative, and 92\% had
   significant life/work functionality improvements. Qualitative feedback
   was overwhelmingly positive, with several unsolicited self-reports of
   transformation. Participant and team feedback enables the program to
   continue improving with each iteration. Results speak to the
   effectiveness of ketamine for psychedelic-assisted therapy, supported by
   a CoP framework. Outcomes are relevant for mental health programming,
   education and healthcare policy.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Dames, S (Corresponding Author), Vancouver Isl Univ, Hlth \& Human Serv, Nanaimo, BC, Canada.
   Dames, Shannon; Kryskow, Pamela, Vancouver Isl Univ, Hlth \& Human Serv, Nanaimo, BC, Canada.},
DOI = {10.3389/fpsyt.2021.803279},
Article-Number = {803279},
ISSN = {1664-0640},
Keywords = {ketamine-assisted psychotherapy; healthcare providers (HCP); resilience;
   psychedelic therapy; group therapy; community of practice;
   post-traumatic stress disorder (PTSD); depression},
Keywords-Plus = {INTRAVENOUS KETAMINE; DISORDER},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {shannon.dames@viu.ca},
Affiliations = {Vancouver Island University},
Funding-Acknowledgement = {Vancouver Island University; Canadian Institutes of Health Research
   Knowledge Synthesis grant; British Columbia Ministry of Health COVID-19
   Research grant; Island Health; British Columbia Nurses Union; First
   Nations Health Authority; philanthropic funds;  {[}COVID-19]},
Funding-Text = {The project was supported by Vancouver Island University, a Canadian
   Institutes of Health Research Knowledge Synthesis grant, a British
   Columbia Ministry of Health COVID-19 Research grant, the Regional
   Initiatives Fund, in-kind support from Island Health, the British
   Columbia Nurses Union, First Nations Health Authority, and philanthropic
   funds.},
Cited-References = {{[}Anonymous], 1991, SITUATED LEARNING LE.
   {[}Anonymous], 1979, HLTH STRESS COPING N.
   Bloch MH, 2012, BIOL PSYCHIAT, V72, P964, DOI 10.1016/j.biopsych.2012.05.028.
   Briggs GG, 2016, DRUGS PREGNANCY LACT.
   Carhart-Harris RL, 2017, NEUROPSYCHOPHARMACOL, V42, P2105, DOI 10.1038/npp.2017.84.
   Chilukuri Harihar, 2014, Indian J Psychol Med, V36, P71, DOI 10.4103/0253-7176.127258.
   Collo Ginetta, 2019, Chronic Stress (Thousand Oaks), V3, p2470547019842545, DOI 10.1177/2470547019842545.
   Dames S, 2021, ROOT STRENGTH HLTH C.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Ezquerra-Romano II, 2018, NEUROPHARMACOLOGY, V142, P72, DOI 10.1016/j.neuropharm.2018.01.017.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5.
   Jones JL, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00277.
   Kirsch I, 2014, Z PSYCHOL, V222, P128, DOI 10.1027/2151-2604/a000176.
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976.
   O'Leary OF, 2015, EUR J PHARMACOL, V753, P32, DOI 10.1016/j.ejphar.2014.07.046.
   Patel V, 2018, LANCET, V392, P1553, DOI 10.1016/S0140-6736(18)31612-X.
   Porges S. W., 2011, NORTON SERIES INTERP.
   Rogers C., 1956, CLIENT CENT THER.
   Rogers C.R., 1959, PSYCHOL STUDY SCI FO, P184.
   Taylor JH, 2018, NEUROPSYCHOPHARMACOL, V43, P325, DOI 10.1038/npp.2017.194.
   The World Health Organization (WHO), 2021, DEPRESSION.
   Tupper KW, 2015, CAN MED ASSOC J, V187, P1054, DOI 10.1503/cmaj.141124.
   Wenger-Treyner E., INTRO COMMUNITIES PR.
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472.},
Number-of-Cited-References = {25},
Times-Cited = {5},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {YO4RX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000747929500001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:001002835500001,
Author = {Batievsky, Daniella and Weiner, Michelle and Kaplan, Shari B. and Thase,
   Michael Edward and Maglione, Domenick Nicholas and Vidot, Denise
   Christina},
Title = {Ketamine-assisted psychotherapy treatment of chronic pain and comorbid
   depression: a pilot study of two approaches},
Journal = {FRONTIERS IN PAIN RESEARCH},
Year = {2023},
Volume = {4},
Month = {MAY 19},
Abstract = {Chronic pain and depression diagnoses are skyrocketing. There is an
   urgent need for more effective treatments. Ketamine was recently
   established to alleviate pain and depression, but many gaps remain in
   the scientific literature. This paper reports the findings of an
   observational preliminary study that explored the efficacy of
   ketamine-assisted psychotherapy (KAPT) for chronic pain/major depressive
   disorder (MDD) comorbidity. Researchers evaluated two KAPT approaches to
   determine optimal route of administration/dose. Ten individuals
   diagnosed with a chronic pain disorder and MDD receiving KAPT were
   recruited: five individuals pursuing the psychedelic approach (high
   doses administered intramuscularly 24 h before therapy) and five
   individuals pursuing the psycholytic approach (low doses administered
   sublingually via oral lozenges during therapy). To evaluate differences
   between altered states of consciousness each approach induces,
   participants completed the Mystical Experience Questionnaire (MEQ30)
   after their first (T-1), third (T-2) and sixth/final (T-3) treatment
   sessions. Primary outcomes were change in Beck Depression Inventory
   (BDI) scores and Brief Pain Inventory (BPI) Short Form scores from
   baseline (T0) to (T-1)-(T-3). Secondary outcomes were changes in
   Generalized Anxiety Disorder (GAD-7) Scale scores and Post-Traumatic
   Stress Disorder Checklist (PCL-5) scores at each timepoint.
   Statistically significant differences between each approach were not
   observed, but the small sample's limited statistical power makes changes
   seen worth noting. All participants' symptoms declined throughout
   treatment. Psychedelic treatment participants saw a larger, more
   consistent decrease. Researchers conclude that KAPT may be effective for
   treating chronic pain/MDD comorbidity, anxiety and Post-Traumatic Stress
   Disorder (PTSD). Findings imply that the psychedelic approach may be
   more effective. This pilot study serves as a basis for more extensive
   research that will inform how clinicians administer treatment to
   optimize outcomes.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Batievsky, D (Corresponding Author), Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
   Batievsky, Daniella, Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
   Weiner, Michelle, Spine \& Wellness Ctr Amer, Miami, FL USA.
   Kaplan, Shari B., Cannectd Wellness, Boca Raton, FL USA.
   Thase, Michael Edward, Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
   Thase, Michael Edward, United States Dept Vet Affairs, Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA.
   Maglione, Domenick Nicholas; Vidot, Denise Christina, Univ Miami, Sch Nursing \& Hlth Studies, Coral Gables, FL USA.},
DOI = {10.3389/fpain.2023.1127863},
Article-Number = {1127863},
EISSN = {2673-561X},
Keywords = {ketamine; depression; pain; intramuscular; therapy; microdose;
   psychedelic; psycholytic},
Keywords-Plus = {ANTIDEPRESSANT; QUESTIONNAIRE; TRIAL},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences},
Author-Email = {daniellabatievskyy@gmail.com},
Affiliations = {University of Pennsylvania; University of Pennsylvania; Pennsylvania
   Medicine; University of Miami},
Funding-Acknowledgement = {University of Pennsylvania's Millstein Family Undergraduate Research
   Grant},
Funding-Text = {This study was funded by University of Pennsylvania's Millstein Family
   Undergraduate Research Grant. The funds allowed researchers to
   compensate participants for their participation in the study.},
Cited-References = {{[}Anonymous], US PTSD CHECKL DSM 5.
   {[}Anonymous], BRIEF PAIN INVENTORY.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Beck A.T., 2011, BECK DEPRESSION INVE, DOI {[}10.1037/t00742-000, DOI 10.1037/T00742-000].
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Blonk MI, 2010, EUR J PAIN, V14, P466, DOI 10.1016/j.ejpain.2009.09.005.
   Close JB, 2020, J CONTEXT BEHAV SCI, V16, P37, DOI 10.1016/j.jcbs.2020.01.005.
   Cusin C, 2017, AUST NZ J PSYCHIAT, V51, P55, DOI 10.1177/0004867416631828.
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2.
   Depression, 2020, DEPR.
   Gaynes BN, 2009, PSYCHIAT SERV, V60, P1439, DOI 10.1176/ps.2009.60.11.1439.
   Greenberg PE, 2021, PHARMACOECONOMICS, V39, P653, DOI 10.1007/s40273-021-01019-4.
   Guirimand F, 2000, ANESTH ANALG, V90, P408, DOI 10.1097/00000539-200002000-00031.
   Hocking G, 2003, ANESTH ANALG, V97, P1730, DOI 10.1213/01.ANE.0000086618.28845.9B.
   Kocarova R, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.661233.
   Lara DR, 2013, INT J NEUROPSYCHOPH, V16, P2111, DOI 10.1017/S1461145713000485.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Marguilho M, 2023, J PSYCHOPHARMACOL, V37, P14, DOI 10.1177/02698811221140011.
   McKernan LC, 2019, CLIN J PAIN, V35, P385, DOI 10.1097/AJP.0000000000000689.
   Michelet D, 2018, EUR J PAIN, V22, P632, DOI 10.1002/ejp.1153.
   Moore TJ, 2017, JAMA INTERN MED, V177, P274, DOI 10.1001/jamainternmed.2016.7507.
   Nahin RL, 2019, J PAIN, V20, P796, DOI 10.1016/j.jpain.2019.01.003.
   Nikkheslat Naghmeh, 2021, Brain Behav Immun Health, V18, P100383, DOI 10.1016/j.bbih.2021.100383.
   Noppers I, 2010, EXPERT OPIN PHARMACO, V11, P2417, DOI 10.1517/14656566.2010.515978.
   Nutt D, 2020, CELL, V181, P24, DOI 10.1016/j.cell.2020.03.020.
   Petryna Adriana, 2006, GLOBAL PHARM ETHICS, P1, DOI DOI 10.1215/9780822387916.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Roughan WH, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.643609.
   Salahudeen MS, 2020, THER ADV DRUG SAF, V11, DOI 10.1177/2042098620937899.
   Schwartzman RJ, 2009, PAIN, V147, P107, DOI 10.1016/j.pain.2009.08.015.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Webster L., 2019, PAIN NEWS NETWORK, V67.
   Williams N, 2014, OCCUP MED-OXFORD, V64, P224, DOI 10.1093/occmed/kqt161.
   Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255.},
Number-of-Cited-References = {34},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Front. Pain Res.},
Doc-Delivery-Number = {I4XU8},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:001002835500001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000791787900001,
Author = {Robison, Reid and Lafrance, Adele and Brendle, Madeline and Smith,
   Michelle and Moore, Claire and Ahuja, Sachin and Richards, Scott and
   Hawkins, Nicole and Strahan, Erin},
Title = {A case series of group-based ketamine-assisted psychotherapy for
   patients in residential treatment for eating disorders with comorbid
   depression and anxiety disorders},
Journal = {JOURNAL OF EATING DISORDERS},
Year = {2022},
Volume = {10},
Number = {1},
Month = {MAY 6},
Abstract = {Background Depression and anxiety outcome measures, safety/tolerability,
   patient satisfaction, and ease of implementation of group-based
   ketamine-assisted psychotherapy (G-KAP) delivered to patients in
   intensive residential eating disorder (ED) treatment were assessed. Case
   presentation This study reports on five participants with a diagnosis of
   an ED and comorbid mood and anxiety disorders who received weekly
   intramuscular ketamine injections in a group setting over 4 weeks.
   Measures of anxiety (GAD-7) and depression (PHQ-9) were administered
   pre-dose, 4-h post-dose, and 24-h post dose. Four of the 5 participants
   experienced clinically significant improvements on the PHQ-9 score
   (i.e., change greater than 5) while 2 of the 5 participants experienced
   clinically significant improvements on the GAD-7 score (i.e., change
   greater than 4) from pre-dose to 24-h post-dose after the last ketamine
   session. Dosing sessions were well tolerated, and no serious adverse
   events were reported. Clinical observations and participant reports
   corroborated improvements in depression and anxiety symptoms, good
   tolerability of ketamine treatment, and practical implementation of the
   G-KAP protocol in a residential ED treatment center. Conclusions This
   study suggests the potential utility of G-KAP as an adjunct to
   intensive, specialized ED treatment. Overall, this novel,
   cross-diagnostic intervention warrants future research to further
   explore its appropriateness in a treatment setting.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Robison, R (Corresponding Author), Ctr Change, Orem, UT 84057 USA.
   Robison, R (Corresponding Author), Novamind Inc, Draper, UT 84020 USA.
   Robison, R (Corresponding Author), Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA.
   Robison, Reid; Smith, Michelle; Richards, Scott; Hawkins, Nicole, Ctr Change, Orem, UT 84057 USA.
   Robison, Reid; Brendle, Madeline; Moore, Claire; Ahuja, Sachin, Novamind Inc, Draper, UT 84020 USA.
   Robison, Reid, Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA.
   Lafrance, Adele, Emot Sci, Denver, CO USA.
   Brendle, Madeline, Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA.
   Strahan, Erin, Wilfrid Laurier Univ, Brantford, ON, Canada.},
DOI = {10.1186/s40337-022-00588-9},
Article-Number = {65},
ISSN = {2050-2974},
Keywords = {Ketamine; Psychotherapy; Feeding and eating disorders; Depression;
   Anxiety; Case series},
Keywords-Plus = {REMISSION; UNIPOLAR; EFFICACY; OUTCOMES; NERVOSA; SAFETY; SINGLE},
Research-Areas = {Psychology; Nutrition \& Dietetics; Psychiatry},
Web-of-Science-Categories  = {Psychology, Clinical; Nutrition \& Dietetics; Psychiatry},
Author-Email = {reid@novamind.ca},
Affiliations = {Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Wilfrid Laurier University},
ResearcherID-Numbers = {Brendle, Madeline/HKM-9736-2023
   },
ORCID-Numbers = {Brendle, Madeline/0000-0003-0692-3706},
Cited-References = {Abdallah CG, 2019, CONTEMP CLIN TRIALS, V81, P11, DOI 10.1016/j.cct.2019.04.009.
   Blinder BJ, 2006, PSYCHOSOM MED, V68, P454, DOI 10.1097/01.psy.0000221254.77675.f5.
   Bulik C.M., 2002, ANXIETY DEPRESSION E.
   CLEMENTS JA, 1982, J PHARM SCI, V71, P539, DOI 10.1002/jps.2600710516.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Fewell LK, 2017, EAT WEIGHT DISORD-ST, V22, P291, DOI 10.1007/s40519-016-0357-6.
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5.
   Glue P, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320922474.
   Hasler G, 2020, CNS SPECTRUMS, V25, P445, DOI 10.1017/S1092852919001007.
   Ho JH., 2016, CRITICAL CARE TOXICO, P1, DOI {[}10.1007/978-3-319-20790-2\_124-1, DOI 10.1007/978-3-319-20790-2\_124-1].
   Ingram R, 2018, NEUROPHARMACOLOGY, V142, P30, DOI 10.1016/j.neuropharm.2018.06.008.
   Keeler JL, 2021, NUTRIENTS, V13, DOI 10.3390/nu13114158.
   Khalsa SS, 2017, J EAT DISORD, V5, DOI 10.1186/s40337-017-0145-3.
   Kishimoto T, 2016, PSYCHOL MED, V46, P1459, DOI 10.1017/S0033291716000064.
   Kraus C, 2017, INT J PSYCHIAT CLIN, V21, P2, DOI 10.1080/13651501.2016.1254802.
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06.
   Kroenke K, 2012, CAN MED ASSOC J, V184, P281, DOI 10.1503/cmaj.112004.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Kurdi Madhuri S, 2014, Anesth Essays Res, V8, P283, DOI 10.4103/0259-1162.143110.
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   Martin J, 2019, EUR EAT DISORD REV, V27, P603, DOI 10.1002/erv.2677.
   Martinotti G, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11070856.
   Marucci S, 2018, ENDOCR METAB IMMUNE, V18, P316, DOI 10.2174/1871530318666180213111637.
   Memon RI, 2020, PSYCHIAT QUART, V91, P1147, DOI 10.1007/s11126-020-09830-6.
   Mills IH, 1998, QJM-MON J ASSOC PHYS, V91, P493, DOI 10.1093/qjmed/91.7.493.
   Ragnhildstveit A, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.764112.
   Rodriguez CI, 2013, NEUROPSYCHOPHARMACOL, V38, P2475, DOI 10.1038/npp.2013.150.
   Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080.
   Schwartz T, 2021, CLIN CASE REP, V9, DOI 10.1002/ccr3.3869.
   Scolnick B, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00763.
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092.
   Szarmach Joanna, 2019, Psychiatr Danub, V31, P585.
   Toussaint A, 2020, J AFFECT DISORDERS, V265, P395, DOI 10.1016/j.jad.2020.01.032.
   Treasure J, 2010, LANCET, V375, P583, DOI 10.1016/S0140-6736(09)61748-7.
   Yao N, 2018, MOL PSYCHIATR, V23, P2066, DOI 10.1038/mp.2017.239.
   Yi D., 1995, THEORY PRACTICE GROU, V4.
   Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255.},
Number-of-Cited-References = {37},
Times-Cited = {6},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {3},
Journal-ISO = {J. Eat. Disord.},
Doc-Delivery-Number = {1A5HP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000791787900001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000811049200011,
Author = {Bottemanne, H. and Baldacci, A. and Muller, C. and Boyreau, A. and
   Claret, A.},
Title = {Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide},
Journal = {ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE},
Year = {2022},
Volume = {48},
Number = {3},
Pages = {304-312},
Month = {JUN},
Abstract = {Ketamine, a non-competitive NMDA receptor antagonist, is used as a
   fast-acting antidepressant therapy in depressive disorders. This
   treatment provokes dissociative effects associating derealization and
   deperso-nalization, and a synaptogenic signaling cascade promoting brain
   plasticity. Despite several preliminary studies suggesting the
   usefulness of its combination with psychotherapy, administration of
   ketamine isn???t generally combined with per-and post-infusion
   psychotherapy protocols in its clinical antidepressant use. However, the
   phenomenology of psychodysleptic experiences and the synaptogenic effect
   could potentiate cognitive and behavioral therapies (CBT). In this
   article, we purpose a practical protocol to Ketamine Augmented
   Psychotherapy (KAP) synthesizing contemporary data from the literature
   and our clinical experience. We detail proposals for clinical practice,
   and propose four important steps for the use of a psychodysleptic
   molecule for antidepressant purposes: preparation, administration,
   integration, and prolongation. Finally, we discuss the limits and
   prospects of this combination in the management of mood disorders. ??
   2021 L???Enc??phale, Paris.},
Publisher = {MASSON EDITEUR},
Address = {21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE},
Type = {Review},
Language = {English},
Affiliation = {Bottemanne, H (Corresponding Author), Sorbonne Univ, AP HP, Pitie Salpetriere Hop, Dept Psychiat,DMU Neurosci, Paris, France.
   Bottemanne, H (Corresponding Author), Sorbonne Univ, Paris Brain Inst, Inst Cerveau ICM, CNRS,Inserm,UMR 7225,UMRS 1127, Paris, France.
   Bottemanne, H (Corresponding Author), Sorbonne Univ, Dept Philosophy, CNRS, UMR 8011, Paris, France.
   Bottemanne, H.; Baldacci, A.; Muller, C.; Boyreau, A.; Claret, A., Sorbonne Univ, AP HP, Pitie Salpetriere Hop, Dept Psychiat,DMU Neurosci, Paris, France.
   Bottemanne, H., Sorbonne Univ, Paris Brain Inst, Inst Cerveau ICM, CNRS,Inserm,UMR 7225,UMRS 1127, Paris, France.
   Bottemanne, H., Sorbonne Univ, Dept Philosophy, CNRS, UMR 8011, Paris, France.},
DOI = {10.1016/j.encep.2021.08.011},
EarlyAccessDate = {JUN 2022},
ISSN = {0013-7006},
EISSN = {2589-4935},
Keywords = {Ketamine; Augmented psychotherapy; Ketamine assisted psychotherapy;
   Belief; Belief updating; Dissociation; Psychedelic; Predictive coding;
   Antidepressant},
Keywords-Plus = {MAJOR DEPRESSIVE DISORDER; INTRAVENOUS KETAMINE; ASSISTED PSYCHOTHERAPY;
   PSILOCYBIN TREATMENT; ANTIDEPRESSANT; EFFICACY; THERAPY; SINGLE; LSD;
   METAANALYSIS},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Neurosciences; Psychiatry},
Author-Email = {hugo.bottemanne@aphp.fr},
Affiliations = {4EU+; UDICE-French Research Universities; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Paul-Brousse - APHP; Hopital Universitaire Pitie-Salpetriere - APHP;
   Universite Paris Cite; Hopital Universitaire Cochin - APHP; Hopital
   Universitaire Hotel-Dieu - APHP; Hopital Universitaire Saint-Louis -
   APHP; 4EU+; UDICE-French Research Universities; Sorbonne Universite;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Institut National de la Sante et de la
   Recherche Medicale (Inserm); 4EU+; UDICE-French Research Universities;
   Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)},
Cited-References = {Aan Het Rot M, 2012, BIOL PSYCHIAT, V72, P537, DOI 10.1016/j.biopsych.2012.05.003.
   Abdallah CG, 2019, CONTEMP CLIN TRIALS, V81, P11, DOI 10.1016/j.cct.2019.04.009.
   Abdallah CG, 2017, NEUROPSYCHOPHARMACOL, V42, P1210, DOI 10.1038/npp.2016.186.
   Adler CM, 1999, AM J PSYCHIAT, V156, P1646, DOI 10.1176/ajp.156.10.1646.
   Albott CS, 2017, J CLIN PSYCHIAT, V78, pE308, DOI 10.4088/JCP.16l11277.
   Alexander L, 2021, NEUROSCI BIOBEHAV R, V127, P531, DOI 10.1016/j.neubiorev.2021.05.003.
   {[}Anonymous], 2013, PREDICTIVE MIND.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bottemanne H, 2021, ENCEPHALE, V47, P171, DOI 10.1016/j.encep.2020.08.006.
   Bottemanne H, 2020, PRESCRIRE PSYCHOTROP, P560.
   Bottemanne H, 2021, PSYARXIV.
   Bottemanne Hugo, 2021, Innov Clin Neurosci, V18, P9.
   Bottemanne H, 2020, J CLIN PSYCHOPHARM, V40, P636, DOI 10.1097/JCP.0000000000001281.
   Braithwaite JJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00719.
   Callesen P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64577-1.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris RL, 2016, PSYCHOL MED, V46, P1379, DOI 10.1017/S0033291715002901.
   Carhart-Harris RL, 2017, NEUROPSYCHOPHARMACOL, V42, P2105, DOI 10.1038/npp.2017.84.
   Chen MH, 2020, INT J NEUROPSYCHOPH, V23, P791, DOI 10.1093/ijnp/pyaa056.
   Conley AA, 2021, PSYCHOPHARMACOLOGY, V238, P1737, DOI 10.1007/s00213-021-05825-8.
   Corlett PR, 2009, PSYCHOPHARMACOLOGY, V206, P515, DOI 10.1007/s00213-009-1561-0.
   Corlett PR, 2016, J PSYCHOPHARMACOL, V30, P1145, DOI 10.1177/0269881116650087.
   Corlett PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065088.
   Daly EJ, 2018, JAMA PSYCHIAT, V75, P139, DOI 10.1001/jamapsychiatry.2017.3739.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   dos Santos RG, 2016, THER ADV PSYCHOPHARM, V6, P193, DOI 10.1177/2045125316638008.
   Farber D, 2017, SIXTIES, V10, P247, DOI 10.1080/17541328.2017.1321294.
   Fattore L, 2018, PSYCHOPHARMACOLOGY, V235, P433, DOI 10.1007/s00213-017-4793-4.
   Fava M, 2020, MOL PSYCHIATR, V25, P1592, DOI 10.1038/s41380-018-0256-5.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Gartner M, 2019, EUR NEUROPSYCHOPHARM, V29, P501, DOI 10.1016/j.euroneuro.2019.02.008.
   Garcia-Romeu A, 2018, INT REV PSYCHIATR, V30, P291, DOI 10.1080/09540261.2018.1486289.
   Gill H, 2020, EXPERT REV NEUROTHER, V20, P1263, DOI 10.1080/14737175.2020.1826931.
   Greenway KT, 2020, EXPERT REV CLIN PHAR, V13, P655, DOI 10.1080/17512433.2020.1772054.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Han Y, 2016, NEUROPSYCH DIS TREAT, V12, P2859, DOI 10.2147/NDT.S117146.
   Harraz MM, 2016, MOL PSYCHIATR, V21, P313, DOI {[}10.1038/mp.2015211, 10.1038/mp.2015.211].
   Hasler G, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00687.
   Hutchison CA, 2020, CLIN SOC WORK J, V48, P421, DOI 10.1007/s10615-018-0676-3.
   Ionescu DF, 2018, HARVARD REV PSYCHIAT, V26, P320, DOI 10.1097/HRP.0000000000000179.
   Kolp E., 2007, INT J TRANSPERSONAL, V26, P1, DOI DOI 10.24972/IJTS.2007.26.1.1.
   Kolp E., 2014, INT J TRANSPERS STUD, V33, P84, DOI {[}DOI 10.24972/IJTS.2014.33.2.84, https://doi.org/10.24972/ijts.2014.33.2.84].
   Krediet E, 2020, INT J NEUROPSYCHOPH, V23, P385, DOI 10.1093/ijnp/pyaa018.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Kryst J, 2020, PHARMACOL REP, V72, P543, DOI 10.1007/s43440-020-00097-z.
   Lebedev AV, 2016, HUM BRAIN MAPP, V37, P3203, DOI 10.1002/hbm.23234.
   Loo CK, 2016, ACTA PSYCHIAT SCAND, V134, P48, DOI 10.1111/acps.12572.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Luoma JB, 2020, J PSYCHOACTIVE DRUGS, V52, P289, DOI 10.1080/02791072.2020.1769878.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   Majic T, 2015, J PSYCHOPHARMACOL, V29, P241, DOI 10.1177/0269881114568040.
   Mathai DS, 2020, J AFFECT DISORDERS, V264, P123, DOI 10.1016/j.jad.2019.12.023.
   MECHANECK R, 1968, COMPR PSYCHIAT, V9, P490, DOI 10.1016/S0010-440X(68)80080-X.
   Mithoefer MC, 2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Moreno JD, 2016, PERSPECT BIOL MED, V59, P107, DOI 10.1353/pbm.2016.0019.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Pennybaker SJ, 2017, J AFFECT DISORDERS, V208, P560, DOI 10.1016/j.jad.2016.10.026.
   Philipp R, 2019, CLIN PSYCHOL PSYCHOT, V26, P227, DOI 10.1002/cpp.2345.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Reynolds CF, 2021, JAMA PSYCHIAT, V78, P476, DOI 10.1001/jamapsychiatry.2020.2901.
   Rief W, 2015, CURR OPIN PSYCHIATR, V28, P378, DOI 10.1097/YCO.0000000000000184.
   Rodriguez CI, 2016, J CLIN PSYCHIAT, V77, P408, DOI 10.4088/JCP.15l10138.
   Rodriguez CI, 2011, J CLIN PSYCHIAT, V72, P567, DOI 10.4088/JCP.10l06653.
   Romeo B, 2015, PSYCHIAT RES, V230, P682, DOI 10.1016/j.psychres.2015.10.032.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Ross C, 2019, ANN CLIN PSYCHIATRY, V31, P271.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rucker JJH, 2018, NEUROPHARMACOLOGY, V142, P200, DOI 10.1016/j.neuropharm.2017.12.040.
   Sar V, 2014, CLIN PSYCHOPHARM NEU, V12, P171, DOI 10.9758/cpn.2014.12.3.171.
   SLATER PE, 1957, J NERV MENT DIS, V125, P312, DOI 10.1097/00005053-195704000-00018.
   SOFIA RD, 1975, ARCH INT PHARMACOD T, V214, P68.
   Solem S, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02908.
   STAFFORD P, 1985, J PSYCHOACTIVE DRUGS, V17, P219, DOI 10.1080/02791072.1985.10524326.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Thomas K, 2017, J PSYCHOACTIVE DRUGS, V49, P446, DOI 10.1080/02791072.2017.1320734.
   Tupper KW, 2015, CAN MED ASSOC J, V187, P1054, DOI 10.1503/cmaj.141124.
   Varker T, 2021, J PSYCHOACTIVE DRUGS, V53, P85, DOI 10.1080/02791072.2020.1817639.
   Voort JLV, 2016, J AFFECT DISORDERS, V206, P300, DOI 10.1016/j.jad.2016.09.008.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.},
Number-of-Cited-References = {86},
Times-Cited = {3},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Enceph.-Rev. Psychiatr. Clin. Biol. Ther.},
Doc-Delivery-Number = {2C7NB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000811049200011},
OA = {Bronze},
DA = {2023-07-30},
}

@article{ WOS:001010552800013,
Author = {Kelly, Daniel F. and Heinzerling, Keith and Sharma, Akanksha and
   Gowrinathan, Shanthi and Sergi, Karina and Mallari, Regin Jay},
Title = {Psychedelic-Assisted Therapy and Psychedelic Science: A Review and
   Perspective on Opportunities in Neurosurgery and Neuro-Oncology},
Journal = {NEUROSURGERY},
Year = {2023},
Volume = {92},
Number = {4},
Pages = {680-694},
Month = {APR},
Abstract = {After a decades-long pause, psychedelics are again being intensely
   investigated for treating a wide range of neuropsychiatric ailments
   including depression, anxiety, addiction, post-traumatic stress
   disorder, anorexia, and chronic pain syndromes. The classic serotonergic
   psychedelics psilocybin and lysergic acid diethylamide and nonclassic
   psychedelics 3,4-methylenedioxymethamphetamine and ketamine are
   increasingly appreciated as neuroplastogens given their potential to
   fundamentally alter mood and behavior well beyond the time window of
   measurable exposure. Imaging studies with psychedelics are also helping
   advance our understanding of neural networks and connectomics. This
   resurgence in psychedelic science and psychedelic-assisted therapy has
   potential significance for the fields of neurosurgery and neuro-oncology
   and their diverse and challenging patients, many of whom continue to
   have mental health issues and poor quality of life despite receiving
   state-of-the-art care. In this study, we review recent and ongoing
   clinical trials, the set and setting model of psychedelic-assisted
   therapy, potential risks and adverse events, proposed mechanisms of
   action, and provide a perspective on how the safe and evidence-based use
   of psychedelics could potentially benefit many patients, including those
   with brain tumors, pain syndromes, ruminative disorders, stroke, SAH,
   TBI, and movement disorders. By leveraging psychedelics' neuroplastic
   potential to rehabilitate the mind and brain, novel treatments may be
   possible for many of these patient populations, in some instances
   working synergistically with current treatments and in some using
   subpsychedelic doses that do not require mind-altering effects for
   efficacy. This review aims to encourage broader multidisciplinary
   collaboration across the neurosciences to explore and help realize the
   transdiagnostic healing potential of psychedelics.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Review},
Language = {English},
Affiliation = {Kelly, DF (Corresponding Author), Pacific Neurosci Inst, Treatment \& Res Psychedel Program, 2125 Arizona Ave, Santa Monica, CA 90404 USA.
   Kelly, Daniel F.; Heinzerling, Keith; Sharma, Akanksha; Gowrinathan, Shanthi; Sergi, Karina; Mallari, Regin Jay, Pacific Neurosci Inst, Treatment \& Res Psychedel Program, Santa Monica, CA USA.
   Kelly, Daniel F.; Heinzerling, Keith; Sharma, Akanksha; Gowrinathan, Shanthi, St Johns Canc Inst, Providence St Johns Hlth Ctr, Santa Monica, CA USA.
   Kelly, Daniel F., Pacific Neurosci Inst, Treatment \& Res Psychedel Program, 2125 Arizona Ave, Santa Monica, CA 90404 USA.},
DOI = {10.1227/neu.0000000000002275},
ISSN = {0148-396X},
EISSN = {1524-4040},
Keywords = {Addiction; Anxiety; Depression; Lysergic acid diethylamide; N-methyl-3;
   4-methylenedioxyamphetamine; Post-traumatic stress disorder; Psilocybin;
   Psychedelic; Serotonin},
Keywords-Plus = {TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; LIFE-THREATENING
   CANCER; SPINAL-CORD-INJURY; FOLLOW-UP; TRIGEMINAL NEURALGIA; CHRONIC
   PAIN; DEPRESSION; PSILOCYBIN; ANXIETY},
Research-Areas = {Neurosciences \& Neurology; Surgery},
Web-of-Science-Categories  = {Clinical Neurology; Surgery},
Author-Email = {dkelly@pacificneuro.org
   keith.heinzerling@providence.org
   akanksha.sharma@providence.org
   shanthi.gowrinathan@providence.org
   karina.sergi@providence.org
   reginjay.mallari@providence.org},
Affiliations = {John Wayne Cancer Institute},
Cited-References = {Aday JS, 2019, J PSYCHOACTIVE DRUGS, V51, P210, DOI 10.1080/02791072.2019.1581961.
   Aleksandrova LR, 2021, TRENDS PHARMACOL SCI, V42, P929, DOI 10.1016/j.tips.2021.08.003.
   Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249.
   Anderson BT, 2020, LANCET PSYCHIAT, V7, P829, DOI 10.1016/S2215-0366(20)30146-2.
   Antonelli M, 2021, ADDICT BEHAV, V114, DOI 10.1016/j.addbeh.2020.106760.
   Appleby BS, 2008, J NEUROPSYCH CLIN N, V20, P447, DOI 10.1176/appi.neuropsych.20.4.447.
   Arnould A, 2013, NEUROPSYCHOL REV, V23, P210, DOI 10.1007/s11065-013-9236-3.
   Azouvi P, 2017, REV NEUROL-FRANCE, V173, P461, DOI 10.1016/j.neurol.2017.07.006.
   Barrett FS, 2020, NEUROIMAGE, V218, DOI 10.1016/j.neuroimage.2020.116980.
   Barrett FS, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01238.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Benzenhofer U, 2010, ADDICTION, V105, P1355, DOI 10.1111/j.1360-0443.2010.02948.x.
   Berman D, 2017, INT J SPINE SURG, V11, DOI 10.14444/4029.
   Bogenschutz MP, 2022, JAMA PSYCHIAT, V79, P953, DOI 10.1001/jamapsychiatry.2022.2096.
   Bogenschutz MP, 2016, PROG NEURO-PSYCHOPH, V64, P250, DOI 10.1016/j.pnpbp.2015.03.002.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bonaventura G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081992.
   Bravo G., 2021, HDB MED HALLUCINOGEN, P327.
   Burton CAC, 2013, INT J STROKE, V8, P545, DOI 10.1111/j.1747-4949.2012.00906.x.
   Byock I, 2018, J PALLIAT MED, V21, P417, DOI 10.1089/jpm.2017.0684.
   Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Carhart-Harris RL, 2017, NEUROPSYCHOPHARMACOL, V42, P2105, DOI 10.1038/npp.2017.84.
   Carhart-Harris RL, 2016, P NATL ACAD SCI USA, V113, P4853, DOI 10.1073/pnas.1518377113.
   Carlson BB, 2016, ORTHOPEDICS, V39, pE318, DOI 10.3928/01477447-20160301-03.
   Castellanos JP, 2020, REGION ANESTH PAIN M, V45, P486, DOI 10.1136/rapm-2020-101273.
   Catelino MP, 2020, NEUROSURG FOCUS, V48, DOI 10.3171/2019.11.FOCUS19773.
   Chang BW, 2019, WORLD NEUROSURG, V128, pE556, DOI 10.1016/j.wneu.2019.04.194.
   Cheng J, 2017, CLIN NEUROL NEUROSUR, V161, P59, DOI 10.1016/j.clineuro.2017.08.011.
   Chung JW, 2021, NEUROLOGY, V96, pE1012, DOI 10.1212/WNL.0000000000011440.
   Dadario NB, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.711646.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   de Vos CMH, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.724606.
   De Witte NAJ, 2017, BRAIN IMAGING BEHAV, V11, P1604, DOI 10.1007/s11682-016-9642-2.
   Doblin RE, 2019, J PSYCHOACTIVE DRUGS, V51, P93, DOI 10.1080/02791072.2019.1606472.
   Dolder PC, 2016, NEUROPSYCHOPHARMACOL, V41, P2638, DOI 10.1038/npp.2016.82.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Doss MK, 2022, BRAIN, V145, P441, DOI 10.1093/brain/awab406.
   Elam JS, 2021, NEUROIMAGE, V244, DOI 10.1016/j.neuroimage.2021.118543.
   Elman I, 2022, NEUROSCI BIOBEHAV R, V134, DOI 10.1016/j.neubiorev.2021.12.005.
   Fakhoury M, 2021, REV NEUROSCIENCE, V32, P289, DOI 10.1515/revneuro-2020-0037.
   Feduccia AA, 2018, PROG NEURO-PSYCHOPH, V84, P221, DOI 10.1016/j.pnpbp.2018.03.003.
   Flanagan TW, 2018, INT REV PSYCHIATR, V30, P363, DOI 10.1080/09540261.2018.1481827.
   Freire RC, 2020, ADV EXP MED BIOL, V1191, P331, DOI 10.1007/978-981-32-9705-0\_18.
   Glasser MF, 2016, NAT NEUROSCI, V19, P1175, DOI 10.1038/nn.4361.
   Graat I, 2017, INT REV PSYCHIATR, V29, P178, DOI 10.1080/09540261.2017.1282439.
   Graupensperger S, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107608.
   Griffiths RR, 2018, J PSYCHOPHARMACOL, V32, P49, DOI 10.1177/0269881117731279.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grof S., 1994, LSD PSYCHOTHERAPY, V2nd ed.
   Gukasyan N, 2022, J PSYCHOPHARMACOL, V36, P151, DOI 10.1177/02698811211073759.
   Health NIoM, 2022, US.
   Hill T, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0701-9.
   Hofmann A., 1979, LSD MY PROBLEM CHILD.
   HOLLAND J, 2001, ECSTASY COMPLETE GUI.
   Holze F, 2022, NEUROPSYCHOPHARMACOL, V47, P1180, DOI 10.1038/s41386-022-01297-2.
   Holze F, 2020, NEUROPSYCHOPHARMACOL, V45, P462, DOI 10.1038/s41386-019-0569-3.
   Inserra A, 2021, PHARMACOL REV, V73, P202, DOI 10.1124/pharmrev.120.000056.
   Jacotte-Simancas A, 2021, INT REV NEUROBIOL, V157, P195, DOI 10.1016/bs.irn.2020.09.003.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Kaelen M, 2016, EUR NEUROPSYCHOPHARM, V26, P1099, DOI 10.1016/j.euroneuro.2016.03.018.
   Kelly JR, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.800072.
   Khan SM, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.685085.
   LaRowe LR, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108171.
   Le J, 2016, SPINAL CORD, V54, P570, DOI 10.1038/sc.2016.15.
   Lebedev AV, 2015, HUM BRAIN MAPP, V36, P3137, DOI 10.1002/hbm.22833.
   Lee DJ, 2019, J NEUROSURG, V131, P333, DOI 10.3171/2019.4.JNS181761.
   Loughan AR, 2021, J CLIN PSYCHOL MED S, V28, P16, DOI 10.1007/s10880-019-09690-8.
   Lukasiewicz K, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.748359.
   Ly C, 2018, CELL REP, V23, P3170, DOI 10.1016/j.celrep.2018.05.022.
   Mahta A, 2021, CLIN NEUROL NEUROSUR, V207, DOI 10.1016/j.clineuro.2021.106770.
   Mainio A, 2006, EUR ARCH PSY CLIN N, V256, P516, DOI 10.1007/s00406-006-0674-2.
   Mainio A, 2011, CLIN NEUROL NEUROSUR, V113, P649, DOI 10.1016/j.clineuro.2011.05.006.
   Majic T, 2015, J PSYCHOPHARMACOL, V29, P241, DOI 10.1177/0269881114568040.
   Malcolm B, 2022, PSYCHOPHARMACOLOGY, V239, P1881, DOI 10.1007/s00213-021-05876-x.
   McMillan R, 2020, REV NEUROSCIENCE, V31, P457, DOI 10.1515/revneuro-2019-0090.
   Medeiros GC, 2020, GEN HOSP PSYCHIAT, V66, P70, DOI 10.1016/j.genhosppsych.2020.06.011.
   Melek LN, 2018, INT J ORAL MAX SURG, V47, P869, DOI 10.1016/j.ijom.2018.02.006.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mithoefer MC, 2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3.
   Navarro PA, 2022, NEUROMODULATION, V25, P171, DOI 10.1111/ner.13348.
   Nichols DE., 2021, HDB MEDICAL HALLUCIN, P3.
   Nutt D, 2020, CELL, V181, P24, DOI 10.1016/j.cell.2020.03.020.
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6.
   Orhurhu V, 2018, PAIN THER, V7, P217, DOI 10.1007/s40122-018-0104-y.
   Panik K., 2021, HDB MED HALLUCINOGEN, P159.
   Petri G, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0873.
   Phelps Janis, 2022, Curr Top Behav Neurosci, V56, P93, DOI 10.1007/7854\_2021\_266.
   POLATIN PB, 1993, SPINE, V18, P66, DOI 10.1097/00007632-199301000-00011.
   Pranckeviciene Aiste, 2015, CNS Oncol, V4, P71, DOI 10.2217/cns.14.60.
   Preller KH, 2020, BIOL PSYCHIAT, V88, P197, DOI 10.1016/j.biopsych.2019.12.027.
   Preller KH, 2019, P NATL ACAD SCI USA, V116, P2743, DOI 10.1073/pnas.1815129116.
   Preller KH, 2018, ELIFE, V7, DOI 10.7554/eLife.35082.
   Rabat Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92639-5.
   Ramachandran V, 2018, NEUROCASE, V24, P105, DOI 10.1080/13554794.2018.1468469.
   Ranjan M, 2020, NEUROL INDIA, V68, P282, DOI 10.4103/0028-3886.302459.
   Raval NR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020835.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Reznikov R, 2017, NEUROMODULATION, V20, P7, DOI 10.1111/ner.12551.
   Arce JMR, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.729425.
   Roseman L, 2018, NEUROPHARMACOLOGY, V142, P263, DOI 10.1016/j.neuropharm.2017.12.041.
   Ross S, 2021, ACS PHARMACOL TRANSL, V4, P553, DOI 10.1021/acsptsci.1c00020.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Saeger HN, 2022, J NEUROCHEM, V162, P109, DOI 10.1111/jnc.15544.
   Schindler EAD, 2015, J PSYCHOACTIVE DRUGS, V47, P372, DOI 10.1080/02791072.2015.1107664.
   Schrag A, 2017, INT REV NEUROBIOL, V133, P623, DOI {[}10.1016/bs.irn.2017.05.024, 10.1016/bs.im.2017.05.024].
   Sha ZQ, 2019, BIOL PSYCHIAT, V85, P379, DOI 10.1016/j.biopsych.2018.11.011.
   Sheth SA, 2022, BIOL PSYCHIAT, V92, P246, DOI 10.1016/j.biopsych.2021.11.007.
   Smigielski L, 2019, NEUROIMAGE, V196, P207, DOI 10.1016/j.neuroimage.2019.04.009.
   Sonmez AI, 2019, PSYCHIAT RES, V273, P770, DOI 10.1016/j.psychres.2018.12.041.
   Stevens Jay, 1987, STORMING HEAVEN LSD.
   Strom J, 2018, SPINE J, V18, P1272, DOI 10.1016/j.spinee.2018.03.017.
   Tagliazucchi E, 2016, CURR BIOL, V26, P1043, DOI 10.1016/j.cub.2016.02.010.
   Tang WK, 2022, J PSYCHOSOM RES, V155, DOI 10.1016/j.jpsychores.2022.110742.
   Tang WK, 2020, J STROKE, V22, P11, DOI 10.5853/jos.2019.02103.
   VanderVeen JD, 2021, ARCH PHYS MED REHAB, V102, P1198, DOI 10.1016/j.apmr.2020.10.112.
   Vargas AS, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090331.
   Vollenweider FX, 2020, NAT REV NEUROSCI, V21, P611, DOI 10.1038/s41583-020-0367-2.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   von Vogelsang AC, 2015, WORLD NEUROSURG, V83, P1090, DOI 10.1016/j.wneu.2014.12.027.
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1.
   Vraa ML, 2022, CLIN J PAIN, V38, P222, DOI 10.1097/AJP.0000000000001006.
   Wellisch DK, 2002, PSYCHO-ONCOLOGY, V11, P230, DOI 10.1002/pon.562.
   Whelan A, 2018, PAIN MANAG, V8, P217, DOI 10.2217/pmt-2017-0068.
   Williams R, 2015, ARCH PHYS MED REHAB, V96, P133, DOI 10.1016/j.apmr.2014.08.016.
   Willing AE, 2020, CNS NEUROSCI THER, V26, P616, DOI 10.1111/cns.13300.
   Winkelman MJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.619890.
   Winkelman MJ., 2021, HDB MED HALLUCINOGEN, P46.
   Wu CS, 2017, J CLIN PSYCHIAT, V78, pE1226, DOI 10.4088/JCP.16m11377.
   Yang AI, 2019, J NEUROSURG, V131, P1805, DOI 10.3171/2018.8.JNS1893.
   Yeung JT, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.19105.},
Number-of-Cited-References = {133},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Neurosurgery},
Doc-Delivery-Number = {J6FM7},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:001010552800013},
OA = {hybrid},
DA = {2023-07-30},
}

@article{ WOS:001024380900001,
Author = {Charlton, Colleen E. E. and Karvelis, Povilas and McIntyre, Roger S. S.
   and Diaconescu, Andreea O. O.},
Title = {Suicide prevention and ketamine: insights from computational modeling},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2023},
Volume = {14},
Month = {JUN 29},
Abstract = {Suicide is a pressing public health issue, with over 700,000 individuals
   dying each year. Ketamine has emerged as a promising treatment for
   suicidal thoughts and behaviors (STBs), yet the complex mechanisms
   underlying ketamine's anti-suicidal effect are not fully understood.
   Computational psychiatry provides a promising framework for exploring
   the dynamic interactions underlying suicidality and ketamine's
   therapeutic action, offering insight into potential biomarkers,
   treatment targets, and the underlying mechanisms of both. This paper
   provides an overview of current computational theories of suicidality
   and ketamine's mechanism of action, and discusses various computational
   modeling approaches that attempt to explain ketamine's anti-suicidal
   effect. More specifically, the therapeutic potential of ketamine is
   explored in the context of the mismatch negativity and the predictive
   coding framework, by considering neurocircuits involved in learning and
   decision-making, and investigating altered connectivity strengths and
   receptor densities targeted by ketamine. Theory-driven computational
   models offer a promising approach to integrate existing knowledge of
   suicidality and ketamine, and for the extraction of model-derived
   mechanistic parameters that can be used to identify patient subgroups
   and personalized treatment approaches. Future computational studies on
   ketamine's mechanism of action should optimize task design and modeling
   approaches to ensure parameter reliability, and external factors such as
   set and setting, as well as psychedelic-assisted therapy should be
   evaluated for their additional therapeutic value.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Charlton, CE (Corresponding Author), Ctr Addict \& Mental Hlth CAMH, Krembil Ctr Neuroinformat, Toronto, ON, Canada.
   Charlton, Colleen E. E.; Karvelis, Povilas; Diaconescu, Andreea O. O., Ctr Addict \& Mental Hlth CAMH, Krembil Ctr Neuroinformat, Toronto, ON, Canada.
   McIntyre, Roger S. S.; Diaconescu, Andreea O. O., Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
   McIntyre, Roger S. S., Univ Toronto, Dept Pharmacol \& Toxicol, Toronto, ON, Canada.
   Diaconescu, Andreea O. O., Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   Diaconescu, Andreea O. O., Univ Toronto, Dept Psychol, Toronto, ON, Canada.},
DOI = {10.3389/fpsyt.2023.1214018},
Article-Number = {1214018},
ISSN = {1664-0640},
Keywords = {ketamine; computational modeling; psychiatry; generative models;
   suicidality},
Keywords-Plus = {MAJOR DEPRESSIVE DISORDER; HIERARCHICAL PREDICTION ERRORS; MEDIAL
   PREFRONTAL CORTEX; D-ASPARTATE ANTAGONIST; MISMATCH NEGATIVITY;
   DECISION-MAKING; NORADRENALINE RELEASE; INTRAVENOUS KETAMINE; LATERAL
   HABENULA; MOOD DISORDERS},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {colleen.charlton@camh.ca},
Affiliations = {University of Toronto; Centre for Addiction \& Mental Health - Canada;
   University of Toronto; University of Toronto; University of Toronto;
   University of Toronto},
Cited-References = {Abbar M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067194.
   Abe R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45833-5.
   Adams RA, 2016, J NEUROL NEUROSUR PS, V87, P53, DOI 10.1136/jnnp-2015-310737.
   Adams RA, 2013, BRAIN STRUCT FUNCT, V218, P611, DOI 10.1007/s00429-012-0475-5.
   Adell A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060947.
   Ago Y, 2019, INT J NEUROPSYCHOPH, V22, P665, DOI 10.1093/ijnp/pyz041.
   Aleksandrova LR, 2021, TRENDS PHARMACOL SCI, V42, P929, DOI 10.1016/j.tips.2021.08.003.
   Alexander L, 2021, NEUROSCI BIOBEHAV R, V127, P531, DOI 10.1016/j.neubiorev.2021.05.003.
   Ambrosi E, 2019, J NEUROPSYCH CLIN N, V31, P49, DOI 10.1176/appi.neuropsych.17120351.
   Amidfar M, 2019, PROG NEURO-PSYCHOPH, V94, DOI 10.1016/j.pnpbp.2019.109668.
   Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249.
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   Bachmann S, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071425.
   Baek K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10541-5.
   Bahji A, 2021, J AFFECT DISORDERS, V278, P542, DOI 10.1016/j.jad.2020.09.071.
   Baik JH, 2020, EXP MOL MED, V52, P1879, DOI 10.1038/s12276-020-00532-4.
   Baker PM, 2016, J NEUROSCI, V36, P11482, DOI 10.1523/JNEUROSCI.2350-16.2016.
   Ballard ED, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20190-4.
   Ballard ED, 2014, J PSYCHIATR RES, V58, P161, DOI 10.1016/j.jpsychires.2014.07.027.
   Brodersen KH, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002079.
   Brown VM, 2020, NEUROPSYCHOPHARMACOL, V45, P1034, DOI 10.1038/s41386-020-0632-0.
   Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160.
   Corlett PR, 2016, J PSYCHOPHARMACOL, V30, P1145, DOI 10.1177/0269881116650087.
   Corlett PR, 2014, LANCET PSYCHIAT, V1, P399, DOI 10.1016/S2215-0366(14)70298-6.
   Van de Cruys S, 2014, PSYCHOL REV, V121, P649, DOI 10.1037/a0037665.
   Dean B, 2016, AUST NZ J PSYCHIAT, V50, P275, DOI 10.1177/0004867415586601.
   Diaconescu AO, 2017, SOC COGN AFFECT NEUR, V12, P618, DOI 10.1093/scan/nsw171.
   DiazGranados N, 2010, J CLIN PSYCHIAT, V71, P1605, DOI 10.4088/JCP.09m05327blu.
   Dombrovski AY, 2022, WIRES COGN SCI, V13, DOI 10.1002/wcs.1561.
   Dombrovski AY, 2019, BIOL PSYCHIAT, V85, P506, DOI 10.1016/j.biopsych.2018.10.006.
   Dombrovski AY, 2017, CURR OPIN PSYCHIATR, V30, P7, DOI 10.1097/YCO.0000000000000297.
   Dong M, 2019, PSYCHOL MED, V49, P1691, DOI 10.1017/S0033291718002301.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Eshel N, 2010, BIOL PSYCHIAT, V68, P118, DOI 10.1016/j.biopsych.2010.01.027.
   Fellows LK, 2007, CEREB CORTEX, V17, P2669, DOI 10.1093/cercor/bhl176.
   Fitzgerald ML, 2017, NEUROPSYCHOPHARMACOL, V42, P974, DOI 10.1038/npp.2016.124.
   Friston KJ, 2019, NEUROIMAGE, V199, P730, DOI 10.1016/j.neuroimage.2017.02.045.
   Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7.
   Fukumoto K, 2020, NEUROPSYCHOPHARMACOL, V45, P1725, DOI 10.1038/s41386-020-0705-0.
   Garnett MF., 2022, NCHS DATA BRIEF NO 4.
   Gilbert JR, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.673159.
   Gilbert JR, 2020, BIOL PSYCHIAT-COGN N, V5, P354, DOI 10.1016/j.bpsc.2019.11.011.
   Gilbert JR, 2018, INT J NEUROPSYCHOPH, V21, P740, DOI 10.1093/ijnp/pyy041.
   Gray AL, 2015, MOL PSYCHIATR, V20, P1057, DOI 10.1038/mp.2015.91.
   Grizzell JA, 2020, FRONT NEURAL CIRCUIT, V14, DOI 10.3389/fncir.2020.00050.
   Hare BD, 2020, NEUROPHARMACOLOGY, V166, DOI 10.1016/j.neuropharm.2020.107947.
   Hare BD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08168-9.
   Harfmann EJ, 2019, J AFFECT DISORDERS, V256, P228, DOI 10.1016/j.jad.2019.05.022.
   Heekeren K, 2008, PSYCHOPHARMACOLOGY, V199, P77, DOI 10.1007/s00213-008-1129-4.
   Hess EM, 2022, BIOCHEM PHARMACOL, V197, DOI 10.1016/j.bcp.2021.114892.
   Holmstrand C, 2008, NORD J PSYCHIAT, V62, P25, DOI 10.1080/08039480801960164.
   Huys QJM, 2016, NAT NEUROSCI, V19, P404, DOI 10.1038/nn.4238.
   Iglesias S, 2017, WIRES COGN SCI, V8, DOI 10.1002/wcs.1420.
   Iglesias S, 2013, NEURON, V80, P519, DOI 10.1016/j.neuron.2013.09.009.
   Jimenez-Trevino L, 2020, CURR TOP BEHAV NEURO, V46, P179, DOI 10.1007/7854\_2020\_168.
   Kadriu Bashkim, 2020, Adv Pharmacol, V89, P195, DOI 10.1016/bs.apha.2020.05.003.
   Kangas ES, 2022, INT J PSYCHOPHYSIOL, V179, P119, DOI 10.1016/j.ijpsycho.2022.07.003.
   Karvelis P., 2022, PSYCHIATRY, V6, P34, DOI {[}10.5334/cpsy.80, DOI 10.5334/CPSY.80].
   Karvelis P, 2023, NEUROSCI BIOBEHAV R, V148, DOI 10.1016/j.neubiorev.2023.105137.
   Klonsky ED, 2021, WORLD PSYCHIATRY, V20, P439, DOI 10.1002/wps.20909.
   Klonsky ED, 2016, ANNU REV CLIN PSYCHO, V12, P307, DOI 10.1146/annurev-clinpsy-021815-093204.
   Kokkinou M, 2018, MOL PSYCHIATR, V23, P59, DOI 10.1038/mp.2017.190.
   Kotoula V, 2022, BIOL PSYCHIAT-COGN N, V7, P285, DOI 10.1016/j.bpsc.2021.05.009.
   Kube T, 2020, BIOL PSYCHIAT, V87, P388, DOI 10.1016/j.biopsych.2019.07.017.
   Kubota T, 1999, CAN J ANAESTH, V46, P388, DOI 10.1007/BF03013235.
   Kubota T, 1999, BRAIN RES, V840, P175, DOI 10.1016/S0006-8993(99)01793-X.
   Lee Y, 2016, J CLIN PSYCHOPHARM, V36, P50, DOI 10.1097/JCP.0000000000000441.
   Letheby C, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/nc/nix016.
   Liebe T, 2018, NEUROIMAGE-CLIN, V20, P715, DOI 10.1016/j.nicl.2018.09.001.
   Lieder F, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003288.
   Liu QY, 2022, DEPRESS ANXIETY, V39, P845, DOI 10.1002/da.23291.
   Lopez-Gil X, 2019, ACS CHEM NEUROSCI, V10, P3318, DOI 10.1021/acschemneuro.9b00288.
   Mann JJ, 2003, NAT REV NEUROSCI, V4, P819, DOI 10.1038/nrn1220.
   Marcus DJ, 2021, ELIFE, V10, DOI 10.7554/eLife.70148.
   Marguilho M, 2023, J PSYCHOPHARMACOL, V37, P14, DOI 10.1177/02698811221140011.
   Marks RB, 2022, FRONT BEHAV NEUROSCI, V16, DOI 10.3389/fnbeh.2022.812952.
   Marroquin B, 2013, J SOC CLIN PSYCHOL, V32, P446, DOI 10.1521/jscp.2013.32.4.446.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Mathews DC, 2013, TRANSL NEUROSCI, V4, P203, DOI 10.2478/s13380-013-0120-7.
   Matsumoto M, 2009, NAT NEUROSCI, V12, P77, DOI 10.1038/nn.2233.
   Matveychuk D, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320916657.
   May AM, 2016, CLIN PSYCHOL-SCI PR, V23, P5, DOI 10.1111/cpsp.12136.
   McIntyre RS, 2021, AM J PSYCHIAT, V178, P383, DOI 10.1176/appi.ajp.2020.20081251.
   McIntyre RS, 2020, J AFFECT DISORDERS, V276, P576, DOI 10.1016/j.jad.2020.06.050.
   Miller OH, 2016, NEUROPHARMACOLOGY, V100, P17, DOI 10.1016/j.neuropharm.2015.07.028.
   Millner AJ, 2020, TRENDS COGN SCI, V24, P704, DOI 10.1016/j.tics.2020.06.007.
   Millner AJ, 2019, J ABNORM PSYCHOL, V128, P106, DOI 10.1037/abn0000395.
   Moran RJ, 2013, J NEUROSCI, V33, P8227, DOI 10.1523/JNEUROSCI.4255-12.2013.
   Moret Chantal, 2011, Neuropsychiatr Dis Treat, V7, P9, DOI 10.2147/NDT.S19619.
   Murrough JW, 2013, BIOL PSYCHIAT, V74, P250, DOI 10.1016/j.biopsych.2012.06.022.
   Muscat SA., 2022, PSYCHOLOGY, V4, P119, DOI {[}10.3390/PSYCH4010012, DOI 10.3390/PSYCH4010012, 10.3390/psych4010012].
   Muthukumaraswamy SD, 2015, J NEUROSCI, V35, P11694, DOI 10.1523/JNEUROSCI.0903-15.2015.
   Myers CE, 2023, PSYCHOL MED, V53, P4245, DOI 10.1017/S0033291722001003.
   Niciu MJ, 2014, J CLIN PSYCHIAT, V75, pE417, DOI 10.4088/JCP.13m08698.
   Nikkheslat Naghmeh, 2021, Brain Behav Immun Health, V18, P100383, DOI 10.1016/j.bbih.2021.100383.
   Oquendo MA, 2014, AM J PSYCHIAT, V171, P1259, DOI 10.1176/appi.ajp.2014.14020194.
   Oranje B, 2000, NEUROPSYCHOPHARMACOL, V22, P293, DOI 10.1016/S0893-133X(99)00118-9.
   Papakostas GI, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19r12889.
   Perrain R, 2021, J AFFECT DISORDERS, V280, P241, DOI 10.1016/j.jad.2020.11.052.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Price Rebecca B, 2022, Am J Psychiatry, V179, P959, DOI 10.1176/appi.ajp.20220216.
   Price RB, 2015, CNS DRUGS, V29, P181, DOI 10.1007/s40263-015-0232-4.
   Price RB, 2014, DEPRESS ANXIETY, V31, P335, DOI 10.1002/da.22253.
   Pulcu E, 2017, ELIFE, V6, DOI 10.7554/eLife.27879.
   Richard-Devantoy S, 2014, PSYCHOL MED, V44, P1663, DOI 10.1017/S0033291713002304.
   Rosburg T, 2016, CLIN NEUROPHYSIOL, V127, P1387, DOI 10.1016/j.clinph.2015.10.062.
   Rosch RE, 2019, BIOL PSYCHIAT-COGN N, V4, P140, DOI 10.1016/j.bpsc.2018.07.003.
   Roser P, 2011, PSYCHOPHARMACOLOGY, V218, P611, DOI 10.1007/s00213-011-2352-y.
   ROY A, 1992, ARCH GEN PSYCHIAT, V49, P447.
   Ryding E, 2008, PROG BRAIN RES, V172, P307, DOI 10.1016/S0079-6123(08)00915-1.
   Rzeszutek MJ, 2022, ARCH SUICIDE RES, V26, P1757, DOI 10.1080/13811118.2021.2022049.
   Safron A., 2020, PREPRINT, DOI {[}10.31234/osf.io/zqh4b, DOI 10.31234/OSF.IO/ZQH4B].
   Sales AC, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006267.
   Sastre-Buades A, 2021, NEUROSCI BIOBEHAV R, V131, P642, DOI 10.1016/j.neubiorev.2021.10.005.
   Schmaal L, 2020, MOL PSYCHIATR, V25, P408, DOI 10.1038/s41380-019-0587-x.
   Schmidt A, 2013, CEREB CORTEX, V23, P2394, DOI 10.1093/cercor/bhs238.
   Schmidt A, 2012, NEUROPSYCHOPHARMACOL, V37, P865, DOI 10.1038/npp.2011.261.
   Shaw AD, 2020, NEUROIMAGE, V221, DOI 10.1016/j.neuroimage.2020.117189.
   Stephan KE, 2017, NEUROIMAGE, V145, P180, DOI 10.1016/j.neuroimage.2016.06.038.
   Stephan KE, 2010, NEUROIMAGE, V49, P3099, DOI 10.1016/j.neuroimage.2009.11.015.
   Sterzer P, 2018, BIOL PSYCHIAT, V84, P634, DOI 10.1016/j.biopsych.2018.05.015.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Sumner RL, 2020, EUR NEUROPSYCHOPHARM, V38, P73, DOI 10.1016/j.euroneuro.2020.07.009.
   Sumner RL, 2020, BIOL PSYCHIAT-COGN N, V5, P45, DOI 10.1016/j.bpsc.2019.07.002.
   Sun X, 2005, J NEUROSCI, V25, P7342, DOI 10.1523/JNEUROSCI.4603-04.2005.
   Suominen K, 2009, J CLIN PSYCHIAT, V70, P1372, DOI 10.4088/JCP.09m05110blu.
   Taylor MJ, 2006, ARCH GEN PSYCHIAT, V63, P1217, DOI 10.1001/archpsyc.63.11.1217.
   Pham TH, 2019, PHARMACOL THERAPEUT, V199, P58, DOI 10.1016/j.pharmthera.2019.02.017.
   Torous J, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0914-y.
   Tseng YJ, 2021, CLIN NEUROPHYSIOL, V132, P2654, DOI 10.1016/j.clinph.2021.06.019.
   Tsypes A, 2022, J PSYCHOPATHOL CLIN, V131, P34, DOI 10.1037/abn0000717.
   Umbricht D, 2000, ARCH GEN PSYCHIAT, V57, P1139, DOI 10.1001/archpsyc.57.12.1139.
   Watabe-Uchida M, 2017, ANNU REV NEUROSCI, V40, P373, DOI 10.1146/annurev-neuro-072116-031109.
   Weber LA, 2020, J NEUROSCI, V40, P5658, DOI 10.1523/JNEUROSCI.3069-19.2020.
   who, 2021, WHO SUICIDE.
   Wilkinson ST, 2021, PSYCHOTHER PSYCHOSOM, V90, P318, DOI 10.1159/000517074.
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472.
   Witt K, 2020, AUST NZ J PSYCHIAT, V54, P29, DOI 10.1177/0004867419883341.
   Wolff M, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00005.
   Wu MZ, 2021, ELIFE, V10, DOI 10.7554/eLife.64041.
   Xiong JQ, 2021, J PSYCHIATR RES, V134, P57, DOI 10.1016/j.jpsychires.2020.12.038.
   Yang Y, 2018, NATURE, V554, P317, DOI 10.1038/nature25509.
   Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255.
   Zanos P, 2018, PHARMACOL REV, V70, P621, DOI 10.1124/pr.117.015198.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zhao YJ, 2008, J CLIN NEUROSCI, V15, P1264, DOI 10.1016/j.jocn.2007.11.007.},
Number-of-Cited-References = {146},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {L6MJ4},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:001024380900001},
OA = {gold},
DA = {2023-07-30},
}

@article{ WOS:000453497800007,
Author = {Ezquerra-Romano, I. Ivan and Lawn, W. and Krupitsky, E. and Morgan, C.
   J. A.},
Title = {Ketamine for the treatment of addiction: Evidence and potential
   mechanisms},
Journal = {NEUROPHARMACOLOGY},
Year = {2018},
Volume = {142},
Number = {SI},
Pages = {72-82},
Month = {NOV},
Abstract = {Ketamine is a dissociative anaesthetic drug which acts on the central
   nervous system chiefly through antagonism of the n-methyl-d-aspartate
   (NMDA) receptor. Recently, ketamine has attracted attention as a
   rapid-acting anti-depressant but other studies have also reported its
   efficacy in reducing problematic alcohol and drug use. This review
   explores the preclinical and clinical research into ketamine's ability
   to treat addiction. Despite methodological limitations and the relative
   infancy of the field, results thus far are promising. Ketamine has been
   shown to effectively prolong abstinence from alcohol and heroin in
   detoxified alcoholics and heroin dependent individuals, respectively.
   Moreover, ketamine reduced craving for and self-administration of
   cocaine in non-treatment seeking cocaine users. However, further
   randomised controlled trials are urgently needed to confirm ketamine's
   efficacy. Possible mechanisms by which ketamine may work within
   addiction include: enhancement of neuroplasticity and neurogenesis,
   disruption of relevant functional neural networks, treating depressive
   symptoms, blocking reconsolidation of drug-related memories, provoking
   mystical experiences and enhancing psychological therapy efficacy.
   Identifying the mechanisms by which ketamine exerts its therapeutic
   effects in addiction, from the many possible candidates, is crucial for
   advancing this treatment and may have broader implications understanding
   other psychedelic therapies. In conclusion, ketamine shows great promise
   as a treatment for various addictions, but well-controlled research is
   urgently needed.
   This article is part of the Special Issue entitled `Psychedelics: New
   Doors, Altered Perceptions'. (C) 2018 Published by Elsevier Ltd.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Morgan, CJA (Corresponding Author), Univ Exeter, Psychopharmacol \& Addict Res Ctr, Exeter, Devon, England.
   Ezquerra-Romano, I. Ivan, UCL, Dept Neurosci Physiol \& Pharmacol, Gower St, London, England.
   Lawn, W.; Morgan, C. J. A., UCL, Clin Psychopharmacol Unit, Gower St, London, England.
   Krupitsky, E., St Petersburg Pavlov State Med Univ, St Petersburg, Russia.
   Krupitsky, E., Bekhterev Res Psychoneurol Inst, St Petersburg, Russia.
   Morgan, C. J. A., Univ Exeter, Psychopharmacol \& Addict Res Ctr, Exeter, Devon, England.},
DOI = {10.1016/j.neuropharm.2018.01.017},
ISSN = {0028-3908},
EISSN = {1873-7064},
Keywords = {Ketamine; Addiction treatment; Alcohol use disorder; Neurogenesis;
   Psychedelic therapy},
Keywords-Plus = {METHYL-D-ASPARTATE; POSITRON-EMISSION-TOMOGRAPHY; ADULT HIPPOCAMPAL
   NEUROGENESIS; NATIONAL EPIDEMIOLOGIC SURVEY; MAJOR DEPRESSIVE DISORDER;
   MYSTICAL-TYPE EXPERIENCES; NMDA RECEPTOR ANTAGONIST; LOW-DOSE KETAMINE;
   SUBANESTHETIC KETAMINE; DOUBLE-BLIND},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Neurosciences; Pharmacology \& Pharmacy},
Author-Email = {celia.morgan@exeter.ac.uk},
Affiliations = {University of London; University College London; University of London;
   University College London; Pavlov First Saint Petersburg State Medical
   University; V.M. Bekhterev National Research Medical Center Psychiatry
   \& Neurology; University of Exeter},
ResearcherID-Numbers = {Krupitsky, Evgeny/M-5935-2016
   },
ORCID-Numbers = {Lawn, Will/0000-0002-0143-2724
   Krupitsky, Evgeny/0000-0002-0529-4525
   Morgan, Celia/0000-0002-8858-4906},
Funding-Acknowledgement = {MRC {[}MR/L023032/1]; HVC; MRC {[}MR/L023032/1] Funding Source: UKRI},
Funding-Text = {This work was funded by an MRC grant (MR/L023032/1) to CJAM and HVC.},
Cited-References = {Alberini CM, 2013, CURR BIOL, V23, pR746, DOI 10.1016/j.cub.2013.06.046.
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI {[}DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596].
   Angelucci F, 2007, J PSYCHOPHARMACOL, V21, P820, DOI 10.1177/0269881107078491.
   {[}Anonymous], 2001, KETAMINE DREAMS REAL.
   {[}Anonymous], 2012, PSYCHEDELIC RENAISSA.
   Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130.
   Ballard ED, 2014, J PSYCHIATR RES, V58, P161, DOI 10.1016/j.jpsychires.2014.07.027.
   Barney W., 1977, SAN FR EXAM, V24.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Berti M, 2009, CURR DRUG TARGETS, V10, P707, DOI 10.2174/138945009788982496.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bonhomme V, 2016, ANESTHESIOLOGY, V125, P873, DOI 10.1097/ALN.0000000000001275.
   Cai YC, 1997, MOL PHARMACOL, V51, P583, DOI 10.1124/mol.51.4.583.
   Canbay O, 2008, BRIT J ANAESTH, V100, P490, DOI 10.1093/bja/aen023.
   Carhart-Harris RL, 2016, P NATL ACAD SCI USA, V113, P4853, DOI 10.1073/pnas.1518377113.
   Carhart-Harris RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00020.
   Carhart-Harris RL, 2012, P NATL ACAD SCI USA, V109, P2138, DOI 10.1073/pnas.1119598109.
   Carstensen M, 2010, BRIT J ANAESTH, V104, P401, DOI 10.1093/bja/aeq041.
   Chambers RA, 2013, DRUG ALCOHOL DEPEN, V130, P1, DOI 10.1016/j.drugalcdep.2012.12.005.
   Clarke H, 2011, PHYSIOTHER CAN, V63, P289, DOI 10.3138/ptc.2009-49P.
   CLEMENTS JA, 1982, J PHARM SCI, V71, P539, DOI 10.1002/jps.2600710516.
   COLLIER BB, 1972, ANAESTHESIA, V27, P120, DOI 10.1111/j.1365-2044.1972.tb08186.x.
   Constantinou N, 2010, DRUG ALCOHOL DEPEN, V109, P220, DOI 10.1016/j.drugalcdep.2010.01.012.
   Corlett PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065088.
   Corominas-Roso M, 2013, EUR NEUROPSYCHOPHARM, V23, P1078, DOI 10.1016/j.euroneuro.2012.08.016.
   Curran HV, 2016, NAT REV NEUROSCI, V17, P293, DOI 10.1038/nrn.2016.28.
   Dakwar E, 2017, MOL PSYCHIATR, V22, P76, DOI 10.1038/mp.2016.39.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Dakwar E, 2014, BIOL PSYCHIAT, V76, P40, DOI 10.1016/j.biopsych.2013.08.009.
   Das RK, 2015, PSYCHOPHARMACOLOGY, V232, P3363, DOI 10.1007/s00213-015-3990-2.
   Das RK, 2013, NEUROSCI BIOBEHAV R, V37, P240, DOI 10.1016/j.neubiorev.2012.11.018.
   DiazGranados N, 2010, J CLIN PSYCHIAT, V71, P1605, DOI 10.4088/JCP.09m05327blu.
   Domino EF, 2010, ANESTHESIOLOGY, V113, P678, DOI 10.1097/ALN.0b013e3181ed09a2.
   DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279.
   Driesen NR, 2013, MOL PSYCHIATR, V18, P1199, DOI 10.1038/mp.2012.194.
   Duman RS, 2016, NAT MED, V22, P238, DOI 10.1038/nm.4050.
   Duncan WC, 2013, INT J NEUROPSYCHOPH, V16, P301, DOI 10.1017/S1461145712000545.
   Ebert B, 1997, EUR J PHARMACOL, V333, P99, DOI 10.1016/S0014-2999(97)01116-3.
   Enderle AK, 2008, VET ANAESTH ANALG, V35, P297, DOI 10.1111/j.1467-2995.2007.00391.x.
   Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044.
   Fattore L, 2018, PSYCHOPHARMACOLOGY, V235, P433, DOI 10.1007/s00213-017-4793-4.
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Garg R, 2012, INDIAN J PALLIAT CAR, V18, P155, DOI 10.4103/0973-1075.105684.
   Giese K.P., 2012, MEMORY MECH HLTH DIS.
   Goulart BK, 2010, NEUROSCIENCE, V167, P969, DOI 10.1016/j.neuroscience.2010.03.032.
   Gowing LR, 2015, ADDICTION, V110, P904, DOI 10.1111/add.12899.
   Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807.
   Greenfield SF, 1998, ARCH GEN PSYCHIAT, V55, P259, DOI 10.1001/archpsyc.55.3.259.
   Griffiths RR, 2008, J PSYCHOPHARMACOL, V22, P621, DOI 10.1177/0269881108094300.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Grof S., 1985, BRAIN BIRTH DEATH TR.
   Haile CN, 2014, INT J NEUROPSYCHOPH, V17, P331, DOI 10.1017/S1461145713001119.
   HANSEN G, 1988, J PSYCHOACTIVE DRUGS, V20, P419, DOI 10.1080/02791072.1988.10472511.
   Harmer Catherine J, 2013, Philos Trans R Soc Lond B Biol Sci, V368, P20120407, DOI 10.1098/rstb.2012.0407.
   Hasin DS, 2005, ARCH GEN PSYCHIAT, V62, P1097, DOI 10.1001/archpsyc.62.10.1097.
   Hoffer A., 1967, PROGRAM TREATMENT AL.
   Huang H, 2016, NEUROTOX RES, V30, P185, DOI 10.1007/s12640-016-9615-7.
   Huge V, 2010, EUR J PAIN, V14, P387, DOI 10.1016/j.ejpain.2009.08.002.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515.
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403.
   Kavalali ET, 2015, CURR OPIN PHARMACOL, V20, P35, DOI 10.1016/j.coph.2014.11.005.
   Keilhoff G, 2004, BIOL PSYCHIAT, V56, P317, DOI 10.1016/j.biopsych.2004.06.010.
   Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095.
   Kolp E., 2009, PRAEGER INT COLLECTI, V3, P403.
   Kolp E., 2014, INT J TRANSPERS STUD, V33, P84, DOI {[}DOI 10.24972/IJTS.2014.33.2.84, https://doi.org/10.24972/ijts.2014.33.2.84].
   Kolp E., 2007, INT J TRANSPERS STUD, V26.
   Kolp E., 2006, HUMANISTIC PSYCHOL, V34, P399, DOI DOI 10.1207/S15473333THP3404\_7.
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110.
   Krebs TS, 2012, J PSYCHOPHARMACOL, V26, P994, DOI 10.1177/0269881112439253.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky E.M., 1992, MULTIDISCIPLINARY AS, V3, P24.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Krystal JH, 1999, PSYCHOPHARMACOLOGY, V145, P193, DOI 10.1007/s002130051049.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Krystal JH, 2000, BIOL PSYCHIAT, V47, P137, DOI 10.1016/S0006-3223(99)00097-9.
   Krystal JH, 1998, PSYCHOPHARMACOLOGY, V135, P213, DOI 10.1007/s002130050503.
   Krystal JH, 2013, BIOL PSYCHIAT, V73, P1133, DOI 10.1016/j.biopsych.2013.03.026.
   Kubota T, 1999, PSYCHOPHARMACOLOGY, V146, P335, DOI 10.1007/s002130051125.
   Kurdi Madhuri S, 2014, Anesth Essays Res, V8, P283, DOI 10.4103/0259-1162.143110.
   Lapidus KAB, 2014, BIOL PSYCHIAT, V76, P970, DOI 10.1016/j.biopsych.2014.03.026.
   Larkin GL, 2011, INT J NEUROPSYCHOPH, V14, P1127, DOI 10.1017/S1461145711000629.
   Lee JLC, 2006, J NEUROSCI, V26, P5881, DOI 10.1523/JNEUROSCI.0323-06.2006.
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007.
   Lee Jonathan L C, 2009, Trends Neurosci, V32, P413, DOI 10.1016/j.tins.2009.05.002.
   Lener MS, 2017, DRUGS, V77, P381, DOI 10.1007/s40265-017-0702-8.
   Lepack AE, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu033.
   LEWIS DJ, 1979, PSYCHOL BULL, V86, P1054, DOI 10.1037/0033-2909.86.5.1054.
   Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287.
   Lingford-Hughes AR, 2012, J PSYCHOPHARMACOL, V26, P899, DOI 10.1177/0269881112444324.
   Lydic R, 2002, SLEEP, V25, P617.
   Machado-Vieira R, 2009, PHARMACOL THERAPEUT, V123, P143, DOI 10.1016/j.pharmthera.2009.02.010.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   Mandyam CD, 2012, TRENDS NEUROSCI, V35, P250, DOI 10.1016/j.tins.2011.12.005.
   Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9.
   Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761.
   McAndrew A, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1895-6.
   McGirr A, 2015, PSYCHOL MED, V45, P693, DOI 10.1017/S0033291714001603.
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689.
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006.
   Moghaddam B, 1997, J NEUROSCI, V17, P2921.
   Morgan C, 2017, CURR OPIN BEHAV SCI, V13, P71, DOI 10.1016/j.cobeha.2016.10.009.
   Morgan CJA, 2012, ADDICTION, V107, P27, DOI 10.1111/j.1360-0443.2011.03576.x.
   Morgan CJA, 2004, PSYCHOPHARMACOLOGY, V172, P298, DOI 10.1007/s00213-003-1656-y.
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052.
   Niesters M, 2012, ANESTHESIOLOGY, V117, P868, DOI 10.1097/ALN.0b013e31826a0db3.
   Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010.
   O'Brien CP, 2005, PHARMACOL THERAPEUT, V108, P18, DOI 10.1016/j.pharmthera.2005.06.018.
   O'Hara D, 2014, BURNS, V40, P48, DOI 10.1016/j.burns.2013.08.021.
   Ota KT, 2013, NEUROBIOL DIS, V57, P28, DOI 10.1016/j.nbd.2012.05.022.
   OYE I, 1992, J PHARMACOL EXP THER, V260, P1209.
   Parwani A, 2005, PSYCHOPHARMACOLOGY, V183, P265, DOI 10.1007/s00213-005-0177-2.
   Paul RK, 2014, ANESTHESIOLOGY, V121, P149, DOI 10.1097/ALN.0000000000000285.
   Peterbauer C, 2008, VET ANAESTH ANALG, V35, P414, DOI 10.1111/j.1467-2995.2008.00402.x.
   Pettinati HM, 2004, BIOL PSYCHIAT, V56, P785, DOI 10.1016/j.biopsych.2004.07.016.
   Price RB, 2009, BIOL PSYCHIAT, V66, P522, DOI 10.1016/j.biopsych.2009.04.029.
   Quello Susan B, 2005, Sci Pract Perspect, V3, P13.
   Ren Q, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.157.
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1.
   Sabino V, 2013, BEHAV BRAIN RES, V247, P9, DOI 10.1016/j.bbr.2013.02.030.
   Scheidegger M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044799.
   Scheller M, 1996, ANESTH ANALG, V83, P830, DOI 10.1097/00000539-199610000-00031.
   Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107.
   Singh I, 2017, LANCET PSYCHIAT, V4, P419, DOI 10.1016/S2215-0366(17)30102-5.
   Singh JB, 2016, AM J PSYCHIAT, V173, P816, DOI 10.1176/appi.ajp.2016.16010037.
   Sleigh J, 2014, TRENDS ANAESTH CRIT, V4, P76, DOI 10.1016/j.tacc.2014.03.002.
   Sonmez MB, 2016, EUR J PSYCHIAT, V30, P109.
   Sos P, 2013, ACT NERV SUPER REDIV, V55, P57.
   Spadavecchia C, 2002, VET ANAESTH ANALG, V29, P20, DOI 10.1046/j.1467-2987.2001.00060.x.
   STRASSMAN RJ, 1995, J NERV MENT DIS, V183, P127, DOI 10.1097/00005053-199503000-00002.
   Sunder RA, 2008, J BRACHIAL PLEX PERI, V3, DOI 10.1186/1749-7221-3-22.
   Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28.
   Tronson NC, 2007, NAT REV NEUROSCI, V8, P262, DOI 10.1038/nrn2090.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P25, DOI 10.1016/S0924-977X(96)00042-9.
   Vollenweider FX, 1997, NEUROPSYCHOPHARMACOL, V16, P357, DOI 10.1016/S0893-133X(96)00246-1.
   Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P9, DOI 10.1016/S0924-977X(96)00039-9.
   Wang JH, 2006, NEUROSCIENCE, V140, P993, DOI 10.1016/j.neuroscience.2006.02.062.
   Wang M, 2012, BRAIN RES, V1476, P154, DOI 10.1016/j.brainres.2012.03.029.
   White Aaron M, 2004, Subst Abus, V25, P53, DOI 10.1300/J465v25n01\_08.
   WHO, 2015, WHO REC INT CONTR KE.
   Willinger U, 2002, ALCOHOL ALCOHOLISM, V37, P609, DOI 10.1093/alcalc/37.6.609.
   Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018.
   WSAVA, 2016, WSAVA GLOB PAIN COUN.
   Xue YX, 2012, SCIENCE, V336, P241, DOI 10.1126/science.1215070.
   Zanardini R, 2011, ALCOHOL CLIN EXP RES, V35, P1529, DOI 10.1111/j.1530-0277.2011.01489.x.
   Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zhai HF, 2008, BEHAV PHARMACOL, V19, P211, DOI 10.1097/FBP.0b013e3282fe88a0.
   Zhang JC, 2014, PHARMACOL BIOCHEM BE, V116, P137, DOI 10.1016/j.pbb.2013.11.033.
   Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033.},
Number-of-Cited-References = {153},
Times-Cited = {58},
Usage-Count-Last-180-days = {7},
Usage-Count-Since-2013 = {63},
Journal-ISO = {Neuropharmacology},
Doc-Delivery-Number = {HE6FD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000453497800007},
OA = {Green Submitted, Green Accepted},
DA = {2023-07-30},
}

@article{ WOS:000779166500001,
Author = {Ragnhildstveit, Anya and Slayton, Matthew and Jackson, Laura Kate and
   Brendle, Madeline and Ahuja, Sachin and Holle, Willis and Moore, Claire
   and Sollars, Kellie and Seli, Paul and Robison, Reid},
Title = {Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence
   and Future Directions},
Journal = {BRAIN SCIENCES},
Year = {2022},
Volume = {12},
Number = {3},
Month = {MAR},
Abstract = {Eating disorders (EDs) are serious, life-threatening psychiatric
   conditions associated with physical and psychosocial impairment, as well
   as high morbidity and mortality. Given the chronic refractory nature of
   EDs and the paucity of evidence-based treatments, there is a pressing
   need to identify novel approaches for this population. The
   noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist,
   ketamine, has recently been approved for treatment-resistant depression,
   exerting rapid and robust antidepressant effects. It is now being
   investigated for several new indications, including
   obsessive-compulsive, post-traumatic, and substance use disorder, and
   shows transdiagnostic potential for EDs, particularly among clinical
   nonresponders. Hence, the aim of this review is to examine contemporary
   findings on the treatment of EDs with ketamine, whether used as a
   primary, adjunctive, or combination psychopharmacotherapy. Avenues for
   future research are also discussed. Overall, results are encouraging and
   point to therapeutic value; however, are limited to case series and
   reports on anorexia nervosa. Further empirical research is thus needed
   to explore ketamine efficacy across ED subgroups, establish safety
   profiles and optimize dosing, and develop theory-driven, targeted
   treatment strategies at the individual patient level.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ragnhildstveit, A (Corresponding Author), Duke Univ, Dept Psychol \& Neurosci, Durham, NC 27708 USA.
   Ragnhildstveit, A (Corresponding Author), Integrated Res Literacy Grp, Draper, UT 84020 USA.
   Ragnhildstveit, Anya; Slayton, Matthew, Duke Univ, Dept Psychol \& Neurosci, Durham, NC 27708 USA.
   Ragnhildstveit, Anya; Slayton, Matthew; Jackson, Laura Kate; Brendle, Madeline; Holle, Willis, Integrated Res Literacy Grp, Draper, UT 84020 USA.
   Jackson, Laura Kate; Brendle, Madeline; Ahuja, Sachin; Moore, Claire; Sollars, Kellie; Robison, Reid, Novamind, Draper, UT 84020 USA.
   Brendle, Madeline, Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT 84112 USA.
   Robison, Reid, Univ Utah, Dept Psychiat, Sch Med, Salt Lake City, UT 84108 USA.},
DOI = {10.3390/brainsci12030382},
Article-Number = {382},
EISSN = {2076-3425},
Keywords = {esketamine; ketamine; ketamine-assisted psychotherapy; eating disorder;
   anorexia nervosa; bulimia nervosa; binge eating disorder; pharmacology;
   psychedelics; treatment},
Keywords-Plus = {QUALITY-OF-LIFE; TREATMENT-RESISTANT DEPRESSION; STATE FUNCTIONAL
   CONNECTIVITY; COGNITIVE-BEHAVIOR THERAPY; D-ASPARTATE ANTAGONIST;
   DEFAULT MODE NETWORK; ANOREXIA-NERVOSA; INTRAVENOUS KETAMINE;
   BULIMIA-NERVOSA; BIPOLAR DEPRESSION},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {anya.ragnhildstveit@duke.edu
   matthew.slayton@duke.edu
   ljackson@cedarpsychiatry.com
   mbrendle@cedarclinicalresearch.com
   sachin@novamind.ca
   willis.holle@irlg.org
   claire@novamind.ca
   ksollars@cedarpsychiatry.com
   paul.seli@duke.edu
   reid@novamind.ca},
Affiliations = {Duke University; Utah System of Higher Education; University of Utah;
   Utah System of Higher Education; University of Utah},
ResearcherID-Numbers = {Brendle, Madeline/HKM-9736-2023
   },
ORCID-Numbers = {Ragnhildstveit, Anya/0000-0002-5796-3428
   Brendle, Madeline/0000-0003-0692-3706},
Cited-References = {ADAMS JD, 1978, P W PHARMACOL SOC, V21, P471.
   Agh T, 2016, EAT WEIGHT DISORD-ST, V21, P353, DOI 10.1007/s40519-016-0264-x.
   Agras WS, 2014, JAMA PSYCHIAT, V71, P1279, DOI 10.1001/jamapsychiatry.2014.1025.
   Allen KL, 2013, J ABNORM PSYCHOL, V122, P720, DOI 10.1037/a0034004.
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI {[}DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596].
   {[}Anonymous], 2011, J AM DIET ASSOC, V111, P1236, DOI 10.1016/j.jada.2011.06.016.
   Appolinario JC, 2019, EXPERT OPIN INV DRUG, V28, P1081, DOI 10.1080/13543784.2019.1692813.
   Arcelus J, 2011, ARCH GEN PSYCHIAT, V68, P724, DOI 10.1001/archgenpsychiatry.2011.74.
   Aroke EN, 2017, NURS RES, V66, P105, DOI 10.1097/NNR.0000000000000197.
   Asim M, 2021, NEUROCHEM INT, V146, DOI 10.1016/j.neuint.2021.105044.
   Attia E, 2019, AM J PSYCHIAT, V176, P449, DOI 10.1176/appi.ajp.2018.18101125.
   Ayton AK, 2004, PROSTAG LEUKOTR ESS, V71, P205, DOI 10.1016/j.plefa.2004.03.007.
   Basso L, 2020, J PSYCHIATR RES, V123, P1, DOI 10.1016/j.jpsychires.2020.01.002.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Biezonski D, 2016, NEUROPSYCHOPHARMACOL, V41, P1560, DOI 10.1038/npp.2015.314.
   BION JF, 1984, ANAESTHESIA, V39, P560, DOI 10.1111/j.1365-2044.1984.tb07362.x.
   Birmingham CL, 2005, INT J EAT DISORDER, V38, P143, DOI 10.1002/eat.20164.
   Blanchet C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020278.
   Boehm I, 2016, J PSYCHIATR NEUROSCI, V41, P377, DOI 10.1503/jpn.150259.
   Boehm I, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00346.
   Brewerton TD, 2022, J PSYCHIATR RES, V149, P128, DOI 10.1016/j.jpsychires.2022.03.008.
   Cardi V, 2018, CURR NEUROPHARMACOL, V16, P1122, DOI 10.2174/1570159X16666180118100028.
   Castro-Fornieles J, 2021, EUR ARCH PSY CLIN N, V271, P1133, DOI 10.1007/s00406-019-00992-4.
   Cha J, 2016, HUM BRAIN MAPP, V37, P3835, DOI 10.1002/hbm.23279.
   Chang CH, 2019, J PSYCHOPHARMACOL, V33, P436, DOI 10.1177/0269881118822157.
   Conley AA, 2021, PSYCHOPHARMACOLOGY, V238, P1737, DOI 10.1007/s00213-021-05825-8.
   Cowdrey FA, 2014, HUM BRAIN MAPP, V35, P483, DOI 10.1002/hbm.22202.
   Crow SJ, 2009, AM J PSYCHIAT, V166, P1342, DOI 10.1176/appi.ajp.2009.09020247.
   Daly EJ, 2019, JAMA PSYCHIAT, V76, P893, DOI 10.1001/jamapsychiatry.2019.1189.
   Davis AK, 2021, J PSYCHEDELIC STUD, V5, P94, DOI 10.1556/2054.2021.00179.
   de Jong M, 2018, CURR OPIN PSYCHIATR, V31, P436, DOI 10.1097/YCO.0000000000000452.
   Dechant E., 2020, J WOMENS HLTH DEV, V3, P373, DOI 10.26502/fjwhd.2644-28840044.
   Deloitte Access Economics, SOC EC COST EAT DIS.
   Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90.
   Dold M, 2015, PSYCHOTHER PSYCHOSOM, V84, P110, DOI 10.1159/000369978.
   Domakonda MJ, 2019, J AM ACAD CHILD PSY, V58, P232, DOI 10.1016/j.jaac.2018.09.433.
   Domino EF, 2010, ANESTHESIOLOGY, V113, P678, DOI 10.1097/ALN.0b013e3181ed09a2.
   DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   DUNDEE JW, 1970, LANCET, V1, P1370.
   Ebert B, 1997, EUR J PHARMACOL, V333, P99, DOI 10.1016/S0014-2999(97)01116-3.
   Eddy KT, 2017, J CLIN PSYCHIAT, V78, P184, DOI 10.4088/JCP.15m10393.
   Ehrlich S, 2015, HUM BRAIN MAPP, V36, P1772, DOI 10.1002/hbm.22736.
   Eisler I, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1129-6.
   Ernst J, 2014, SOC COGN AFFECT NEUR, V9, P857, DOI 10.1093/scan/nst058.
   Erskine HE, 2016, CURR OPIN PSYCHIATR, V29, P346, DOI 10.1097/YCO.0000000000000276.
   Fedgchin M, 2019, INT J NEUROPSYCHOPH, V22, P616, DOI 10.1093/ijnp/pyz039.
   Fichter MM, 2008, INT J EAT DISORDER, V41, P577, DOI 10.1002/eat.20539.
   Fichter MM, 2017, INT J EAT DISORDER, V50, P1018, DOI 10.1002/eat.22736.
   Finch JE, 2021, PSYCHIAT RES-NEUROIM, V317, DOI 10.1016/j.pscychresns.2021.111379.
   Frank GKW, 2019, CHILD ADOL PSYCH CL, V28, P629, DOI 10.1016/j.chc.2019.05.007.
   Frank GKW, 2019, CURR OPIN PSYCHIATR, V32, P478, DOI 10.1097/YCO.0000000000000544.
   Frank GKW, 2018, INT J EAT DISORDER, V51, P250, DOI 10.1002/eat.22829.
   Frank GKW, 2017, INT J EAT DISORDER, V50, P447, DOI 10.1002/eat.22704.
   Franko DL, 2013, AM J PSYCHIAT, V170, P917, DOI 10.1176/appi.ajp.2013.12070868.
   Galmiche M, 2019, AM J CLIN NUTR, V109, P1402, DOI 10.1093/ajcn/nqy342.
   Gaudio S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10818.
   Geisler D, 2016, J PSYCHIATR NEUROSCI, V41, P6, DOI 10.1503/jpn.140310.
   Halstead M, 2021, CLIN CASE STUD, V20, P310, DOI 10.1177/1534650121990894.
   Hans-Christoph F., 2019, ANOREXIA NERVOSA FOC.
   Harding F, 2021, J INTEGR NEUROSCI, V20, P551, DOI 10.31083/j.jin2003059.
   Hart S, 2011, J HUM NUTR DIET, V24, P144, DOI 10.1111/j.1365-277X.2010.01140.x.
   Hart S, 2018, J EAT DISORD, V6, DOI 10.1186/s40337-018-0192-4.
   Hasler G, 2020, CNS SPECTRUMS, V25, P445, DOI 10.1017/S1092852919001007.
   Hay P, 2017, J EAT DISORD, V5, DOI 10.1186/s40337-017-0149-z.
   Hay P, 2015, J EAT DISORD, V3, DOI 10.1186/s40337-015-0056-0.
   Hay P, 2014, AUST NZ J PSYCHIAT, V48, P977, DOI 10.1177/0004867414555814.
   Hay PJ, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010827.pub2.
   Haynos AF, 2019, HUM BRAIN MAPP, V40, P652, DOI 10.1002/hbm.24402.
   Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295.
   Heruc G, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-00334-z.
   Hilbert A, 2017, CURR OPIN PSYCHIATR, V30, P423, DOI 10.1097/YCO.0000000000000360.
   Himmerich H., 2021, KOMPENDIUM PSYCHIAT, P739.
   Himmerich H, 2021, PHARMACOL THERAPEUT, V217, DOI 10.1016/j.pharmthera.2020.107667.
   HOLMAN RT, 1995, J NUTR, V125, P901.
   Hu YD, 2016, PSYCHOL MED, V46, P623, DOI 10.1017/S0033291715002159.
   Ionescu DF, 2015, BIPOLAR DISORD, V17, P438, DOI 10.1111/bdi.12277.
   ITO Y, 1974, ANAESTHESIA, V29, P222, DOI 10.1111/j.1365-2044.1974.tb00626.x.
   Jelen LA, 2021, J PSYCHOPHARMACOL, V35, P109, DOI 10.1177/0269881120959644.
   Kheirabadi G, 2019, ADV BIOMED RES-INDIA, V8, DOI 10.4103/abr.abr\_166\_18.
   Kim KR, 2012, NEUROSCI LETT, V521, P152, DOI 10.1016/j.neulet.2012.05.075.
   King JA, 2018, BIOL PSYCHIAT, V83, P224, DOI 10.1016/j.biopsych.2017.08.011.
   Kishimoto T, 2016, PSYCHOL MED, V46, P1459, DOI 10.1017/S0033291716000064.
   Kotilahti E, 2020, INT J EAT DISORDER, V53, P1280, DOI 10.1002/eat.23322.
   Krupitsky E.M., 2001, MAPS B, V9, P21.
   Kryst J, 2020, PHARMACOL REP, V72, P543, DOI 10.1007/s43440-020-00097-z.
   Krystal JH, 2019, NEURON, V101, P774, DOI 10.1016/j.neuron.2019.02.005.
   Kullmann S, 2014, NEUROIMAGE-CLIN, V4, P615, DOI 10.1016/j.nicl.2014.04.002.
   Le Grange D, 2016, J AM ACAD CHILD PSY, V55, P683, DOI 10.1016/j.jaac.2016.05.007.
   Lee S, 2014, PSYCHIAT RES-NEUROIM, V221, P43, DOI 10.1016/j.pscychresns.2013.11.004.
   Lener MS, 2017, BIOL PSYCHIAT, V81, P886, DOI 10.1016/j.biopsych.2016.05.005.
   Li DJ, 2017, EUR NEUROPSYCHOPHARM, V27, P29, DOI 10.1016/j.euroneuro.2016.11.008.
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   Madden S, 2009, MED J AUSTRALIA, V190, P410, DOI 10.5694/j.1326-5377.2009.tb02487.x.
   Marcantoni WS, 2020, J AFFECT DISORDERS, V277, P831, DOI 10.1016/j.jad.2020.09.007.
   Martinotti G, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11070856.
   Matveychuk D, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320916657.
   McElroy SL, 2019, CNS DRUGS, V33, P31, DOI 10.1007/s40263-018-0594-5.
   McFadden KL, 2014, J PSYCHIATR NEUROSCI, V39, P178, DOI 10.1503/jpn.130046.
   McIntosh VVW, 2005, AM J PSYCHIAT, V162, P741, DOI 10.1176/appi.ajp.162.4.741.
   McMaster CM, 2021, NUTR REV, V79, P914, DOI 10.1093/nutrit/nuaa105.
   McMaster CM, 2021, EAT WEIGHT DISORD-ST, V26, P1467, DOI 10.1007/s40519-020-00955-y.
   McMaster CM, 2020, INT J EAT DISORDER, V53, P1480, DOI 10.1002/eat.23330.
   McMullen EP, 2021, ADV THER, V38, P2795, DOI 10.1007/s12325-021-01732-8.
   Mehler PS, 2015, J EAT DISORD, V3, DOI 10.1186/s40337-015-0044-4.
   Mehler PS, 2015, J EAT DISORD, V3, DOI 10.1186/s40337-015-0040-8.
   Mills IH, 1998, QJM-MON J ASSOC PHYS, V91, P493, DOI 10.1093/qjmed/91.7.493.
   Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099.
   Mitchell JE, 2020, NEW ENGL J MED, V382, P1343, DOI 10.1056/NEJMcp1803175.
   Mitchison D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048450.
   Mond J, 2012, AUST NZ J PSYCHIAT, V46, P561, DOI 10.1177/0004867411433967.
   Monteleone AM, 2018, PROG NEURO-PSYCHOPH, V80, P132, DOI 10.1016/j.pnpbp.2017.02.020.
   Nakazato M, 2010, ANN GEN PSYCHIATR, V9, DOI 10.1186/1744-859X-9-29.
   Newport DJ, 2015, AM J PSYCHIAT, V172, P950, DOI 10.1176/appi.ajp.2015.15040465.
   Papadopoulos FC, 2009, BRIT J PSYCHIAT, V194, P10, DOI 10.1192/bjp.bp.108.054742.
   Park BY, 2018, BEHAV BRAIN RES, V337, P114, DOI 10.1016/j.bbr.2017.10.001.
   Peat CM, 2017, EUR EAT DISORD REV, V25, P317, DOI 10.1002/erv.2517.
   Peyrovian B, 2020, J PSYCHIATR RES, V127, P1, DOI 10.1016/j.jpsychires.2020.03.020.
   Qian J, 2022, EAT WEIGHT DISORD-ST, V27, P415, DOI 10.1007/s40519-021-01162-z.
   Quadflieg N, 2019, INT J EAT DISORDER, V52, P834, DOI 10.1002/eat.23084.
   Ragnhildstveit A, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.764112.
   Rangaprakash D, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00273.
   Ren L, 2018, J PSYCHIATR RES, V104, P144, DOI 10.1016/j.jpsychires.2018.07.003.
   Renelli M, 2020, EAT WEIGHT DISORD-ST, V25, P437, DOI 10.1007/s40519-018-0619-6.
   Robinson P, SEVERE ENDURING EATI.
   Satogami K, 2019, PROSTAG LEUKOTR ESS, V142, P11, DOI 10.1016/j.plefa.2019.01.001.
   Schmidt U., 2018, COGNITIVE INTERPERSO.
   Schmidt U, 2016, LANCET PSYCHIAT, V3, P313, DOI 10.1016/S2215-0366(16)00081-X.
   Schmidt U, 2015, J CONSULT CLIN PSYCH, V83, P796, DOI 10.1037/ccp0000019.
   Schwartz T, 2021, CLIN CASE REP, V9, DOI 10.1002/ccr3.3869.
   Scolnick B, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00763.
   Sheehan David V, 2015, Prim Care Companion CNS Disord, V17, DOI 10.4088/PCC.14r01732.
   Shih PB, 2016, MOL PSYCHIATR, V21, P537, DOI 10.1038/mp.2015.26.
   Siegel AN, 2021, J PSYCHIATR RES, V139, P71, DOI 10.1016/j.jpsychires.2021.05.019.
   Sleigh J, 2014, TRENDS ANAESTH CRIT, V4, P76, DOI 10.1016/j.tacc.2014.03.002.
   Smink FRE, 2012, CURR PSYCHIAT REP, V14, P406, DOI 10.1007/s11920-012-0282-y.
   Spriggs MJ, 2021, EAT WEIGHT DISORD-ST, V26, P1265, DOI 10.1007/s40519-020-01000-8.
   Spriggs MJ, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.735523.
   Steinhausen HC, 2009, AM J PSYCHIAT, V166, P1331, DOI 10.1176/appi.ajp.2009.09040582.
   Steinhausen HC, 2002, AM J PSYCHIAT, V159, P1284, DOI 10.1176/appi.ajp.159.8.1284.
   Stippl A, 2021, J PSYCHIATR RES, V136, P402, DOI 10.1016/j.jpsychires.2021.02.028.
   Stopyra MA, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1207.
   Strand M, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00472-8.
   Strasburger SE, 2017, J CLIN PHARM THER, V42, P147, DOI 10.1111/jcpt.12497.
   Strober M, 2012, INT J EAT DISORDER, V45, P155, DOI 10.1002/eat.22005.
   Strong CE, 2020, FRONT BEHAV NEUROSCI, V14, DOI 10.3389/fnbeh.2020.593860.
   Svaldi J, 2019, PSYCHOL MED, V49, P898, DOI 10.1017/S0033291718003525.
   Touyz S, 2013, PSYCHOL MED, V43, P2501, DOI 10.1017/S0033291713000949.
   Treasure J, 2020, LANCET, V395, P899, DOI 10.1016/S0140-6736(20)30059-3.
   Treasure J, 2015, EARLY INTERV PSYCHIA, V9, P173, DOI 10.1111/eip.12170.
   van den Berg E, 2019, EUR EAT DISORD REV, V27, P331, DOI 10.1002/erv.2683.
   van Hoeken D, 2020, CURR OPIN PSYCHIATR, V33, P521, DOI 10.1097/YCO.0000000000000641.
   Veraart JKE, 2021, J AFFECT DISORDERS, V281, P82, DOI 10.1016/j.jad.2020.11.123.
   Vocks S, 2010, INT J EAT DISORDER, V43, P205, DOI 10.1002/eat.20696.
   Walsh Z, 2021, BJPSYCH OPEN, V8, DOI 10.1192/bjo.2021.1061.
   Watson HJ, 2019, NAT GENET, V51, P1207, DOI 10.1038/s41588-019-0439-2.
   Westmoreland P, 2016, J PSYCHIATR PRACT, V22, P313, DOI 10.1097/PRA.0000000000000160.
   WHITE PF, 1980, ANESTHESIOLOGY, V52, P231, DOI 10.1097/00000542-198003000-00008.
   WHITE PF, 1985, BRIT J ANAESTH, V57, P197, DOI 10.1093/bja/57.2.197.
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Wonderlich S, 2012, INT J EAT DISORDER, V45, P467, DOI 10.1002/eat.20978.
   Xiong JQ, 2021, J PSYCHIATR RES, V134, P57, DOI 10.1016/j.jpsychires.2020.12.038.
   Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zarate CA, 2012, BIOL PSYCHIAT, V71, P939, DOI 10.1016/j.biopsych.2011.12.010.
   Zheng W, 2019, J AFFECT DISORDERS, V250, P123, DOI 10.1016/j.jad.2019.02.044.
   Zipfel S, 2014, LANCET, V383, P127, DOI 10.1016/S0140-6736(13)61746-8.},
Number-of-Cited-References = {168},
Times-Cited = {6},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Brain Sci.},
Doc-Delivery-Number = {0I1DK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000779166500001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000903672600003,
Author = {Mccartney, Annie M. and Mcgovern, Hugh T. and De Foe, Alexander},
Title = {Psychedelic assisted therapy for major depressive disorder: Recent work
   and clinical directions},
Journal = {JOURNAL OF PSYCHEDELIC STUDIES},
Year = {2022},
Volume = {6},
Number = {1},
Pages = {10-22},
Month = {MAY},
Abstract = {Psychedelic substances such as psilocybin and ketamine may represent the
   future of antidepressant treatment, due to their rapid and prolonged
   effects on mood and cognition. The current body of psychedelic research
   has focused on administration and treatment within a psychiatric
   context. Here, instead, we put to the test the contention that it is
   necessary to evaluate the current state of this literature from a
   broader biopsychosocial perspective. Examining these arguably neglected
   social and psychological aspects of psychedelic treatment can provide a
   more holistic understanding of the interplay between the interconnected
   domains. This review of six major clinical trials applies a
   biopsychosocial model to evaluate the antidepressant effects of
   psilocybin and ketamine assisted therapy. We conclude that combination
   psychedelic treatment and psychotherapy facilitate more enduring and
   profound antidepressant effects than produced by ketamine or psilocybin
   alone. Emphasising the advantages of therapeutic intervention will
   encourage those who may attempt to self-medicate with psychedelics to
   instead seek a framework of psychological support, minimising associated
   risks of unregulated use.},
Publisher = {AKADEMIAI KIADO ZRT},
Address = {BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY},
Type = {Review},
Language = {English},
Affiliation = {Mcgovern, HT (Corresponding Author), Univ Queensland, Brisbane, Australia.
   Mccartney, Annie M.; De Foe, Alexander, RMIT Univ, Melbourne, Australia.
   Mcgovern, Hugh T., Univ Queensland, Brisbane, Australia.},
DOI = {10.1556/2054.2022.00211},
EISSN = {2559-9283},
Keywords = {psychedelics; depression; clinical; therapy; review},
Keywords-Plus = {SUICIDAL IDEATION; KETAMINE USE; PSILOCYBIN; DRUGS; ANTIDEPRESSANTS;
   FUTURE; LONG; PSYCHOTHERAPY; MECHANISMS; GUIDELINES},
Research-Areas = {Pharmacology \& Pharmacy; Psychiatry; Psychology},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy; Psychiatry; Psychology, Multidisciplinary},
Author-Email = {h.mcgovern@uqconnect.edu.au},
Affiliations = {Royal Melbourne Institute of Technology (RMIT); University of Queensland},
ResearcherID-Numbers = {De Foe, Alexander/HLV-6625-2023},
ORCID-Numbers = {De Foe, Alexander/0000-0002-5532-3291},
Cited-References = {Al-Harbi KS, 2012, PATIENT PREFER ADHER, V6, P369, DOI 10.2147/PPA.S29716.
   Aleksandrova LR, 2017, J PSYCHIATR NEUROSCI, V42, P222, DOI 10.1503/jpn.160175.
   Baldwin DS, 2007, INT J NEUROPSYCHOPH, V10, P73, DOI 10.1017/S1461145705006358.
   Ballard ED, 2014, J PSYCHIATR RES, V58, P161, DOI 10.1016/j.jpsychires.2014.07.027.
   Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1038/nrdp.2016.65.
   Belouin SJ, 2018, NEUROPHARMACOLOGY, V142, P7, DOI 10.1016/j.neuropharm.2018.02.018.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Bonson KR, 1996, BEHAV BRAIN RES, V73, P229.
   Bottemanne H., 2021, CAN WE CHANGE DEPRES, DOI {[}10.31234/OSF.IO/ZX5VR, DOI 10.31234/OSF.IO/ZX5VR].
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Carhart-Harris RL, 2017, NEUROPSYCHOPHARMACOL, V42, P2105, DOI 10.1038/npp.2017.84.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Carhart-Harris RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00020.
   Cartwright C, 2016, PATIENT PREFER ADHER, V10, P1401, DOI 10.2147/PPA.S110632.
   Cornwell BR, 2012, BIOL PSYCHIAT, V72, P555, DOI 10.1016/j.biopsych.2012.03.029.
   Cowen PJ, 2015, WORLD PSYCHIATRY, V14, P158, DOI 10.1002/wps.20229.
   Craighead WE, 2014, ANNU REV PSYCHOL, V65, P267, DOI 10.1146/annurev.psych.121208.131653.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   De Gregorio D, 2021, J NEUROSCI, V41, P891, DOI 10.1523/JNEUROSCI.1659-20.2020.
   DiazGranados N, 2010, J CLIN PSYCHIAT, V71, P1605, DOI 10.4088/JCP.09m05327blu.
   Dierker L, 2018, ADDICT BEHAV, V76, P161, DOI 10.1016/j.addbeh.2017.08.013.
   Disner SG, 2011, NAT REV NEUROSCI, V12, P467, DOI 10.1038/nrn3027.
   Domany Y, 2022, ARCH SUICIDE RES, V26, P1250, DOI 10.1080/13811118.2021.1878078.
   Domany Y, 2020, DEPRESS ANXIETY, V37, P224, DOI 10.1002/da.22975.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Duff C, 2005, INT J DRUG POLICY, V16, P161, DOI 10.1016/j.drugpo.2005.02.001.
   Dunlop BW, 2019, AM J PSYCHIAT, V176, P275, DOI 10.1176/appi.ajp.2018.18091075.
   Earleywine M, 2022, J PSYCHOACTIVE DRUGS, V54, P70, DOI 10.1080/02791072.2021.1912863.
   Erritzoe D, 2019, J PSYCHOPHARMACOL, V33, P1068, DOI 10.1177/0269881119827891.
   Featherstone RE, 2012, NEUROBIOL DIS, V47, P338, DOI 10.1016/j.nbd.2012.05.003.
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5.
   Gable RS, 2004, J PSYCHOACTIVE DRUGS, V36, P303, DOI 10.1080/02791072.2004.10400031.
   George JR, 2020, J PSYCHEDELIC STUD, V4, P4, DOI 10.1556/2054.2019.015.
   Gorman I, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.645246.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Gukasyan N, 2022, J PSYCHOPHARMACOL, V36, P151, DOI 10.1177/02698811211073759.
   Hall W, 2021, WORLD PSYCHIATRY, V20, P197, DOI 10.1002/wps.20847.
   Harmer CJ, 2009, BRIT J PSYCHIAT, V195, P102, DOI 10.1192/bjp.bp.108.051193.
   Hashimoto K, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113935.
   Hendawy A.O., 2018, NOV APPRO DRUG DEV, V4, P555636, DOI {[}10.19080/NAPDD.2018.04.555636, DOI 10.19080/NAPDD.2018.04.555636].
   Hutchison C, 2021, CLIN SOC WORK J, V49, P356, DOI 10.1007/s10615-019-00743-x.
   Jakobsen JC, 2020, BMJ EVID-BASED MED, V25, P130, DOI 10.1136/bmjebm-2019-111238.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Kelly Karen, 2008, Dialogues Clin Neurosci, V10, P409.
   Kemprai P, 2020, FLAVOUR FRAG J, V35, P5, DOI 10.1002/ffj.3521.
   Kirkham N, 2022, PHILOS PSYCHOL, DOI 10.1080/09515089.2022.2057290.
   Kolovos S, 2017, J AFFECT DISORDERS, V210, P72, DOI 10.1016/j.jad.2016.12.013.
   Kunst LE, 2018, SUBST USE MISUSE, V53, P2077, DOI 10.1080/10826084.2018.1455700.
   Kupfer DJ, 2012, LANCET, V379, P1045, DOI 10.1016/S0140-6736(11)60602-8.
   Lepow L, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.710004.
   Loizaga-Velder A, 2014, J PSYCHOACTIVE DRUGS, V46, P63, DOI 10.1080/02791072.2013.873157.
   Luo Y, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00035.
   Luoma JB, 2020, J PSYCHOACTIVE DRUGS, V52, P289, DOI 10.1080/02791072.2020.1769878.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   Mahapatra A, 2017, THER ADV PSYCHOPHARM, V7, P54, DOI 10.1177/2045125316676092.
   Marcus M., 2012, DEPRESSION GLOBAL PU, DOI {[}10.1037/e517532013-004, DOI 10.1037/E517532013-004].
   Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438.
   McGovern HT, 2022, PSYCHOPHARMACOLOGY, V239, P1809, DOI 10.1007/s00213-022-06153-1.
   Meikle SE, 2020, AUST NZ J PSYCHIAT, V54, P225, DOI 10.1177/0004867419888575.
   Morgan CJA, 2012, ADDICTION, V107, P27, DOI 10.1111/j.1360-0443.2011.03576.x.
   Morilak DA, 2004, INT J NEUROPSYCHOPH, V7, P193, DOI 10.1017/S1461145704004080.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   Nichols DE, 2016, PHARMACOL REV, V68, P264, DOI 10.1124/pr.115.011478.
   Nutt D, 2021, JAMA PSYCHIAT, V78, P121, DOI 10.1001/jamapsychiatry.2020.2171.
   Penn E, 2012, THER ADV PSYCHOPHARM, V2, P179, DOI 10.1177/2045125312445469.
   Petranker R, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01681.
   Phelps J, 2017, J HUMANIST PSYCHOL, V57, P450, DOI 10.1177/0022167817711304.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Pilecki B, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00489-1.
   Preller KH, 2020, BIOL PSYCHIAT, V88, P197, DOI 10.1016/j.biopsych.2019.12.027.
   Price RB, 2014, DEPRESS ANXIETY, V31, P335, DOI 10.1002/da.22253.
   Rea K, 2021, INT J DRUG POLICY, V98, DOI 10.1016/j.drugpo.2021.103429.
   Read J, 2018, CURR DRUG SAF, V13, P176, DOI 10.2174/1574886313666180605095130.
   Reid S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1468.
   Riggs LM, 2021, ANNU REV CLIN PSYCHO, V17, P207, DOI 10.1146/annurev-clinpsy-072120-014126.
   Ritter P, 2020, PHARMACOPSYCHIATRY, V53, P45, DOI 10.1055/a-0991-0582.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Rucker JJH, 2016, J PSYCHOPHARMACOL, V30, P1220, DOI 10.1177/0269881116679368.
   Sahib AK, 2020, EUR NEUROPSYCHOPHARM, V33, P89, DOI 10.1016/j.euroneuro.2020.01.017.
   Schatzberg AF, 2014, AM J PSYCHIAT, V171, P262, DOI 10.1176/appi.ajp.2014.13101434.
   Schlag AK, 2022, J PSYCHOPHARMACOL, V36, P258, DOI 10.1177/02698811211069100.
   Schwartz J, 2016, EVID-BASED MENT HEAL, V19, P35, DOI 10.1136/eb-2016-102355.
   Short B, 2018, LANCET PSYCHIAT, V5, P65, DOI 10.1016/S2215-0366(17)30272-9.
   Sobiecki J. F., 2002, Transactions of the Royal Society of South Africa, V57, P1.
   Studerus E, 2011, J PSYCHOPHARMACOL, V25, P1434, DOI 10.1177/0269881110382466.
   Pham TH, 2019, PHARMACOL THERAPEUT, V199, P58, DOI 10.1016/j.pharmthera.2019.02.017.
   Tsai YC, 2015, UROL SCI, V26, P153, DOI 10.1016/j.urols.2014.11.003.
   Varley TF, 2020, NEUROIMAGE, V220, DOI 10.1016/j.neuroimage.2020.117049.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Wei Y, 2020, PHARMACOL BIOCHEM BE, V190, DOI 10.1016/j.pbb.2020.172870.
   Wesson DR, 2011, J PSYCHOACTIVE DRUGS, V43, P153, DOI 10.1080/02791072.2011.587708.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Williams M., 2012, PSYCHOL CULTURE.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P1, DOI 10.1556/2054.2019.032.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P125, DOI 10.1556/2054.2020.00137.
   Winstock A. R., 2019, GLOBAL DRUGS SURVEY.},
Number-of-Cited-References = {97},
Times-Cited = {1},
Usage-Count-Last-180-days = {9},
Usage-Count-Since-2013 = {9},
Journal-ISO = {J. Psychedelic Stud.},
Doc-Delivery-Number = {7I1RR},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000903672600003},
OA = {gold},
DA = {2023-07-30},
}

@article{ WOS:000942700600001,
Author = {Robison, Reid and Brendle, Madeline and Moore, Claire and Cross, Hannah
   and Helm, Lindsay and Darling, Shannon and Thayer, Stephen and
   Thielking, Paul and Shannon, Scott},
Title = {Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers
   with COVID-19-Related Burnout and PTSD: A Case Series of
   Effectiveness/Safety for 10 Participants},
Journal = {JOURNAL OF PSYCHOACTIVE DRUGS},
Year = {2023},
Month = {2023 MAR 4},
Abstract = {This study reports on 10 frontline healthcare workers, employed during
   the COVID-19 pandemic and experiencing symptoms of burnout and PTSD,
   treated with group ketamine-assisted psychotherapy (KAP) in a private
   outpatient clinic setting. Participants attended 6 sessions once weekly.
   These included 1 preparation session, 3 ketamine sessions (2 sublingual,
   1 intramuscular), 2 integration sessions. Measures of PTSD (PCL-5),
   depression (PHQ-9), and anxiety (GAD-7) were administered at baseline
   and post-treatment. During ketamine sessions, the Emotional Breakthrough
   Inventory (EBI) and the 30-item Mystical Experience Questionnaire
   (MEQ-30) were recorded. Participant feedback was gathered 1-month
   post-treatment. We observed improvements in participants' average PCL-5
   (59\% reduction), PHQ-9 (58\% reduction), and GAD-7 (36\% reduction)
   scores from pre- to post-treatment. At post-treatment, 100\% of
   participants screened negative for PTSD, 90\% had minimal/mild
   depression or clinically significant improvement, and 60\% had
   minimal/mild anxiety or clinically significant improvement. MEQ and EBI
   scores had large variations among participants at each ketamine session.
   Ketamine was well tolerated, and no significant adverse events were
   reported. Participant feedback corroborated findings of improvements
   observed in mental health symptoms. We found immediate improvements
   treating 10 frontline healthcare workers experiencing burnout, PTSD,
   depression, and anxiety using weekly group KAP and integration.},
Publisher = {ROUTLEDGE JOURNALS, TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND},
Type = {Article; Early Access},
Language = {English},
Affiliation = {Brendle, M (Corresponding Author), Univ Utah, LS Skaggs Pharm Inst, Dept Pharmacotherapy, Coll Pharm, 30 South 2000 East, 4th floor, Salt Lake City, UT 84112 USA.
   Robison, Reid; Brendle, Madeline; Moore, Claire; Cross, Hannah; Helm, Lindsay; Thayer, Stephen; Thielking, Paul, Numinus Wellness, Draper, UT USA.
   Robison, Reid, Univ Utah, SL, Sch Med, Salt Lake City, UT USA.
   Brendle, Madeline, Univ Utah, SLC, Coll Pharm, Salt Lake City, UT USA.
   Darling, Shannon; Shannon, Scott, Wholeness Ctr, Ft Collins, CO USA.
   Brendle, Madeline, Univ Utah, LS Skaggs Pharm Inst, Dept Pharmacotherapy, Coll Pharm, 30 South 2000 East, 4th floor, Salt Lake City, UT 84112 USA.},
DOI = {10.1080/02791072.2023.2186285},
EarlyAccessDate = {MAR 2023},
ISSN = {0279-1072},
EISSN = {2159-9777},
Keywords = {Ketamine; psychotherapy; post-traumatic stress disorder; depression;
   anxiety; case series},
Keywords-Plus = {POSTTRAUMATIC-STRESS-DISORDER; MYSTICAL EXPERIENCE QUESTIONNAIRE;
   GENERALIZED ANXIETY DISORDER; DEPRESSION},
Research-Areas = {Psychology; Substance Abuse},
Web-of-Science-Categories  = {Psychology, Clinical; Substance Abuse},
Author-Email = {Madeline.Brendle@utah.edu},
Affiliations = {Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah},
Cited-References = {Albott CS, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11634.
   APA, 2020, SUMM REC APA GUID DE.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Barsuglia J, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02459.
   Dames S, 2022, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.803279.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Dutheil F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226361.
   FDA, 2022, INTR MID FDA LAB.
   Feder A, 2021, AM J PSYCHIAT, V178, P193, DOI 10.1176/appi.ajp.2020.20050596.
   Feder Adriana, 2020, Adv Pharmacol, V89, P261, DOI 10.1016/bs.apha.2020.05.004.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Hagerty SL, 2022, CLIN PSYCHOL SCI, V10, P1060, DOI 10.1177/21677026211057554.
   Hasler G, 2020, CNS SPECTRUMS, V25, P445, DOI 10.1017/S1092852919001007.
   Hochschild A, 2021, PREV MED, V152, DOI 10.1016/j.ypmed.2021.106524.
   Hoskins M, 2015, BRIT J PSYCHIAT, V206, P93, DOI 10.1192/bjp.bp.114.148551.
   Hough D, 2019, ESKETAMINE.
   Kane L., 2019, MEDSCAPE NATL PHYS B.
   Kim J, 2019, NEW ENGL J MED, V381, P1, DOI 10.1056/NEJMp1903305.
   Krediet E, 2020, INT J NEUROPSYCHOPH, V23, P385, DOI 10.1093/ijnp/pyaa018.
   Kristensen TS, 2005, WORK STRESS, V19, P192, DOI 10.1080/02678370500297720.
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x.
   Kroenke K, 2012, CAN MED ASSOC J, V184, P281, DOI 10.1503/cmaj.112004.
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x.
   Marvaldi M, 2021, NEUROSCI BIOBEHAV R, V126, P252, DOI 10.1016/j.neubiorev.2021.03.024.
   McIntyre RS, 2021, AM J PSYCHIAT, V178, P383, DOI 10.1176/appi.ajp.2020.20081251.
   McIntyre RS, 2020, J AFFECT DISORDERS, V276, P576, DOI 10.1016/j.jad.2020.06.050.
   Medscape, 2021, DEATH 1000 CUTS MEDS.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Moghaddam B., 2021, KETAMINE.
   Newport DJ, 2015, AM J PSYCHIAT, V172, P950, DOI 10.1176/appi.ajp.2015.15040465.
   Pereira-Lima K, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16097.
   Phillips JL, 2020, NEUROPSYCHOPHARMACOL, V45, P606, DOI 10.1038/s41386-019-0570-x.
   Rodriguez P, 2012, J REHABIL RES DEV, V49, P649, DOI 10.1682/JRRD.2011.09.0162.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Rosendahl J, 2021, AM J PSYCHOTHER, V74, P52, DOI 10.1176/appi.psychotherapy.20200031.
   Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080.
   Sessa B, 2017, NEUROSCI LETT, V649, P176, DOI 10.1016/j.neulet.2016.07.004.
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092.
   Szarmach Joanna, 2019, Psychiatr Danub, V31, P585.
   Tawfik DS, 2019, ANN INTERN MED, V171, P555, DOI 10.7326/M19-1152.
   Toussaint A, 2020, J AFFECT DISORDERS, V265, P395, DOI 10.1016/j.jad.2020.01.032.
   VA, 2022, US PTSD CHECKL DSM 5.
   Walsh Z, 2021, BJPSYCH OPEN, V8, DOI 10.1192/bjo.2021.1061.
   Yalom I. D., 1995, THEORY PRACTICE GROU.
   Zuromski KL, 2019, DEPRESS ANXIETY, V36, P790, DOI 10.1002/da.22942.},
Number-of-Cited-References = {46},
Times-Cited = {0},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {2},
Journal-ISO = {J. Psychoact. Drugs},
Doc-Delivery-Number = {9N1TG},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000942700600001},
DA = {2023-07-30},
}

@article{ WOS:000823045100013,
Author = {Mathai, David S. and Lee, Scott M. and Mora, Victoria and O'Donnell,
   Kelley C. and Garcia-Romeu, Albert and Storch, Eric A.},
Title = {Mapping consent practices for outpatient psychiatric use of ketamine},
Journal = {JOURNAL OF AFFECTIVE DISORDERS},
Year = {2022},
Volume = {312},
Pages = {113-121},
Month = {SEP 1},
Abstract = {Background: Given increasing community-based and off-label use of
   ketamine for psychiatric indications, we examined current informed
   consent processes from a convenience sample of outpatient ketamine
   clinics to identify areas of congruence with current evidence and
   opportunities for growth.Methods: Using a rubric developed from existing
   practice guidelines, we conducted an exploratory analysis of informed
   consent documents (IC-Docs) from 23 American clinics offering ketamine
   as a psychiatric treatment. Domains assessed included clinical content,
   procedures, and syntax.Results: Participating clinics (23/288) varied
   widely in their constitution, training, and services provided. We found
   that IC-Docs addressed a majority of consent elements, though did so
   variably on an item-level. Areas for improvement included communication
   around long-term adverse effects, treatment alternatives,
   medical/psychiatric evaluation prior to treatment, medical/psychological
   support during treatment, adjunctive psychological interventions, and
   subjective/dissociative-type effects. All forms were limited by poor
   readability. Limitations. Our study was limited by convenience sampling
   along with possible underestimation of verbal consent
   processes.Conclusions: As ketamine continues to emerge as a psychiatric
   intervention, both patients and providers will benefit from a deliberate
   consent process informed by scientific, ethical, and pragmatic factors
   toward the goal of shared decision-making regarding treatment.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Mathai, DS (Corresponding Author), Johns Hopkins Univ, Sch Med, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA.
   Mathai, David S.; Garcia-Romeu, Albert, Johns Hopkins Univ, Dept Psychiat \& Behav Sci, Sch Med, Baltimore, MD USA.
   Lee, Scott M., Harvard Med Sch, Dept Psychiat, Vet Affairs Boston Healthcare Syst, Brockton, MA USA.
   Mora, Victoria; Storch, Eric A., Baylor Coll Med, Dept Psychiat \& Behav Sci, Houston, TX USA.
   O'Donnell, Kelley C., New York Univ, Dept Psychiat, Grossman Sch Med, New York, NY USA.
   Mathai, David S., Johns Hopkins Univ, Sch Med, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA.},
DOI = {10.1016/j.jad.2022.06.036},
ISSN = {0165-0327},
EISSN = {1573-2517},
Keywords = {Ketamine; Depression; Consent; Off-label; Ethics; Psychedelics},
Keywords-Plus = {MAJOR DEPRESSIVE DISORDER; OFF-LABEL USE; INFORMED-CONSENT; ORAL
   KETAMINE; ANTIDEPRESSANT; INTRANASAL; GUIDELINES; TRIAL},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Psychiatry},
Author-Email = {d.s.mathai@gmail.com},
Affiliations = {Johns Hopkins University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Harvard University; VA Boston Healthcare
   System; Baylor College of Medicine; New York University; Johns Hopkins
   University},
ORCID-Numbers = {O'Donnell, Kelley C./0000-0001-9983-2699},
Funding-Acknowledgement = {Johns Hopkins Center for Psychedelic and Consciousness Research; Heffter
   Research Institute; NIH; Ream Foundation; Greater Houston Community
   Foundation; International OCD Foundation; Texas Higher Education
   Coordinating Board},
Funding-Text = {DSM and AGR receive support from the Johns Hopkins Center for
   Psychedelic and Consciousness Research provided by Tim Ferriss, Matt
   Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra
   Cohen Foundation. AGR also receives support from the Heffter Research
   Institute and serves as a scientific advisor to ETHA Natural Botanicals
   and NeonMind Biosciences. SML and VM have no competing financial
   interests to disclose. KCO practices ketamine- assisted psychotherapy in
   her private psychiatry practice. EAS receives grant support from NIH,
   the Ream Foundation, Greater Houston Community Foundation, International
   OCD Foundation, and Texas Higher Education Coordinating Board. He
   receives book royalties from Elsevier, Springer, American Psychological
   Association, Jessica Kingsley, Oxford, and Lawrence Erlbaum. He holds
   stock in NView, where he serves on the clinical advisory board. He was a
   consultant for Levo Therapeutics and is currently a consultant for
   Biohaven Pharmaceuticals.},
Cited-References = {AHMED SN, 1980, BRIT J PSYCHIAT, V137, P303, DOI 10.1192/bjp.137.3.303b.
   Bennett R., 2022, FRONTIERSPSYCHIATRY, V13.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Breeksema JJ, 2020, CNS DRUGS, V34, P925, DOI 10.1007/s40263-020-00748-y.
   Chen G, 2022, INT J NEUROPSYCHOPH, V25, P269, DOI 10.1093/ijnp/pyab084.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   DuBay W. H., 2004, PRINCIPLES READABILI.
   Eguale T, 2016, JAMA INTERN MED, V176, P55, DOI 10.1001/jamainternmed.2015.6058.
   Fedson SE, 2018, ASAIO J, V64, P630, DOI 10.1097/MAT.0000000000000696.
   Fincham JE, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj720243.
   Gastaldon C, 2020, PSYCHOTHER PSYCHOSOM, V90, P41, DOI 10.1159/000510703.
   Gorman I, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.645246.
   Gunning R., 1952, TECHNIQUE CLEAR WRIT.
   Gupta SK, 2014, J PHARMACOL PHARMACO, V5, P88, DOI 10.4103/0976-500X.130046.
   Hall DE, 2012, CAN MED ASSOC J, V184, P533, DOI 10.1503/cmaj.112120.
   Ho R., 2016, BJPSYCH ADV, V22, P222, DOI {[}10.1192/apt.bp.114.014274, DOI 10.1192/APT.BP.114.014274].
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Kheirabadi D, 2020, J CLIN PSYCHOPHARM, V40, P588, DOI 10.1097/JCP.0000000000001289.
   KHORRAMZADEH E, 1973, PSYCHOSOMATICS, V14, P344.
   Kincaid P, 1975, DERIVATION NEW READA, DOI {[}10.21236/ADA006655, DOI 10.21236/ADA006655].
   Le TT, 2022, J PSYCHIATR RES, V151, P476, DOI 10.1016/j.jpsychires.2022.04.035.
   Loo CK, 2016, ACTA PSYCHIAT SCAND, V134, P48, DOI 10.1111/acps.12572.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Mathai DS, 2020, J AFFECT DISORDERS, V264, P123, DOI 10.1016/j.jad.2019.12.023.
   McIntyre RS, 2021, AM J PSYCHIAT, V178, P383, DOI 10.1176/appi.ajp.2020.20081251.
   McIntyre RS, 2020, J AFFECT DISORDERS, V276, P576, DOI 10.1016/j.jad.2020.06.050.
   MCLAUGHLIN GH, 1969, J READING, V12, P639.
   Mithani Zain, 2012, Virtual Mentor, V14, P576, DOI 10.1001/virtualmentor.2012.14.7.oped1-1207.
   Paterick TJ, 2008, MAYO CLIN PROC, V83, P313, DOI 10.4065/83.3.313.
   Phelps J, 2017, J HUMANIST PSYCHOL, V57, P450, DOI 10.1177/0022167817711304.
   Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021.
   Riley James B Jr, 2007, Nephrol News Issues, V21, P43.
   Rothberg RL, 2021, J PSYCHOPHARMACOL, V35, P150, DOI 10.1177/0269881120970879.
   Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080.
   Schatzberg AF, 2019, AM J PSYCHIAT, V176, P422, DOI 10.1176/appi.ajp.2019.19040423.
   Shah P., 2021, INFORM CONSENT.
   Short B, 2018, LANCET PSYCHIAT, V5, P65, DOI 10.1016/S2215-0366(17)30272-9.
   Singh I, 2017, LANCET PSYCHIAT, V4, P419, DOI 10.1016/S2215-0366(17)30102-5.
   Smith M.C., 2006, J PHARM MARK MANAG, V18, P17, DOI {[}10.3109/J058v18n01\_03, DOI 10.3109/J058v18n01\_03].
   Sullivan P., 2020, STANDARDS PRACTICE T.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Syed SA, 2021, J AM ACAD PSYCHIATRY, V49, P53, DOI 10.29158/JAAPL.200049-20.
   Tai SJ, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.586682.
   U.S. Food and Drug Administration, 1998, OFF LAB INV US MARK.
   Vollenweider FX, 2020, NAT REV NEUROSCI, V21, P611, DOI 10.1038/s41583-020-0367-2.
   Wajs E, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19m12891.
   Wesley R., 2020, J PSYCHEDELICPSYCHIA, V2.
   Wilkinson ST, 2017, AM J PSYCHIAT, V174, P695, DOI 10.1176/appi.ajp.2017.17020239.
   Wilson A, 2011, FOOD DRUG LAW J, V66, P569.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zhang MW, 2016, BMC MED ETHICS, V17, DOI 10.1186/s12910-016-0087-3.
   Zhang MWB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173202.
   Zhang MWB, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4467.},
Number-of-Cited-References = {54},
Times-Cited = {2},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Affect. Disord.},
Doc-Delivery-Number = {2U3FN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000823045100013},
DA = {2023-07-30},
}

@article{ WOS:000910864800007,
Author = {Hull, Thomas D. and Malgaroli, Matteo and Gazzaley, Adam and Akiki,
   Teddy J. and Madan, Alok and Vando, Leonardo and Arden, Kristin and
   Swain, Jack and Klotz, Madeline and Paleos, Casey},
Title = {At-home, sublingual ketamine telehealth is a safe and effective
   treatment for moderate to severe anxiety and depression: Findings from a
   large, prospective, open-label effectiveness trial},
Journal = {JOURNAL OF AFFECTIVE DISORDERS},
Year = {2022},
Volume = {314},
Pages = {59-67},
Month = {OCT 1},
Abstract = {Background: At-home Ketamine-assisted therapy (KAT) with psychosocial
   support and remote monitoring through telehealth platforms addresses
   access barriers, including the COVID-19 pandemic. Large-scale evaluation
   of this approach is needed for questions regarding safety and
   effectiveness for depression and anxiety.
   Methods: In this prospective study, a large outpatient sample received
   KAT over four weeks through a telehealth provider. Symptoms were
   assessed using the Patient Health Questionnaire (PHQ-9) for depression,
   and the Generalized Anxiety Disorder scale (GAD-7) for anxiety.
   Demographics, adverse events, and patient-reported dissociation were
   also analyzed. Symptom trajectories were identified using Growth Mixture
   Modeling, along with outcome predictors.
   Results: A sample of 1247 completed treatment with sufficient data, 62.8
   \% reported a 50 \% or greater improvement on the PHQ-9, d = 1.61, and
   62.9 \% on the GAD-7, d = 1.56. Remission rates were 32.6 \% for PHQ9
   and 31.3 \% for GAD-7, with 0.9 \% deteriorating on the PHQ-9, and 0.6
   \% on the GAD-7. Four patients left treatment early due to side effects
   or clinician disqualification, and two more due to adverse events. Three
   patient subpopulations emerged, characterized by Improvement (79.3 \%),
   Chronic (11.4 \%), and Delayed Improvement (9.3 \%) for PHQ-9 and GAD-7.
   Endorsing side effects at Session 2 was associated with delayed symptom
   improvement, and Chronic patients were more likely than the other two
   groups to report dissociation at
   Session 4. Conclusion: At-home KAT response and remission rates
   indicated rapid and significant antidepressant and anxiolytic effects.
   Rates were consistent with laboratory- and clinic-administered ketamine
   treatment. Patient screening and remote monitoring maintained low levels
   of adverse events. Future research should assess durability of effects.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Hull, TD (Corresponding Author), 1317 Edgewater Dr 1583, Orlando, FL 32804 USA.
   Hull, Thomas D., Inst Psycholinguist \& Digital Hlth, New York, NY USA.
   Malgaroli, Matteo, NYU, Dept Psychiat, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   Gazzaley, Adam, Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Akiki, Teddy J., Cleveland Clin, Neurol Inst, Ctr Behav Hlth, Cleveland, OH USA.
   Madan, Alok, Houston Methodist Behav Hlth, Houston, TX 77058 USA.
   Vando, Leonardo; Arden, Kristin; Swain, Jack; Klotz, Madeline; Paleos, Casey, Mindbloom, New York, NY USA.},
DOI = {10.1016/j.jad.2022.07.004},
ISSN = {0165-0327},
EISSN = {1573-2517},
Keywords = {Telemedicine; Major depression; Anxiety; Digital health;
   Ketamine-assisted therapy; Psychedelic-assisted therapy; Real-world},
Keywords-Plus = {STAR-ASTERISK-D; MENTAL-HEALTH; PRIMARY-CARE; BIPOLAR DEPRESSION;
   SCREENING-TEST; ANTIDEPRESSANT; PSYCHOTHERAPY; EFFICACY; SINGLE;
   PREVALENCE},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Psychiatry},
Author-Email = {tdh732@mail.harvard.edu},
Affiliations = {New York University; University of California System; University of
   California San Francisco; Cleveland Clinic Foundation; The Methodist
   Hospital System; The Methodist Hospital - Houston},
ResearcherID-Numbers = {Akiki, Teddy/D-4502-2019},
ORCID-Numbers = {Akiki, Teddy/0000-0003-1988-9201},
Cited-References = {aan het Rot M, 2010, BIOL PSYCHIAT, V67, P139, DOI 10.1016/j.biopsych.2009.08.038.
   Abbar M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067194.
   Akiki TJ, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18ac12473.
   Asparouhov T., 2012, MPLUS WEB NOTES, V15, P1.
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   Baumel A, 2019, TRANSL BEHAV MED, V9, P1020, DOI 10.1093/tbm/ibz147.
   Bhatt Kush, 2021, Prim Care Companion CNS Disord, V23, DOI 10.4088/PCC.20l02811.
   Bremner JD, 1998, J TRAUMA STRESS, V11, P125, DOI 10.1023/A:1024465317902.
   Brody Debra J, 2020, NCHS Data Brief, P1, DOI 10.15620/cdc:101197.
   Bucci S, 2019, PSYCHOL PSYCHOTHER-T, V92, P277, DOI 10.1111/papt.12222.
   Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789.
   Chong C, 2009, CLIN DRUG INVEST, V29, P317, DOI 10.2165/00044011-200929050-00004.
   CLEMENTS JA, 1982, J PHARM SCI, V71, P539, DOI 10.1002/jps.2600710516.
   Coley RY, 2020, PSYCHIAT SERV, V71, P312, DOI 10.1176/appi.ps.201900295.
   Cook JM, 2010, PSYCHOTHERAPY, V47, P260, DOI 10.1037/a0019788.
   Core, 2021, R LANG ENV STAT COMP.
   Cuijpers P, 2019, JAMA PSYCHIAT, V76, P700, DOI 10.1001/jamapsychiatry.2019.0268.
   Fava M, 2020, MOL PSYCHIATR, V25, P1592, DOI 10.1038/s41380-018-0256-5.
   Figueroa JF, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1210.
   Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943.
   Friborg and Johnsen n.d.O Friborg TJ Johnsen, 2017, EFFECT COGNITIVE BEH.
   Glue P, 2018, J PSYCHOPHARMACOL, V32, P663, DOI 10.1177/0269881118762073.
   Gruber J, 2021, AM PSYCHOL, V76, P409, DOI 10.1037/amp0000707.
   Guinart D, 2021, PSYCHIAT SERV, V72, P704, DOI 10.1176/appi.ps.202000441.
   Hoge M.A., 2019, SUBSTANCE ABUSE ADDI, P433.
   Holmes EA, 2018, LANCET PSYCHIAT, V5, P237, DOI 10.1016/S2215-0366(17)30513-8.
   Hull TD, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02721-x.
   Imel ZE, 2017, J COUNS PSYCHOL, V64, P385, DOI 10.1037/cou0000213.
   JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12.
   Johnsen TJ, 2015, PSYCHOL BULL, V141, P747, DOI 10.1037/bul0000015.
   Katalinic N, 2013, AUST NZ J PSYCHIAT, V47, P710, DOI 10.1177/0004867413486842.
   Kennedy Sidney H, 2007, Ann Clin Psychiatry, V19, P279, DOI 10.1080/10401230701675222.
   Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359.
   Kilbourne AM, 2018, WORLD PSYCHIATRY, V17, P30, DOI 10.1002/wps.20482.
   Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947.
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06.
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x.
   Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Kryst J, 2020, PHARMACOL REP, V72, P543, DOI 10.1007/s43440-020-00097-z.
   Lara DR, 2013, INT J NEUROPSYCHOPH, V16, P2111, DOI 10.1017/S1461145713000485.
   Layard R, 2007, NATL INST ECON REV, V202, P90, DOI 10.1177/0027950107086171.
   Lee EE, 2015, GEN HOSP PSYCHIAT, V37, P178, DOI 10.1016/j.genhosppsych.2015.01.003.
   Lener MS, 2017, DRUGS, V77, P381, DOI 10.1007/s40265-017-0702-8.
   Liu QQ, 2020, J PSYCHIATR RES, V126, P134, DOI 10.1016/j.jpsychires.2019.08.002.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   McInnes LA, 2022, J AFFECT DISORDERS, V301, P486, DOI 10.1016/j.jad.2021.12.097.
   McLachlan G, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k5354.
   McLenon J, 2019, J ADV NURS, V75, P30, DOI 10.1111/jan.13818.
   Mello RP, 2021, J PSYCHIATR RES, V138, P576, DOI 10.1016/j.jpsychires.2021.05.014.
   Miranda J, 2008, AM J PSYCHIAT, V165, P1102, DOI 10.1176/appi.ajp.2008.08030333.
   Mohr DC, 2006, ANN BEHAV MED, V32, P254, DOI 10.1207/s15324796abm3203\_12.
   Mojtabai R, 2011, PSYCHOL MED, V41, P1751, DOI 10.1017/S0033291710002291.
   Muth┬u┬n L.K., 1998, MPLUS USERS GUIDE.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Niciu MJ, 2014, J CLIN PSYCHIAT, V75, pE417, DOI 10.4088/JCP.13m08698.
   Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396.
   Pennybaker SJ, 2017, J AFFECT DISORDERS, V208, P560, DOI 10.1016/j.jad.2016.10.026.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905.
   Sanacora G, 2017, JAMA PSYCHIAT, V74, P399, DOI 10.1001/jamapsychiatry.2017.0080.
   Schenberg EE, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00733.
   Short B, 2018, LANCET PSYCHIAT, V5, P65, DOI 10.1016/S2215-0366(17)30272-9.
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092.
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597.
   Substance Abuse and Mental Health Services Administration, 2020, KEY SUBSTANCE USE ME.
   Swainson J, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19lr13146.
   Titov N, 2017, AUST NZ J PSYCHIAT, V51, P1227, DOI 10.1177/0004867416671598.
   Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28.
   Valentine GW, 2011, PSYCHIAT RES-NEUROIM, V191, P122, DOI 10.1016/j.pscychresns.2010.10.009.
   Vaughan B, 2014, COMPR PSYCHIAT, V55, P849, DOI 10.1016/j.comppsych.2014.01.001.
   Villalobos-Gallegos L, 2015, SALUD MENT, V38, P89, DOI 10.17711/SM.0185-3325.2015.012.
   Wilkinson ST, 2019, BIOL PSYCHIAT, V85, P454, DOI 10.1016/j.biopsych.2018.09.004.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336.
   Zeifman RJ, 2022, J CLIN PSYCHIAT, V83, DOI 10.4088/JCP.21r14057.},
Number-of-Cited-References = {78},
Times-Cited = {10},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {8},
Journal-ISO = {J. Affect. Disord.},
Doc-Delivery-Number = {7S6LC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000910864800007},
OA = {hybrid},
DA = {2023-07-30},
}

@article{ WOS:000985978500001,
Author = {Gold, Noah D. and Mallard, Austin J. and Hermann, Jacob C. and Zeifman,
   Richard J. and Pagni, Broc A. and Bogenschutz, Michael P. and Ross,
   Stephen},
Title = {Exploring the Potential Utility of Psychedelic Therapy for Patients With
   Amyotrophic Lateral Sclerosis},
Journal = {JOURNAL OF PALLIATIVE MEDICINE},
Year = {2023},
Month = {2023 MAY 11},
Abstract = {Background: Amyotrophic lateral sclerosis (ALS) is an aggressive,
   terminal neurodegenerative disease that causes death of motor neurons
   and has an average survival time of 3-4 years. ALS is the most common
   motor neuron degenerative disease and is increasing in prevalence. There
   is a pressing need for more effective ALS treatments as available
   pharmacotherapies do not reverse disease progression or provide
   substantial clinical benefit. Furthermore, despite psychological
   distress being highly prevalent in ALS patients, psychological
   treatments remain understudied. Psychedelics (i.e., serotonergic
   psychedelics and related compounds like ketamine) have seen a resurgence
   of research into therapeutic applications for treating a multitude of
   neuropsychiatric conditions, including psychiatric and existential
   distress in life-threatening illnesses.Methods: We conducted a narrative
   review to examine the potential of psychedelic assisted-psychotherapy
   (PAP) to alleviate psychiatric and psychospiritual distress in ALS. We
   also discussed the safety of using psychedelics in this population and
   proposed putative neurobiological mechanisms that may therapeutically
   intervene on ALS neuropathology.Results: PAP has the potential to treat
   psychological dimensions and may also intervene on neuropathological
   dimensions of ALS. Robust improvements in psychiatric and
   psychospiritual distress from PAP in other populations provide a strong
   rationale for utilizing this therapy to treat ALS-related psychiatric
   and existential distress. Furthermore, relevant neuroprotective
   properties of psychedelics warrant future preclinical trials to
   investigate this area in ALS models.Conclusion: PAP has the potential to
   serve as an effective treatment in ALS. Given the lack of effective
   treatment options, researchers should rigorously explore this therapy
   for ALS in future trials.},
Publisher = {MARY ANN LIEBERT, INC},
Address = {140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA},
Type = {Review; Early Access},
Language = {English},
Affiliation = {Gold, ND (Corresponding Author), NYU, Grossman Sch Med, NYU Langone Ctr Psychedel Med, Dept Psychiat, One Pk Ave,8th Floor, New York, NY 10016 USA.
   Gold, Noah D.; Mallard, Austin J.; Zeifman, Richard J.; Pagni, Broc A.; Bogenschutz, Michael P.; Ross, Stephen, NYU, Grossman Sch Med, NYU Langone Ctr Psychedel Med, Dept Psychiat, New York, NY USA.
   Hermann, Jacob C., Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA.
   Gold, Noah D., NYU, Grossman Sch Med, NYU Langone Ctr Psychedel Med, Dept Psychiat, One Pk Ave,8th Floor, New York, NY 10016 USA.},
DOI = {10.1089/jpm.2022.0604},
EarlyAccessDate = {MAY 2023},
ISSN = {1096-6218},
EISSN = {1557-7740},
Keywords = {amyotrophic lateral sclerosis; ketamine; neurodegenerative; psilocybin;
   psychedelic-assisted psychotherapy},
Keywords-Plus = {QUALITY-OF-LIFE; PSYCHOLOGICAL FLEXIBILITY; PALLIATIVE CARE; ASSISTED
   PSYCHOTHERAPY; EXISTENTIAL DISTRESS; PSILOCYBIN MUSHROOMS; THREATENING
   CANCER; KETAMINE; ALS; SPIRITUALITY},
Research-Areas = {Health Care Sciences \& Services},
Web-of-Science-Categories  = {Health Care Sciences \& Services},
Author-Email = {noah.gold@nyulangone.org},
Affiliations = {New York University; Icahn School of Medicine at Mount Sinai; New York
   University},
ORCID-Numbers = {Gold, Noah/0000-0002-1279-6937},
Cited-References = {Abbar M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067194.
   Abdallah CG, 2018, NEUROPSYCHOPHARMACOL, V43, P2154, DOI 10.1038/s41386-018-0136-3.
   Abrahams S, 1996, BRAIN, V119, P2105, DOI 10.1093/brain/119.6.2105.
   Agin-Liebes G, 2022, J PSYCHOPHARMACOL, V36, P295, DOI 10.1177/02698811221080165.
   Agin-Liebes G, 2021, J HUMANIST PSYCHOL, DOI 10.1177/00221678211022949.
   Agin-Liebes GI, 2020, J PSYCHOPHARMACOL, V34, P155, DOI 10.1177/0269881119897615.
   AI-Chalabi A, 2014, LANCET NEUROL, V13, P1108, DOI 10.1016/S1474-4422(14)70219-4.
   Aleksandrova LR, 2021, TRENDS PHARMACOL SCI, V42, P929, DOI 10.1016/j.tips.2021.08.003.
   Anderson BT, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100538.
   Andrade C, 2017, J CLIN PSYCHIAT, V78, pE852, DOI 10.4088/JCP.17f11738.
   {[}Anonymous], 2022, PHARMATHER ANN FDA A.
   {[}Anonymous], 1979, PSYCHEDELIC DRUGS RE.
   Arthur KC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12408.
   Atassi N, 2011, AMYOTROPH LATERAL SC, V12, P109, DOI 10.3109/17482968.2010.536839.
   Averill AJ, 2007, AMYOTROPH LATERAL SC, V8, P243, DOI 10.1080/17482960701374643.
   Baethge C, 2019, RES INTEGR PEER REV, V4, DOI 10.1186/s41073-019-0064-8.
   Banks MI, 2021, MOL BIOL CELL, V32, P1135, DOI 10.1091/mbc.E20-05-0340.
   Barker SA, 2022, PSYCHOPHARMACOLOGY, V239, P1749, DOI 10.1007/s00213-022-06065-0.
   Becker AM, 2023, INT J NEUROPSYCHOPH, V26, P97, DOI 10.1093/ijnp/pyac075.
   Beers DR, 2019, LANCET NEUROL, V18, P211, DOI 10.1016/S1474-4422(18)30394-6.
   Beland LC, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa124.
   Bell JD, 2017, ANESTH ANALG, V124, P1237, DOI 10.1213/ANE.0000000000001856.
   Belser AB, 2017, J HUMANIST PSYCHOL, V57, P354, DOI 10.1177/0022167817706884.
   Beukelman D, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/714693.
   Bogenschutz MP, 2022, JAMA PSYCHIAT, V79, P953, DOI 10.1001/jamapsychiatry.2022.2096.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bovero A, 2019, PALLIAT SUPPORT CARE, V17, P596, DOI 10.1017/S1478951519000191.
   Brown RH, 2017, NEW ENGL J MED, V377, P1602, DOI {[}10.1056/NEJMra1603471, 10.1056/NEJMc1710379, 10.1016/S0140-6736(10)61156-7, 10.1038/nrdp.2017.85, 10.1016/S0140-6736(17)31287-4].
   Bryson HM, 1996, DRUGS, V52, P549, DOI 10.2165/00003495-199652040-00010.
   Calder AE, 2023, NEUROPSYCHOPHARMACOL, V48, P104, DOI 10.1038/s41386-022-01389-z.
   Carbonaro TM, 2016, J PSYCHOPHARMACOL, V30, P1268, DOI 10.1177/0269881116662634.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Chochinov HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147607.
   Close JB, 2020, J CONTEXT BEHAV SCI, V16, P37, DOI 10.1016/j.jcbs.2020.01.005.
   D'Souza K, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-0701-y.
   Dadiomov David, 2019, Ment Health Clin, V9, P48, DOI 10.9740/mhc.2019.01.048.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   Davis Alan K, 2020, Chronic Stress (Thousand Oaks), V4, p2470547020939564, DOI 10.1177/2470547020939564.
   de Vos CMH, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.724606.
   Erdmann A, 2021, BMJ SUPPORT PALLIAT, V11, P271, DOI 10.1136/bmjspcare-2020-002640.
   Erritzoe D, 2018, ACTA PSYCHIAT SCAND, V138, P368, DOI 10.1111/acps.12904.
   Fang F, 2008, BRAIN, V131, P2729, DOI 10.1093/brain/awn161.
   Flanagan TW, 2018, INT REV PSYCHIATR, V30, P363, DOI 10.1080/09540261.2018.1481827.
   Fogarty MJ, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0347-y.
   Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444.
   Galvao-Coelho NL, 2020, J PSYCHOPHARMACOL, V34, P1125, DOI 10.1177/0269881120936486.
   Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406.
   Garcia-Romeu Albert, 2022, Curr Top Behav Neurosci, V56, P287, DOI 10.1007/7854\_2021\_267.
   Gasser P, 2014, J NERV MENT DIS, V202, P513, DOI 10.1097/NMD.0000000000000113.
   Goldman N, 2019, J PALLIAT MED, V22, P1154, DOI 10.1089/jpm.2018.0627.
   Goodwin GM, 2022, NEW ENGL J MED, V387, P1637, DOI 10.1056/NEJMoa2206443.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Haley RW, 2003, NEUROLOGY, V61, P750, DOI 10.1212/WNL.61.6.750.
   Hardiman Orla, 2017, Nat Rev Dis Primers, V3, P17071, DOI 10.1038/nrdp.2017.71.
   Hochschild A, 2021, PREV MED, V152, DOI 10.1016/j.ypmed.2021.106524.
   Hogden A, 2017, J MULTIDISCIP HEALTH, V10, P205, DOI 10.2147/JMDH.S134992.
   Holze F, 2023, BIOL PSYCHIAT, V93, P215, DOI 10.1016/j.biopsych.2022.08.025.
   Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA.
   Hu Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09097-1.
   Huda N, 2022, CANCER NURS, V45, pE487, DOI 10.1097/NCC.0000000000000940.
   Jaffa JL, 2017, J NEUROSCI NURS, V49, P318, DOI 10.1097/JNN.0000000000000309.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kadriu B, 2021, INT J NEUROPSYCHOPH, V24, P8, DOI 10.1093/ijnp/pyaa087.
   Kapur S, 2002, MOL PSYCHIATR, V7, P837, DOI 10.1038/sj.mp.4001093.
   KAST E, 1967, PSYCHIAT QUART, V41, P646, DOI 10.1007/BF01575629.
   KAST EC, 1964, ANESTH ANALG, V43, P285.
   Kawatake-Kuno A, 2021, FRONT BEHAV NEUROSCI, V15, DOI 10.3389/fnbeh.2021.749180.
   Kelley DP, 2022, ACS CHEM NEUROSCI, V13, P257, DOI 10.1021/acschemneuro.1c00660.
   Khairoalsindi OA, 2018, NEUROL RES INT, V2018, DOI 10.1155/2018/6534150.
   Kiernan MC, 2021, NAT REV NEUROL, V17, P104, DOI 10.1038/s41582-020-00434-z.
   Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7.
   Ko KM, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.917199.
   Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039.
   Kopra E, 2021, J PSYCHOPHARMACOL, V35, P934, DOI 10.1177/02698811211026426.
   Kozlowska U, 2022, J NEUROCHEM, V162, P89, DOI 10.1111/jnc.15509.
   Kurt A, 2007, CNS DRUGS, V21, P279, DOI 10.2165/00023210-200721040-00003.
   Lepow L, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.710004.
   Liechti ME, 2017, NEUROPSYCHOPHARMACOL, V42, P2114, DOI 10.1038/npp.2017.86.
   da Cruz RVL, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00312.
   Linse K, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00603.
   Longinetti E, 2019, CURR OPIN NEUROL, V32, P771, DOI 10.1097/WCO.0000000000000730.
   Lund EM, 2021, MUSCLE NERVE, V63, P807, DOI 10.1002/mus.27181.
   Ly C, 2018, CELL REP, V23, P3170, DOI 10.1016/j.celrep.2018.05.022.
   Maessen M, 2014, J NEUROL, V261, P1894, DOI 10.1007/s00415-014-7424-6.
   Mangini P, 2021, J PSYCHEDELIC STUD, V5, P149, DOI 10.1556/2054.2021.00176.
   Marin B, 2016, EUR J NEUROL, V23, P787, DOI 10.1111/ene.12941.
   Masrori P, 2020, EUR J NEUROL, V27, P1918, DOI 10.1111/ene.14393.
   MCDONALD ER, 1994, ARCH NEUROL-CHICAGO, V51, P17, DOI 10.1001/archneur.1994.00540130027010.
   Mitchell JD, 2007, LANCET, V369, P2031, DOI 10.1016/S0140-6736(07)60944-1.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Mitsumoto H, 2007, JAMA-J AM MED ASSOC, V298, P207, DOI 10.1001/jama.298.2.207.
   Moda-Sava RN, 2019, SCIENCE, V364, P147, DOI 10.1126/science.aat8078.
   Morales-Garcia JA, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-01011-0.
   Morgan S, 2016, BRIT MED BULL, V119, P87, DOI 10.1093/bmb/ldw026.
   Murphy PL, 2000, NEUROLOGY, V55, P1581, DOI 10.1212/WNL.55.10.1581.
   Murphy R, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.788155.
   National Clinical Guideline C, 2016, NAT I HLTH CAR EXC C.
   Nichols DE, 2017, CLIN PHARMACOL THER, V101, P209, DOI 10.1002/cpt.557.
   Nichols DE, 2016, PHARMACOL REV, V68, P264, DOI 10.1124/pr.115.011478.
   O'Brien MR, 2015, PALLIAT SUPPORT CARE, V13, P1603, DOI 10.1017/S1478951515000097.
   Oberstadt MCF, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00231.
   Paganoni S, 2022, J NEUROL NEUROSUR PS, V93, P871, DOI 10.1136/jnnp-2022-329024.
   Pagnini F, 2013, INT J PSYCHOL, V48, P194, DOI 10.1080/00207594.2012.691977.
   Pahnke W. N., 1969, HARVARD THEOL REV, V62, P1, DOI {[}https://doi.org/10.1017/S0017816000027577, DOI 10.1017/S0017816000027577].
   Paillisse C, 2005, AMYOTROPH LATERAL SC, V6, P37, DOI 10.1080/14660820510027035.
   Patchett-Marble R, 2022, CAN FAM PHYSICIAN, V68, P823, DOI 10.46747/cfp.6811823.
   Pearlman JR, 2019, PEERJ, V7, DOI 10.7717/peerj.6527.
   Prell Tino, 2019, eNeurologicalSci, V16, P100198, DOI 10.1016/j.ensci.2019.100198.
   Price RB, 2009, BIOL PSYCHIAT, V66, P522, DOI 10.1016/j.biopsych.2009.04.029.
   Puchalski CM, 2012, ANN ONCOL, V23, P49, DOI 10.1093/annonc/mds088.
   Re DB, 2014, NEURON, V81, P1001, DOI 10.1016/j.neuron.2014.01.011.
   Ross S, 2022, NEUROPHARMACOLOGY, V216, DOI 10.1016/j.neuropharm.2022.109174.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Prado LDR, 2017, EINSTEIN-SAO PAULO, V15, P58, DOI {[}10.1590/S1679-45082017AO3870, 10.1590/s1679-45082017ao3870].
   Rucker JJH, 2018, NEUROPHARMACOLOGY, V142, P200, DOI 10.1016/j.neuropharm.2017.12.040.
   Sagiraju HKR, 2020, MIL MED, V185, pE501, DOI 10.1093/milmed/usz350.
   Sassano-Higgins S, 2016, DEPRESS ANXIETY, V33, P718, DOI 10.1002/da.22536.
   Schlag AK, 2022, J PSYCHOPHARMACOL, V36, P258, DOI 10.1177/02698811211069100.
   Seals RM, 2016, EPIDEMIOLOGY, V27, P188, DOI 10.1097/EDE.0000000000000417.
   Shao LX, 2021, NEURON, V109, P2535, DOI 10.1016/j.neuron.2021.06.008.
   Shinohara R, 2021, BIOL PSYCHIAT, V90, P85, DOI 10.1016/j.biopsych.2020.12.006.
   Shnayder S, 2023, J AFFECT DISORDERS, V323, P592, DOI 10.1016/j.jad.2022.11.046.
   Simmons Z, 2000, NEUROLOGY, V55, P388, DOI 10.1212/WNL.55.3.388.
   Singh NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149499.
   Sloshower J, 2020, J CONTEXT BEHAV SCI, V15, P12, DOI 10.1016/j.jcbs.2019.11.002.
   Smith F., 2022, DRUG SCI POLICY LAW, V8, p20503245221124117.
   Spataro R, 2021, J NEUROL, V268, P219, DOI 10.1007/s00415-020-10136-7.
   Stanford JA., 2021, RRNMF NEUROMUSC J, V2, P34.
   Steinhauser KE, 2017, J PAIN SYMPTOM MANAG, V54, P428, DOI 10.1016/j.jpainsymman.2017.07.028.
   Stutzki R, 2014, AMYOTROPH LAT SCL FR, V15, P68, DOI 10.3109/21678421.2013.837928.
   Sullivan DR, 2022, J PALLIAT MED, V25, P15, DOI 10.1089/jpm.2021.0246.
   Sun QH, 2021, NEURODEGENER DIS, V21, P87, DOI 10.1159/000522078.
   Szabo A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00423.
   Szabo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106533.
   Szabo A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00358.
   Takeda T, 2007, J NEUROL SCI, V260, P225, DOI 10.1016/j.jns.2007.05.010.
   Talbott EO, 2016, HAND CLINIC, V138, P225, DOI 10.1016/B978-0-12-802973-2.00013-6.
   Taylor EJ, 2006, ONCOL NURS FORUM, V33, P729, DOI 10.1188/06.ONF.729-735.
   Thakore NJ, 2016, NEUROLOGY, V86, P1031, DOI 10.1212/WNL.0000000000002465.
   Thompson C, 2020, IMMUNOL LETT, V228, P45, DOI 10.1016/j.imlet.2020.10.001.
   Tortelli R, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.552295.
   Uthaug MV, 2020, PSYCHOPHARMACOLOGY, V237, P773, DOI 10.1007/s00213-019-05414-w.
   van Groenestijn AC, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0507-6.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-3.
   Witt K, 2020, AUST NZ J PSYCHIAT, V54, P29, DOI 10.1177/0004867419883341.
   Wu MZ, 2021, BIOL PSYCHIAT, V89, P1096, DOI 10.1016/j.biopsych.2020.12.022.
   Yaden David B, 2022, Curr Top Behav Neurosci, V56, P169, DOI 10.1007/7854\_2021\_278.
   Yamanaka K, 2018, NEUROSCI RES, V126, P31, DOI 10.1016/j.neures.2017.09.011.
   Yavi Mani, 2022, Discov Ment Health, V2, P9, DOI 10.1007/s44192-022-00012-3.
   Zeifman RJ, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00782.
   Zeifman RJ., 2022, J CLIN PSYCHIAT, V83, p21r14057.
   Zucchi E, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00175.},
Number-of-Cited-References = {160},
Times-Cited = {0},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {3},
Journal-ISO = {J. Palliat. Med.},
Doc-Delivery-Number = {G0ED5},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000985978500001},
DA = {2023-07-30},
}

@article{ WOS:000441142400007,
Author = {Horsley, Rachel R. and Palenicek, Tomas and Kolin, Jan and Vales, Karel},
Title = {Psilocin and ketamine microdosing: effects of subchronic intermittent
   microdoses in the elevated plus-maze in male Wistar rats},
Journal = {BEHAVIOURAL PHARMACOLOGY},
Year = {2018},
Volume = {29},
Number = {6},
Pages = {530-536},
Month = {SEP},
Abstract = {Short-term moderate doses of serotonergic and dissociative hallucinogens
   can be useful in the treatment of anxiety. Recently, a trend has
   developed for long-term intermittent microdosing' (usually one-tenth of
   a full' active dose), with reports of long-lasting relief from anxiety
   and related disorders; however, there is no scientific evidence for the
   efficacy of therapeutic microdosing nor to show its lasting effects. The
   objective of this study was to test for lasting effects on anxiety in
   rats after microdosing with ketamine or psilocin. Over 6 days, Wistar
   rats (N=40) were administered ketamine (0.5 or 3mg/kg), psilocin (0.05
   or 0.075mg/kg), or saline on three occasions. A 5-min elevated plus-maze
   test was conducted 48h after the final drug treatment (n=8). Dependent
   variables were entries (frequency), spent time (\%), and distance
   traveled (cm) in each zone, as well as total frequency of rears,
   stretch-attend postures, and head dips. Statistical analyses of drug
   effects used separate independent one-way analysis of variance and
   pair-wise comparisons using independent t-tests. Statistical effects
   were modest or borderline and were most consistent with a mildly
   anxiogenic profile, which was significant at lower doses; however, this
   conclusion remains tentative. The lower doses of ketamine and psilocin
   produced comparable effects (to one another) across each variable, as
   did the higher doses. This pattern of effects may suggest a common (e.g.
   neurotransmitter/receptor) mechanism. We conclude that microdosing with
   hallucinogens for therapeutic purposes might be counter-productive;
   however, more research is needed to confirm our findings and to
   establish their translational relevance to clinical psychedelic'
   therapy.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Horsley, RR (Corresponding Author), Natl Inst Mental Hlth Czech Republ NIMH CZ, Topolova 748, Klecany 25067, Czech Republic.
   Horsley, Rachel R.; Palenicek, Tomas; Kolin, Jan; Vales, Karel, Natl Inst Mental Hlth CZ, Klecany, Czech Republic.
   Palenicek, Tomas, Charles Univ Prague, Med Fac 3, Prague, Czech Republic.
   Kolin, Jan; Vales, Karel, Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic.},
DOI = {10.1097/FBP.0000000000000394},
ISSN = {0955-8810},
EISSN = {1473-5849},
Keywords = {anxiety; elevated plus-maze; ketamine; microdose; microdosing; psilocin;
   psychedelic; rat},
Keywords-Plus = {STRIATAL DOPAMINE; ANIMAL-MODEL; ANXIETY; RECEPTOR; PHARMACOKINETICS;
   SCHIZOPHRENIA; HALLUCINOGENS; (S)-KETAMINE; PHARMACOLOGY; MODULATION},
Research-Areas = {Behavioral Sciences; Neurosciences \& Neurology; Pharmacology \&
   Pharmacy},
Web-of-Science-Categories  = {Behavioral Sciences; Neurosciences; Pharmacology \& Pharmacy},
Author-Email = {rachel.horsley@nudz.cz},
Affiliations = {National Institute of Mental Health - Czech Republic; 4EU+; Charles
   University Prague; Czech Academy of Sciences; Institute of Physiology of
   the Czech Academy of Sciences},
ResearcherID-Numbers = {Palenicek, Tomas/AAA-2549-2021
   Horsley, Rachel R/C-7465-2019
   Valeš, Karel/C-2941-2012},
ORCID-Numbers = {Palenicek, Tomas/0000-0002-3109-9539
   Horsley, Rachel R/0000-0003-2536-2465
   Valeš, Karel/0000-0001-7892-4535},
Funding-Acknowledgement = {MEYS CR under the NPU I program {[}LO1611]},
Funding-Text = {This research is the result of work funded by the project Nr. LO1611
   with financial support from the MEYS CR under the NPU I program.},
Cited-References = {Adams HA, 1997, ANAESTHESIST, V46, P1026, DOI 10.1007/s001010050503.
   Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6.
   Babar E, 2001, EUR J PHARMACOL, V431, P315, DOI 10.1016/S0014-2999(01)01340-1.
   Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6.
   Becker A, 2003, PROG NEURO-PSYCHOPH, V27, P687, DOI 10.1016/S0278-5846(03)00080-0.
   Bluelight, 2017, KET QUEST PAN ATT.
   Bogenschutz MP, 2012, DRUG TEST ANAL, V4, P543, DOI 10.1002/dta.1376.
   Can A, 2016, J PHARMACOL EXP THER, V359, P159, DOI 10.1124/jpet.116.235838.
   Chen JB, 2011, J CHROMATOGR B, V879, P2669, DOI 10.1016/j.jchromb.2011.07.003.
   CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3.
   dos Santos RG, 2014, THER DRUG MONIT, V36, P131, DOI 10.1097/FTD.0000000000000028.
   Engin E, 2009, NEUROSCIENCE, V161, P359, DOI 10.1016/j.neuroscience.2009.03.038.
   Erowid, 2017, KET DOS.
   Fadiman J., 2011, PSYCHEDELIC EXPLORER.
   File SE, 2000, CURR PROTOC NEUROSCI, V10, P1.
   File SE, 1992, EXPT APPROACHES ANXI, P73.
   Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811.
   Geyer MA, 1999, INTERACTIVE MONOAMIN, P343.
   Geyer MA, 2008, TRENDS PHARMACOL SCI, V29, P445, DOI 10.1016/j.tips.2008.06.006.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   HANDLEY SL, 1993, PSYCHOPHARMACOLOGY, V112, P13, DOI 10.1007/BF02247358.
   Hasler F, 2002, J PHARMACEUT BIOMED, V30, P331, DOI 10.1016/S0731-7085(02)00278-9.
   Hasler F, 1997, Pharm Acta Helv, V72, P175, DOI 10.1016/S0031-6865(97)00014-9.
   Hayase T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-25.
   Horsley RR, 2007, PROG NEURO-PSYCHOPH, V31, P906, DOI 10.1016/j.pnpbp.2007.02.007.
   howtousepsychedelicsorg, TAK KET TREAT DEPR A.
   Ibrahim L, 2012, NEUROPSYCHOPHARMACOL, V37, P1526, DOI 10.1038/npp.2011.338.
   Irwin SA, 2013, J PALLIAT MED, V16, P958, DOI 10.1089/jpm.2012.0617.
   Jones KA, 2009, P NATL ACAD SCI USA, V106, P19575, DOI 10.1073/pnas.0905884106.
   Lapidus KAB, 2014, BIOL PSYCHIAT, V76, P970, DOI 10.1016/j.biopsych.2014.03.026.
   Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099.
   Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002.
   Palenicek T, 2011, NEUROPSYCHOBIOLOGY, V63, P202, DOI 10.1159/000321803.
   Parise EM, 2013, BIOL PSYCHIAT, V74, P750, DOI 10.1016/j.biopsych.2013.04.027.
   Passie T, 2002, ADDICT BIOL, V7, P357, DOI 10.1080/1355621021000005937.
   PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6.
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7.
   Rambousek L, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00180.
   Ray TS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009019.
   Reddit, 2017, MICR KET METH.
   RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M.
   Shroomery, 2017, LONG TERM ANX CAUS M.
   Silvestre JS, 2002, J PSYCHOPHARMACOL, V16, P305, DOI 10.1177/026988110201600404.
   Stebelska K, 2013, THER DRUG MONIT, V35, P420, DOI 10.1097/FTD.0b013e31828741a5.
   Swerdlow NR, 1998, SCHIZOPHRENIA BULL, V24, P285, DOI 10.1093/oxfordjournals.schbul.a033326.
   The Third Wave, 2017, 3 WAVE.
   Tizabi Y, 2012, NEUROSCIENCE, V213, P72, DOI 10.1016/j.neuroscience.2012.03.052.
   Tyls F, 2016, BEHAV PHARMACOL, V27, P309, DOI 10.1097/FBP.0000000000000198.
   Tyls F, 2014, EUR NEUROPSYCHOPHARM, V24, P342, DOI 10.1016/j.euroneuro.2013.12.006.
   Veilleux-Lemieux D, 2013, J AM ASSOC LAB ANIM, V52, P567.
   Vollenweider F X, 2001, Dialogues Clin Neurosci, V3, P265.
   Vollenweider FX, 2000, J PSYCHIATR RES, V34, P35, DOI 10.1016/S0022-3956(99)00031-X.
   Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V20, P424, DOI 10.1016/S0893-133X(98)00108-0.
   White JM, 1996, DRUG ALCOHOL REV, V15, P145, DOI 10.1080/09595239600185801.
   Zarate CA, 2012, BIOL PSYCHIAT, V71, P939, DOI 10.1016/j.biopsych.2011.12.010.},
Number-of-Cited-References = {57},
Times-Cited = {26},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {32},
Journal-ISO = {Behav. Pharmacol.},
Doc-Delivery-Number = {GP8EI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000441142400007},
DA = {2023-07-30},
}

@article{ WOS:000834570000001,
Author = {Ko, Kwonmok and Knight, Gemma and Rucker, James J. and Cleare, Anthony
   J.},
Title = {Psychedelics, Mystical Experience, and Therapeutic Efficacy: A
   Systematic Review},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2022},
Volume = {13},
Month = {JUL 12},
Abstract = {The mystical experience is a potential psychological mechanism to
   influence outcome in psychedelic therapy. It includes features such as
   oceanic boundlessness, ego dissolution, and universal
   interconnectedness, which have been closely linked to both symptom
   reduction and improved quality of life. In this review, 12 studies of
   psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were
   analyzed for association between mystical experience and symptom
   reduction, in areas as diverse as cancer-related distress, substance use
   disorder, and depressive disorders to include treatment-resistant. Ten
   of the twelve established a significant association of correlation,
   mediation, and/or prediction. A majority of the studies are limited,
   however, by their small sample size and lack of diversity (gender,
   ethnic, racial, educational, and socioeconomic), common in this newly
   re-emerging field. Further, 6 out of 12 studies were open-label in
   design and therefore susceptible to bias. Future studies of this nature
   should consider a larger sample size with greater diversity and thus
   representation by use of randomized design. More in-depth exploration
   into the nature of mystical experience is needed, including predictors
   of intensity, in order to maximize its positive effects on treatment
   outcome benefits and minimize concomitant anxiety.Systematic Review
   Registration: PROSPERO, identifier CRD42021261752.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Ko, KM (Corresponding Author), Kings Coll London, Inst Psychiat Psychol \& Neurosci, Ctr Affect Disorders, London, England.
   Ko, Kwonmok; Knight, Gemma; Rucker, James J.; Cleare, Anthony J., Kings Coll London, Inst Psychiat Psychol \& Neurosci, Ctr Affect Disorders, London, England.
   Rucker, James J.; Cleare, Anthony J., Kings Coll London, South London \& Maudsley NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England.
   Rucker, James J.; Cleare, Anthony J., South London \& Maudsley NHS Fdn Trust, Bethlem Royal Hosp, Beckenham, England.},
DOI = {10.3389/fpsyt.2022.917199},
Article-Number = {917199},
ISSN = {1664-0640},
Keywords = {psychedelic therapy; mystical experience; psilocybin; ayahuasca;
   ketamine; cancer-related distress; substance use disorder (SUD);
   depressive disorders},
Keywords-Plus = {LIFE-THREATENING CANCER; PSILOCYBIN; DEPRESSION; CONSCIOUSNESS;
   DECREASES; ANXIETY; MODEL; RISK},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {kwon.ko@kcl.ac.uk},
Affiliations = {University of London; King's College London; South London \& Maudsley
   NHS Trust; University of London; King's College London; South London \&
   Maudsley NHS Trust},
ResearcherID-Numbers = {Rucker, James/H-6374-2019
   },
ORCID-Numbers = {Rucker, James/0000-0003-4647-8088
   Ko, Kwonmok/0000-0001-5160-7767},
Funding-Acknowledgement = {NIHR Biomedical Research Centre (BRC) at South London; Maudsley NHS
   Foundation Trust; King's College London},
Funding-Text = {This research was supported by the NIHR Biomedical Research Centre (BRC)
   at South London and Maudsley NHS Foundation Trust and King's College
   London.},
Cited-References = {Agin-Liebes GI, 2020, J PSYCHOPHARMACOL, V34, P155, DOI 10.1177/0269881119897615.
   Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249.
   {[}Anonymous], 1960, PHILOSOPHY.
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   Barrett FS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59282-y.
   Barrett FS, 2018, CURR TOP BEHAV NEURO, V36, P393, DOI 10.1007/7854\_2017\_474.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Breeksema JJ, 2021, ACS PHARMACOL TRANSL, V4, P1471, DOI 10.1021/acsptsci.1c00149.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Chi TY, 2020, J NEUROL SCI, V411, DOI 10.1016/j.jns.2020.116715.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Davis AK, 2020, J CONTEXT BEHAV SCI, V15, P39, DOI 10.1016/j.jcbs.2019.11.004.
   de Vos CMH, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.724606.
   Dittrich A, 1998, PHARMACOPSYCHIATRY, V31, P80, DOI 10.1055/s-2007-979351.
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006.
   Hendricks PS, 2018, INT REV PSYCHIATR, V30, P331, DOI 10.1080/09540261.2018.1474185.
   Holze F, 2020, NEUROPSYCHOPHARMACOL, V45, P462, DOI 10.1038/s41386-019-0569-3.
   HOOD RW, 1993, PSYCHOL REP, V73, P1176, DOI 10.2466/pr0.1993.73.3f.1176.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Jones GM, 2022, J PSYCHOPHARMACOL, V36, P57, DOI 10.1177/02698811211066714.
   Jylkka J, 2021, ACS PHARMACOL TRANSL, V4, P1468, DOI 10.1021/acsptsci.1c00137.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Kuypers KPC, 2019, MED HYPOTHESES, V125, P21, DOI 10.1016/j.mehy.2019.02.029.
   Liechti ME, 2017, PSYCHOPHARMACOLOGY, V234, P1499, DOI 10.1007/s00213-016-4453-0.
   Liriano Felix, 2019, Drugs Context, V8, P212305, DOI 10.7573/dic.212305.
   Moher D, 2015, SYST REV-LONDON, V4, DOI {[}10.1186/s13643-015-0087-2, 10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299].
   Muttoni S, 2019, J AFFECT DISORDERS, V258, P11, DOI 10.1016/j.jad.2019.07.076.
   Nichols DE, 2017, CLIN PHARMACOL THER, V101, P209, DOI 10.1002/cpt.557.
   Nour MM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00269.
   Olson DE, 2021, ACS PHARMACOL TRANSL, V4, P563, DOI 10.1021/acsptsci.0c00192.
   Pahnke W N, 1966, J Relig Health, V5, P175, DOI 10.1007/BF01532646.
   Pahnke W. N., 1966, INT J PARAPSYCHOLOGY, VVIII, P295.
   Palhano-Fontes F, 2019, PSYCHOL MED, V49, P655, DOI 10.1017/S0033291718001356.
   Romeo B, 2021, J PSYCHIATR RES, V137, P273, DOI 10.1016/j.jpsychires.2021.03.002.
   Romeo B, 2020, J PSYCHOPHARMACOL, V34, P1079, DOI 10.1177/0269881120919957.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Ross S, 2018, INT REV PSYCHIATR, V30, P317, DOI 10.1080/09540261.2018.1482261.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rothberg RL, 2021, J PSYCHOPHARMACOL, V35, P150, DOI 10.1177/0269881120970879.
   Sanders JW, 2021, ACS PHARMACOL TRANSL, V4, P1253, DOI 10.1021/acsptsci.1c00097.
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898.
   STRASSMAN RJ, 1994, ARCH GEN PSYCHIAT, V51, P98.
   Voineskos D, 2020, NEUROPSYCH DIS TREAT, V16, P221, DOI 10.2147/NDT.S198774.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Wells G, 2014, NEWCASTLE OTTAWA QUA.
   Yaden DB, 2021, ACS PHARMACOL TRANSL, V4, P568, DOI 10.1021/acsptsci.0c00194.},
Number-of-Cited-References = {53},
Times-Cited = {14},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {3L2AW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000834570000001},
OA = {gold, Green Published},
DA = {2023-07-30},
}

@article{ WOS:000791458400001,
Author = {Stein, Cindy A. and Penn, Andrew and Van Hope, Stephanie and Dorsen,
   Caroline G. and Mangini, Mariavittoria},
Title = {The Pharmacology and Clinical Applications of Psychedelic Medicines
   Within Midwifery Practice},
Journal = {JOURNAL OF MIDWIFERY \& WOMENS HEALTH},
Year = {2022},
Volume = {67},
Number = {3},
Pages = {373-383},
Month = {MAY},
Abstract = {The research and use of psychedelic medicines to treat common mental
   health disorders has increased substantially in the past 2 decades. At
   the same time, knowledge is relatively uncommon among midwives regarding
   (1) the relative benefits of psychedelic-assisted therapy, (2) best
   practices associated with the delivery of psychedelic-assisted therapy,
   and (3) responsible integration of this potentially useful intervention
   into mental health treatment plans. The purpose of this review is to
   describe current applications of psychedelic medicines to treat common
   mental health disorders, to describe the current legal status of these
   medicines used in this context, and to explore the potential for
   midwifery practice in this area with further training. This article also
   addresses the disparities regarding LGBTQIA+ and BIPOC populations in
   relation to this topic and their historical exclusion from research and
   treatment access in this field.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Review},
Language = {English},
Affiliation = {Stein, CA (Corresponding Author), Calif State Univ Monterey Bay, Sch Nursing, Seaside, CA 93955 USA.
   Stein, Cindy A., Calif State Univ Monterey Bay, Sch Nursing, Seaside, CA 93955 USA.
   Penn, Andrew, Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
   Van Hope, Stephanie, Nursing \& Sacred Med, New York, NY USA.
   Dorsen, Caroline G., Rutgers Sch Nursing, Div Adv Nursing Practice, Newark, NJ USA.
   Mangini, Mariavittoria, Calif Inst Integral Studies, Integral \& Transpersonal Psychol Dept, San Francisco, CA USA.},
DOI = {10.1111/jmwh.13371},
EarlyAccessDate = {MAY 2022},
ISSN = {1526-9523},
EISSN = {1542-2011},
Keywords = {psychedelics; psilocybin; ketamine; MDMA; depression; PTSD; midwives},
Keywords-Plus = {LIFE-THREATENING CANCER; ASSISTED PSYCHOTHERAPY; DOUBLE-BLIND;
   PSILOCYBIN; KETAMINE; DEPRESSION; ANXIETY; EXPERIENCES; SYMPTOMS;
   DISORDER},
Research-Areas = {Nursing},
Web-of-Science-Categories  = {Nursing},
Author-Email = {csteinsecure@gmail.com},
Affiliations = {California State University System; California State University Monterey
   Bay; University of California System; University of California San
   Francisco; Rutgers State University New Brunswick; Rutgers State
   University Medical Center},
ResearcherID-Numbers = {Dorsen, Caroline/GMW-4050-2022
   Penn, Andrew D/HJI-9943-2023
   },
ORCID-Numbers = {Dorsen, Caroline/0000-0001-8972-9954
   Penn, Andrew D/0000-0001-5552-7078
   Stein, Cindy/0000-0001-5390-1804},
Cited-References = {Aday JS., 2020, DRUG SCI POLICY LAW, P6, DOI {[}10.1177/2050324520974484, DOI 10.1177/2050324520974484].
   Agin-Liebes GI, 2020, J PSYCHOPHARMACOL, V34, P155, DOI 10.1177/0269881119897615.
   Alipoor Mina, 2021, J Med Life, V14, P87, DOI 10.25122/jml-2020-0116.
   Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249.
   Bahji A, 2021, J AFFECT DISORDERS, V278, P542, DOI 10.1016/j.jad.2020.09.071.
   Bahr Rebecca, 2019, P T, V44, P340.
   Belser AB, 2017, J HUMANIST PSYCHOL, V57, P354, DOI 10.1177/0022167817706884.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Byock I, 2018, J PALLIAT MED, V21, P417, DOI 10.1089/jpm.2017.0684.
   Carbonaro TM, 2016, J PSYCHOPHARMACOL, V30, P1268, DOI 10.1177/0269881116662634.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Carhart-Harris RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00020.
   Chen MH, 2022, HUM PSYCHOPHARM CLIN, V37, DOI 10.1002/hup.2820.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Dorsen C, 2019, ADDICT RES THEORY, V27, P68, DOI 10.1080/16066359.2018.1455187.
   dos Santos RG, 2016, J PSYCHOPHARMACOL, V30, P1230, DOI 10.1177/0269881116652578.
   ETKIN NL, 1988, ANNU REV ANTHROPOL, V17, P23, DOI 10.1146/annurev.an.17.100188.000323.
   Feduccia AA, 2018, PSYCHOPHARMACOLOGY, V235, P561, DOI 10.1007/s00213-017-4779-2.
   Garcia-Romeu A, 2018, INT REV PSYCHIATR, V30, P291, DOI 10.1080/09540261.2018.1486289.
   George JR, 2020, J PSYCHEDELIC STUD, V4, P4, DOI 10.1556/2054.2019.015.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grittiths, 2016, PSYCHOPHARMACOLOGY B, V187, P268.
   Hamill J, 2019, CURR NEUROPHARMACOL, V17, P108, DOI 10.2174/1570159X16666180125095902.
   Hartogsohn Ido, 2017, DRUG SCI POLICY LAW, V3, P1, DOI DOI 10.1177/2050324516683325.
   Heal DJ, 2018, NEUROPHARMACOLOGY, V142, P89, DOI 10.1016/j.neuropharm.2018.01.049.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Fuentes JJ, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00943.
   Kaelen M, 2015, PSYCHOPHARMACOLOGY, V232, P3607, DOI 10.1007/s00213-015-4014-y.
   Kaelen M, 2018, PSYCHOPHARMACOLOGY, V235, P505, DOI 10.1007/s00213-017-4820-5.
   Kaertner LS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81446-7.
   Kolp, 2015, INT J TRANSPERS STUD, V33, P84.
   Lee EE, 2015, GEN HOSP PSYCHIAT, V37, P178, DOI 10.1016/j.genhosppsych.2015.01.003.
   Li LD, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00612.
   Marcantoni WS, 2020, J AFFECT DISORDERS, V277, P831, DOI 10.1016/j.jad.2020.09.007.
   Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Mithoefer M.C., 2017, MANUAL MDMA ASSISTED.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611.
   Morgan CJA, 2009, ADDICTION, V104, P77, DOI 10.1111/j.1360-0443.2008.02394.x.
   Muttoni S, 2019, J AFFECT DISORDERS, V258, P11, DOI 10.1016/j.jad.2019.07.076.
   Nichols DE, 2016, PHARMACOL REV, V68, P264, DOI 10.1124/pr.115.011478.
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002.
   Oregon Psilocybin Services, OREGON HLTH AUTHORIT.
   Parrott AC, 2014, HUM PSYCHOPHARM CLIN, V29, P109, DOI 10.1002/hup.2390.
   Passie T, 2002, ADDICT BIOL, V7, P357, DOI 10.1080/1355621021000005937.
   Passie T, 2008, CNS NEUROSCI THER, V14, P295, DOI 10.1111/j.1755-5949.2008.00059.x.
   Penn A, 2021, AM J NURS, V121, P34, DOI 10.1097/01.NAJ.0000753464.35523.29.
   Penn AD, 2021, J HUMANIST PSYCHOL, DOI 10.1177/00221678211011013.
   Phelps J, 2017, J HUMANIST PSYCHOL, V57, P450, DOI 10.1177/0022167817711304.
   Pilecki B, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00489-1.
   Reiche S, 2018, PROG NEURO-PSYCHOPH, V81, P1, DOI 10.1016/j.pnpbp.2017.09.012.
   Reiff CM, 2020, AM J PSYCHIAT, V177, P391, DOI 10.1176/appi.ajp.2019.19010035.
   Richards WA, 2017, J HUMANIST PSYCHOL, V57, P323, DOI 10.1177/0022167816670996.
   Rodrigues LS, 2022, EUR ARCH PSY CLIN N, V272, P541, DOI 10.1007/s00406-021-01267-7.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Serbin JW, 2016, J MIDWIFERY WOM HEAL, V61, P694, DOI 10.1111/jmwh.12572.
   ShinLM DoughertyDD, BIOL PSYCHIAT, V48, P43.
   Strickland JC, 2021, ACS PHARMACOL TRANSL, V4, P472, DOI 10.1021/acsptsci.0c00187.
   Szigeti B, 2021, ELIFE, V10, DOI 10.7554/eLife.62878.
   Thomas K, 2017, J PSYCHOACTIVE DRUGS, V49, P446, DOI 10.1080/02791072.2017.1320734.
   Usona Institute, 2021, INV BROCH PSIL 3 2 D.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P1, DOI 10.1556/2054.2019.032.
   Yao JX, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1715.
   Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255.
   Zarate C, 2010, HARVARD REV PSYCHIAT, V18, P293, DOI 10.3109/10673229.2010.511059.},
Number-of-Cited-References = {70},
Times-Cited = {0},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {10},
Journal-ISO = {J. Midwifery Women Health},
Doc-Delivery-Number = {2A8XN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000791458400001},
OA = {Green Published},
DA = {2023-07-30},
}

@article{ WOS:000709698000004,
Author = {Rea, Kerri and Wallace, Bruce},
Title = {Enhancing equity-oriented care in psychedelic medicine: Utilizing the
   EQUIP framework},
Journal = {INTERNATIONAL JOURNAL OF DRUG POLICY},
Year = {2021},
Volume = {98},
Month = {DEC},
Abstract = {Psychedelic-assisted therapies are experiencing a re-emergence in
   mainstream medicine and mental health contexts. A wide variety of
   psychedelic-assisted therapy modalities are being utilized to address
   mental health issues such as substance use disorders, end of life
   anxiety, treatment-resistant depression, suicidality, PTSD and other
   conditions. The novel and inchoate acceptance of psychedelic-assisted
   therapies into mainstream medical and therapeutic realms raises
   questions of equity. Concerns have been raised that individuals and
   communities facing structural inequities are perhaps least able to
   access these treatments including Black, Indigenous and people of colour
   (BIPOC) as well as people who use drugs. Psychedelic-assisted therapies
   may exemplify the inverse law of care whereby services are most
   inaccessible to communities with the most need, especially if these
   therapies are regulated into the private sector. As legalization and
   wider implementation of these therapies appears to be imminent, now is a
   critical time to consider how health equity may be promoted within
   psychedelic medicine. This paper examines how the EQUIP Health Care
   approach ( https://equiphealthcare.ca ) may inform the development and
   provision of equity-oriented psychedelic-assisted therapies. The EQUIP
   approach seeks to reduce the effects of structural inequities on
   people's health, the impacts of discrimination and stigma, and the
   mismatches between usual approaches to care and the needs of people most
   affected by health and social inequities. Key dimensions of the EQUIP
   intervention include cultural safety, harm reduction, trauma and
   violence-informed care, and contextual tailoring.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Wallace, B (Corresponding Author), Univ Victoria, Sch Social Work, Canadian Inst Subst Use Res CISUR, UVIC Sch Social Work, POB 1700,STN CSC, Victoria, BC V8W 2Y2, Canada.
   Rea, Kerri, Univ Victoria, Sch Social Work, POB 1700,STN CSC, Victoria, BC V8W 2Y2, Canada.
   Wallace, Bruce, Univ Victoria, Sch Social Work, Canadian Inst Subst Use Res CISUR, UVIC Sch Social Work, POB 1700,STN CSC, Victoria, BC V8W 2Y2, Canada.},
DOI = {10.1016/j.drugpo.2021.103429},
EarlyAccessDate = {AUG 2021},
Article-Number = {103429},
ISSN = {0955-3959},
EISSN = {1873-4758},
Keywords = {Psychedelic-assisted therapy; Psychedelic medicine; Health equity; Harm
   reduction; Culturally safe care; Trauma and violence informed care;
   EQUIP intervention},
Keywords-Plus = {DEPRESSION; KETAMINE; SUICIDE; ANXIETY; PEOPLE},
Research-Areas = {Substance Abuse},
Web-of-Science-Categories  = {Substance Abuse},
Author-Email = {barclay@uvic.ca},
Affiliations = {University of Victoria; University of Victoria},
ORCID-Numbers = {Wallace, Bruce/0000-0003-0360-7302},
Cited-References = {ALPERT R, 1969, J SEX RES, V5, P50, DOI 10.1080/00224496909550596.
   Association American Psychological, 1998, AM PSYCHOL, V53, P934.
   BALL J R, 1961, Can Psychiatr Assoc J, V6, P231.
   Balneaves l, 2019, MEDICAL CANNABIS CAN.
   Bartram M, 2019, CAN J PUBLIC HEALTH, V110, P395, DOI 10.17269/s41997-019-00204-5.
   Bartram M, 2019, HEALTH POLICY, V123, P45, DOI 10.1016/j.healthpol.2018.10.011.
   Belser A., 2019, CHACRUNA.
   Browne AJ, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0820-2.
   Browne AJ, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0271-y.
   Browne AJ, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-59.
   Bryan A, 2017, SEXUALITIES, V20, P65, DOI 10.1177/1363460716648099.
   Business Wire, 2019, BUSINESS WIRE.
   Canadian Institute for Health Information, 2016, TRENDS INC REL HLTH.
   Carlin S, 2020, MULTIDISCIPLINARY AS, V30.
   Carpenter DE, 2020, FORBES.
   Dakwar E, 2014, BIOL PSYCHIAT, V76, P40, DOI 10.1016/j.biopsych.2013.08.009.
   Davis D, 2020, HABITAT LOSS DECRIMI.
   Dehmoobadsharifabadi A, 2016, CAN J PUBLIC HEALTH, V107, pE538, DOI {[}10.17269/cjph.107.5454, 10.17269/CJPH.107.5454].
   Dubus Z, 2020, ANN MED-PSYCHOL, V178, P650, DOI 10.1016/j.amp.2020.04.009.
   Escarment J, 2017, J BURN CARE RES, V38, pE689, DOI 10.1097/BCR.0000000000000346.
   Feeney K, 2017, HUM ORGAN, V76, P59, DOI 10.17730/0018-7259.76.1.59.
   Fotiou E, 2016, ANTHROPOL CONSCIOUS, V27, P151, DOI 10.1111/anoc.12056.
   Garcia-Romeu A, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00955.
   Garcia-Romeu A, 2019, J PSYCHOPHARMACOL, V33, P1088, DOI 10.1177/0269881119845793.
   Gashi L, 2021, INT J DRUG POLICY, V87, DOI 10.1016/j.drugpo.2020.102997.
   George JR, 2020, J PSYCHEDELIC STUD, V4, P4, DOI 10.1556/2054.2019.015.
   Gerlach A, 2021, J CHILD HEALTH CARE, V25, P457, DOI 10.1177/1367493520953354.
   Goodman RD, 2015, INT CULT PSYCHOL, P55, DOI 10.1007/978-1-4939-1283-4\_5.
   Government of Canada, 2020, PROP REST POT ACC RE.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Hager M., 2020, GLOBE MAIL.
   HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X.
   Hartogsohn I., 2016, DRUG SCI POLICY LAW, V30, P1, DOI {[}10.1177/0269881116677852, DOI 10.1177/0269881116677852].
   Hutchison C, 2021, CLIN SOC WORK J, V49, P356, DOI 10.1007/s10615-019-00743-x.
   Joiner W, 2020, WASH POST.
   Jones P. N., 2007, CONT JUSTICE REV, V10, P411, DOI {[}10.1080/10282580701677477, DOI 10.1080/10282580701677477].
   Kira IA, 2021, CURR PSYCHOL, V40, P2665, DOI 10.1007/s12144-019-00206-z.
   Kisely S, 2017, J PSYCHIATR RES, V84, P137, DOI 10.1016/j.jpsychires.2016.09.032.
   Levine S, 2021, J INTERPROF CARE, V35, P46, DOI 10.1080/13561820.2019.1708871.
   Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6.
   Miller MJ, 2019, P NATL ACAD SCI USA, V116, P11207, DOI 10.1073/pnas.1902174116.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Multidisciplinary Association of Psychedelic Studies/, PHAS 3 PROGR MDMA AS.
   Negrin D., 2020, COLONIAL SHADOWS PSY.
   Nielson EM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00132.
   Nielson J. L, 2014, AYAHUASCA CANDIDATE, P41, DOI {[}10.1007/978-3-642-40426-9\_3, DOI 10.1007/978-3-642-40426-9\_3].
   Noh JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166238.
   Noller GE, 2018, AM J DRUG ALCOHOL AB, V44, P37, DOI 10.1080/00952990.2017.1310218.
   Orhurhu V, 2019, ANESTH ANALG, V129, P241, DOI 10.1213/ANE.0000000000004185.
   Pauly B, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0764-6.
   Pilecki B, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00489-1.
   Samorini G., 2019, J PSYCHEDELIC STUD, V3, P63, DOI {[}10.1556/2054.2019.008, DOI 10.1556/2054.2019.008].
   Scragg R, 2014, AUST NZ J PUBL HEAL, V38, P194, DOI 10.1111/1753-6405.12199.
   Slomski A, 2014, J AMER MED ASSOC, V312, P327, DOI {[}10.1001/jama.2014.9149, DOI 10.1001/JAMA.2014.9149].
   Smutylo T., 2016, VICTIMS CRIME RES DI.
   Suite DH, 2007, J NATL MED ASSOC, V99, P879.
   Thielking M, 2018, SCI AM.
   Tupper KW, 2015, CAN MED ASSOC J, V187, P1054, DOI 10.1503/cmaj.141124.
   van Roode T, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01276-3.
   Varcoe C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4494-2.
   Wagner A., 2019, MAPS B, V29.
   Wallace B., JBI DATABASE SYSTEMA, V19, P1, DOI {[}10.11124/JBIES, DOI 10.11124/JBIES].
   Wallace B, 2021, INT J EQUITY HEALTH, V20, DOI 10.1186/s12939-021-01394-6.
   Wallace B, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009519.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P1, DOI 10.1556/2054.2019.032.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P40, DOI 10.1556/2054.2019.016.},
Number-of-Cited-References = {66},
Times-Cited = {7},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Int. J. Drug Policy},
Doc-Delivery-Number = {WK4LG},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000709698000004},
OA = {hybrid},
DA = {2023-07-30},
}

@article{ WOS:000541994800001,
Author = {Greenway, Kyle T. and Garel, Nicolas and Jerome, Lisa and Feduccia,
   Allison A.},
Title = {Integrating psychotherapy and psychopharmacology: psychedelic-assisted
   psychotherapy and other combined treatments},
Journal = {EXPERT REVIEW OF CLINICAL PHARMACOLOGY},
Year = {2020},
Volume = {13},
Number = {6},
Pages = {655-670},
Month = {JUN 2},
Abstract = {Introduction Combinations of psychotherapy with antidepressants are
   gold-standard psychiatric treatments. They operate through complex and
   interactional mechanisms, not unlike the reemergent paradigm of
   psychedelic-assisted psychotherapy, which promising research suggests
   may also be highly effective in even challenging populations. Areas
   covered We review the therapeutic mechanisms behind both conventional
   and psychedelic paradigms, including the evolution of this knowledge and
   the associated explanatory frameworks. We explore how psychedelics have
   provided insights about psychiatric illnesses and treatments over the
   past decades. We discuss limitations to early explanatory models while
   highlighting and comparing the psychological and biological mechanisms
   underlying many psychiatric treatments. Methods A narrative review was
   conducted based on a search in Medline/Pubmed up to January 1(st), 2020,
   and iterative retrieval of references from recent reviews and clinical
   trials. Expert opinion The contextual model of the common factors of
   psychotherapy provides a powerful perspective on psychotherapy,
   antidepressants, and psychedelics, as well as
   3,4-methylenedioxymethamphetamine (MDMA) and ketamine. It aligns well
   with key tenets of psychedelic-assisted psychotherapy. Conventional
   antidepressants and especially psychedelics may improve the efficacy of
   psychotherapy via neurochemical changes and increased environmental
   sensitivity. Combined treatments hold significant promise for advancing
   the knowledge and treatment of many forms of psychopathology.},
Publisher = {TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Greenway, KT (Corresponding Author), McGill Univ, Dept Psychiat, 1033 Ave Des Pins, Montreal, PQ, Canada.
   Greenway, Kyle T.; Garel, Nicolas, McGill Univ, Dept Psychiat, 1033 Ave Des Pins, Montreal, PQ, Canada.
   Jerome, Lisa, MAPS Public Benefit Corp, Data Serv, Montreal, PQ, Canada.
   Feduccia, Allison A., Project New Day, Psychedel Support, Montreal, PQ, Canada.},
DOI = {10.1080/17512433.2020.1772054},
EarlyAccessDate = {JUN 2020},
ISSN = {1751-2433},
EISSN = {1751-2441},
Keywords = {Psychedelics; mdma; lsd; psilocybin; psychotherapy; antidepressants;
   psychiatry; psychedelic-assisted psychotherapy; mdma-assisted
   psychotherapy; ketamine; ketamine-assisted psychotherapy},
Keywords-Plus = {LYSERGIC-ACID DIETHYLAMIDE; POSTTRAUMATIC-STRESS-DISORDER; MAJOR
   DEPRESSIVE DISORDER; COMMON FACTORS; DOUBLE-BLIND;
   3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; ANTIDEPRESSANT
   MEDICATION; PSYCHIATRIC-DISORDERS; PSILOCYBIN TREATMENT; HALLUCINOGEN
   USE},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {kyle.greenway@mail.mcgill.ca},
Affiliations = {McGill University},
ORCID-Numbers = {Garel, Nicolas/0000-0002-4031-9943
   Greenway, Kyle/0000-0002-7829-493X},
Cited-References = {Alboni S, 2017, MOL PSYCHIATR, V22, P635, DOI 10.1038/mp.2015.191.
   Amick HR, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6019.
   Andrews PW, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00117.
   Andrews-Hanna JR, 2011, NEUROSCIENTIST.
   Angermann CE, 2016, JAMA-J AM MED ASSOC, V315, P2683, DOI 10.1001/jama.2016.7635.
   Ankarberg P, 2008, PSYCHOTHERAPY, V45, P329, DOI 10.1037/a0013309.
   {[}Anonymous], 1991, PERSUASION HEALING C, DOI DOI 10.56021/9780801840678.
   {[}Anonymous], 2019, FDA GRANTS BREAKTHRO.
   {[}Anonymous], 2010, PHILOS COGNITIVE BEH.
   {[}Anonymous], 1972, J MUSIC THER, DOI {[}DOI 10.1093/JMT/9.2.64, 10.1093/jmt/9.2.64].
   {[}Anonymous], 2017, TRANSFUSION, V57, p3A.
   {[}Anonymous], 1992, ACID DREAMS COMPLETE.
   Bahr Rebecca, 2019, P T, V44, P340.
   Ballesta S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147136.
   Baltenberger EP., 2015, MENT HLTH CLIN, V5, P123, DOI {[}10.9740/mhc.2015.05.123, DOI 10.9740/MHC.2015.05.123].
   Ban Thomas A, 2007, Neuropsychiatr Dis Treat, V3, P495.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   BARRETT FS, 2018, CEREB CORTEX, V28, P3939, DOI DOI 10.1093/CERCOR/BHX257.
   Barsaglini A, 2014, PROG NEUROBIOL, V114, P1, DOI 10.1016/j.pneurobio.2013.10.006.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Blewet DB, 1959, HDB THERAPEUTIC USE.
   Brent DA, 1998, J ABNORM CHILD PSYCH, V26, P17, DOI 10.1023/A:1022678622119.
   Brown C, 2005, MED CARE, V43, P1203, DOI 10.1097/01.mlr.0000185733.30697.f6.
   Brown J, 2015, AM J PSYCHOTHER, V69, P301, DOI 10.1176/appi.psychotherapy.2015.69.3.301.
   Buckner RL, 2008, YEAR COGN NEUROSCI.
   Budd R, 2009, CLIN PSYCHOL PSYCHOT, V16, P510, DOI 10.1002/cpp.648.
   Busch AK, 1950, DIS NERV SYST, V11, P241.
   Campbell LF, 2013, PSYCHOTHERAPY, V50, P98, DOI 10.1037/a0031817.
   Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160.
   Carhart-Harris RL, 2015, PSYCHOPHARMACOLOGY, V232, P785, DOI 10.1007/s00213-014-3714-z.
   Carhart-Harris RL, 2014, INT J NEUROPSYCHOPH, V17, P527, DOI 10.1017/S1461145713001405.
   Carhart-Harris RL, 2010, BRAIN, V133, P1265, DOI 10.1093/brain/awq010.
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Carhart-Harris RL, 2016, P NATL ACAD SCI USA, V113, P4853, DOI 10.1073/pnas.1518377113.
   Carhart-Harris RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00020.
   Castelnuovo G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00563.
   Cautin RL, 2011, HIST PSYCHOTHER CONT.
   Charney DA, 2015, ALCOHOL CLIN EXP RES, V39, P1756, DOI 10.1111/acer.12802.
   Chiarotti F, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.35.
   Cipriani A, 2018, LANCET, V392, P1012, DOI 10.1016/S0140-6736(18)31780-X.
   Clark DM, 2009, BEHAV RES THER, V47, P910, DOI 10.1016/j.brat.2009.07.010.
   Clayton DO, 1998, DRUG SAFETY, V19, P299, DOI 10.2165/00002018-199819040-00005.
   Clifford Terry, 1984, TIBETAN BUDDHIST MED.
   Cooper MD, 2017, WORLD J BIOL PSYCHIA, V18, P410, DOI 10.3109/15622975.2016.1139747.
   Corrigan-Curay J, 2018, NEW ENGL J MED, V378, P1457, DOI 10.1056/NEJMc1801222.
   Craighead WE, 2014, ANNU REV PSYCHOL, V65, P267, DOI 10.1146/annurev.psych.121208.131653.
   Crawford MJ, 2016, BRIT J PSYCHIAT, V209, P6, DOI 10.1192/bjp.bp.115.179747.
   Cristea IA, 2015, CLIN PSYCHOL REV, V42, P62, DOI 10.1016/j.cpr.2015.08.003.
   Cuijpers P, 2019, ANNU REV CLIN PSYCHO, V15, P207, DOI 10.1146/annurev-clinpsy-050718-095424.
   Cuijpers P, 2014, WORLD PSYCHIATRY, V13, P56, DOI 10.1002/wps.20089.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Dakwar E, 2019, AM J PSYCHIAT, V176, P923, DOI 10.1176/appi.ajp.2019.18101123.
   Danforth AL, 2018, PSYCHOPHARMACOLOGY, V235, P3137, DOI 10.1007/s00213-018-5010-9.
   Davies J, 2019, ADDICT BEHAV, V97, P111, DOI 10.1016/j.addbeh.2018.08.027.
   de la Torre R, 2004, THER DRUG MONIT, V26, P137, DOI 10.1097/00007691-200404000-00009.
   Demyttenaere K, 2019, INT J NEUROPSYCHOPH, V22, P85, DOI 10.1093/ijnp/pyy052.
   DeRubeis RJ, 2008, NAT REV NEUROSCI, V9, P788, DOI 10.1038/nrn2345.
   Dijkstra K, 2006, J ADV NURS, V56, P166, DOI 10.1111/j.1365-2648.2006.03990.x.
   DIRKSNAYLOR AJ, 2016, FASEB J S1, V30.
   Doblin RE, 2019, J PSYCHOACTIVE DRUGS, V51, P93, DOI 10.1080/02791072.2019.1606472.
   Dobscha SK, 2007, PSYCHOSOMATICS, V48, P482, DOI 10.1176/appi.psy.48.6.482.
   Dolder PC, 2016, NEUROPSYCHOPHARMACOL, V41, P2638, DOI 10.1038/npp.2016.82.
   Domino EF, 2010, ANESTHESIOLOGY, V113, P678, DOI 10.1097/ALN.0b013e3181ed09a2.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Duman RS, 2012, SCIENCE, V338, P68, DOI 10.1126/science.1222939.
   Elliott C, 1994, BMJ-BRIT MED J, V308.
   Elmer Lori, 2003, HUMANISTIC PSYCHOL, V31, P159, DOI DOI 10.1080/08873267.2003.9986929.
   Emmelkamp PMG, 2014, INT J METH PSYCH RES, V23, P58, DOI 10.1002/mpr.1411.
   Erritzoe D, 2018, ACTA PSYCHIAT SCAND, V138, P368, DOI 10.1111/acps.12904.
   Faria V, 2017, EBIOMEDICINE, V24, P179, DOI 10.1016/j.ebiom.2017.09.031.
   Fava GA, 2018, PSYCHOTHER PSYCHOSOM, V87, P1, DOI 10.1159/000485001.
   Fava GA, 2014, PSYCHOTHER PSYCHOSOM, V83, P1, DOI 10.1159/000355205.
   Feduccia AA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00650.
   Felger Jennifer C, 2019, Handb Exp Pharmacol, V250, P255, DOI 10.1007/164\_2018\_166.
   Foa Edna B, 2010, Dialogues Clin Neurosci, V12, P199.
   FRANK JD, 1971, AM J PSYCHOTHER, V25, P350, DOI 10.1176/appi.psychotherapy.1971.25.3.350.
   FREUD S, 1994, INTERPRETATION DREAM.
   Freud S, 2007, HIST PSYCHOANALYTIC.
   Friedrich M J, 2017, JAMA, V317, P1517, DOI 10.1001/jama.2017.3826.
   Gaynes BN, 2009, PSYCHIAT SERV, V60, P1439, DOI 10.1176/ps.2009.60.11.1439.
   Geyer MA, 2008, TRENDS PHARMACOL SCI, V29, P445, DOI 10.1016/j.tips.2008.06.006.
   Glue P, 2020, J PSYCHOPHARMACOL, V34, P267, DOI 10.1177/0269881119874457.
   Gnanasakthy A, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15\_suppl.e18730.
   Goldstone D, 2017, S AFR J PSYCHOL, V47, P84, DOI 10.1177/0081246316653860.
   Greenberg PE, 2015, J CLIN PSYCHIAT, V76, P155, DOI 10.4088/JCP.14m09298.
   GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319, DOI 10.1080/02791072.1986.10472364.
   Gribkoff VK, 2017, NEUROPHARMACOLOGY, V120, P11, DOI 10.1016/j.neuropharm.2016.03.021.
   Griffiths BB, 2018, FASEB J, V32.
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5.
   GRINSPOON L, 1981, SCIENCES, V21, P20, DOI 10.1002/j.2326-1951.1981.tb01901.x.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   GROF S, 1973, INT PHARMACOPSYCHIAT, V8, P129, DOI 10.1159/000467984.
   Grof S, 2008, LSD PSYCHOTHERAPY BE.
   Gross R, 1998, GEN HOSP PSYCHIAT, V20, P108, DOI 10.1016/S0163-8343(98)00007-3.
   Guo YC, 2016, INT J MOD PHYS A, V31, DOI 10.1142/S0217751X1650086X.
   Haijen ECHM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00897.
   Haile CN, 2014, INT J NEUROPSYCHOPH, V17, P331, DOI 10.1017/S1461145713001119.
   Hartberg J, 2018, PSYCHOPHARMACOLOGY, V235, P393, DOI 10.1007/s00213-017-4786-3.
   Hartogsohn Ido, 2017, DRUG SCI POLICY LAW, V3, P1, DOI DOI 10.1177/2050324516683325.
   Heifets BD, 2019, JAMA PSYCHIAT, V76, P775, DOI 10.1001/jamapsychiatry.2019.1145.
   Hendricks PS, 2018, J PSYCHOPHARMACOL, V32, P37, DOI 10.1177/0269881117735685.
   Hendricks PS, 2014, J PSYCHOPHARMACOL, V28, P62, DOI 10.1177/0269881113513851.
   Hengartner MP, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00275.
   Hewitt K, 2016, HIST SCI, V54, P307, DOI 10.1177/0073275316674724.
   Hillhouse TM, 2015, EXP CLIN PSYCHOPHARM, V23, P1, DOI 10.1037/a0038550.
   HOFFER A, 1965, CLIN PHARMACOL THER, V6, P183.
   Holze F, 2020, NEUROPSYCHOPHARMACOL, V45, P462, DOI 10.1038/s41386-019-0569-3.
   Hu R, 2019, ADV MATER INTERFACES, V6, DOI 10.1002/admi.201901834.
   Huhn M, 2014, JAMA PSYCHIAT, V71, P706, DOI 10.1001/jamapsychiatry.2014.112.
   Hurth KP, 2020, CARE MED, V1.
   Iacobucci G., 2019, BMJ, V364, pl87, DOI 10.1136/bmj.l8730622107.
   Imel ZE, 2008, J AFFECT DISORDERS, V110, P197, DOI 10.1016/j.jad.2008.03.018.
   Johnson CF, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0643-z.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Johnson MW, 2018, INT REV PSYCHIATR, V30, P285, DOI 10.1080/09540261.2018.1509544.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kaelen M, 2015, PSYCHOPHARMACOLOGY, V232, P3607, DOI 10.1007/s00213-015-4014-y.
   Kaelen M, 2018, PSYCHOPHARMACOLOGY, V235, P505, DOI 10.1007/s00213-017-4820-5.
   Kamenov K, 2017, PSYCHOL MED, V47, P414, DOI 10.1017/S0033291716002774.
   Kaplan RM, INT J HUMANIT SOC SC.
   Karapanagiotidis T, 2017, NEUROIMAGE, V147, P272, DOI 10.1016/j.neuroimage.2016.12.031.
   Kasprow M C, 1999, J Psychother Pract Res, V8, P12.
   Katzman MA, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-S1-S1.
   Keefe JR, 2014, CLIN PSYCHOL REV, V34, P309, DOI 10.1016/j.cpr.2014.03.004.
   Keller MB, 2002, INT CLIN PSYCHOPHARM, V17, P265, DOI 10.1097/00004850-200211000-00001.
   Kennedy SH, 2016, CAN J PSYCHIAT, V61, P540, DOI 10.1177/0706743716659417.
   Kirkpatrick M, 2015, J PSYCHOPHARMACOL, V29, P661, DOI 10.1177/0269881115573806.
   Kirsch I., 2002, PREV TREAT, V5, P23, DOI 10.1037/1522-3736.5.1.523a.
   Kirsch I, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00407.
   KLAVETTER RE, 1967, J HUMANIST PSYCHOL, V7, P171, DOI 10.1177/002216786700700206.
   Koch JM, 2009, PSYCHOTHER PSYCHOSOM, V78, P187, DOI 10.1159/000209350.
   Kolp E., 2007, INT J TRANSPERSONAL, V26, P1, DOI DOI 10.24972/IJTS.2007.26.1.1.
   Kolp E., 2014, INT J TRANSPERS STUD, V33, P84, DOI {[}DOI 10.24972/IJTS.2014.33.2.84, https://doi.org/10.24972/ijts.2014.33.2.84].
   Kolp E., 2006, HUMANISTIC PSYCHOL, V34, P399, DOI DOI 10.1207/S15473333THP3404\_7.
   Kraehenmann R, 2017, PSYCHOPHARMACOLOGY, V234, P2031, DOI 10.1007/s00213-017-4610-0.
   Krebs TS, 2012, J PSYCHOPHARMACOL, V26, P994, DOI 10.1177/0269881112439253.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Kryst J, 2020, PHARMACOL REP, V72, P543, DOI 10.1007/s43440-020-00097-z.
   Kulak-Bejda A, 2017, PHARMACOL REP, V69, P1366, DOI 10.1016/j.pharep.2017.05.014.
   Layard R, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01713.
   Leary T, 2007, PSYCHEDELIC EXPERIEN.
   Leubner D, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01109.
   Leuchter AF, 2014, BRIT J PSYCHIAT, V205, P443, DOI 10.1192/bjp.bp.113.140343.
   Liechti ME, 2017, NEUROPSYCHOPHARMACOL, V42, P2114, DOI 10.1038/npp.2017.86.
   Lindemann E, 1932, AM J PSYCHIAT, V11, P1083.
   Liu BS, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00305.
   Liu Y, 2016, BRAIN RES BULL, V126, P68, DOI 10.1016/j.brainresbull.2016.05.016.
   Lowe LM, 2015, J ANAL TOXICOL, V39, P668, DOI 10.1093/jat/bkv092.
   Lur G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213721.
   Lyons T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15\_suppl.531.
   Masand PS, 2003, CLIN THER, V25, P2289, DOI 10.1016/S0149-2918(03)80220-5.
   McAndrew A, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1895-6.
   McHugh RK, 2013, J CLIN PSYCHIAT, V74, P595, DOI 10.4088/JCP.12r07757.
   Meduna LJ, 1950, CARBON DIOXIDE THERA, DOI DOI 10.1037/13238-000.
   Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6.
   Milliere R, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01475.
   Mithoefer M., 2017, MANUAL MDMA ASSISTED.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611.
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371.
   Moda-Sava RN, 2019, SCIENCE, V364, P147, DOI 10.1126/science.aat8078.
   Moncrieff J, 2004, Cochrane Database Syst Rev, pCD003012.
   Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999.
   Moore TJ, 2017, JAMA INTERN MED, V177, P274, DOI 10.1001/jamainternmed.2016.7507.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Morrison AP, 2018, LANCET PSYCHIAT, V5, P411, DOI 10.1016/S2215-0366(18)30096-8.
   Muller F, 2018, NEUROIMAGE-CLIN, V18, P694, DOI 10.1016/j.nicl.2018.03.005.
   Mullen LS, 1999, DEPRESS ANXIETY, V10, P168, DOI 10.1002/(SICI)1520-6394(1999)10:4<168::AID-DA5>3.0.CO;2-5.
   Muttoni S, 2019, J AFFECT DISORDERS, V258, P11, DOI 10.1016/j.jad.2019.07.076.
   Nichols DE, 2016, PHARMACOL REV, V68, P264, DOI 10.1124/pr.115.011478.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Norrie C, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1464-9.
   Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887.
   Nutt David, 2011, Eur Neuropsychopharmacol, V21, P495, DOI 10.1016/j.euroneuro.2011.05.004.
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6.
   Orsolini L, 2017, CNS NEUROL DISORD-DR, V16, P65, DOI 10.2174/1871527315666161025140111.
   Osorio H, 2015, REV BRAS HIST, V35, DOI 10.1590/1806-93472015v35n70013.
   Ostergaard SD, 2018, ACTA NEUROPSYCHIATR, V30, P241, DOI 10.1017/neu.2017.6.
   Palmer SC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004541.pub3.
   Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714.
   Passie T, 2018, DRUG SCI POLICY LAW, V4, P1, DOI {[}10.1177/2050324518767442, DOI 10.1177/2050324518767442].
   Passie T, 2008, CNS NEUROSCI THER, V14, P295, DOI 10.1111/j.1755-5949.2008.00059.x.
   Perroud N, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.140.
   Peters SK, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00104.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Pollan M., 2018, CHANGE YOUR MIND WHA.
   Preller KH, 2019, P NATL ACAD SCI USA, V116, P2743, DOI 10.1073/pnas.1815129116.
   Preller KH, 2017, CURR BIOL, V27, P451, DOI 10.1016/j.cub.2016.12.030.
   Prosser A, 2016, BRIT J PSYCHIAT, V208, P309, DOI 10.1192/bjp.bp.115.178368.
   Ramachandraih Chaitra T, 2011, Indian J Psychiatry, V53, P180, DOI 10.4103/0019-5545.82567.
   Ramsberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042003.
   Richards DA, 2016, LANCET, V388, P871, DOI 10.1016/S0140-6736(16)31140-0.
   Richards W. A., 2015, SACRED KNOWLEDGE PSY.
   Rivera-Chavez F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003267.
   Roberts S, 2015, DEPRESS ANXIETY, V32, P861, DOI 10.1002/da.22430.
   Rock PL, 2014, PSYCHOL MED, V44, P2029, DOI 10.1017/S0033291713002535.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Rosenzweig S, 1936, AM J ORTHOPSYCHIAT, V6, P412, DOI 10.1111/j.1939-0025.1936.tb05248.x.
   Ross EL, 2019, ANN INTERN MED, V171, P785, DOI 10.7326/M18-1480.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rubio-Valera M, 2019, EUR J HEALTH ECON, V20, P703, DOI 10.1007/s10198-019-01034-5.
   SANDISON RA, 1954, J MENT SCI, V100, P491, DOI 10.1192/bjp.100.419.491.
   SANDISON RA, 1954, J MENT SCI, V100, P508, DOI 10.1192/bjp.100.419.508.
   Sansone RA, 2012, CLIN NEUROSCI, V9.
   Schenberg EE, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00733.
   Scott LJ, 2019, DRUGS, V79, P779, DOI 10.1007/s40265-019-01121-0.
   Singh JB, 2016, AM J PSYCHIAT, V173, P816, DOI 10.1176/appi.ajp.2016.16010037.
   Sleigh J, 2014, TRENDS ANAESTH CRIT, V4, P76, DOI 10.1016/j.tacc.2014.03.002.
   Sos P, 2013, NEUROENDOCRINOL LETT, V34, P287.
   Stahl SM, 2012, J CLIN PHARM THER, V37, P249, DOI 10.1111/j.1365-2710.2011.01301.x.
   Steinkamp JM, 2019, JMIR MENT HEALTH, V6, DOI 10.2196/12493.
   Stockings GT, 1940, J NERV MENT DIS, V92.
   Strassman Rick, 2001, DMT SPIRIT MOL DOCTO.
   Studerus E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030800.
   Studerus E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012412.
   Taking Psychedelics BI, 2018, J PALLIAT MED, V21.
   Thiessen MS, 2018, J PSYCHOPHARMACOL.
   Thomas L, 2013, BR J GEN PRACT, V63, pe852.
   Thomas P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1327-4.
   van Ballegooijen W, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0735-7.
   van der Schaaf PS, 2013, BRIT J PSYCHIAT, V202, P142, DOI 10.1192/bjp.bp.112.118422.
   Viglione A, 2019, PHARMACOGENOMICS J, V19, P538, DOI 10.1038/s41397-019-0080-6.
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2.
   Wajs E, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19m12891.
   Walsh Z, 2016, J PSYCHOPHARMACOL, V30, P601, DOI 10.1177/0269881116642538.
   Waltz M, 2013, AUTISM: A SOCIAL AND MEDICAL HISTORY, P73.
   Wampold BE, 2015, GREAT PSYCHOTHERAPY DEBATE: THE EVIDENCE FOR WHAT MAKES PSYCHOTHERAPY WORK, 2ND EDITION, P1.
   Wampold BE, 2015, WORLD PSYCHIATRY, V14, P270, DOI 10.1002/wps.20238.
   Watanabe N, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-18.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Weinberger AH, 2018, PSYCHOL MED, V48, P1308, DOI 10.1017/S0033291717002781.
   Wenthur CJ, 2014, ACS CHEM NEUROSCI, V5, P14, DOI 10.1021/cn400186j.
   Wentink C, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0989-5.
   Winnicott DW, 1953, INT J PSYCHOANAL, V34, P89.
   WOOLLEY DW, 1954, P NATL ACAD SCI USA, V40, P228, DOI 10.1073/pnas.40.4.228.
   Zilcha-Mano S, 2015, PSYCHOTHER PSYCHOSOM, V84, DOI 10.1159/000379756.},
Number-of-Cited-References = {238},
Times-Cited = {23},
Usage-Count-Last-180-days = {6},
Usage-Count-Since-2013 = {25},
Journal-ISO = {Expert Rev. Clin. Pharmacol.},
Doc-Delivery-Number = {MR6FQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000541994800001},
DA = {2023-07-30},
}

@article{ WOS:000970566100001,
Author = {Feduccia, Allison and Agin-Liebes, Gabby and Price, Collin M. and
   Grinsell, Nicole and Paradise, Summer and Rabin, David M.},
Title = {The need for establishing best practices and gold standards in
   psychedelic medicine},
Journal = {JOURNAL OF AFFECTIVE DISORDERS},
Year = {2023},
Volume = {332},
Pages = {47-54},
Month = {JUL 1},
Abstract = {Psychedelic substances are under investigation in several drug
   development programs. Controlled clinical trials are providing evidence
   for safe and effective use of psychedelic therapies for treating mental
   health conditions. With the anticipated FDA approval of MDMA-assisted
   therapy for posttraumatic stress disorder in 2023 and psilocybin therapy
   for depression disorders soon after, now is the time for the medical
   community to become informed on best practices and to actively
   participate in developing standards of care for these new treatments.
   Given the emergence of numerous drug sponsors and other companies
   developing therapeutic modalities for combination with psychedelic
   medications, it is essential that the medical professional field is at
   the forefront of communicating unbiased information related to safety
   and effectiveness. Gold standards have long been a part of medicine and
   serve to distinguish treatments and assessments as the highest quality
   by which all others can be compared to. For a treatment to be
   established as a gold standard, several factors are considered including
   the quantity and quality of the supporting data, the rigor of trials,
   and the safety and efficacy compared to other treatments. In this
   article, we review the origins of psychedelic-assisted therapy (PAT),
   minimum requirements for safe use of psychedelics, criteria for gold
   standards in mental health, and the nuances regarding how to establish
   gold standards in psychedelic medicine and guide clinical decision
   making.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Feduccia, A (Corresponding Author), 1146 Soquel Ave,POB 3688, Santa Cruz, CA 95062 USA.
   Feduccia, Allison, Psychedel Support, Santa Cruz, CA USA.
   Agin-Liebes, Gabby, Univ Calif San Francisco, Weill Inst Neurosci, Dept Psychiat, Neuroscape, San Francisco, CA USA.
   Price, Collin M., Univ Calif Los Angeles, UCLA Semel Inst Neurosci \& Human Behav, Dept Psychiat, Los Angeles, CA USA.
   Grinsell, Nicole; Paradise, Summer, Apollo Clin, Salt Lake City, UT USA.
   Rabin, David M., Apollo Clin, Board Med, Salt Lake City, UT USA.},
DOI = {10.1016/j.jad.2023.03.083},
EarlyAccessDate = {APR 2023},
ISSN = {0165-0327},
EISSN = {1573-2517},
Keywords = {Psychedelic medicines; MDMA; Psilocybin; Ketamine; Esketamine; Gold
   standards},
Keywords-Plus = {LIFE-THREATENING CANCER; PSILOCYBIN; THERAPY; LSD; RESISTANT; DISORDER;
   MDMA; KETAMINE; ANXIETY; ANTIDEPRESSANTS},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Psychiatry},
Author-Email = {alli@psychedelic.support
   gabrielle.agin-liebes@ucsf.edu
   CollinPrice@mednet.ucla.edu
   nicole@apollo.clinic
   drparadise@apollo.clinic
   drrabin@theboardofmedicine.org},
Affiliations = {University of California System; University of California San Francisco;
   University of California System; University of California Los Angeles},
Funding-Acknowledgement = {National Institutes of Health {[}T32DA007250]},
Funding-Text = {Author statement This work was supported by the National Institutes of
   Health {[}T32DA007250] to Gabby Agin-Liebes, PhD.},
Cited-References = {Aday JS, 2022, PSYCHOPHARMACOLOGY, V239, P1989, DOI 10.1007/s00213-022-06123-7.
   Anderson BT, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100538.
   Anderson BT, 2020, LANCET PSYCHIAT, V7, P829, DOI 10.1016/S2215-0366(20)30146-2.
   {[}Anonymous], 1972, J MUSIC THER, DOI {[}DOI 10.1093/JMT/9.2.64, 10.1093/jmt/9.2.64].
   {[}Anonymous], 1979, PSYCHEDELIC DRUGS RE.
   Baghai Thomas C, 2008, Dialogues Clin Neurosci, V10, P105.
   Balan-Moshe L, 2021, EUR CHILD ADOLES PSY, V30, P681, DOI 10.1007/s00787-021-01765-y.
   Becker AM, 2022, CLIN PHARMACOL THER, V111, P886, DOI 10.1002/cpt.2487.
   Bogenschutz MP, 2022, JAMA PSYCHIAT, V79, P953, DOI 10.1001/jamapsychiatry.2022.2096.
   Bogenschutz MP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00100.
   Bogenschutz MP, 2017, J HUMANIST PSYCHOL, V57, P389, DOI 10.1177/0022167816673493.
   Bonson KR, 2018, PSYCHOPHARMACOLOGY, V235, P591, DOI 10.1007/s00213-017-4777-4.
   Bonson KR, 1996, NEUROPSYCHOPHARMACOL, V14, P425, DOI 10.1016/0893-133X(95)00145-4.
   Bonson KR, 1996, BEHAV BRAIN RES, V73, P229.
   Brady LS, 2019, EXPERT OPIN DRUG DIS, V14, P1213, DOI 10.1080/17460441.2019.1666102.
   Brodsky SL, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00562.
   Bullen C, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5351-7.
   Butler M, 2022, PSYCHOPHARMACOLOGY, V239, P3047, DOI 10.1007/s00213-022-06221-6.
   Cameron LP, 2021, NATURE, V589, P474, DOI 10.1038/s41586-020-3008-z.
   Carhart-Harris RL, 2015, PSYCHOPHARMACOLOGY, V232, P785, DOI 10.1007/s00213-014-3714-z.
   Carhart-Harris RL, 2010, BRAIN, V133, P1265, DOI 10.1093/brain/awq010.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Cavarra M, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.887255.
   Claassen J.A.H.R., 2005, BMJ-BRIT MED J, V330, P1121, DOI DOI 10.1136/BMJ.330.7500.1121.
   Cohen S., 1965, PSYCHOSOM MED, V27, P397.
   Dakwar E, 2020, AM J PSYCHIAT, V177, P125, DOI 10.1176/appi.ajp.2019.19070684.
   David D, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00004.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   Doblin R, 2002, J PSYCHOACTIVE DRUGS, V34, P185, DOI 10.1080/02791072.2002.10399952.
   DUGGAN PF, 1992, BRIT MED J, V304, P1568, DOI 10.1136/bmj.304.6841.1568-b.
   Espinoza RT, 2022, NEW ENGL J MED, V386, P667, DOI 10.1056/NEJMra2034954.
   Feduccia AA, 2021, PSYCHOPHARMACOLOGY, V238, P581, DOI 10.1007/s00213-020-05710-w.
   Feduccia AA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00650.
   FEINSTEIN AR, 1982, NEW ENGL J MED, V307, P1611, DOI 10.1056/NEJM198212233072604.
   Frecska Ede, 2006, Neuropsychopharmacol Hung, V8, P189.
   Galvao-Coelho NL, 2021, PSYCHOPHARMACOLOGY, V238, P341, DOI 10.1007/s00213-020-05719-1.
   Garcia-Romeu A, 2018, INT REV PSYCHIATR, V30, P291, DOI 10.1080/09540261.2018.1486289.
   Gazdag G, 2019, WORLD J PSYCHIATR, V9, P1, DOI 10.5498/wjp.v9.i1.1.
   Goldberg JF, 2022, CNS SPECTRUMS, V27, P525, DOI 10.1017/S1092852921000110.
   Goodwin GM, 2022, NEW ENGL J MED, V387, P1637, DOI 10.1056/NEJMoa2206443.
   Gouzoulis-Mayfrank G, 1998, PHARMACOPSYCHIATRY, V31, P114, DOI 10.1055/s-2007-979356.
   GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319, DOI 10.1080/02791072.1986.10472364.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grof S., 1772, J SCI STUD RELIG.
   Guerra-Doce E, 2015, TIME MIND, V8, P91, DOI 10.1080/1751696X.2014.993244.
   Gukasyan N, 2022, J PSYCHOPHARMACOL, V36, P151, DOI 10.1177/02698811211073759.
   Guss J., 2020, YALE MANUAL PSILOCYB, DOI {[}10.31234/osf.io/u6v9y.PsyArXiv, DOI 10.31234/OSF.IO/U6V9Y.PSYARXIV].
   Hull TD, 2022, J AFFECT DISORDERS, V314, P59, DOI 10.1016/j.jad.2022.07.004.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Jones DS, 2015, LANCET, V385, P1502, DOI 10.1016/S0140-6736(15)60742-5.
   Kaertner LS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81446-7.
   Kelmendi B, 2016, EUR J PSYCHOTRAUMATO, V7, DOI 10.3402/ejpt.v7.31858.
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Langlitz N, 2022, BIOSOCIETIES, DOI 10.1057/s41292-022-00294-4.
   Lebedev AV, 2015, HUM BRAIN MAPP, V36, P3137, DOI 10.1002/hbm.22833.
   Luoma JB, 2020, J PSYCHOACTIVE DRUGS, V52, P289, DOI 10.1080/02791072.2020.1769878.
   Marks M., 2021, HARV L REV F, V135.
   Masuda T, 2019, JAMA PSYCHIAT, V76, P1052, DOI 10.1001/jamapsychiatry.2019.1702.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Mithoefer M., 2017, MANUAL MDMA ASSISTED.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mittal ML, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0126-1.
   Murphy R, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.788155.
   Muthukumaraswamy SD, 2021, EXPERT REV CLIN PHAR, V14, P1133, DOI 10.1080/17512433.2021.1933434.
   Noel Jason M, 2020, Am J Health Syst Pharm, V77, P2114, DOI 10.1093/ajhp/zxaa303.
   Noorani T, 2021, PHILOS PSYCHIATR PSY, V28, P201.
   Nour MM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00269.
   Ocker AC, 2020, PAIN PRACT, V20, P95, DOI 10.1111/papr.12829.
   Oehen P, 2013, J PSYCHOPHARMACOL, V27, P40, DOI 10.1177/0269881112464827.
   OSMOND H, 1957, ANN NY ACAD SCI, V66, P418, DOI 10.1111/j.1749-6632.1957.tb40738.x.
   Pahnke W N, 1969, Int Psychiatry Clin, V5, P149.
   PAHNKE WN, 1970, J AMER MED ASSOC, V212, P1856, DOI 10.1001/jama.212.11.1856.
   Passie T, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1020505.
   Pilecki B, 2021, HARM REDUCT J, V18, DOI 10.1186/s12954-021-00489-1.
   Richards WA, 2017, J HUMANIST PSYCHOL, V57, P323, DOI 10.1177/0022167816670996.
   Roseman L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00204.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rucker JJH, 2018, NEUROPHARMACOLOGY, V142, P200, DOI 10.1016/j.neuropharm.2017.12.040.
   Sarparast A, 2022, PSYCHOPHARMACOLOGY, V239, P1945, DOI 10.1007/s00213-022-06083-y.
   Stein DJ, 2006, INT J PSYCHIAT CLIN, V10, P16, DOI 10.1080/13651500600552487.
   Tai SJ, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.586682.
   Tancer M, 2007, PSYCHOPHARMACOLOGY, V189, P565, DOI 10.1007/s00213-006-0576-z.
   Tondo L, 2019, INT J BIPOLAR DISORD, V7, DOI 10.1186/s40345-019-0151-2.
   Villeneuve N., 2022, EXAMINING DARK SIDES, P34.
   Volkmann C, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00377.
   Wagner AC, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.702838.
   Wilkinson ST, 2021, PSYCHOTHER PSYCHOSOM, V90, P318, DOI 10.1159/000517074.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Winslow BT, 2016, AM FAM PHYSICIAN, V93, P457.
   Wolfson P., 2016, KETAMINE PAPERS SCI.
   Wolraich ML, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1682.
   World Health Organization, 2021, WHO DEPR FACT SHEET.
   Yang CS, 2019, PHARMACOPSYCHIATRY, V52, P7, DOI 10.1055/s-0043-124872.
   Yu CL, 2021, PSYCHIAT INVEST, V18, P958, DOI 10.30773/pi.2021.0209.},
Number-of-Cited-References = {100},
Times-Cited = {2},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {J. Affect. Disord.},
Doc-Delivery-Number = {D7NU4},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000970566100001},
DA = {2023-07-30},
}

@article{ WOS:000942813100001,
Author = {Emmerich, Nathan and Humphries, Bryce},
Title = {Is the Requirement for First-Person Experience of Psychedelic Drugs a
   Justified Component of a Psychedelic Therapist's Training?},
Journal = {CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS},
Year = {2023},
Month = {2023 MAR 2},
Abstract = {Recent research offers good reason to think that various psychedelic
   drugs-including psilocybin, ayahuasca, ketamine, MDMA, and LSD-may have
   significant therapeutic potential in the treatment of various mental
   health conditions, including post-traumatic stress disorder, depression,
   existential distress, and addiction. Although the use of psychoactive
   drugs, such as Diazepam or Ritalin, is well established, psychedelics
   arguably represent a therapeutic step change. As experiential therapies,
   their value would seem to lie in the subjective experiences they induce.
   As it is the only way for trainee psychedelic therapists to fully
   understand their subjective effects, some have suggested that firsthand
   experience of psychedelics should form part of training programs. We
   question this notion. First, we consider whether the epistemic benefits
   offered by drug-induced psychedelic experience are as unique as is
   supposed. We then reflect on the value it might have in regard to the
   training of psychedelic therapists. We conclude that, absent stronger
   evidence of the contribution drug-induced experiences make to the
   training of psychedelic therapists, requiring trainees to take
   psychedelic drugs does not seem ethically legitimate. However, given the
   potential for epistemic benefit cannot be entirely ruled out, permitting
   trainees who wish to gain first-hand experience of psychedelics may be
   permissible.},
Publisher = {CAMBRIDGE UNIV PRESS},
Address = {32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA},
Type = {Article; Early Access},
Language = {English},
Affiliation = {Emmerich, N (Corresponding Author), Australian Natl Univ, Sch Med \& Psychol, Florey Bldg, Canberra, ACT, Australia.
   Emmerich, Nathan; Humphries, Bryce, Australian Natl Univ, Sch Med \& Psychol, Florey Bldg, Canberra, ACT, Australia.},
DOI = {10.1017/S0963180123000099},
EarlyAccessDate = {MAR 2023},
Article-Number = {PII S0963180123000099},
ISSN = {0963-1801},
EISSN = {1469-2147},
Keywords = {psychedelics; psychedelic therapy; psychedelic experience; training},
Keywords-Plus = {STANDARD},
Research-Areas = {Health Care Sciences \& Services; Biomedical Social Sciences},
Web-of-Science-Categories  = {Health Care Sciences \& Services; Health Policy \& Services; Social
   Sciences, Biomedical},
Author-Email = {nathan.emmerich@anu.edu.au},
Affiliations = {Australian National University},
ResearcherID-Numbers = {Emmerich, Nathan/R-3518-2018},
ORCID-Numbers = {Emmerich, Nathan/0000-0001-8199-4673},
Cited-References = {{[}Anonymous], 2012, PSYCHEDELIC RENAISSA.
   Brennan W, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.866018.
   Brennan W, 2021, J HUMANIST PSYCHOL, DOI 10.1177/00221678211045265.
   dreamachine world, US.
   Earleywine M, 2022, CURR CONTENTS, P1.
   Forstmann M, 2021, PUBLIC UNDERST SCI, V30, P302, DOI 10.1177/0963662520981728.
   Giffort D, 2020, ACID REV PSYCHEDELIC, V1st.
   Greenway KT, 2020, EXPERT REV CLIN PHAR, V13, P655, DOI 10.1080/17512433.2020.1772054.
   Griffiths RR, 2008, J PSYCHOPHARMACOL, V22, P621, DOI 10.1177/0269881108094300.
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5.
   Grob C. S, 2021, HDB MED HALLUCINOGEN.
   Hartogsohn I, 2020, AM TRIP SET SETTING, P77.
   Hartogsohn I, 2023, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.1073235.
   Hayes C, 2022, THER ADV PSYCHOPHARM, V12, DOI 10.1177/20451253221090822.
   Holmes SW, 1996, PSYCHOTHER, V33, P114, DOI 10.1037/0033-3204.33.1.114.
   JACKSON F, 1982, PHILOS QUART, V32, P127, DOI 10.2307/2960077.
   James E, 2020, HUM PSYCHOPHARM CLIN, V35, DOI 10.1002/hup.2742.
   Kious B, 2023, J PSYCHOPHARMACOL, V37, P45, DOI 10.1177/02698811221133461.
   Kirkham N, 2022, PHILOS PSYCHOL, DOI 10.1080/09515089.2022.2057290.
   Langlitz N., 2013, NEUROPSYCHEDELIA REV.
   MAPS, 2010, TRAIN PROT MDMA ASS.
   McCarroll V, 2022, INTERDISCIPL SCI REV, DOI 10.1080/03080188.2022.2075199.
   Nielson E.M., 2018, J PSYCHEDELIC STUD, V2, P64, DOI {[}10.1556/ 2054.2018.009, DOI 10.1556/2054.2018.009, 10.1556/2054.2018.009].
   Olson D. E., 2021, ALIUS B, V5, P40, DOI {[}https://doi.org/10.34700/0v21-5n82, DOI 10.34700/0V21-5N82].
   Olson DE, 2021, ACS PHARMACOL TRANSL, V4, P563, DOI 10.1021/acsptsci.0c00192.
   Phelps Janis, 2022, Curr Top Behav Neurosci, V56, P93, DOI 10.1007/7854\_2021\_266.
   Phelps J, 2017, J HUMANIST PSYCHOL, V57, P450, DOI 10.1177/0022167817711304.
   Rasmussen K, 2022, CAMB Q HEALTHC ETHIC, V31, P477, DOI 10.1017/S096318012200010X.
   Reiff CM, AM J PSYCHIAT.
   Schenberg EE, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00733.
   Smith WR, 2022, NEUROPHARMACOLOGY, V216, DOI 10.1016/j.neuropharm.2022.109165.
   Tai SJ, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.586682.
   Winkelman MJ., 2019, ADV PSYCHEDELIC MED.
   Wolfson E, 2022, J PSYCHEDELIC STUD, V6, P191.
   Wong C, 2022, NEW SCI, V253, P35.
   Yaden DB, 2022, CAMB Q HEALTHC ETHIC, V31, P464, DOI 10.1017/S096318012200007X.
   Yaden DB, 2021, ACS PHARMACOL TRANSL, V4, P568, DOI 10.1021/acsptsci.0c00194.},
Number-of-Cited-References = {37},
Times-Cited = {0},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Camb. Q. Healthc. Ethics},
Doc-Delivery-Number = {9N3JX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000942813100001},
DA = {2023-07-30},
}

@article{ WOS:000924511500001,
Author = {Mathai, David S. and Nayak, Sandeep M. and Yaden, David B. and
   Garcia-Romeu, Albert},
Title = {Reconsidering ``dissociation{''} as a predictor of antidepressant
   efficacy for esketamine},
Journal = {PSYCHOPHARMACOLOGY},
Year = {2023},
Volume = {240},
Number = {4},
Pages = {827-836},
Month = {APR},
Abstract = {Rationale The relationship between subjective drug experience and
   antidepressant outcomes for ketamine derivatives is poorly understood
   but of high clinical relevance. Esketamine is the patented
   (S)-enantiomer of ketamine and has regulatory approval for psychiatric
   applications.
   Objectives We examined the relationship between acute dissociation, as
   measured by the Clinician-Administered Dissociative States Scale
   (CADSS), and antidepressant efficacy, as measured by the
   Montgomery-angstrom sberg Depression Rating Scale (MADRS), for
   esketamine across the 4-week induction phase of treatment.
   Methods This post hoc analysis combined data (N = 576) from the
   TRANSFORM-1 and TRANSFORM-2 clinical trials of esketamine for
   treatment-resistant depression. Linear mixed models were performed using
   total MADRS score as the outcome variable with the following independent
   variables: baseline MADRS score, treatment condition x time interaction,
   and CADSS x time interaction. To assess whether initial dissociation
   predicted rapid antidepressant benefit with esketamine, a separately
   planned regression was performed with day 2 MADRS as the outcome
   variable with the following dependent variables: baseline MADRS,
   treatment condition, and day 1 CADSS.
   Results The linear mixed model did not show any effect of a CADSS x time
   interaction (p = 0.7). Looking solely at the effect of day 1 CADSS on
   day 2 MADRS revealed that each additional CADSS point was associated
   with a - .04 {[}95\% CI - .08, - .002] (p = .04) decrease in MADRS
   score.
   Conclusions We found no evidence of a clinically significant positive or
   negative association between dissociation and antidepressant effect for
   esketamine. Our findings suggest that subsequent inquiry in this area
   will benefit from improved characterization of drug experiences relevant
   to therapeutic outcomes.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Mathai, DS (Corresponding Author), Johns Hopkins Univ, Ctr Psychedel \& Consciousness Res, Dept Psychiat \& Behav Sci, Sch Med, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA.
   Mathai, David S.; Nayak, Sandeep M.; Yaden, David B.; Garcia-Romeu, Albert, Johns Hopkins Univ, Ctr Psychedel \& Consciousness Res, Dept Psychiat \& Behav Sci, Sch Med, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA.},
DOI = {10.1007/s00213-023-06324-8},
EarlyAccessDate = {FEB 2023},
ISSN = {0033-3158},
EISSN = {1432-2072},
Keywords = {Esketamine; Ketamine; Depression; Phenomenology; Subjective;
   Dissociation; Psychedelic; Trance},
Keywords-Plus = {KETAMINE ASSISTED PSYCHOTHERAPY; TREATMENT-RESISTANT DEPRESSION; NMDA
   ANTAGONIST; MOOD DISORDERS; ANXIETY; SELF; EXPERIENCE; MEDIATE},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry},
Web-of-Science-Categories  = {Neurosciences; Pharmacology \& Pharmacy; Psychiatry},
Author-Email = {d.s.mathai@gmail.com},
Affiliations = {Johns Hopkins University},
Funding-Acknowledgement = {Steven and Alexandra Cohen Foundation},
Funding-Text = {Funding for this research through the Johns Hopkins Center for
   Psychedelic and Consciousness Research was provided by Tim Ferriss, Matt
   Mullenweg, Blake Mycoskie, Craig Nerenberg, and the Steven and Alexandra
   Cohen Foundation. The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Amada N, 2020, J CONSCIOUSNESS STUD, V27, P6.
   American Psychiatric Association, 1980, DSM3 AM PSYCH ASS.
   {[}Anonymous], J TRAUM STRESS.
   {[}Anonymous], 1973, HASHISH MENTAL ILLNE.
   Bahr Rebecca, 2019, P T, V44, P340.
   Ballard ED, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20190-4.
   Bennett R, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.867484.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bonaventura J, 2021, MOL PSYCHIATR, V26, P6704, DOI 10.1038/s41380-021-01093-2.
   Bowins BE, 2012, COUNS PSYCHOL Q, V25, P307, DOI 10.1080/09515070.2012.695278.
   Bremner JD, 1998, J TRAUMA STRESS, V11, P125, DOI 10.1023/A:1024465317902.
   Butler LD, 2006, PSYCHIAT CLIN N AM, V29, P45, DOI 10.1016/j.psc.2005.10.004.
   Carlson EB, 2012, PSYCHOL TRAUMA-US, V4, P479, DOI 10.1037/a0027748.
   Castle C, 2017, J PSYCHOPHARMACOL, V31, P1306, DOI 10.1177/0269881117725685.
   Chen G, 2022, INT J NEUROPSYCHOPH, V25, P269, DOI 10.1093/ijnp/pyab084.
   Chen MH, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20m13232.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Davis AK, 2021, JAMA PSYCHIAT, V78, P481, DOI 10.1001/jamapsychiatry.2020.3285.
   Dell PF, 2011, DISSOCIATION AND THE DISSOCIATIVE DISORDERS: DSM-V AND BEYOND, P1.
   DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Drozdz SJ, 2022, J PAIN RES, V15, P1691, DOI 10.2147/JPR.S360733.
   Fedgchin M, 2019, INT J NEUROPSYCHOPH, V22, P616, DOI 10.1093/ijnp/pyz039.
   Fox J., 2019, R COMPANION APPL REG, V3rd ed..
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Grabski M, 2020, BEHAV BRAIN RES, V392, DOI 10.1016/j.bbr.2020.112629.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Haarsma Joost, 2021, Brain Neurosci Adv, V5, p23982128211007772, DOI 10.1177/23982128211007772.
   Hartogsohn I, 2016, J PSYCHOPHARMACOL, V30, P1259, DOI 10.1177/0269881116677852.
   Hase A, 2022, PSYCHOPHARMACOLOGY, V239, P643, DOI 10.1007/s00213-022-06062-3.
   Herrmann N, 1998, STROKE, V29, P618, DOI 10.1161/01.STR.29.3.618.
   Hull TD, 2022, J AFFECT DISORDERS, V314, P59, DOI 10.1016/j.jad.2022.07.004.
   Jensen MP, 2015, INT J CLIN EXP HYP, V63, P34, DOI 10.1080/00207144.2014.961875.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Krystal JH, 2019, NEURON, V101, P774, DOI 10.1016/j.neuron.2019.02.005.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Mathai DS, 2022, BRIT J PSYCHIAT, V221, P496, DOI 10.1192/bjp.2022.58.
   Mathai DS, 2022, J AFFECT DISORDERS, V312, P113, DOI 10.1016/j.jad.2022.06.036.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Mathai DS, 2021, J CHILD ADOL PSYCHOP, V31, P553, DOI 10.1089/cap.2021.0078.
   Mathai DS, 2020, J AFFECT DISORDERS, V264, P123, DOI 10.1016/j.jad.2019.12.023.
   McInnes LA, 2022, J AFFECT DISORDERS, V301, P486, DOI 10.1016/j.jad.2021.12.097.
   Mello RP, 2021, J PSYCHIATR RES, V138, P576, DOI 10.1016/j.jpsychires.2021.05.014.
   Mollaahmetoglu OM, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.695335.
   MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Palhano-Fontes Fernanda, 2019, Psychol Med, V49, P655, DOI 10.1017/S0033291718001356.
   Petersen M., 2020, TOXICOLOGY CASES CLI, P295, DOI {[}10.1016/B978-0-12-815846-3.00016-8, DOI 10.1016/B978-0-12-815846-3.00016-8].
   Popova V, 2019, AM J PSYCHIAT, V176, P428, DOI 10.1176/appi.ajp.2019.19020172.
   Ramaekers JG, 2021, J PSYCHOPHARMACOL, V35, P398, DOI 10.1177/0269881120940937.
   REIER CE, 1971, NEW ENGL J MED, V284, P791.
   Reissig CJ, 2012, PSYCHOPHARMACOLOGY, V223, P1, DOI 10.1007/s00213-012-2680-6.
   Rodrigues NB, 2021, J AFFECT DISORDERS, V282, P160, DOI 10.1016/j.jad.2020.12.119.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Ross Colin A., 1996, P3.
   Rothberg RL, 2021, J PSYCHOPHARMACOL, V35, P150, DOI 10.1177/0269881120970879.
   Scalabrini A, 2020, PROG NEURO-PSYCHOPH, V101, DOI 10.1016/j.pnpbp.2020.109928.
   Seligman R, 2008, CULT MED PSYCHIAT, V32, P31, DOI 10.1007/s11013-007-9077-8.
   SNAITH RP, 1986, BRIT J PSYCHIAT, V148, P599, DOI 10.1192/bjp.148.5.599.
   SPIEGEL D, 1988, J TRAUMA STRESS, V1, P17, DOI {[}DOI 10.1002/jts.2490010104, DOI 10.1002/JTS.2490010104].
   Stocker K, 2019, PSYCHOTHER PSYCHOSOM, V88, P182, DOI 10.1159/000497441.
   Studerus E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012412.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Turkoz I, 2021, J CLIN PSYCHIAT, V82, DOI 10.4088/JCP.20m13800.
   U.S. Food and Drug Administration, 2019, FDA APPR NEW NAS SPR.
   van Schalkwyk GI, 2018, J AFFECT DISORDERS, V227, P11, DOI 10.1016/j.jad.2017.09.023.
   Wilkinson ST, 2019, NEUROPSYCHOPHARMACOL, V44, P1233, DOI 10.1038/s41386-019-0317-8.
   Yaden DB, 2021, ACS PHARMACOL TRANSL, V4, P568, DOI 10.1021/acsptsci.0c00194.
   Yaden DB, 2017, REV GEN PSYCHOL, V21, P143, DOI 10.1037/gpr0000102.},
Number-of-Cited-References = {73},
Times-Cited = {2},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Psychopharmacology},
Doc-Delivery-Number = {9T0JW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000924511500001},
DA = {2023-07-30},
}

@article{ WOS:000551462400004,
Author = {Krediet, Erwin and Bostoen, Tijmen and Breeksema, Joost and van Schagen,
   Annette and Passie, Torsten and Vermetten, Eric},
Title = {Reviewing the Potential of Psychedelics for the Treatment of PTSD},
Journal = {INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY},
Year = {2020},
Volume = {23},
Number = {6},
Pages = {385-400},
Month = {JUN},
Abstract = {There are few medications with demonstrated efficacy for the treatment
   of posttraumatic stress disorder (PTSD). Treatment guidelines have
   unequivocally designated psychotherapy as a first line treatment for
   PTSD. Yet, even after psychotherapy, PTSD often remains a chronic
   illness, with high rates of psychiatric and medical comorbidity.
   Meanwhile, the search for and development of drugs with new mechanisms
   of action has stalled. Therefore, there is an urgent need to explore not
   just novel compounds but novel approaches for the treatment of PTSD. A
   promising new approach involves the use of psychedelic drugs. Within the
   past few years, 2 psychedelics have received breakthrough designations
   for psychiatric indications from the US Food and Drug Administration,
   and several psychedelics are currently being investigated for the
   treatment of PTSD. This review discusses 4 types of compounds:
   3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics
   (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We
   describe the therapeutic rationale, the setting in which they are being
   administered, and their current state of evidence in the treatment of
   PTSD. Each compound provides unique qualities for the treatment of PTSD,
   from their use to rapidly target symptoms to their use as adjuncts to
   facilitate psychotherapeutic treatments. Several questions are
   formulated that outline an agenda for future research.},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Vermetten, E (Corresponding Author), Leiden Univ, Dept Psychiat, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
   Krediet, Erwin; Bostoen, Tijmen; Breeksema, Joost; Vermetten, Eric, Leiden Univ, Dept Psychiat, Med Ctr, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
   Krediet, Erwin; Bostoen, Tijmen; van Schagen, Annette; Vermetten, Eric, ARQ Natl Psychotrauma Ctr, Diemen, Netherlands.
   Breeksema, Joost, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands.
   Vermetten, Eric, Mil Mental Hlth Care, Utrecht, Netherlands.
   Passie, Torsten, Hannover Med Sch, Dept Psychiat Social Psychiat \& Psychotherapy, Hannover, Germany.
   Passie, Torsten, Goethe Univ Frankfurt Main, Dr Senckenberg Inst Hist \& Eth Med, Frankfurt, Germany.},
DOI = {10.1093/ijnp/pyaa018},
ISSN = {1461-1457},
EISSN = {1469-5111},
Keywords = {PTSD; psychedelics; MDMA; ketamine; cannabinoids},
Keywords-Plus = {POSTTRAUMATIC-STRESS-DISORDER; KETAMINE-ASSISTED PSYCHOTHERAPY;
   LIFE-THREATENING CANCER; METHYL-D-ASPARTATE; FEAR EXTINCTION;
   DOUBLE-BLIND; SYMPTOM SEVERITY; CANNABIS USE;
   3,4-METHYLENEDIOXYMETHAMPHETAMINE-ASSISTED PSYCHOTHERAPY; INTRAVENOUS
   KETAMINE},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences; Pharmacology \& Pharmacy; Psychiatry},
Author-Email = {e.vermetten@lumc.nl},
Affiliations = {Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; University of Groningen; Hannover Medical
   School; Goethe University Frankfurt},
ResearcherID-Numbers = {Vermetten, Eric/B-1335-2008
   },
ORCID-Numbers = {Vermetten, Eric/0000-0003-0579-4404
   Breeksema, Joost J./0000-0002-8787-4610
   van Schagen, Annette/0000-0003-3231-1383},
Funding-Acknowledgement = {Nypels-Tans PTSD Fund at Leiden University},
Funding-Text = {The authors thank the Nypels-Tans PTSD Fund at Leiden University for its
   financial support.},
Cited-References = {Akram H, 2019, J PSYCHOPHARMACOL, V33, P271, DOI 10.1177/0269881119826592.
   Albott CS, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11634.
   {[}Anonymous], 1997, PSYCHOLYTIC PSYCHEDE.
   {[}Anonymous], 1981, HALLUZINOGENE PSYCHI.
   {[}Anonymous], 2012, HEALING ENTACTOGENS.
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   BARRETT FS, 2018, CEREB CORTEX, V28, P3939, DOI DOI 10.1093/CERCOR/BHX257.
   Bastiaans J., 1983, PSYCHEDELIC REFLECTI, P143.
   Berman P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32651-4.
   Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9.
   Biezonski DK, 2011, CURR NEUROPHARMACOL, V9, P84, DOI 10.2174/157015911795017146.
   Black N, 2019, LANCET PSYCHIAT, V6, P995, DOI 10.1016/S2215-0366(19)30401-8.
   Bogenschutz MP, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00100.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bonn-Miller MO, 2007, J TRAUMA STRESS, V20, P577, DOI 10.1002/jts.20243.
   Bonn-Miller MO, 2013, PSYCHOL TRAUMA-US, V5, P193, DOI 10.1037/a0026621.
   Bordieri MJ, 2014, J CONTEXT BEHAV SCI, V3, P273, DOI 10.1016/j.jcbs.2014.08.005.
   Bouso JC, 2008, J PSYCHOACTIVE DRUGS, V40, P225, DOI 10.1080/02791072.2008.10400637.
   Bryant RA, 2016, CLIN PSYCHOL SCI, V4, P493, DOI 10.1177/2167702615598756.
   Cameron C, 2014, J CLIN PSYCHOPHARM, V34, P559, DOI 10.1097/JCP.0000000000000180.
   Cameron LP, 2018, ACS CHEM NEUROSCI, V9, P1582, DOI 10.1021/acschemneuro.8b00134.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Carhart-Harris RL, 2015, BIOL PSYCHIAT, V78, P554, DOI 10.1016/j.biopsych.2013.12.015.
   Catlow BJ, 2013, EXP BRAIN RES, V228, P481, DOI 10.1007/s00221-013-3579-0.
   Cipriani A, 2018, PSYCHOL MED, V48, P1975, DOI 10.1017/S003329171700349X.
   COHEN S, 1960, J NERV MENT DIS, V130, P30, DOI 10.1097/00005053-196001000-00005.
   Curran HV, 2018, PSYCHOPHARMACOLOGY, V235, P373, DOI 10.1007/s00213-017-4822-3.
   Dahlgren MK, 2018, PSYCHOL MED, V48, P1128, DOI 10.1017/S003329171700263X.
   Danforth AL, 2018, PSYCHOPHARMACOLOGY, V235, P3137, DOI 10.1007/s00213-018-5010-9.
   Das RK, 2013, NEUROSCI BIOBEHAV R, V37, P240, DOI 10.1016/j.neubiorev.2012.11.018.
   de Wit H, 2020, NEUROPSYCHOPHARMACOL, V45, P217, DOI 10.1038/s41386-019-0473-x.
   {*}DEP VET AFF DEP D, 2017, VA DOD CLIN PRACT GU.
   DePierro J, 2019, BIOL PSYCHIAT, V86, P454, DOI 10.1016/j.biopsych.2019.07.009.
   Di Forti M, 2019, LANCET PSYCHIAT, V6, P427, DOI 10.1016/S2215-0366(19)30048-3.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Duclot F, 2016, NEUROPHARMACOLOGY, V109, P293, DOI 10.1016/j.neuropharm.2016.06.022.
   Duman RS, 2016, NAT MED, V22, P238, DOI 10.1038/nm.4050.
   Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62.
   Feduccia AA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00650.
   Feduccia AA, 2018, PROG NEURO-PSYCHOPH, V84, P221, DOI 10.1016/j.pnpbp.2018.03.003.
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5.
   Francati V, 2007, DEPRESS ANXIETY, V24, P202, DOI 10.1002/da.20208.
   Fraser GA, 2009, CNS NEUROSCI THER, V15, P84, DOI 10.1111/j.1755-5949.2008.00071.x.
   Freeman TP, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1141.
   Freudenmann RW, 2006, ADDICTION, V101, P1241, DOI 10.1111/j.1360-0443.2006.01511.x.
   Gamma A, 2000, NEUROPSYCHOPHARMACOL, V23, P388, DOI 10.1016/S0893-133X(00)00130-5.
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Gasser P, 1996, SCHWEIZ ARCH NEUROL, V147, P59.
   Girgenti MJ, 2017, NEUROBIOL DIS, V100, P1, DOI 10.1016/j.nbd.2016.12.026.
   Goetter EM, 2015, J TRAUMA STRESS, V28, P401, DOI 10.1002/jts.22038.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Grof S., 1980, LSD PSYCHOTHERAPY.
   Haagen JFG, 2015, CLIN PSYCHOL REV, V40, P184, DOI 10.1016/j.cpr.2015.06.008.
   Hamilton I, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1044-x.
   Haney M, 2018, NEUROPSYCHOPHARMACOL, V43, P1, DOI 10.1038/npp.2017.255.
   Hasin DS, 2016, AM J PSYCHIAT, V173, P588, DOI 10.1176/appi.ajp.2015.15070907.
   Heal DJ, 2018, NEUROPHARMACOLOGY, V142, P89, DOI 10.1016/j.neuropharm.2018.01.049.
   Heifets BD, 2019, JAMA PSYCHIAT, V76, P775, DOI 10.1001/jamapsychiatry.2019.1145.
   Hill MN, 2018, NEUROPSYCHOPHARMACOL, V43, P80, DOI 10.1038/npp.2017.162.
   Hindocha C, 2020, J DUAL DIAGN, V16, P120, DOI 10.1080/15504263.2019.1652380.
   Holze F, 2020, NEUROPSYCHOPHARMACOL, V45, P462, DOI 10.1038/s41386-019-0569-3.
   Hoskins M, 2015, BRIT J PSYCHIAT, V206, P93, DOI 10.1192/bjp.bp.114.148551.
   Hysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161.
   Inserra A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00330.
   Jetly R, 2015, PSYCHONEUROENDOCRINO, V51, P585, DOI 10.1016/j.psyneuen.2014.11.002.
   Johnson MW, 2018, NEUROPHARMACOLOGY, V142, P143, DOI 10.1016/j.neuropharm.2018.05.012.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kaelen M, 2015, PSYCHOPHARMACOLOGY, V232, P3607, DOI 10.1007/s00213-015-4014-y.
   Kaelen M, 2018, PSYCHOPHARMACOLOGY, V235, P505, DOI 10.1007/s00213-017-4820-5.
   Kitchiner NJ, 2019, EUR J PSYCHOTRAUMATO, V10, DOI 10.1080/20008198.2019.1684226.
   Kometer M, 2015, PSYCHOPHARMACOLOGY, V232, P3663, DOI 10.1007/s00213-015-4026-7.
   Kraehenmann R, 2015, BIOL PSYCHIAT, V78, P572, DOI 10.1016/j.biopsych.2014.04.010.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Krystal JH, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0829-z.
   Krystal JH, 2017, BIOL PSYCHIAT, V82, pE51, DOI 10.1016/j.biopsych.2017.03.007.
   Kuypers KPC, 2016, PSYCHOPHARMACOLOGY, V233, P3395, DOI 10.1007/s00213-016-4377-8.
   Kuypers KPC, 2017, J PSYCHOPHARMACOL, V31, P589, DOI 10.1177/0269881117699617.
   Kyzar EJ, 2017, TRENDS PHARMACOL SCI, V38, P992, DOI 10.1016/j.tips.2017.08.003.
   Labate, 2014, THERAPEUTIC USE AYAH.
   Lebedev AV, 2016, HUM BRAIN MAPP, V37, P3203, DOI 10.1002/hbm.23234.
   Levine A, 2017, J AM ACAD CHILD PSY, V56, P214, DOI 10.1016/j.jaac.2016.12.014.
   Li NX, 2011, BIOL PSYCHIAT, V69, P754, DOI 10.1016/j.biopsych.2010.12.015.
   Liechti ME, 2001, PSYCHOPHARMACOLOGY, V154, P161, DOI 10.1007/s002130000648.
   Ly C, 2018, CELL REP, V23, P3170, DOI 10.1016/j.celrep.2018.05.022.
   MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   MALLESON N, 1971, BRIT J PSYCHIAT, V118, P229, DOI 10.1192/bjp.118.543.229.
   MAYOR S, 2019, BMJ-BRIT MED J, V364, DOI DOI 10.1136/BMJ.L574.
   McGirr A, 2015, PSYCHOL MED, V45, P693, DOI 10.1017/S0033291714001603.
   McKenna DJ, 2004, PHARMACOL THERAPEUT, V102, P111, DOI 10.1016/j.pharmathera.2004.03.002.
   Mithoefer M.C., 2017, MANUAL MDMA ASSISTED.
   Mithoefer MC, 2019, PSYCHOPHARMACOLOGY, V236, P2735, DOI 10.1007/s00213-019-05249-5.
   Mithoefer MC, 2018, LANCET PSYCHIAT, V5, P486, DOI 10.1016/S2215-0366(18)30135-4.
   Mithoefer MC, 2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3.
   Mithoefer MC, 2013, J PSYCHOPHARMACOL, V27, P28, DOI 10.1177/0269881112456611.
   Mithoefer MC, 2011, J PSYCHOPHARMACOL, V25, P439, DOI 10.1177/0269881110378371.
   Monson C. M., 2012, COGNITIVE BEHAV CONJ.
   Moreira FA, 2010, CURR TOP BEHAV NEURO, V2, P429, DOI 10.1007/7854\_2009\_16.
   Morena M, 2016, NEUROPSYCHOPHARMACOL, V41, P80, DOI 10.1038/npp.2015.166.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Mott JM, 2014, J TRAUMA STRESS, V27, P265, DOI 10.1002/jts.21927.
   Mueller F, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.54.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   Murrough JW, 2013, BIOL PSYCHIAT, V74, P250, DOI 10.1016/j.biopsych.2012.06.022.
   Nader R, 2015, CORPORATE WELFARE: CRONY CAPITALISM THAT ENRICHES THE RICH, P1.
   Nardou R, 2019, NATURE, V569, P116, DOI 10.1038/s41586-019-1075-9.
   National Institute for Health and Care Excellence, 2018, GUID POST TRAUM STRE.
   Ney LJ, 2019, PROG NEURO-PSYCHOPH, V93, P124, DOI 10.1016/j.pnpbp.2019.03.017.
   Nichols DE, 2017, CLIN PHARMACOL THER, V101, P209, DOI 10.1002/cpt.557.
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002.
   Nielson N. L., 2014, THERAPEUTIC USE AYAH, P41, DOI {[}10.1007/978-3-642-40426-9\_3, DOI 10.1007/978-3-642-40426-9\_3].
   Norrholm SD, 2011, BIOL PSYCHIAT, V69, P556, DOI 10.1016/j.biopsych.2010.09.013.
   Ossebaard H, 1999, MAPS B, V9, P3.
   Ot'alora M, 2018, J PSYCHOPHARMACOL, V32, P1295, DOI 10.1177/0269881118806297.
   Papini S, 2017, J ABNORM PSYCHOL, V126, P117, DOI 10.1037/abn0000224.
   Parrott AC, 2014, J PSYCHOACTIVE DRUGS, V46, P37, DOI 10.1080/02791072.2014.873690.
   Passie T, 2002, ADDICT BIOL, V7, P357, DOI 10.1080/1355621021000005937.
   Passie T, 2018, DRUG SCI POLICY LAW, V4, P1, DOI {[}10.1177/2050324518767442, DOI 10.1177/2050324518767442].
   Passie T, 2008, CNS NEUROSCI THER, V14, P295, DOI 10.1111/j.1755-5949.2008.00059.x.
   Passie T, 2012, DRUG TEST ANAL, V4, P649, DOI 10.1002/dta.1377.
   Phan KL, 2008, J NEUROSCI, V28, P2313, DOI 10.1523/JNEUROSCI.5603-07.2008.
   Pisanti S, 2017, TRENDS PHARMACOL SCI, V38, P195, DOI 10.1016/j.tips.2016.12.002.
   Pokorny T, 2017, INT J NEUROPSYCHOPH, V20, P747, DOI 10.1093/ijnp/pyx047.
   Pradhan B., 2017, ASIA PAC J CLIN TRIA, V2, P80, DOI {[}10.4103/2542-3932.211589, DOI 10.4103/2542-3932.211589].
   Pradhan B, 2018, BBA-PROTEINS PROTEOM, V1866, P831, DOI 10.1016/j.bbapap.2018.03.006.
   Rabinak CA, 2014, NEUROBIOL LEARN MEM, V113, P125, DOI 10.1016/j.nlm.2013.09.009.
   Rabinak CA, 2013, NEUROPHARMACOLOGY, V64, P396, DOI 10.1016/j.neuropharm.2012.06.063.
   Resick PA., 2016, COGN PROCESS.
   Rogers G, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13060.
   Roitman P, 2014, CLIN DRUG INVEST, V34, P587, DOI 10.1007/s40261-014-0212-3.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rybakowski JK., 2016, KETAMINE TREATMENT R, P57.
   Sampedro F, 2017, INT J NEUROPSYCHOPH, V20, P698, DOI 10.1093/ijnp/pyx036.
   Sanz C, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00007.
   Schenk S, 2018, J CLIN PSYCHOPHARM, V38, P632, DOI 10.1097/JCP.0000000000000962.
   Schmid Y, 2014, J PSYCHOPHARMACOL, V28, P847, DOI 10.1177/0269881114542454.
   Schreiner AM, 2012, EXP CLIN PSYCHOPHARM, V20, P420, DOI 10.1037/a0029117.
   Scott JC, 2018, JAMA PSYCHIAT, V75, P585, DOI 10.1001/jamapsychiatry.2018.0335.
   Sessa B, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-230109.
   Soler J, 2016, PSYCHOPHARMACOLOGY, V233, P823, DOI 10.1007/s00213-015-4162-0.
   Steenkamp MM, 2017, DEPRESS ANXIETY, V34, P207, DOI 10.1002/da.22596.
   Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370.
   Stern CAJ, 2017, NEUROPHARMACOLOGY, V125, P220, DOI 10.1016/j.neuropharm.2017.07.024.
   Stroud JB, 2018, PSYCHOPHARMACOLOGY, V235, P459, DOI 10.1007/s00213-017-4754-y.
   Thompson MR, 2007, NEUROSCIENCE, V146, P509, DOI 10.1016/j.neuroscience.2007.02.032.
   Veen C, 2018, CURR TOP BEHAV NEURO, V38, P137, DOI 10.1007/7854\_2017\_34.
   Vermetten E, 2018, BEHAV NEUROBIOLOGY P.
   Vizeli P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199384.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Wagner AC, 2019, J PSYCHOACTIVE DRUGS, V51, P166, DOI 10.1080/02791072.2019.1589028.
   Wagner MT, 2017, J PSYCHOPHARMACOL, V31, P967, DOI 10.1177/0269881117711712.
   Walsh Z, 2018, INT REV PSYCHIATR, V30, P343, DOI 10.1080/09540261.2018.1474088.
   Watkins LE, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00258.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358.
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472.
   Wilkinson ST, 2015, J CLIN PSYCHIAT, V76, P1174, DOI 10.4088/JCP.14m09475.
   Yehuda R, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.57.
   Young MB, 2017, PSYCHOPHARMACOLOGY, V234, P2883, DOI 10.1007/s00213-017-4684-8.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zuardi AW, 2006, REV BRAS PSIQUIATR, V28, P153, DOI 10.1590/S1516-44462006000200015.
   Zuj DV, 2016, DEPRESS ANXIETY, V33, P203, DOI 10.1002/da.22463.},
Number-of-Cited-References = {169},
Times-Cited = {69},
Usage-Count-Last-180-days = {19},
Usage-Count-Since-2013 = {92},
Journal-ISO = {Int. J. Neuropsychopharmacol.},
Doc-Delivery-Number = {MO3XG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000551462400004},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000634820800001,
Author = {Gorman, Ingmar and Nielson, Elizabeth M. and Molinar, Aja and Cassidy,
   Ksenia and Sabbagh, Jonathan},
Title = {Psychedelic Harm Reduction and Integration: A Transtheoretical Model for
   Clinical Practice},
Journal = {FRONTIERS IN PSYCHOLOGY},
Year = {2021},
Volume = {12},
Month = {MAR 15},
Abstract = {Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical
   and transdiagnostic clinical approach to working with patients who are
   using or considering using psychedelics in any context. The ongoing
   discussion of psychedelics in academic research and mainstream media,
   coupled with recent law enforcement deprioritization of psychedelics and
   compassionate use approvals for psychedelic-assisted therapy, make this
   model exceedingly timely. Given the prevalence of psychedelic use, the
   therapeutic potential of psychedelics, and the unique cultural and
   historical context in which psychedelics are placed, it is important
   that mental health providers have an understanding of the unique
   motivations, experiences, and needs of people who use them. PHRI
   incorporates elements of harm reduction psychotherapy and
   psychedelic-assisted psychotherapy, and can be applied in both brief and
   ongoing psychotherapy interactions. PHRI represents a shift away from
   assessment limited to untoward outcomes of psychedelic use and
   abstinence-based addiction treatment paradigms and toward a stance of
   compassionate, destigmatizing acceptance of patients' choices.
   Considerations for assessment, preparation, and working with difficult
   experiences are presented.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Gorman, I; Nielson, EM (Corresponding Author), MAPS Publ Benefit Corp, Santa Cruz, CA 95060 USA.
   Gorman, I; Nielson, EM (Corresponding Author), Fluence, Woodstock, NY 12498 USA.
   Gorman, I; Nielson, EM (Corresponding Author), New York State Psychiat Inst \& Hosp, Depress Evaluat Serv, New York, NY 10032 USA.
   Gorman, I (Corresponding Author), Journey Clin Inc, Dover, DE 19904 USA.
   Gorman, Ingmar; Nielson, Elizabeth M., MAPS Publ Benefit Corp, Santa Cruz, CA 95060 USA.
   Gorman, Ingmar; Nielson, Elizabeth M., Fluence, Woodstock, NY 12498 USA.
   Gorman, Ingmar; Nielson, Elizabeth M., New York State Psychiat Inst \& Hosp, Depress Evaluat Serv, New York, NY 10032 USA.
   Gorman, Ingmar; Sabbagh, Jonathan, Journey Clin Inc, Dover, DE 19904 USA.
   Molinar, Aja; Cassidy, Ksenia; Sabbagh, Jonathan, New Sch Social Res, Todman Psychopathol Lab, Psychol Dept, New York, NY 10011 USA.
   Cassidy, Ksenia, New Sch Social Res, Attachment Lab, Psychol Dept, Ctr Attachment Res, New York, NY 10011 USA.},
DOI = {10.3389/fpsyg.2021.645246},
Article-Number = {645246},
ISSN = {1664-1078},
Keywords = {psychedelics; harm reduction; psychotherapy; integration; preparation;
   psilocybin; MDMA; PHRI},
Keywords-Plus = {MYSTICAL EXPERIENCE QUESTIONNAIRE; KETAMINE-ASSISTED PSYCHOTHERAPY;
   POSTTRAUMATIC-STRESS-DISORDER; PSYCHOLOGICAL DISTRESS; CHALLENGING
   EXPERIENCES; SUBSTANCE USE; DRUG-USE; COMMITMENT THERAPY; RELAPSE
   PREVENTION; AYAHUASCA USERS},
Research-Areas = {Psychology},
Web-of-Science-Categories  = {Psychology, Multidisciplinary},
Author-Email = {ingmar@fluence8.com
   elizabeth@fluence8.com},
Affiliations = {New York State Psychiatry Institute; The New School; The New School},
Cited-References = {Ackerman SJ, 2003, CLIN PSYCHOL REV, V23, P1, DOI 10.1016/S0272-7358(02)00146-0.
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI {[}DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596].
   {[}Anonymous], 2011, HARM REDUCTION PRAGM.
   {[}Anonymous], 2013, RELATIONAL DEPTH NEW.
   {[}Anonymous], 2012, MINDFULNESS BASED CO.
   {[}Anonymous], GOVERNABLE PLACES RE, DOI DOI 10.4324/9780429427114-8.
   {[}Anonymous], 2013, APPL MOTIVATIONAL IN.
   {[}Anonymous], PHASE 3 PROGRAM MDMA.
   {[}Anonymous], 2002, SEEKING SAFETY TREAT.
   {[}Anonymous], 1960, PHILOSOPHY.
   {[}Anonymous], 2010, HOLOTROPIC BREATHWOR.
   {[}Anonymous], 2015, PSYCHEDELICS CREATIV.
   {[}Anonymous], 2007, HARM REDUCTION PSYCH.
   BACHE CM, 1991, J RELIG HEALTH, V30, P215, DOI 10.1007/BF00986399.
   Bauml J, 2006, SCHIZOPHRENIA BULL, V32, pS1, DOI 10.1093/schbul/sbl017.
   Barrett FS, 2017, PERS INDIV DIFFER, V117, P155, DOI 10.1016/j.paid.2017.06.004.
   Barrett FS, 2016, J PSYCHOPHARMACOL, V30, P1279, DOI 10.1177/0269881116678781.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Bogenschutz MP, 2017, J HUMANIST PSYCHOL, V57, P389, DOI 10.1177/0022167816673493.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bowen S, 2014, PRACT RESOUR MENT, P141, DOI 10.1016/B978-0-12-416031-6.00007-4.
   Burrows CJ, 2013, CLIN CASE STUD, V12, P246, DOI 10.1177/1534650113479652.
   Carbonaro TM, 2016, J PSYCHOPHARMACOL, V30, P1268, DOI 10.1177/0269881116662634.
   Carey B., 2019, NEW YORK TIMES.
   Carhart-Harris R, 2013, J NEUROL NEUROSUR PS, V84, pe1, DOI DOI 10.1136/JNNP-2013-306103.17.
   Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160.
   Carhart-Harris RL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13282-7.
   Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7.
   Cavnar C, 2014, J PSYCHOACTIVE DRUGS, V46, P252, DOI 10.1080/02791072.2014.920117.
   Clare S., 2018, MAPS B, V28, P30.
   Cloitre M, 2002, J CONSULT CLIN PSYCH, V70, P1067, DOI 10.1037//0022-006X.70.5.1067.
   Collins E., 2019, MINDFULNESS BASED CO.
   Conners GJ, 1997, J CONSULT CLIN PSYCH, V65, P588, DOI 10.1037/0022-006X.65.4.588.
   Coppock TE, 2010, PSYCHOTHER RES, V20, P619, DOI 10.1080/10503307.2010.497508.
   Crane RS, 2015, MINDFULNESS, V6, P1104, DOI 10.1007/s12671-014-0361-8.
   Cushing RE, 2018, J ALTERN COMPLEM MED, V24, P106, DOI 10.1089/acm.2017.0176.
   Dalgarno P, 2005, ADDICT RES THEORY, V13, P259, DOI 10.1080/16066350500053562.
   Davis AK, 2020, J CONTEXT BEHAV SCI, V15, P39, DOI 10.1016/j.jcbs.2019.11.004.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Dorsen C, 2019, ADDICT RES THEORY, V27, P68, DOI 10.1080/16066359.2018.1455187.
   Elsey J. W., 2017, DRUG SCI POLICY LAW, V3, DOI DOI 10.1177/2050324517723232.
   ENGLER J, 1984, J TRANSPERSONAL PSY, V16, P25.
   EPSTEIN M, 1988, J TRANSPERSONAL PSY, V20, P61.
   Feduccia AA, 2018, PROG NEURO-PSYCHOPH, V84, P221, DOI 10.1016/j.pnpbp.2018.03.003.
   Feller CP, 2003, J HUMANISTIC COUNSEL, V42, P53, DOI {[}DOI 10.1002/J.2164-490X.2003.TB00168.X, https://doi.org/10.1002/j.2164-490X.2003.tb00168.x].
   Fischman L. G., 2019, NEUROPSYCHOANALYSIS, V21, P53, DOI {[}10.1080/15294145.2019.1689528, DOI 10.1080/15294145.2019.1689528].
   Ford Julian D, 2006, Am J Psychother, V60, P335.
   Frecska E, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00035.
   Gadeikis D, 2017, BEHAV RES THER, V92, P68, DOI 10.1016/j.brat.2017.02.005.
   Garcia-Romeu A, 2019, J PSYCHOPHARMACOL, V33, P1088, DOI 10.1177/0269881119845793.
   Garcia-Romeu A, 2018, INT REV PSYCHIATR, V30, P291, DOI 10.1080/09540261.2018.1486289.
   Goodyear K, 2018, DRUG ALCOHOL DEPEN, V185, P339, DOI 10.1016/j.drugalcdep.2017.12.037.
   Grabbe L, 2018, J AM PSYCHIAT NURSES, V24, P76, DOI 10.1177/1078390317745133.
   Griffiths RR, 2008, J PSYCHOPHARMACOL, V22, P621, DOI 10.1177/0269881108094300.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Grinspoon L, 1981, Curr Psychiatr Ther, V20, P275.
   Grof S., 1994, LSD PSYCHOTHERAPY, V2nd ed.
   Haijen ECHM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00897.
   Hargrove D. S., 2009, WILEY BLACKWELL HDB, P286, DOI DOI 10.1002/9781444310238.CH19.
   Hartogsohn I, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00129.
   Hartogsohn I, 2016, J PSYCHOPHARMACOL, V30, P1259, DOI 10.1177/0269881116677852.
   Hartogsohn Ido, 2017, DRUG SCI POLICY LAW, V3, P1, DOI DOI 10.1177/2050324516683325.
   Hayes SC, 2006, BEHAV RES THER, V44, P1, DOI 10.1016/j.brat.2005.06.006.
   Henderson NL, 2017, CULT MED PSYCHIAT, V41, P480, DOI 10.1007/s11013-017-9531-1.
   Hendricks PS, 2015, J PSYCHOPHARMACOL, V29, P1041, DOI 10.1177/0269881115598338.
   Hendricks PS, 2015, J PSYCHOPHARMACOL, V29, P280, DOI 10.1177/0269881114565653.
   Herbeck DA, 2008, ADDICT BEHAV, V33, P699, DOI 10.1016/j.addbeh.2007.12.003.
   Heriot-Maitland CP, 2008, MENT HEALTH RELIG CU, V11, P301, DOI 10.1080/13674670701287680.
   HOOD RW, 1975, J SCI STUD RELIG, V14, P29, DOI 10.2307/1384454.
   Inserra A, 2019, AUST NZ J PSYCHIAT, V53, P190, DOI 10.1177/0004867418824018.
   Jade R., 2018, INTEGRATING UNDERGRO.
   James W., 2008, VARIETIES RELIG EXPE, DOI {[}10.1017/CBO9781139149822, DOI 10.1017/CBO9781139149822].
   Johansen PO, 2015, J PSYCHOPHARMACOL, V29, P270, DOI 10.1177/0269881114568039.
   Johnson CV, 2008, J HUMANIST PSYCHOL, V48, P505, DOI 10.1177/0022167808314174.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Johnson MW, 2019, PHARMACOL THERAPEUT, V197, P83, DOI 10.1016/j.pharmthera.2018.11.010.
   Johnson MW, 2014, J PSYCHOPHARMACOL, V28, P983, DOI 10.1177/0269881114548296.
   Kaasik H, 2020, J PSYCHOACTIVE DRUGS, V52, P255, DOI 10.1080/02791072.2020.1748773.
   Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016.
   Knudsen HK, 2005, J SUBST ABUSE TREAT, V29, P95, DOI 10.1016/j.jsat.2005.05.002.
   Kometer M, 2013, J NEUROSCI, V33, P10544, DOI 10.1523/JNEUROSCI.3007-12.2013.
   Krebs Teri S, 2013, F1000Res, V2, P98, DOI 10.12688/f1000research.2-98.v1.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Kuypers KPC, 2019, MED HYPOTHESES, V125, P21, DOI 10.1016/j.mehy.2019.02.029.
   Kuypers KPC, 2016, PSYCHOPHARMACOLOGY, V233, P3395, DOI 10.1007/s00213-016-4377-8.
   Labate BC, 2012, INT J DRUG POLICY, V23, P154, DOI 10.1016/j.drugpo.2011.06.006.
   Larimer ME, 1999, ALCOHOL RES HEALTH, V23, P151.
   Lawn W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14700-6.
   Leahy RL, 2012, INT J COGN THER, V5, P362, DOI 10.1521/ijct.2012.5.4.362.
   Leary Timothy, 2000, PSYCHEDELIC EXPERIEN.
   LEVENSON EA, 1976, CONTEMP PSYCHOANAL, V12, P1.
   MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   Majic T, 2015, J PSYCHOPHARMACOL, V29, P241, DOI 10.1177/0269881114568040.
   Mangrum LF, 2006, J SUBST ABUSE TREAT, V30, P79, DOI 10.1016/j.jsat.2005.10.004.
   Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1.
   Masuda A, 2012, J EVID-BASED INTEGR, V17, P66, DOI 10.1177/2156587211423400.
   McCown D, 2010, TEACHING MINDFULNESS: A PRACTICAL GUIDE FOR CLINICIANS AND EDUCATORS, P1, DOI 10.1007/978-0-387-09484-7.
   Milliere R, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01475.
   Mitchell S.A., 2009, RELATIONAL CONCEPTS, DOI {[}10.2307/j.ctvk12rmv, DOI 10.2307/J.CTVK12RMV].
   Mithoefer M., 2013, MAPS B SPECIAL EDITI, P10.
   Mithoefer MC., 2008, MANUAL MDMA ASSISTED.
   Moro L, 2011, J PSYCHOACTIVE DRUGS, V43, P188, DOI 10.1080/02791072.2011.605661.
   Murphy-Beiner A, 2020, PSYCHOPHARMACOLOGY, V237, P1161, DOI 10.1007/s00213-019-05445-3.
   Myrick AC, 2015, J TRAUMA DISSOCIATIO, V16, P51, DOI 10.1080/15299732.2014.949020.
   Nichols DE, 2016, PHARMACOL REV, V68, P264, DOI 10.1124/pr.115.011478.
   Nielson N. L., 2014, THERAPEUTIC USE AYAH, P41, DOI {[}10.1007/978-3-642-40426-9\_3, DOI 10.1007/978-3-642-40426-9\_3].
   Noakes J., 2019, THE GUARDIAN 0414.
   Nour MM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00269.
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6.
   Oehen P, 2013, J PSYCHOPHARMACOL, V27, P40, DOI 10.1177/0269881112464827.
   Ostafin BD, 2006, COGN BEHAV PRACT, V13, P191, DOI 10.1016/j.cbpra.2005.12.001.
   Pahnke W N, 1969, Int Psychiatry Clin, V5, P149.
   Palamar JJ, 2015, DRUG ALCOHOL DEPEN, V152, P24, DOI 10.1016/j.drugalcdep.2015.05.002.
   Paulhus D. L., 1997, HDB PERSONALITY PSYC, P543, DOI DOI 10.1016/B978-012134645-4/50023-8.
   Phelps J., 2019, ADV PSYCHEDELIC MED, P274.
   Phelps J, 2017, J HUMANIST PSYCHOL, V57, P450, DOI 10.1177/0022167817711304.
   Pickard H, 2017, NEUROETHICS-NETH, V10, P169, DOI 10.1007/s12152-016-9295-2.
   Pisano VD, 2017, J PSYCHOPHARMACOL, V31, P606, DOI 10.1177/0269881117691453.
   POLAK F, 2000, FORDHAM URBAN LAW J, V28, P351.
   Pollan M., 2018, CHANGE YOUR MIND WHA.
   Prayag G, 2015, ANN TOURISM RES, V52, P175, DOI 10.1016/j.annals.2015.03.008.
   Quednow BB, 2012, NEUROPSYCHOPHARMACOL, V37, P630, DOI 10.1038/npp.2011.228.
   Rieckmann TR, 2011, J SUBST ABUSE TREAT, V41, P374, DOI 10.1016/j.jsat.2011.05.005.
   Ritter A, 2006, DRUG ALCOHOL REV, V25, P611, DOI 10.1080/09595230600944529.
   Russ SL, 2019, PSYCHOPHARMACOLOGY, V236, P3221, DOI 10.1007/s00213-019-05279-z.
   Sampedro F, 2017, INT J NEUROPSYCHOPH, V20, P698, DOI 10.1093/ijnp/pyx036.
   Sessa B, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00138.
   Sloshower J., 2018, PLANT MED HEALING PS, P113, DOI {[}DOI 10.1007/978-3-319-76720-8\_7, 10.1007/978-3-319-76720-8, DOI 10.1007/978-3-319-76720-8].
   Snyder WU, 1945, J GEN PSYCHOL, V33, P193, DOI 10.1080/00221309.1945.10544506.
   Szott K, 2015, HEALTH-LONDON, V19, P507, DOI 10.1177/1363459314556904.
   Tatarsky A, 2003, J SUBST ABUSE TREAT, V25, P249, DOI 10.1016/S0740-5472(03)00085-0.
   Tatarsky A, 2010, J CLIN PSYCHOL, V66, P123, DOI 10.1002/jclp.20666.
   Tatarsky A, 2010, J CLIN PSYCHOL, V66, P117, DOI 10.1002/jclp.20672.
   Taves A, 2020, PERSPECT PSYCHOL SCI, V15, P669, DOI 10.1177/1745691619895047.
   Taylor K., 2014, MANIFESTING MINDS RE, V136.
   The International Center for Ethnobotanical Education Research Service (ICEERS), 2020, MYTHS REAL AYAH LEG.
   Tihanyi BT, 2016, EUR J MENT HEALTH, V11, P112, DOI 10.5708/EJMH.11.2016.1-2.7.
   Treleaven D. A., 2018, TRAUMA SENSITIVE MIN, V1.
   Valentino T., 2020, PAPER PRESENTATION P.
   Van De Veer E, 2016, J CONSUM RES, V42, P783, DOI 10.1093/jcr/ucv058.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   WELWOOD J, 1984, J TRANSPERSONAL PSY, V16, P63.
   Wilkinson ST, 2019, BIOL PSYCHIAT, V85, P454, DOI 10.1016/j.biopsych.2018.09.004.
   Winkelman M, 2005, J PSYCHOACTIVE DRUGS, V37, P209, DOI 10.1080/02791072.2005.10399803.
   Woods S.L., 2016, CONTEMPLATIVE DIALOG.
   World Health Organization, 1958, STUD GROUP M HELD GE.
   Xia J, 2011, SCHIZOPHRENIA BULL, V37, P21, DOI 10.1093/schbul/sbq138.
   Yaden D.B., 2017, PSYCHOL CONSCIOUS, V4, P54, DOI {[}10.1037/cns0000098, DOI 10.1037/CNS0000098].
   Yockey RA, 2020, DRUG ALCOHOL DEPEN, V212, DOI 10.1016/j.drugalcdep.2020.108071.},
Number-of-Cited-References = {152},
Times-Cited = {30},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Front. Psychol.},
Doc-Delivery-Number = {RF4OY},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000634820800001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000354902100001,
Author = {Majic, Tomislav and Schmidt, Timo T. and Gallinat, Juergen},
Title = {Peak experiences and the afterglow phenomenon: When and how do
   therapeutic effects of hallucinogens depend on psychedelic experiences?},
Journal = {JOURNAL OF PSYCHOPHARMACOLOGY},
Year = {2015},
Volume = {29},
Number = {3},
Pages = {241-253},
Month = {MAR},
Abstract = {Interest in the therapeutic potential of psychedelic substances has
   recently resumed. During an early phase of human psychedelic research,
   their therapeutic application in different pathologies had been
   suggested, and the first evidence for efficacy was provided. The range
   of recent clinical applications of psychedelics spans from cluster
   headaches and obsessive-compulsive disorder to addiction and the
   treatment of fear and anxiety in patients suffering from terminal
   illness, indicating potentially different therapeutic mechanisms. A
   variety of approaches in psychotherapy emphasize subjective experiences,
   such as so-called peak experiences or afterglow phenomena, as
   differentially mediating therapeutic action. This review aims to
   re-evaluate earlier and recent concepts of how psychedelic substances
   may exert beneficial effects. After a short outline of
   neurophenomenological aspects, we discuss different approaches to how
   psychedelics are used in psychotherapy. Finally, we summarize evidence
   for the relationship between subjective experiences and therapeutic
   success. While the distinction between pharmacological and psychological
   action obviously cannot be clearcut, they do appear to contribute
   differently from each other when their effects are compared with regard
   to pathologies.},
Publisher = {SAGE PUBLICATIONS LTD},
Address = {1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Majic, T (Corresponding Author), Charite, Grosse Hamburger Str 5-11, D-10115 Berlin, Germany.
   Majic, Tomislav; Gallinat, Juergen, Charite, Clin Psychiat \& Psychotherapy, D-10115 Berlin, Germany.
   Schmidt, Timo T., Free Univ Berlin, Neurocomputat \& Neuroimaging Unit, Berlin, Germany.
   Schmidt, Timo T., Bernstein Ctr Computat Neurosci, Berlin, Germany.
   Gallinat, Juergen, Univ Med Ctr Hamburg Eppendorf, Dept Psychiat \& Psychotherapy, Hamburg, Germany.},
DOI = {10.1177/0269881114568040},
ISSN = {0269-8811},
EISSN = {1461-7285},
Keywords = {Hallucinogens; psychedelics; serotonin; psilocybin; ketamine; LSD;
   substance-assisted psychotherapy; psychedelic therapy; psycholytic
   therapy; obsessive-compulsive disorder; substance addiction},
Keywords-Plus = {LYSERGIC-ACID DIETHYLAMIDE; D-ASPARTATE ANTAGONIST;
   POSITRON-EMISSION-TOMOGRAPHY; LSD-ASSISTED PSYCHOTHERAPY; MYSTICAL-TYPE
   EXPERIENCES; METABOLIC HYPERFRONTALITY; CLUSTER HEADACHE; DOSE-RESPONSE;
   KETAMINE; PSILOCYBIN},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences; Pharmacology \& Pharmacy; Psychiatry},
Author-Email = {tomislav.majic@charite.de},
Affiliations = {Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; University of
   Hamburg; University Medical Center Hamburg-Eppendorf},
ORCID-Numbers = {Schmidt, Timo Torsten/0000-0003-1612-1301},
Funding-Acknowledgement = {Research Training Group GRK `Sensory Computation in Neural Systems' by
   the German Research Foundation (DFG) {[}1589/1]},
Funding-Text = {The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: TTS is
   supported by the Research Training Group GRK 1589/1 `Sensory Computation
   in Neural Systems' by the German Research Foundation (DFG).},
Cited-References = {Aan Het Rot M, 2012, BIOL PSYCHIAT, V72, P537, DOI 10.1016/j.biopsych.2012.05.003.
   ABRAMSON HA, 1956, J PSYCHOL, V42, P51, DOI 10.1080/00223980.1956.9713025.
   ABUZZAHAB FS, 1971, INT PHARMACOPSYCHIAT, V6, P223, DOI 10.1159/000468273.
   Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS16.
   Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS122, DOI 10.1016/S0893-133X(99)00106-2.
   Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6.
   ALBAUGH BJ, 1974, AM J PSYCHIAT, V131, P1247, DOI 10.1176/ajp.131.11.1247.
   Alper KR, 1999, AM J ADDICTION, V8, P234.
   Anand A, 2000, ARCH GEN PSYCHIAT, V57, P270, DOI 10.1001/archpsyc.57.3.270.
   ANDRITZKY W, 1989, J PSYCHOACTIVE DRUGS, V21, P77, DOI 10.1080/02791072.1989.10472145.
   {[}Anonymous], 1967, LSD MAN SOC.
   {[}Anonymous], 1997, PSYCHOLYTIC PSYCHEDE.
   {[}Anonymous], 1966, VARIETIES PSYCHEDELI.
   {[}Anonymous], 1981, HALLUZINOGENE PSYCHI.
   {[}Anonymous], 2012, PSYCHEDELIC RENAISSA.
   {[}Anonymous], 1972, J MUSIC THER, DOI {[}DOI 10.1093/JMT/9.2.64, 10.1093/jmt/9.2.64].
   {[}Anonymous], HALLUCINOGENIC DRUGS.
   {[}Anonymous], 2006, GOD SCI MEET BRAIN E.
   {[}Anonymous], MESKALINRAUSCH SEINE.
   {[}Anonymous], 1979, PSYCHEDELIC DRUGS RE.
   BAKER EFW, 1964, CAN MED ASSOC J, V91, P1200.
   Barrau-Alonso VM, 2013, EUROPEAN PSYCHIAT S1, V28, P1.
   Bastos AM, 2012, NEURON, V76, P695, DOI 10.1016/j.neuron.2012.10.038.
   Blewett DB., 1959, HDB THERAPEUTIC USE.
   Bloch MH, 2012, BIOL PSYCHIAT, V72, P964, DOI 10.1016/j.biopsych.2012.05.028.
   BRANDRUP E, 1977, ACTA PSYCHIAT SCAND, V55, P127, DOI 10.1111/j.1600-0447.1977.tb00149.x.
   Bruhn JG, 2002, LANCET, V359, P1866, DOI 10.1016/S0140-6736(02)08701-9.
   BUCKHOLTZ NS, 1990, NEUROPSYCHOPHARMACOL, V3, P137.
   Calabrese J D, 1997, Psychoanal Rev, V84, P237.
   Calabrese JD, 2007, PSYCHEDELIC MED NEW, V2, P29.
   Cardena E, 2013, CORTEX, V49, P375, DOI 10.1016/j.cortex.2012.04.001.
   Carhart-Harris RL, 2013, SCHIZOPHRENIA BULL, V39, P1343, DOI 10.1093/schbul/sbs117.
   Carhart-Harris RL, 2012, P NATL ACAD SCI USA, V109, P2138, DOI 10.1073/pnas.1119598109.
   Bouso JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042421.
   CHANDLER AL, 1960, ARCH GEN PSYCHIAT, V2, P286.
   Corlett PR, 2007, J PSYCHOPHARMACOL, V21, P238, DOI 10.1177/0269881107077716.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Deakin JFW, 2008, ARCH GEN PSYCHIAT, V65, P154, DOI 10.1001/archgenpsychiatry.2007.37.
   DiazGranados N, 2010, J CLIN PSYCHIAT, V71, P1605, DOI 10.4088/JCP.09m05327blu.
   Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90.
   DITMAN KS, 1959, ARCH GEN PSYCHIAT, V1, P47.
   Dittrich A., 1985, ATIOLOGIE UNABHANGIG.
   DOBLIN R, 1991, J TRANSPERSONAL PSY, V23, P1.
   dos Santos RG, 2013, J PSYCHOACTIVE DRUGS, V45, P68, DOI 10.1080/02791072.2013.763564.
   Dyck B, 2008, PSYCHEDELIC PSYCHIAT.
   EISNER BG, 1958, J NERV MENT DIS, V127, P528, DOI 10.1097/00005053-195812000-00006.
   Friston KJ, 2005, PHILOS T R SOC B, V360, P815, DOI 10.1098/rstb.2005.1622.
   Frood A, 2007, NAT MED, V13, P10, DOI 10.1038/nm0107-10.
   Galanter M, 2013, J ADDICT MED, V7, P189, DOI 10.1097/ADM.0b013e31828a0265.
   Gallinat J, 2012, CURR PHARM DESIGN, V18, P4938, DOI 10.2174/138161212802884582.
   Gasser P, 1995, JB TRANSKULTURELLE M, P143.
   Gasser P, 2008, THERAPIE PSYCHOAKTIV, P315.
   Gasser P, 2014, J NERV MENT DIS, V202, P513, DOI 10.1097/NMD.0000000000000113.
   Geyer MA, 2008, TRENDS PHARMACOL SCI, V29, P445, DOI 10.1016/j.tips.2008.06.006.
   Griffiths RR, 2008, J PSYCHOPHARMACOL, V22, P621, DOI 10.1177/0269881108094300.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Griffiths RR, 2011, PSYCHOPHARMACOLOGY, V218, P649, DOI 10.1007/s00213-011-2358-5.
   Griffiths RR, 2010, SCI AM, V303, P76, DOI 10.1038/scientificamerican1210-76.
   Grinspoon L, 1981, Curr Psychiatr Ther, V20, P275.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Grob CS, 1996, J NERV MENT DIS, V184, P86, DOI 10.1097/00005053-199602000-00004.
   GROF S, 1973, INT PHARMACOPSYCHIAT, V8, P104, DOI 10.1159/000467979.
   GROF S, 1973, INT PHARMACOPSYCHIAT, V8, P129, DOI 10.1159/000467984.
   Grof S, 1979, LSD PSYCHOTHERAPY.
   Grof S., 1977, HUMAN ENCOUNTER DEAT.
   Grof S., 1969, C EUR ASS PSYCH THER.
   Halberstadt AL, 2011, NEUROPHARMACOLOGY, V61, P364, DOI 10.1016/j.neuropharm.2011.01.017.
   Halpern JH, 2005, BIOL PSYCHIAT, V58, P624, DOI 10.1016/j.biopsych.2005.06.038.
   Halpern JH, 2007, PSYCHEDELIC MED NEW, V2, P1, DOI DOI 10.1017/CBO9781107415324.004.
   Halpern JH, 2008, MED SCI MONITOR, V14, pSR15.
   Halpern John H, 2003, Curr Psychiatry Rep, V5, P347, DOI 10.1007/s11920-003-0067-4.
   HARMAN WW, 1966, PSYCHOL REP, V19, P211, DOI 10.2466/pr0.1966.19.1.211.
   HERMLE L, 1992, BIOL PSYCHIAT, V32, P976, DOI 10.1016/0006-3223(92)90059-9.
   Hoffer A, 1968, NEW HOPE ALCOHOLICS.
   HOFFER ABRAM, 1967, P343.
   Juckel G, 2007, SCHIZOPHR RES, V97, P109, DOI 10.1016/j.schres.2007.08.015.
   Karst M, 2010, CEPHALALGIA, V30, P1140, DOI 10.1177/0333102410363490.
   KAST E, 1967, PSYCHIAT QUART, V41, P646, DOI 10.1007/BF01575629.
   Kast E, 1966, Chic Med Sch Q, V26, P80.
   KAST EC, 1964, ANESTH ANALG, V43, P285.
   Kelly JF, 2011, ALCOHOL CLIN EXP RES, V35, P454, DOI 10.1111/j.1530-0277.2010.01362.x.
   Kometer M, 2013, J NEUROSCI, V33, P10544, DOI 10.1523/JNEUROSCI.3007-12.2013.
   Krebs TS, 2012, J PSYCHOPHARMACOL, V26, P994, DOI 10.1177/0269881112439253.
   KRIPPNER S, 1964, AM J CLIN HYPN, V7, P140, DOI 10.1080/00029157.1964.10402408.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   KURLAND AA, 1967, AM J PSYCHIAT, V123, P1202, DOI 10.1176/ajp.123.10.1202.
   Langlitz N, 2010, HIST HUM SCI, V23, P37, DOI 10.1177/0952695109352413.
   Lee HM, 2012, P NATL ACAD SCI USA, V109, P1820, DOI 10.1073/pnas.1121358109.
   LEONARD HL, 1987, AM J PSYCHIAT, V144, P1239.
   Leuner H, 1963, HALLUCINOGENIC DRUGS.
   LEUNER HANSCARL, 1967, P101.
   Lloyd D, 2002, J COGNITIVE NEUROSCI, V14, P818, DOI 10.1162/089892902760191027.
   LUDWIG A, 1969, AM J PSYCHIAT, V126, P59, DOI 10.1176/ajp.126.1.59.
   MACLEAN JR, 1961, Q J STUD ALCOHOL, V22, P34.
   MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x.
   MacLean KA, 2011, J PSYCHOPHARMACOL, V25, P1453, DOI 10.1177/0269881111420188.
   Mangini M, 1998, J PSYCHOACTIVE DRUGS, V30, P381.
   MARONALEWICKA D, 1995, PSYCHOPHARMACOLOGY, V120, P384, DOI 10.1007/BF02245809.
   Mash DC, 1998, ANN NY ACAD SCI, V844, P274, DOI 10.1111/j.1749-6632.1998.tb08242.x.
   Maslow A.H., 1964, RELIG VALUES PEAK EX.
   Mathews DC, 2013, J CLIN PSYCHIAT, V74, P516, DOI 10.4088/JCP.13ac08382.
   Matsushima Y, 2009, BIOSCI BIOTECH BIOCH, V73, P1866, DOI 10.1271/bbb.90095.
   MCGLOTHLIN W, 1967, ARCH GEN PSYCHIAT, V17, P521, DOI 10.1001/archpsyc.1967.01730290009002.
   Metzner R, 1998, J PSYCHOACTIVE DRUGS, V30, P333.
   Moreno FA, 1997, AM J PSYCHIAT, V154, P1037.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Muthukumaraswamy SD, 2013, J NEUROSCI, V33, P15171, DOI 10.1523/JNEUROSCI.2063-13.2013.
   NARANJO P, 1979, J ETHNOPHARMACOL, V1, P121, DOI 10.1016/0378-8741(79)90003-5.
   Nichols DE, 2004, PHARMACOL THERAPEUT, V101, P131, DOI 10.1016/j.pharmthera.2003.11.002.
   NICHOLS DE, 1986, J PSYCHOACTIVE DRUGS, V18, P305, DOI 10.1080/02791072.1986.10472362.
   Oehen P, 2008, THERAPIE PSYCHOAKTIV, P131.
   Oram M, 2014, J HIST MED ALL SCI, V69, P221, DOI 10.1093/jhmas/jrs050.
   OSMOND H, 1957, ANN NY ACAD SCI, V66, P418, DOI 10.1111/j.1749-6632.1957.tb40738.x.
   OSMOND H, 1959, Can Med Assoc J, V80, P91.
   Osmond Humphry, 1969, PSYCHEDELIC DRUGS, P217.
   Pahnke W N, 1969, Int Psychiatry Clin, V5, P149.
   Pahnke W. N., 1969, HARVARD THEOL REV, V62, P1, DOI {[}https://doi.org/10.1017/S0017816000027577, DOI 10.1017/S0017816000027577].
   Pahnke W. N., 1966, INT J PARAPSYCHOLOGY, VVIII, P295.
   PAHNKE WN, 1970, J PSYCHEDEL DRUG, V3, P63, DOI 10.1080/02791072.1970.10471363.
   PAHNKE WN, 1970, J AMER MED ASSOC, V212, P1856, DOI 10.1001/jama.212.11.1856.
   Passie T, 2002, ADDICT BIOL, V7, P357, DOI 10.1080/1355621021000005937.
   Passie T, 2007, BEWUSSTSEINSZUSTANDE, V4.
   Passie T, 2008, CNS NEUROSCI THER, V14, P295, DOI 10.1111/j.1755-5949.2008.00059.x.
   PEKALA RJ, 1986, PERCEPT MOTOR SKILL, V63, P983, DOI 10.2466/pms.1986.63.2.983.
   PRITCHARD W, 1974, J CONTEMP PSYCHOTHER, V6, P141, DOI 10.1007/BF01664708.
   Ratsch Ch, 2005, ENCY PSYCHOACTIVE PL, V1st ed..
   Richards W A, 1978, J Relig Health, V17, P117, DOI 10.1007/BF01532413.
   RICHARDS WA, 1979, OMEGA-J DEATH DYING, V10, P9, DOI 10.2190/NGUB-V4RM-T7DC-XTH3.
   RICHARDS WA, 1977, J PSYCHEDEL DRUG, V9, P1.
   Rodriguez CI, 2013, NEUROPSYCHOPHARMACOL, V38, P2475, DOI 10.1038/npp.2013.150.
   Ross S., 2008, PRIMARY PSYCHIAT, V15, P61.
   Ross S, 2012, PSYCHIAT CLIN N AM, V35, P357, DOI 10.1016/j.psc.2012.04.002.
   SANDISON R A, 1959, Bull World Health Organ, V21, P495.
   Santos RG, 2007, J ETHNOPHARMACOL, V112, P507, DOI 10.1016/j.jep.2007.04.012.
   SAVAGE C, 1973, ARCH GEN PSYCHIAT, V28, P808.
   SAVAGE C, 1963, J NEUROPSYCHIATRY, V5, P4.
   SAVAGE C, 1962, J NERV MENT DIS, V135, P429.
   SAVAGE C, 1964, PSYCHOL REP, V14, P111, DOI 10.2466/pr0.1964.14.1.111.
   SAVAGE C, 1966, INT J NEUROPSYCH, V2, P241.
   Schmidt A, 2013, CEREB CORTEX, V23, P2394, DOI 10.1093/cercor/bhs238.
   Schmidt A, 2012, NEUROPSYCHOPHARMACOL, V37, P865, DOI 10.1038/npp.2011.261.
   Sewell RA, 2006, NEUROLOGY, V66, P1920, DOI 10.1212/01.wnl.0000219761.05466.43.
   Sewell RA., 2008, ENTHEOGEN REV, V16, P117.
   Shanahan NA, 2011, BIOL PSYCHIAT, V70, P1039, DOI 10.1016/j.biopsych.2011.07.032.
   SHERWOOD JN, 1962, J NEUROPSYCHIATRY, V4, P69.
   SMITH CM, 1958, Q J STUD ALCOHOL, V19, P406.
   Sos P, 2013, NEUROENDOCRINOL LETT, V34, P287.
   STRASSMAN RJ, 1995, J NERV MENT DIS, V183, P127, DOI 10.1097/00005053-199503000-00002.
   STRASSMAN RJ, 1994, ARCH GEN PSYCHIAT, V51, P98.
   Studerus E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030800.
   Studerus E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012412.
   Thomas Gerald, 2013, Curr Drug Abuse Rev, V6, P30.
   Umbricht D, 2003, NEUROPSYCHOPHARMACOL, V28, P170, DOI 10.1038/sj.npp.1300005.
   Vollenweider F X, 2001, Dialogues Clin Neurosci, V3, P265.
   Vollenweider FX, 2010, NAT REV NEUROSCI, V11, P642, DOI 10.1038/nrn2884.
   Vollenweider FX, 1997, NEUROPSYCHOPHARMACOL, V16, P357, DOI 10.1016/S0893-133X(96)00246-1.
   Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P9, DOI 10.1016/S0924-977X(96)00039-9.
   Vollenweider FX, 1998, NEUROREPORT, V9, P3897, DOI 10.1097/00001756-199812010-00024.
   Vollenweider FX, 2008, THERAPIE PSYCHOAKTIV, P111.
   WATTS A, 1968, CALIF LAW REV, V56, P74, DOI 10.2307/3479497.
   Watts A., 2013, JOYOUS COSMOLOGY ADV.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.
   Zghoul T, 2003, INT J NEUROPSYCHOPH, V6, P13, DOI 10.1017/S1461145702003218.},
Number-of-Cited-References = {165},
Times-Cited = {119},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {96},
Journal-ISO = {J. Psychopharmacol.},
Doc-Delivery-Number = {CI6VO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000354902100001},
DA = {2023-07-30},
}

@article{ WOS:000992750900001,
Author = {Breeksema, Joost J. and Niemeijer, Alistair and Kuin, Bouwe and Veraart,
   Jolien and Vermetten, Eric and Kamphuis, Jeanine and van den Brink, Wim
   and Schoevers, Robert},
Title = {Phenomenology and therapeutic potential of patient experiences during
   oral esketamine treatment for treatment-resistant depression: an
   interpretative phenomenological study},
Journal = {PSYCHOPHARMACOLOGY},
Year = {2023},
Volume = {240},
Number = {7},
Pages = {1547-1560},
Month = {JUL},
Abstract = {BackgroundKetamine and its enantiomers are widely researched and
   increasingly used to treat mental disorders, especially
   treatment-resistant depression. The phenomenology of ketamine-induced
   experiences and their relation to its psychotherapeutic potential have
   not yet been systematically investigated.AimsTo describe the
   phenomenology of patient experiences during oral esketamine treatment
   for treatment-resistant depression (TRD) and to explore the potential
   therapeutic relevance of these experiences.MethodsIn-depth interviews
   were conducted with 17 patients after a 6-week, twice-weekly `off label'
   generic oral esketamine (0.5-3.0mg/kg) treatment program. Interviews
   explored participants' perspectives, expectations, and experiences with
   oral esketamine treatment. Audio interviews were transcribed and
   analyzed using an Interpretative Phenomenological Analysis (IPA)
   framework.ResultsThe effects of ketamine were highly variable, and
   psychological distress was common in most patients. Key themes included
   (a) perceptual effects (auditory, visual, proprioceptive), (b)
   detachment (from body, self, emotions, and the world), (c) stillness and
   openness, (d) mystical-type effects (transcendence, relativeness,
   spirituality), and (e) fear and anxiety. Key themes related to
   post-session reports included (a) feeling hungover and fatigued, and (b)
   lifting the blanket: neutralizing mood effects.ConclusionPatients
   reported several esketamine effects with psychotherapeutic potential,
   such as increased openness, detachment, an interruption of negativity,
   and mystical-type experiences. These experiences deserve to be explored
   further to enhance treatment outcomes in patients with TRD. Given the
   frequency and severity of the perceived distress, we identify a need for
   additional support in all stages of esketamine treatment.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Breeksema, JJ (Corresponding Author), Univ Groningen, Univ Med Ctr Groningen, Res Sch Behav \& Cognit Neurosci BCN, Dept Psychiat, Postbus 30-001, NL-9700 RB Groningen, Netherlands.
   Breeksema, Joost J.; Kuin, Bouwe; Veraart, Jolien; Kamphuis, Jeanine; Schoevers, Robert, Univ Groningen, Univ Med Ctr Groningen, Res Sch Behav \& Cognit Neurosci BCN, Dept Psychiat, Postbus 30-001, NL-9700 RB Groningen, Netherlands.
   Niemeijer, Alistair, Univ Humanist Studies, Dept Care Ethics, Utrecht, Netherlands.
   Veraart, Jolien, Parnassia Psychiat Inst, PsyQ Haaglanden, The Hague, Netherlands.
   van den Brink, Wim, Acad Med Ctr, locat Dept Psychiat, Amsterdam UMC, Amsterdam, Netherlands.
   van den Brink, Wim, Amsterdam Neurosci Res, Program Compuls Impuls \& Attent, Amsterdam, Netherlands.
   Vermetten, Eric, Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands.},
DOI = {10.1007/s00213-023-06388-6},
EarlyAccessDate = {MAY 2023},
ISSN = {0033-3158},
EISSN = {1432-2072},
Keywords = {Esketamine; Phenomenology; Psychotherapy; Treatment-resistant
   depression; Patient experiences; Qualitative research},
Keywords-Plus = {KETAMINE ASSISTED PSYCHOTHERAPY; REPORTING QUALITATIVE RESEARCH;
   INTRAVENOUS KETAMINE; ANTIDEPRESSANT; QUESTIONNAIRE; DISSOCIATION;
   DISORDERS},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry},
Web-of-Science-Categories  = {Neurosciences; Pharmacology \& Pharmacy; Psychiatry},
Author-Email = {j.j.breeksema@umcg.nl},
Affiliations = {University of Groningen; Parnassia Psychiatric Institute; University of
   Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC},
Cited-References = {{[}Anonymous], QUALITATIVE RES PSYC, DOI {[}10.1191/1478088704qp004oa, DOI 10.1191/1478088704QP004OA].
   Aust S, 2019, EUR NEUROPSYCHOPHARM, V29, P529, DOI 10.1016/j.euroneuro.2019.02.005.
   Azhari N, 2021, AM J DRUG ALCOHOL AB, V47, P92, DOI 10.1080/00952990.2020.1808982.
   Bahji A, 2022, EXPERT OPIN DRUG SAF, V21, P853, DOI 10.1080/14740338.2022.2047928.
   Barrett FS, 2016, J PSYCHOPHARMACOL, V30, P1279, DOI 10.1177/0269881116678781.
   Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019.
   Breeksema JJ, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.948115.
   Breeksema JJ, 2022, J PSYCHOPHARMACOL, V36, P1100, DOI 10.1177/02698811221116926.
   Bremner JD, 1998, J TRAUMA STRESS, V11, P125, DOI 10.1023/A:1024465317902.
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710.
   Ceban F, 2021, CNS DRUGS, V35, P925, DOI 10.1007/s40263-021-00846-5.
   Chen G, 2022, INT J NEUROPSYCHOPH, V25, P269, DOI 10.1093/ijnp/pyab084.
   Chen MH, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20m13232.
   Corbin J., 2015, BASICS QUALITATIVE R, V4th.
   CORSSEN G, 1966, ANESTH ANAL CURR RES, V45, P29.
   Dakwar E, 2018, NEUROPHARMACOLOGY, V142, P270, DOI 10.1016/j.neuropharm.2018.01.005.
   Dakwar E, 2014, DRUG ALCOHOL DEPEN, V136, P153, DOI 10.1016/j.drugalcdep.2013.12.019.
   Dakwar E, 2019, AM J PSYCHIAT, V176, P923, DOI 10.1176/appi.ajp.2019.18101123.
   DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279.
   Dore J, 2019, J PSYCHOACTIVE DRUGS, V51, P189, DOI 10.1080/02791072.2019.1587556.
   Drozdz SJ, 2022, J PAIN RES, V15, P1691, DOI 10.2147/JPR.S360733.
   Eisner B, 1997, J PSYCHOACTIVE DRUGS, V29, P213.
   Finlay L, 2014, QUAL RES PSYCHOL, V11, P121, DOI 10.1080/14780887.2013.807899.
   Grabski M, 2022, AM J PSYCHIAT, V179, P152, DOI 10.1176/appi.ajp.2021.21030277.
   Grabski M, 2020, BEHAV BRAIN RES, V392, DOI 10.1016/j.bbr.2020.112629.
   Griffiths C., 2021, J AFFECT DISORD REP, V4, P100079, DOI {[}10.1016/j.jadr.2021.100079, DOI 10.1016/J.JADR.2021.100079].
   Horowitz M, 2021, BRIT J PSYCHIAT, V219, P621, DOI 10.1192/bjp.2021.163.
   Jilka S, 2021, BJPSYCH OPEN, V7, DOI 10.1192/bjo.2020.165.
   Johnson MW, 2008, J PSYCHOPHARMACOL, V22, P603, DOI 10.1177/0269881108093587.
   Johnson MW, 2019, PHARMACOL THERAPEUT, V197, P83, DOI 10.1016/j.pharmthera.2018.11.010.
   Joneborg I, 2022, J AFFECT DISORDERS, V315, P105, DOI 10.1016/j.jad.2022.07.030.
   Karp D, 1997, SPEAKING SADNESS DEP.
   Kendler KS, 2016, AM J PSYCHIAT, V173, P771, DOI 10.1176/appi.ajp.2016.15121509.
   KHORRAMZADEH E, 1973, PSYCHOSOMATICS, V14, P344.
   Ko KM, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.917199.
   Krupitsky E., 2007, PSYCHEDELIC MED NEW, P67.
   Krupitsky EM, 1997, J PSYCHOACTIVE DRUGS, V29, P165.
   KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004.
   Lapidos A, 2023, J AFFECT DISORDERS, V323, P534, DOI 10.1016/j.jad.2022.11.090.
   Lascelles K, 2020, BJPSYCH OPEN, V7, DOI 10.1192/bjo.2020.132.
   Lascelles K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029108.
   Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017.
   Lyssenko L, 2018, AM J PSYCHIAT, V175, P37, DOI 10.1176/appi.ajp.2017.17010025.
   MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x.
   Mashour GA, 2022, ANESTHESIOLOGY, V136, P675, DOI 10.1097/ALN.0000000000004172.
   Mathai DS, 2022, BRIT J PSYCHIAT, V221, P496, DOI 10.1192/bjp.2022.58.
   Mathai DS, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.868103.
   Mathai DS, 2020, J AFFECT DISORDERS, V264, P123, DOI 10.1016/j.jad.2019.12.023.
   Miller RM., 2016, J MENTAL HLTH COUNSE, V38, P47, DOI {[}10.17744/mehc.38.1.04, DOI 10.17744/MEHC.38.1.04].
   Mollaahmetoglu OM, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.695335.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Niemeijer AR., 2015, EXPLORING GOOD CARE.
   Nour MM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00269.
   O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388.
   Osler L, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.928186.
   Payne JE, 2021, ACS PHARMACOL TRANSL, V4, P416, DOI 10.1021/acsptsci.1c00034.
   Pietkiewicz I., 2014, PSYCHOL J, V20, P7, DOI {[}10.14691/CPPJ.20.1.7, DOI 10.14691/CPPJ.20.1.7].
   Pradhan B., 2017, ASIA PAC J CLIN TRIA, V2, P80, DOI {[}10.4103/2542-3932.211589, DOI 10.4103/2542-3932.211589].
   PRADHAN B, 2020, CUREUS J MED SCIENCE, V12, P10, DOI DOI 10.7759/CUREUS.11798.
   Rothrock RJ, 2020, J NEUROSURG-SPINE, V33, P680, DOI 10.3171/2020.4.SPINE20118.
   Servaas Michelle N, 2021, Lancet Psychiatry, V8, P1022, DOI 10.1016/S2215-0366(21)00353-9.
   Smith J. A., 2003, QUALITATIVE PSYCHOL, P51, DOI DOI 10.1037/13620-005.
   Sos P, 2013, NEUROENDOCRINOL LETT, V34, P287.
   Stocker K, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.916641.
   Studerus E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012412.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042.
   van Schalkwyk GI, 2018, J AFFECT DISORDERS, V227, P11, DOI 10.1016/j.jad.2017.09.023.
   Veraart JKE, 2021, INT J NEUROPSYCHOPH, V24, P808, DOI 10.1093/ijnp/pyab039.
   Watts R, 2022, PSYCHOPHARMACOLOGY, V239, P3461, DOI 10.1007/s00213-022-06187-5.
   Wilkinson ST, 2021, PSYCHOTHER PSYCHOSOM, V90, P318, DOI 10.1159/000517074.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Yaden DB, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.873279.},
Number-of-Cited-References = {73},
Times-Cited = {0},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Psychopharmacology},
Doc-Delivery-Number = {I8RU4},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000992750900001},
OA = {Green Published, hybrid},
DA = {2023-07-30},
}

@article{ WOS:000563233800001,
Author = {Zeifman, Richard J. and Wagner, Anne C. and Watts, Ros and Kettner,
   Hannes and Mertens, Lea J. and Carhart-Harris, Robin L.},
Title = {Post-Psychedelic Reductions in Experiential Avoidance Are Associated
   With Decreases in Depression Severity and Suicidal Ideation},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2020},
Volume = {11},
Month = {AUG 7},
Abstract = {Psychedelic therapy shows promise as a novel intervention for a wide
   range of mental health concerns but its therapeutic action is
   incompletely understood. In line with acceptance and commitment
   therapy's (ACT's) transdiagnostic model, qualitative research has
   suggested that reductions in experiential avoidance are an important
   component of therapeutic outcomes associated with psychedelics. However,
   limited research has quantitatively explored the association between
   decreases in experiential avoidance and therapeutic outcomes associated
   with psychedelics. Therefore, in two prospective studies, using
   convenience samples of individuals with plans to use a psychedelic, we
   explored the impact of psychedelic use on experiential avoidance,
   depression severity, and suicidal ideation, as well as relationships
   between changes in these outcomes. Participants (Study 1,N=104; Study
   2,N=254) completed self-report questionnaires of depression severity,
   suicidal ideation, and experiential avoidance: 1) before using a
   psychedelic (in ceremonial and non-ceremonial contexts), as well as 2)
   2-weeks and 3) 4-weeks after psychedelic use. Across both studies,
   repeated measures ANOVAs indicated significant decreases in experiential
   avoidance, depression severity, and suicidal ideation after psychedelic
   use. Furthermore, decreases in experiential avoidance were significantly
   associated with decreases in depression severity and suicidal ideation.
   These results suggest that psychedelics may lead to significant
   decreases in experiential avoidance, depression severity, and suicidal
   ideation. Additionally, these findings imply that reduced experiential
   avoidance may be a transdiagnostic mechanism mediating treatment success
   within psychedelic therapy. We conclude that integrating psychedelics
   with psychotherapeutic interventions that target experiential avoidance
   (e.g. ACT) may enhance therapeutic outcomes.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Zeifman, RJ (Corresponding Author), Imperial Coll London, Fac Med, Dept Brain Sci, Ctr Psychedel Res, London, England.
   Zeifman, Richard J.; Watts, Ros; Kettner, Hannes; Mertens, Lea J.; Carhart-Harris, Robin L., Imperial Coll London, Fac Med, Dept Brain Sci, Ctr Psychedel Res, London, England.
   Wagner, Anne C., Remedy, Toronto, ON, Canada.
   Mertens, Lea J., Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth CIMH, Dept Mol Neuroimaging, Mannheim, Germany.},
DOI = {10.3389/fpsyt.2020.00782},
Article-Number = {782},
ISSN = {1664-0640},
Keywords = {psychedelics; experiential avoidance; suicidal ideation; depression
   severity; transdiagnostic mechanisms},
Keywords-Plus = {LIFE-THREATENING CANCER; PSYCHOLOGICAL FLEXIBILITY; COMMITMENT THERAPY;
   PSILOCYBIN TREATMENT; ASSISTED THERAPY; SELF-REPORT; ACCEPTANCE;
   ANTIDEPRESSANTS; KETAMINE; ANXIETY},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {rzeifman@ryerson.ca},
Affiliations = {Imperial College London; 4EU+; Ruprecht Karls University Heidelberg;
   Central Institute of Mental Health},
Funding-Acknowledgement = {Canadian Institutes of Health Research; Alex Mosley Charitable Trust; Ad
   Astra Chandaria Foundation; Nikean Foundation},
Funding-Text = {RZ received funding from the Canadian Institutes of Health Research.
   RC-H is supported by the Alex Mosley Charitable Trust and the Centre for
   Psychedelic Research was Founded by Tim Ferriss, Ad Astra Chandaria
   Foundation, Alexander and Bohdana Tamas, and the Nikean Foundation.},
Cited-References = {A-Tjak JGL, 2015, PSYCHOTHER PSYCHOSOM, V84, P30, DOI 10.1159/000365764.
   {[}Anonymous], 2017, DEPR OTH COMM MENT D.
   {[}Anonymous], 2012, ACCEPTANCE COMMITMEN.
   {[}Anonymous], 2014, RES PRIOR TASK FORC.
   {[}Anonymous], ACCEPTANCE CHANGE CO, DOI DOI 10.1111/J.1743-6109.2008.00800.X.
   Bala A, 2018, SEX MED REV, V6, P29, DOI 10.1016/j.sxmr.2017.07.002.
   Ballard ED, 2018, J AFFECT DISORDERS, V241, P86, DOI 10.1016/j.jad.2018.07.077.
   Ballard ED, 2014, J PSYCHIATR RES, V58, P161, DOI 10.1016/j.jpsychires.2014.07.027.
   Barrera AZ, 2007, INT REV PSYCHIATR, V19, P655, DOI 10.1080/09540260701797894.
   Berking M, 2009, BEHAV RES THER, V47, P663, DOI 10.1016/j.brat.2009.04.011.
   Bogenschutz MP, 2015, J PSYCHOPHARMACOL, V29, P289, DOI 10.1177/0269881114565144.
   Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007.
   Braillon A, 2019, ACTA PSYCHIAT SCAND, V139, P294, DOI 10.1111/acps.13010.
   Carhart-Harris RL, 2019, PHARMACOL REV, V71, P316, DOI 10.1124/pr.118.017160.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P547, DOI 10.1007/s00213-017-4701-y.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris RL, 2017, J PSYCHOPHARMACOL, V31, P1091, DOI 10.1177/0269881117725915.
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710.
   Carhart-Harris RL, 2017, NEUROPSYCHOPHARMACOL, V42, P2105, DOI 10.1038/npp.2017.84.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Ceskova E, 2018, NEUROPSYCH DIS TREAT, V14, P741, DOI 10.2147/NDT.S157475.
   Cipriani Andrea, 2018, Focus (Am Psychiatr Publ), V16, P420, DOI 10.1176/appi.focus.16407.
   Close JB, 2020, J CONTEXT BEHAV SCI, V16, P37, DOI 10.1016/j.jcbs.2020.01.005.
   Cuijpers P, 2019, EPIDEMIOL PSYCH SCI, V28, P21, DOI 10.1017/S2045796018000057.
   Cuijpers P, 2014, J AFFECT DISORDERS, V159, P118, DOI 10.1016/j.jad.2014.02.026.
   Cuijpers P, 2013, J AFFECT DISORDERS, V144, P183, DOI 10.1016/j.jad.2012.06.025.
   Curtin Sally C, 2016, NCHS Data Brief, P1.
   Davis AK, 2020, J CONTEXT BEHAV SCI, V15, P39, DOI 10.1016/j.jcbs.2019.11.004.
   Davis AK, 2019, AM J DRUG ALCOHOL AB, V45, P161, DOI 10.1080/00952990.2018.1545024.
   Dominguez-Clave E, 2019, PSYCHOPHARMACOLOGY, V236, P573, DOI 10.1007/s00213-018-5085-3.
   Dutta R, 2017, PSYCHOL MED, V47, P2438, DOI 10.1017/S0033291717000940.
   Ellis TE, 2016, ARCH SUICIDE RES, V20, P59, DOI 10.1080/13811118.2015.1004483.
   Fagerland MW, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-78.
   Fava GA, 2018, PSYCHOTHER PSYCHOSOM, V87, P195, DOI 10.1159/000491524.
   Forstmann M, 2020, P NATL ACAD SCI USA, V117, P2338, DOI 10.1073/pnas.1918477117.
   Gamez W, 2014, PSYCHOL ASSESSMENT, V26, P35, DOI 10.1037/a0034473.
   Gamez W, 2011, PSYCHOL ASSESSMENT, V23, P692, DOI 10.1037/a0023242.
   Garcia-Romeu A, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00955.
   Garcia-Romeu A, 2019, J PSYCHOPHARMACOL, V33, P1088, DOI 10.1177/0269881119845793.
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Ghasemi A, 2012, INT J ENDOCRINOL MET, V10, P486, DOI 10.5812/ijem.3505.
   Goodwin GM, 2017, J AFFECT DISORDERS, V221, P31, DOI 10.1016/j.jad.2017.05.048.
   Griffiths JJ, 2014, AM J PREV MED, V47, pS195, DOI 10.1016/j.amepre.2014.06.012.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Haijen ECHM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00897.
   Haslam N, 2020, PSYCHOL MED, V50, P1418, DOI 10.1017/S003329172000183X.
   Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492.
   Hegerl U, 2012, J AFFECT DISORDERS, V138, P183, DOI 10.1016/j.jad.2011.05.015.
   Hengartner MP, 2019, PSYCHOTHER PSYCHOSOM, V88, P247, DOI 10.1159/000501215.
   Hengartner MP, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00517.
   Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379.
   Johnson MW, 2019, PHARMACOL THERAPEUT, V197, P83, DOI 10.1016/j.pharmthera.2018.11.010.
   Johnson MW, 2017, AM J DRUG ALCOHOL AB, V43, P55, DOI 10.3109/00952990.2016.1170135.
   Kazdin AE, 2007, ANNU REV CLIN PSYCHO, V3, P1, DOI 10.1146/annurev.clinpsy.3.022806.091432.
   Krafft J, 2019, SUICIDE LIFE-THREAT, V49, P1488, DOI 10.1111/sltb.12533.
   Krebs TS, 2012, J PSYCHOPHARMACOL, V26, P994, DOI 10.1177/0269881112439253.
   Lewis G, 2019, LANCET PSYCHIAT, V6, P903, DOI 10.1016/S2215-0366(19)30366-9.
   Luoma JB, 2019, J CONTEXT BEHAV SCI, V14, P136, DOI 10.1016/j.jcbs.2019.10.003.
   Lyons T, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01721.
   Machado-Vieira R, 2010, PHARMACEUTICALS, V3, P19, DOI 10.3390/ph3010019.
   Mihalopoulos C, 2013, EXPERT REV PHARM OUT, V13, P237, DOI {[}10.1586/ERP.13.5, 10.1586/erp.13.5].
   Miron O, 2019, JAMA-J AM MED ASSOC, V321, P2362, DOI 10.1001/jama.2019.5054.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Moroz M, 2019, BEHAV RES THER, V112, P18, DOI 10.1016/j.brat.2018.11.006.
   Naber D, 2018, DIALOGUES CLIN NEURO, V20, P223.
   Naslund J, 2018, BRIT J PSYCHIAT, V212, P148, DOI 10.1192/bjp.2017.24.
   Nock MK, 2010, MOL PSYCHIATR, V15, P868, DOI 10.1038/mp.2009.29.
   Palhano-Fontes Fernanda, 2019, Psychol Med, V49, P655, DOI 10.1017/S0033291718001356.
   Price RB, 2014, DEPRESS ANXIETY, V31, P335, DOI 10.1002/da.22253.
   Price RB, 2009, BIOL PSYCHIAT, V66, P522, DOI 10.1016/j.biopsych.2009.04.029.
   Puglisi-Allegra S, 2015, BEHAV BRAIN RES, V277, P58, DOI 10.1016/j.bbr.2014.07.052.
   Rochefort C, 2018, BEHAV THER, V49, P435, DOI 10.1016/j.beth.2017.08.008.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Roseman L, 2018, NEUROPHARMACOLOGY, V142, P263, DOI 10.1016/j.neuropharm.2017.12.041.
   Roseman L, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00974.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Rufino KA, 2018, SUICIDE LIFE-THREAT, V48, P271, DOI 10.1111/sltb.12353.
   Rush AJ, 2006, PSYCHIAT SERV, V57, P829, DOI 10.1176/appi.ps.57.6.829.
   Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8.
   Sampedro F, 2017, INT J NEUROPSYCHOPH, V20, P698, DOI 10.1093/ijnp/pyx036.
   Shallcross AJ, 2010, BEHAV RES THER, V48, P921, DOI 10.1016/j.brat.2010.05.025.
   Sloshower J, 2020, J CONTEXT BEHAV SCI, V15, P12, DOI 10.1016/j.jcbs.2019.11.002.
   Soler J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00224.
   Soler J, 2016, PSYCHOPHARMACOLOGY, V233, P823, DOI 10.1007/s00213-015-4162-0.
   Spinhoven P, 2016, COGNITIVE THER RES, V40, P150, DOI 10.1007/s10608-015-9747-8.
   Stroud JB, 2018, PSYCHOPHARMACOLOGY, V235, P459, DOI 10.1007/s00213-017-4754-y.
   Tyndall I, 2019, J CONTEXT BEHAV SCI, V12, P278, DOI 10.1016/j.jcbs.2018.09.005.
   Uthaug MV, 2019, PSYCHOPHARMACOLOGY, V236, P2653, DOI 10.1007/s00213-019-05236-w.
   Uthaug MV, 2018, PSYCHOPHARMACOLOGY, V235, P2979, DOI 10.1007/s00213-018-4988-3.
   van Spijker BAJ, 2014, SUICIDE LIFE-THREAT, V44, P408, DOI 10.1111/sltb.12084.
   Vaughan-Johnston TI, 2017, PERS INDIV DIFFER, V105, P335, DOI 10.1016/j.paid.2016.10.011.
   Walser RD, 2015, BEHAV RES THER, V74, P25, DOI 10.1016/j.brat.2015.08.012.
   Walsh Z, 2018, INT REV PSYCHIATR, V30, P343, DOI 10.1080/09540261.2018.1474088.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Wolff M, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00005.
   Wolgast M, 2014, BEHAV THER, V45, P831, DOI 10.1016/j.beth.2014.07.002.
   Zeifman RJ, 2020, J CONTEXT BEHAV SCI, V15, P1, DOI 10.1016/j.jcbs.2019.11.001.
   Zeifman RJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01325.},
Number-of-Cited-References = {100},
Times-Cited = {42},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {28},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {NF3YH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000563233800001},
OA = {gold, Green Published},
DA = {2023-07-30},
}

@article{ WOS:001001594000009,
Author = {Butler, Matthew and Seynaeve, Mathieu and Bradley-Westguard, Abigail and
   Bao, Jianan and Crawshaw, Ania and Pick, Susannah and Edwards, Mark and
   Nicholson, Timothy and Rucker, James},
Title = {Views on Using Psychoactive Substances to Self-Manage Functional
   Neurological Disorder: Online Patient Survey Results},
Journal = {JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES},
Year = {2023},
Volume = {35},
Number = {1},
Pages = {77-85},
Abstract = {Objective: Functional neurological disorder (FND) causes a high burden
   of disability and distress. Although it is a com-mon disorder, there is
   a pressing need for improved access to evidence-based treatments. With
   difficulties in finding effective treatment, some people with FND may
   seek al-ternative means of symptom relief, such as legal and illicit
   psychoactive substances, although the prevalence and nature of such
   self-management strategies are currently unclear. Additionally,
   psychoactive substances may represent novel treatment research
   opportunities, particularly for those with suboptimal improvement. The
   investigators examined the use of self-management techniques, as well as
   per-spectives on novel therapies, in this patient population.Methods: An
   online survey was created to assess self -management strategies and
   views on novel treatments for FND, including psychedelic therapy. The
   survey was acces-sible for 1 month, and respondents were recruited
   interna-tionally through social media and patient groups. A total of
   1,048 respondents from 16 countries completed the survey. Results:
   Almost half (46\%) of 980 respondents reported having tried legal
   psychoactive substances for the manage-ment of their FND symptoms and,
   on average, nicotine, al-cohol, and cannabidiol were reported as
   modestly effective. Additionally, 15\% of respondents reported having
   used illicit substances, mostly cannabis, to manage FND, with the
   ma-jority reporting moderate effectiveness and experiencing no or
   minimal physical (90\%) and psychological (95\%) sequelae. Many
   respondents (46\%) reported that they would be willing to try medically
   supervised psychedelic therapy (with 19\% of re-spondents ambivalent) if
   it were found to be safe and effective.Conclusions: Many people with FND
   seek alternative means of symptom management outside usual medical care,
   in-cluding legal and illicit psychoactive substances. Further research
   exploring novel treatment options, such as psy-chedelics, in FND may be
   warranted.},
Publisher = {AMER PSYCHIATRIC PUBLISHING, INC},
Address = {800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA},
Type = {Article},
Language = {English},
Affiliation = {Butler, M (Corresponding Author), Kings Coll London, Inst Psychiat Psychol \& Neurosci, Neuropsychiat Res \& Educ Grp, London, England.
   Butler, Matthew; Pick, Susannah; Nicholson, Timothy, Kings Coll London, Inst Psychiat Psychol \& Neurosci, Neuropsychiat Res \& Educ Grp, London, England.
   Seynaeve, Mathieu; Bao, Jianan; Rucker, James, Kings Coll London, Inst Psychiat Psychol \& Neurosci, London, England.
   Crawshaw, Ania, Natl Hlth Serv Fdn Trust, London, England.
   Edwards, Mark, St Georges Univ Hosp, Dept Neurol, London, England.
   Crawshaw, Ania; Edwards, Mark, St Georges Univ London, Inst Mol \& Clin Sci, London, England.
   Edwards, Mark, UCL, Queen Sq Inst Neurol, Sobell Dept Motor Neurosci \& Movement Disorders, London, England.},
DOI = {10.1176/appi.neuropsych.21080213},
ISSN = {0895-0172},
EISSN = {1545-7222},
Keywords-Plus = {PSYCHOGENIC NONEPILEPTIC SEIZURES; COGNITIVE-BEHAVIORAL THERAPY; CLUSTER
   HEADACHE; KETAMINE; RESISTANT; PHARMACOLOGY; PSILOCYBIN; CANNABIS; MDMA;
   PSYCHOTHERAPY},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences; Psychiatry},
Author-Email = {matthew.butler@kcl.ac.uk},
Affiliations = {University of London; King's College London; University of London;
   King's College London; St Georges University London; St Georges
   University London; University of London; University College London},
ORCID-Numbers = {Rucker, James/0000-0003-4647-8088
   Butler, Matt/0000-0002-9734-6539
   Pick, Susannah/0000-0003-2001-6723
   Nicholson, Timothy/0000-0002-2350-2332},
Funding-Acknowledgement = {U.K. National Institute for Health Research (NIHR) {[}CS-2014-14-016,
   CS-2017-17-007]; NIHR Biomedical Research Centre at South London,
   Maudsley National Health Service Foundation Trust; King's College
   London; Compass Pathways, Ltd; National Institutes of Health Research
   (NIHR) {[}CS-2017-17-007, CS-2014-14-016] Funding Source: National
   Institutes of Health Research (NIHR)},
Funding-Text = {This work was supported by the U.K. National Institute for Health
   Research (NIHR) via Clinician Scientist Fellowship Awards to Dr.
   Nicholson (CS-2014-14-016) and Dr. Rucker (CS-2017-17-007) and by the
   NIHR Biomedical Research Centre at South London, Maudsley National
   Health Service Foundation Trust, and King's College London.King's
   College London receives grant funding for phase 1 and 2 trials with
   psilocybin, led by Dr. Rucker, from Compass Pathways, Ltd.},
Cited-References = {Ahmad O, 2016, J CLIN NEUROSCI, V28, P93, DOI 10.1016/j.jocn.2015.11.020.
   {[}Anonymous], 2013, DESOXYN PRESCRIBING.
   Blessing EM, 2015, NEUROTHERAPEUTICS, V12, P825, DOI 10.1007/s13311-015-0387-1.
   Blockmans Daniel, 2006, Am J Med, V119, DOI 10.1016/j.amjmed.2005.07.047.
   Bornemann J, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.735427.
   Bryson A, 2017, INT J NEUROPSYCHOPH, V20, P422, DOI 10.1093/ijnp/pyx011.
   Burke MJ, 2021, NAT MED, V27, P1687, DOI 10.1038/s41591-021-01524-1.
   Burke MJ, 2020, J NEUROPSYCH CLIN N, V32, P101, DOI 10.1176/appi.neuropsych.19030077.
   Butler M, 2021, EUR J NEUROL, V28, P3591, DOI 10.1111/ene.15018.
   Butler M, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320912125.
   Carhart-Harris RL, 2018, PSYCHOPHARMACOLOGY, V235, P399, DOI 10.1007/s00213-017-4771-x.
   Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7.
   Carson A, 2011, J NEUROL NEUROSUR PS, V82, P810, DOI 10.1136/jnnp.2010.220640.
   Castells X, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007813.pub3.
   Chaves C, 2020, PAIN MED, V21, P2212, DOI 10.1093/pm/pnaa303.
   Chong MS, 2006, MULT SCLER J, V12, P646, DOI 10.1177/1352458506070947.
   de la Torre R, 2004, THER DRUG MONIT, V26, P137, DOI 10.1097/00007691-200404000-00009.
   DELAY J, 1951, Ann Med Psychol (Paris), V109, P186.
   Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631.
   Di Lorenzo C, 2016, CEPHALALGIA, V36, P194, DOI 10.1177/0333102415583145.
   Espay AJ, 2018, JAMA NEUROL, V75, P1132, DOI 10.1001/jamaneurol.2018.1264.
   Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966.
   Faraone SV, 2018, NEUROSCI BIOBEHAV R, V87, P255, DOI 10.1016/j.neubiorev.2018.02.001.
   Feder A, 2021, AM J PSYCHIAT, V178, P193, DOI 10.1176/appi.ajp.2020.20050596.
   Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x.
   Ganos C, 2016, PSYCHIAT RES, V246, P821, DOI 10.1016/j.psychres.2016.10.021.
   Garcia-Romeu Albert, 2014, Curr Drug Abuse Rev, V7, P157.
   Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658.
   Goldstein LH, 2020, LANCET PSYCHIAT, V7, P491, DOI 10.1016/S2215-0366(20)30128-0.
   Guindon J, 2009, CNS NEUROL DISORD-DR, V8, P403, DOI 10.2174/187152709789824660.
   HAFEIZ HB, 1980, BRIT J PSYCHIAT, V136, P548, DOI 10.1192/bjp.136.6.548.
   Heal DJ, 2014, NEUROPHARMACOLOGY, V87, P19, DOI 10.1016/j.neuropharm.2014.06.012.
   Hurley R, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l753.
   Jelen LA, 2021, J PSYCHOPHARMACOL, V35, P109, DOI 10.1177/0269881120959644.
   Krebs TS, 2012, J PSYCHOPHARMACOL, V26, P994, DOI 10.1177/0269881112439253.
   Krediet E, 2020, INT J NEUROPSYCHOPH, V23, P385, DOI 10.1093/ijnp/pyaa018.
   LaFrance WC, 2014, JAMA PSYCHIAT, V71, P997, DOI 10.1001/jamapsychiatry.2014.817.
   Lim K, 2017, CLIN PSYCHOPHARM NEU, V15, P301, DOI 10.9758/cpn.2017.15.4.301.
   Ludwig L, 2018, LANCET PSYCHIAT, V5, P307, DOI 10.1016/S2215-0366(18)30051-8.
   MacNeil SD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236356.
   Matin N, 2017, J NEUROPSYCH CLIN N, V29, P375, DOI 10.1176/appi.neuropsych.16110302.
   Mitchell JM, 2021, NAT MED, V27, P1025, DOI 10.1038/s41591-021-01336-3.
   Mithoefer MC, 2018, LANCET PSYCHIAT, V5, P486, DOI 10.1016/S2215-0366(18)30135-4.
   Mithoefer MC, 2016, LANCET PSYCHIAT, V3, P481, DOI 10.1016/S2215-0366(15)00576-3.
   Moccia L, 2022, INT CLIN PSYCHOPHARM, V37, P21, DOI 10.1097/YIC.0000000000000378.
   Moreno FA, 2006, J CLIN PSYCHIAT, V67, P1735, DOI 10.4088/JCP.v67n1110.
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392.
   National Institute for Heath and Care Excellence (NICE), 2019, CANN BAS MED PROD.
   Nicholson C, 2022, BRIT J OCCUP THER, V85, P262, DOI 10.1177/03080226211020658.
   Niciu MJ, 2018, J AFFECT DISORDERS, V232, P310, DOI 10.1016/j.jad.2018.02.049.
   Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6.
   Oehen P, 2013, J PSYCHOPHARMACOL, V27, P40, DOI 10.1177/0269881112464827.
   Korman GP, 2019, EPILEPSY BEHAV, V94, P183, DOI 10.1016/j.yebeh.2019.03.005.
   Phillips JL, 2019, AM J PSYCHIAT, V176, P401, DOI 10.1176/appi.ajp.2018.18070834.
   Pick S, 2020, J NEUROL NEUROSUR PS, V91, P638, DOI 10.1136/jnnp-2019-322180.
   Poole NA, 2010, BRIT J PSYCHIAT, V197, P91, DOI 10.1192/bjp.bp.109.066894.
   Popkirov S, 2019, J NEUROL NEUROSUR PS, V90, P608, DOI 10.1136/jnnp-2018-318298.
   Reiche S, 2018, PROG NEURO-PSYCHOPH, V81, P1, DOI 10.1016/j.pnpbp.2017.09.012.
   Riezzo I, 2012, CURR MED CHEM, V19, P5624, DOI 10.2174/092986712803988893.
   Robbins NM, 2016, EPILEPSY BEHAV, V55, P174, DOI 10.1016/j.yebeh.2015.12.022.
   Rucker JJH, 2018, NEUROPHARMACOLOGY, V142, P200, DOI 10.1016/j.neuropharm.2017.12.040.
   Rucker JJH, 2016, J PSYCHOPHARMACOL, V30, P1220, DOI 10.1177/0269881116679368.
   Saleemi S, 2017, J PSYCHOPHARMACOL, V31, P1056, DOI 10.1177/0269881117715596.
   Sarrouy C, 1960, SOC FRANCAISE PEDIAT, V15, P71.
   Schindler EAD, 2021, NEUROTHERAPEUTICS, V18, P534, DOI 10.1007/s13311-020-00962-y.
   Sewell RA, 2006, NEUROLOGY, V66, P1920, DOI 10.1212/01.wnl.0000219761.05466.43.
   Spriggs MJ, 2021, EAT WEIGHT DISORD-ST, V26, P1265, DOI 10.1007/s40519-020-01000-8.
   Stewart B, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.688.
   Stone J, 2014, J PSYCHOSOM RES, V76, P165, DOI 10.1016/j.jpsychores.2013.10.003.
   UK Office for National Statistics, 2020, DRUG MIS ENGL WAL YE.
   Vendrell-Serres J, 2021, THER ADV PSYCHOPHARM, V11, DOI 10.1177/20451253211022187.
   YENSEN R, 1976, J NERV MENT DIS, V163, P233, DOI 10.1097/00005053-197610000-00002.
   Zorumski CF, 2017, JAMA PSYCHIAT, V74, P405, DOI 10.1001/jamapsychiatry.2017.0078.},
Number-of-Cited-References = {73},
Times-Cited = {1},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {J. Neuropsychiatr. Clin. Neurosci.},
Doc-Delivery-Number = {I3CN0},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:001001594000009},
DA = {2023-07-30},
}

@article{ WOS:000935203600001,
Author = {Ragnhildstveit, Anya and Kaiyo, Miriam and Snyder, Matthew Brian and
   Jackson, Laura Kate and Lopez, Alex and Mayo, Chasity and Miranda,
   Alyssa Claire and August, River Jude and Seli, Paul and Robison, Reid
   and Averill, Lynnette Astrid},
Title = {Cannabis-assisted psychotherapy for complex dissociative posttraumatic
   stress disorder: A case report},
Journal = {FRONTIERS IN PSYCHIATRY},
Year = {2023},
Volume = {14},
Month = {FEB 9},
Abstract = {BackgroundA dissociative subtype of posttraumatic stress disorder, known
   as ``D-PTSD{''}, has been included in the Diagnostic and Statistical
   Manual of Mental Disorders, Fifth Edition. In addition to meeting
   criteria for PTSD, patients endorse prominent dissociative symptoms,
   namely depersonalization and derealization, or detachment from one's
   self and surroundings. At present, this population is supported by a
   highly heterogeneous and undeveloped literature. Targeted interventions
   are therefore lacking, and those indicated for PTSD are limited by poor
   efficacy, delayed onset of action, and low patient engagement. Here, we
   introduce cannabis-assisted psychotherapy (CAP) as a novel treatment for
   D-PTSD, drawing parallels to psychedelic therapy. Case presentationA
   28-year-old female presented with complex D-PTSD. In a naturalistic
   setting, she underwent 10 sessions of CAP, scheduled twice monthly over
   5 months, coupled with integrative cognitive behavioral therapy. An
   autonomic and relational approach to CAP was leveraged, specifically
   psychedelic somatic interactional psychotherapy. Acute effects included
   oceanic boundlessness, ego dissolution, and emotional breakthrough. From
   baseline to post-treatment, the patient showed a 98.5\% reduction in
   pathological dissociation, as measured by the Multidimensional Inventory
   of Dissociation, no longer meeting criteria for D-PTSD. This was
   accompanied by decreased cognitive distractibility and emotional
   suffering, as well as increased psychosocial functioning. Anecdotally,
   the patient has sustained improvements for over 2 years to date.
   ConclusionsThere is urgency to identify treatments for D-PTSD. The
   present case, while inherently limited, underscores the potential of CAP
   as a therapeutic option, leading to robust and sustained improvement.
   Subjective effects were comparable to those produced by classic and
   non-classic psychedelics, such as psilocybin and ketamine. Further
   research is warranted to explore, establish, and optimize CAP in D-PTSD,
   and to characterize its role in the pharmacological landscape.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ragnhildstveit, A (Corresponding Author), Integrated Res Literacy Grp, Draper, UT 84020 USA.
   Ragnhildstveit, A (Corresponding Author), Univ Cambridge, Dept Psychiat, Cambridge, England.
   Ragnhildstveit, A (Corresponding Author), Duke Univ, Dept Psychol \& Neurosci, Durham, NC 27708 USA.
   Ragnhildstveit, Anya; Kaiyo, Miriam; Snyder, Matthew Brian; Jackson, Laura Kate; Lopez, Alex; Mayo, Chasity; Miranda, Alyssa Claire; August, River Jude, Integrated Res Literacy Grp, Draper, UT 84020 USA.
   Ragnhildstveit, Anya, Univ Cambridge, Dept Psychiat, Cambridge, England.
   Ragnhildstveit, Anya; Seli, Paul, Duke Univ, Dept Psychol \& Neurosci, Durham, NC 27708 USA.
   Kaiyo, Miriam; August, River Jude, Univ Utah, Dept Family \& Consumer Studies, Salt Lake City, UT USA.
   Miranda, Alyssa Claire, Natl Univ, Consciousness \& Transformat Studies, San Diego, CA USA.
   Robison, Reid, Numinus Wellness, Draper, UT USA.
   Robison, Reid, Univ Utah, Dept Psychiat, Sch Med, Salt Lake City, UT USA.
   Averill, Lynnette Astrid, Baylor Coll Med, Menninger Dept Psychiat \& Behav Sci, Houston, TX USA.
   Averill, Lynnette Astrid, Michael E DeBakey VA Med Ctr, Houston, TX USA.
   Averill, Lynnette Astrid, Yale Sch Med, Dept Psychiat, New Haven, CT USA.
   Averill, Lynnette Astrid, Natl Ctr PTSD, Dept Vet Affairs, Clin Neurosci Div, West Haven, CT USA.},
DOI = {10.3389/fpsyt.2023.1051542},
Article-Number = {1051542},
ISSN = {1664-0640},
Keywords = {cannabis; medicinal cannabis; cannabis-assisted psychotherapy;
   dissociation; posttraumatic stress disorder; trauma; treatment; case
   report},
Keywords-Plus = {NIGHTMARES; MANAGEMENT; PTSD; ANTIDEPRESSANTS; EXPERIENCES; RISK},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {amr210@cam.ac.uk},
Affiliations = {University of Cambridge; Duke University; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah; Baylor College of Medicine; Baylor College of
   Medicine; Yale University},
ORCID-Numbers = {Ragnhildstveit, Anya/0000-0002-5796-3428},
Cited-References = {Aleksandrova LR, 2021, TRENDS PHARMACOL SCI, V42, P929, DOI 10.1016/j.tips.2021.08.003.
   American Psychiatric Association, 2013, JAMA-J AM MED ASSOC, V5, DOI DOI 10.1001/JAMA.1994.03520100096046.
   Averill LA, 2022, EXPERT OPIN INV DRUG, V31, P133, DOI 10.1080/13543784.2022.2035358.
   Barrett FS, 2018, CANNABIS CANNABINOID, V3, P85, DOI 10.1089/can.2017.0052.
   Bedard-Gilligan M, 2022, CURR ADDICT REP, V9, P203, DOI 10.1007/s40429-022-00414-x.
   Belouin SJ, 2018, NEUROPHARMACOLOGY, V142, P7, DOI 10.1016/j.neuropharm.2018.02.018.
   Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004.
   Boehnke KF, 2022, JAMA-HEALTH FORUM, V3, DOI 10.1001/jamahealthforum.2022.1618.
   Bonn-Miller MO, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246990.
   Brenneisen R., 2007, CHEM ANAL PHYTOCANNA.
   Cameron C, 2014, J CLIN PSYCHOPHARM, V34, P559, DOI 10.1097/JCP.0000000000000180.
   Carbonaro TM, 2016, J PSYCHOPHARMACOL, V30, P1268, DOI 10.1177/0269881116662634.
   Carhart-Harris RL, 2018, J PSYCHOPHARMACOL, V32, P725, DOI 10.1177/0269881118754710.
   Choi S, 2020, J CLIN NEUROPHYSIOL, V37, P39, DOI 10.1097/WNP.0000000000000617.
   Cougle JR, 2011, PSYCHOL ADDICT BEHAV, V25, P554, DOI 10.1037/a0023076.
   Dell Paul F, 2006, J Trauma Dissociation, V7, P77, DOI 10.1300/J229v07n02\_06.
   dos Santos RG, 2021, J PSYCHOPHARMACOL, V35, P453, DOI 10.1177/0269881120986422.
   Earleywine Mitch, 2022, Cannabis, V5, P16, DOI 10.26828/cannabis/2022.02.02.
   Earleywine M, 2021, J PSYCHOPHARMACOL, V35, P841, DOI 10.1177/0269881121997099.
   Eidhof MB, 2019, J TRAUMA DISSOCIATIO, V20, P564, DOI 10.1080/15299732.2019.1597806.
   El-Solh AA, 2018, NAT SCI SLEEP, V10, P409, DOI 10.2147/NSS.S166089.
   Farmer S, 2019, J PSYCHOACTIVE DRUGS, V51, P413, DOI 10.1080/02791072.2019.1645371.
   First M. B., 2016, USERS GUIDE SCID 5 C.
   Fraser GA, 2009, CNS NEUROSCI THER, V15, P84, DOI 10.1111/j.1755-5949.2008.00071.x.
   Frewen PA, 2015, EUR J PSYCHOTRAUMATO, V6, DOI 10.3402/ejpt.v6.26406.
   Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI {[}10.3238/arztebl.2013.0603, 10.1136/bcr-2013-201554, 10.7453/gahmj.2013.008, 10.1186/1752-1947-7-223].
   Goldstein RB, 2016, SOC PSYCH PSYCH EPID, V51, P1137, DOI 10.1007/s00127-016-1208-5.
   Ipser J, 2006, SAMJ S AFR MED J, V96, P1088.
   Jericho B, 2022, ACTA PSYCHIAT SCAND, V145, P132, DOI 10.1111/acps.13366.
   Jetly R, 2015, PSYCHONEUROENDOCRINO, V51, P585, DOI 10.1016/j.psyneuen.2014.11.002.
   Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338.
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617.
   Koenen KC, 2017, PSYCHOL MED, V47, P2260, DOI 10.1017/S0033291717000708.
   Lanius RA, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0983-y.
   Legare CA, 2022, PHARMACOLOGY, V107, P131, DOI 10.1159/000521683.
   Levinsohn EA, 2020, J NEUROL SCI, V411, DOI 10.1016/j.jns.2020.116717.
   Liechti ME, 2017, PSYCHOPHARMACOLOGY, V234, P1499, DOI 10.1007/s00213-016-4453-0.
   Luoma JB, 2020, J PSYCHOACTIVE DRUGS, V52, P289, DOI 10.1080/02791072.2020.1769878.
   Marguilho M, 2023, J PSYCHOPHARMACOL, V37, P14, DOI 10.1177/02698811221140011.
   Mullerova J, 2016, PSYCHOL TRAUMA-US, V8, P601, DOI 10.1037/tra0000148.
   Orsolini L, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090525.
   Penn A, 2021, AM J NURS, V121, P34, DOI 10.1097/01.NAJ.0000753464.35523.29.
   Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004.
   Pertwee RG, 2006, BRIT J PHARMACOL, V147, pS163, DOI 10.1038/sj.bjp.0706406.
   Petersen Meagan, 2021, Ment Health Clin, V11, P238, DOI 10.9740/mhc.2021.07.238.
   Razvi S., 2020, J PSYCHEDELIC PSYCHO, V2, P3.
   Rehman Y, 2021, AIMS NEUROSCI, V8, P414, DOI 10.3934/Neuroscience.2021022.
   Reiff Collin M, 2021, Focus (Am Psychiatr Publ), V19, P95, DOI 10.1176/appi.focus.19104.
   Sareen J., 2019, UPTODATE, V1, P1.
   Sarris J, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-019-2409-8.
   Schiavone FL., 2018, PTSD, V2, P3.
   Schnurr PP, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.36921.
   Simon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41.
   Stanciu CN, 2021, PSYCHIAT SERV, V72, P429, DOI 10.1176/appi.ps.202000189.
   Stein DJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002795.pub2.
   Sumner RL, 2021, J PSYCHOPHARMACOL, V35, P946, DOI 10.1177/0269881121998321.
   van Dis EAM, 2020, JAMA PSYCHIAT, V77, P265, DOI 10.1001/jamapsychiatry.2019.3986.
   Watts R, 2020, J CONTEXT BEHAV SCI, V15, P92, DOI 10.1016/j.jcbs.2019.12.004.
   White WF, 2022, PSYCHOL MED, V52, P1629, DOI 10.1017/S0033291722001647.},
Number-of-Cited-References = {59},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Front. Psychiatry},
Doc-Delivery-Number = {9C1RT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000935203600001},
OA = {Green Published, gold},
DA = {2023-07-30},
}

@article{ WOS:000832614300004,
Author = {Letheby, Chris},
Title = {Psychedelics, Atheism, and Naturalism Myth and Reality},
Journal = {JOURNAL OF CONSCIOUSNESS STUDIES},
Year = {2022},
Volume = {29},
Number = {7-8},
Pages = {69-92},
Abstract = {An emerging body of research suggests that psychedelic experiences can
   change users' religious or metaphysical beliefs. Here I explore issues
   concerning psychedelic-induced belief change via a critique of some
   recent arguments by Wayne Glausser. Two scientific studies seem to show
   that psychedelic experiences can convert atheists to belief in God, but
   Glausser holds that academic and popular discussions of these studies
   are misleading. I offer a different analysis of the relevant findings,
   attempting to preserve the insights of Glausser's critique while setting
   the record straight on some important points. For one thing, the studies
   provide stronger evidence for atheist `deconversion' than Glausser
   allows. For another, Glausser's arguments against the Metaphysical
   Belief Theory' of psychedelic therapy involve scientifically dubious
   claims and inferences. Finally, in evaluating this theory, we ought to
   focus on its strongest version, which posits belief shifts from
   metaphysical naturalism to non-naturalism, rather than from atheism to
   classical monotheism.},
Publisher = {IMPRINT ACADEMIC},
Address = {PO BOX 200, EXETER EX5 5YX, DEVON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Letheby, C (Corresponding Author), Univ Western Australia, Perth, WA, Australia.
   Letheby, C (Corresponding Author), Univ Adelaide, Adelaide, SA, Australia.
   Letheby, Chris, Univ Western Australia, Perth, WA, Australia.
   Letheby, Chris, Univ Adelaide, Adelaide, SA, Australia.},
DOI = {10.53765/20512201.29.7.069},
ISSN = {1355-8250},
Keywords-Plus = {LIFE-THREATENING CANCER; PSILOCYBIN TREATMENT; ANXIETY; DEPRESSION;
   KETAMINE},
Research-Areas = {Philosophy; Social Sciences - Other Topics},
Web-of-Science-Categories  = {Philosophy; Social Sciences, Interdisciplinary},
Author-Email = {chris.letheby@uwa.edu.au},
Affiliations = {University of Western Australia; University of Adelaide},
ORCID-Numbers = {Letheby, Chris/0000-0002-6293-7873},
Funding-Acknowledgement = {Australian Government through the Australian Research Council
   {[}DP190101451]},
Funding-Text = {For helpful feedback on earlier versions, I would like to thank Miri
   Albahari, Vince Polito, audiences at the University of Glasgow
   Philosophy, Psychology, and Neuroscience seminar series and the
   Australian Research Group on Psychedelic Science, and two anonymous
   referees for the Journal of Consciousness Studies. Institutional support
   during the writing of this paper was provided by the University of
   Western Australia and the University of Adelaide. This research was
   partially supported by the Australian Government through the Australian
   Research Council's Discovery Projects funding scheme (project
   DP190101451).},
Cited-References = {Aday J.S., 2019, DRUG SCI POLICY LAW, V6, DOI DOI 10.1177/2050324520974484.
   Aleksandrova LR, 2021, TRENDS PHARMACOL SCI, V42, P929, DOI 10.1016/j.tips.2021.08.003.
   Amada N, 2020, J CONSCIOUSNESS STUD, V27, P6.
   Andersen KAA, 2021, ACTA PSYCHIAT SCAND, V143, P101, DOI 10.1111/acps.13249.
   {[}Anonymous], 2012, PSYCHEDELIC RENAISSA.
   {[}Anonymous], 1945, PERENNIAL PHILOS.
   {[}Anonymous], 2000, CLEANSING DOORS PERC.
   Breeksema JJ, 2020, CNS DRUGS, V34, P925, DOI 10.1007/s40263-020-00748-y.
   Carhart-Harris R, 2021, NEW ENGL J MED, V384, P1402, DOI 10.1056/NEJMoa2032994.
   Bouso JC, 2021, ADV EXP MED BIOL, V1305, P515, DOI 10.1007/978-981-33-6044-0\_26.
   Davidson S., 2021, TUFTS MAGAZINE.
   Davis AK, 2021, J PSYCHOPHARMACOL, V35, P437, DOI 10.1177/0269881120967878.
   Davis AK, 2020, J PSYCHOPHARMACOL, V34, P1008, DOI 10.1177/0269881120916143.
   Dawson B., 2021, DAZED.
   Farah T., 2021, ITS OFFICIAL DMT MAK.
   Gallimore AR, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00211.
   Gasser P, 2015, J PSYCHOPHARMACOL, V29, P57, DOI 10.1177/0269881114555249.
   Glausser W, 2021, RELIGIONS, V12, DOI 10.3390/rel12080614.
   Griffiths RR, 2006, PSYCHOPHARMACOLOGY, V187, P268, DOI 10.1007/s00213-006-0457-5.
   Griffiths RR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214377.
   Griffiths RR, 2016, J PSYCHOPHARMACOL, V30, P1181, DOI 10.1177/0269881116675513.
   Grob CS, 2011, ARCH GEN PSYCHIAT, V68, P71, DOI 10.1001/archgenpsychiatry.2010.116.
   Harman W.W., 2021, MAIN CURRENTS, V20, P5.
   Horst S, 2009, PHILOS COMPASS, V4, P219, DOI 10.1111/j.1747-9991.2008.00191.x.
   James W., 2002, VARIETIES RELIG EXPE.
   Johnson MW, 2021, ACS PHARMACOL TRANSL, V4, P578, DOI 10.1021/acsptsci.0c00198.
   Kadriu B, 2021, INT J NEUROPSYCHOPH, V24, P8, DOI 10.1093/ijnp/pyaa087.
   Kuypers K.P.C., 2021, MODERN CNS DRUG DISC, P257, DOI {[}10.1007/978-3-030-62351-7\_18, DOI 10.1007/978-3-030-62351-7\_18].
   Kuypers KPC, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320950567.
   Letheby C., 2021, HIS PHILOS PSYCHEDEL.
   Letheby C, 2016, CONSCIOUS COGN, V39, P28, DOI 10.1016/j.concog.2015.11.012.
   Ly C, 2018, CELL REP, V23, P3170, DOI 10.1016/j.celrep.2018.05.022.
   Olson DE, 2021, ACS PHARMACOL TRANSL, V4, P563, DOI 10.1021/acsptsci.0c00192.
   Oppy G, 2021, SOPHIA, V60, P517, DOI 10.1007/s11841-021-00843-7.
   Pallavicini C, 2019, NEUROIMAGE, V200, P281, DOI 10.1016/j.neuroimage.2019.06.053.
   Petersen R., 2021, OUTLINE.
   Pollan M., 2021, NEW YORKER.
   Pollan M., 2018, CHANGE YOUR MIND WHA.
   Potnis N., 2021, BINGEDAILY.
   Roseman L, 2019, J PSYCHOPHARMACOL, V33, P1076, DOI 10.1177/0269881119855974.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Shanon B., 2002, ANTIPODES MIND CHART.
   Shanon B, 2010, PHENOMENOL COGN SCI, V9, P263, DOI 10.1007/s11097-010-9161-3.
   Strassman Rick, 2001, DMT SPIRIT MOL DOCTO.
   Szabo A., 2014, PSYCHOLOGIA HUNGARIC, V2, P7, DOI DOI 10.12663/PSYHUNG.2.2014.2.1.
   Timmermann Christopher, 2021, Sci Rep, V11, P22166, DOI 10.1038/s41598-021-01209-2.
   Watts R, 2017, J HUMANIST PSYCHOL, V57, P520, DOI 10.1177/0022167817709585.
   Wikipedia, 2021, GOD.
   Yaden DB, 2021, ACS PHARMACOL TRANSL, V4, P568, DOI 10.1021/acsptsci.0c00194.},
Number-of-Cited-References = {49},
Times-Cited = {1},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Conscious. Stud.},
Doc-Delivery-Number = {3I3IF},
Web-of-Science-Index = {Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)},
Unique-ID = {WOS:000832614300004},
DA = {2023-07-30},
}

@article{ WOS:001018043300001,
Author = {Oliveira, Debora and Fontenele, Rodrigo and Weleff, Jeremy and Sofuoglu,
   Mehmet and De Aquino, Joao P.},
Title = {Developing non-opioid therapeutics to alleviate pain among persons with
   opioid use disorder: a review of the human evidence},
Journal = {INTERNATIONAL REVIEW OF PSYCHIATRY},
Year = {2023},
Month = {2023 JUN 27},
Abstract = {The opioid crisis remains a major public health concern, causing
   significant morbidity and mortality worldwide. Pain is frequently
   observed among individuals with opioid use disorder (OUD), and the
   current opioid agonist therapies (OAT) have limited efficacy in
   addressing the pain needs of this population. We reviewed the most
   promising non-opioid analgesic therapies for opioid-dependent
   individuals synthesising data from randomised controlled trials in the
   Medline database from December 2022 to March 2023. Ketamine, gabapentin,
   serotoninergic antidepressants, and GABAergic drugs were found to be the
   most extensively studied non-opioid analgesics with positive results.
   Additionally, we explored the potential of cannabinoids, glial
   activation inhibitors, psychedelics, cholecystokinin antagonists,
   alpha-2 adrenergic agonists, and cholinergic drugs. Methodological
   improvements are required to advance the development of novel analgesic
   strategies and establish their safety profile for opioid-dependent
   populations. We highlight the need for greater integration of
   experimental pain methods and abuse liability assessments, more granular
   assessments of prior opioid exposure, greater uniformity of pain types
   within study samples, and a particular focus on individuals with OUD
   receiving OAT. Finally, future research should investigate
   pharmacokinetic interactions between OAT and various non-opioid
   analgesics and perform reverse translation basic experiments,
   particularly with methadone and buprenorphine, which remain the standard
   OUD treatment.},
Publisher = {TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND},
Type = {Review; Early Access},
Language = {English},
Affiliation = {Oliveira, D; De Aquino, JP (Corresponding Author), Yale Sch Med, Dept Psychiat, 950 campbell Ave,151D, West Haven, CT 06510 USA.
   Oliveira, Debora; Fontenele, Rodrigo; Weleff, Jeremy; Sofuoglu, Mehmet; De Aquino, Joao P., Yale Univ, Dept Psychiat, Sch Med, New Haven, CT USA.
   Fontenele, Rodrigo; Weleff, Jeremy; Sofuoglu, Mehmet; De Aquino, Joao P., VA Connecticut Healthcare Syst, West Haven, CT USA.
   Weleff, Jeremy, Cleveland Clin, Neurol Inst, Ctr Behav Hlth, Dept Psychiat \& Psychol, Cleveland, OH USA.
   De Aquino, Joao P., Connecticut Mental Hlth Ctr, Clin Neurosci Res Unit, New Haven, CT USA.
   Oliveira, Debora; De Aquino, Joao P., Yale Sch Med, Dept Psychiat, 950 campbell Ave,151D, West Haven, CT 06510 USA.},
DOI = {10.1080/09540261.2023.2229430},
EarlyAccessDate = {JUN 2023},
ISSN = {0954-0261},
EISSN = {1369-1627},
Keywords = {Non-opioid analgesics; pain sensitivity; opioid use disorder;
   experimental pain; pharmacotherapy development},
Keywords-Plus = {KETAMINE-ASSISTED PSYCHOTHERAPY; LOW-BACK-PAIN; DOUBLE-BLIND; INDUCED
   HYPERALGESIA; INTRAVENOUS KETAMINE; POSTOPERATIVE PAIN; MORPHINE
   ANALGESIA; CANCER; THERAPY; DEXTROMETHORPHAN},
Research-Areas = {Psychiatry},
Web-of-Science-Categories  = {Psychiatry},
Author-Email = {debora.oliveira@yale.edu
   joao.deaquino@yale.edu},
Affiliations = {Yale University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Connecticut Healthcare System; Cleveland Clinic
   Foundation; Yale University},
Funding-Acknowledgement = {National Institute on Drug Abuse (NIDA) {[}K23DA052682, R21DA057240];
   VISN 1 Mental Illness Research Education Clinical Centre (MIRECC); New
   England Veterans Administration VISN 1 Mental Illness Research,
   Education and Clinical Centre (MIRECC)},
Funding-Text = {JPD is supported by the National Institute on Drug Abuse (NIDA) Grants
   K23DA052682 and R21DA057240, and by the VISN 1 Mental Illness Research
   Education Clinical Centre (MIRECC). MS is supported by the New England
   Veterans Administration VISN 1 Mental Illness Research, Education and
   Clinical Centre (MIRECC). Other than providing funding, NIDA, and the VA
   had no role in the conception and conduction of this project, nor the
   interpretation or reporting of its findings.},
Cited-References = {Abdelemam RM, 2022, CLIN J PAIN, V38, P693, DOI 10.1097/AJP.0000000000001071.
   Abrams DI, 2011, CLIN PHARMACOL THER, V90, P844, DOI 10.1038/clpt.2011.188.
   Afzalimoghaddam Mohammad, 2016, Curr Drug Abuse Rev, V9, P142, DOI 10.2174/1874473710666170106122455.
   Ahmed S, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00228.
   Alper KR, 1999, AM J ADDICTION, V8, P234.
   AlSharari SD, 2012, J PHARMACOL EXP THER, V342, P742, DOI 10.1124/jpet.112.194506.
   Andersson M, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0186-6.
   Argento E, 2022, INT J DRUG POLICY, V100, DOI 10.1016/j.drugpo.2021.103518.
   Arout CA, 2019, PSYCHOPHARMACOLOGY, V236, P2857, DOI 10.1007/s00213-018-5146-7.
   Babalonis S, 2019, PSYCHOPHARMACOLOGY, V236, P3341, DOI 10.1007/s00213-019-05293-1.
   Ballreich J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.23677.
   Barrett FS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59282-y.
   Bernstein ZP, 1998, J PAIN SYMPTOM MANAG, V15, P314, DOI 10.1016/S0885-3924(98)00003-7.
   Bleakman D, 2006, SEMIN CELL DEV BIOL, V17, P592, DOI 10.1016/j.semcdb.2006.10.008.
   Bonilla-Jaime H, 2022, CURR NEUROPHARMACOL, V20, P384, DOI 10.2174/1570159X19666210609161447.
   Bornemann J, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.735427.
   Boswell G, 1997, CLIN THER, V19, P1024, DOI 10.1016/S0149-2918(97)80054-9.
   Branton MW, 2021, INT J CLIN PHARM-NET, V43, P394, DOI 10.1007/s11096-020-01216-9.
   Bredlau AL, 2013, PAIN MED, V14, P1505, DOI 10.1111/pme.12182.
   Brown TK, 2018, AM J DRUG ALCOHOL AB, V44, P24, DOI 10.1080/00952990.2017.1320802.
   Caraci F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01024.
   Carroll KM, 2019, AM J ADDICTION, V28, P238, DOI 10.1111/ajad.12904.
   Castellanos JP, 2020, REGION ANESTH PAIN M, V45, P486, DOI 10.1136/rapm-2020-101273.
   Chen TZ, 2019, CURR OPIN PSYCHIATR, V32, P282, DOI 10.1097/YCO.0000000000000509.
   Cheung KWA, 2020, ANN PALLIAT MED, V9, P4478, DOI 10.21037/apm.2019.09.09.
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559.
   Cobb J, 2021, INT J OBSTET ANESTH, V47, DOI 10.1016/j.ijoa.2021.103170.
   Compton P, 2010, DRUG ALCOHOL DEPEN, V109, P213, DOI 10.1016/j.drugalcdep.2010.01.006.
   Compton PA, 2008, ADDICT BIOL, V13, P393, DOI 10.1111/j.1369-1600.2008.00112.x.
   Cook MI, 2022, J PAIN RES, V15, P1191, DOI 10.2147/JPR.S358045.
   Cooper ZD, 2017, DRUG ALCOHOL DEPEN, V178, P340, DOI 10.1016/j.drugalcdep.2017.04.029.
   Cooper ZD, 2018, NEUROPSYCHOPHARMACOL, V43, P2046, DOI 10.1038/s41386-018-0011-2.
   Cooper ZD, 2012, EXPERT OPIN INV DRUG, V21, P169, DOI 10.1517/13543784.2012.651123.
   Culp C, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.599721.
   Davis AK, 2020, J CONTEXT BEHAV SCI, V15, P39, DOI 10.1016/j.jcbs.2019.11.004.
   Davis Alan K, 2017, J Psychedelic Stud, V1, P65, DOI 10.1556/2054.01.2017.009.
   Davis AK, 2018, J PSYCHOACTIVE DRUGS, V50, P287, DOI 10.1080/02791072.2018.1487607.
   De Aquino JP, 2021, DRUG ALCOHOL DEPEN, V228, DOI 10.1016/j.drugalcdep.2021.109097.
   De Aquino JP, CLINICALTRIALSGOV.
   De Aquino JP, CLINICALTRIALSGOV.
   De Aquino JP, CLINICALTRIALSGOV.
   de Oliveira GR, 2020, J CLIN ANESTH, V63, DOI 10.1016/j.jclinane.2020.109785.
   Dieterle M, 2022, PAIN, V163, P1919, DOI 10.1097/j.pain.0000000000002591.
   Drozdz SJ, 2022, J PAIN RES, V15, P1691, DOI 10.2147/JPR.S360733.
   Dudgeon DJ, 2007, J PAIN SYMPTOM MANAG, V33, P365, DOI 10.1016/j.jpainsymman.2006.09.017.
   Dunn KE, 2021, NEUROPSYCHOPHARMACOL, V46, P1451, DOI 10.1038/s41386-021-01007-4.
   Dunn KE, 2019, J PHARMACOL EXP THER, V371, P422, DOI 10.1124/jpet.119.258004.
   Dworkin RH, 2022, J PAIN, V23, P1666, DOI 10.1016/j.jpain.2022.05.003.
   Elman I, 2016, NEURON, V89, P11, DOI 10.1016/j.neuron.2015.11.027.
   Farsani DM, 2021, AM J CLIN EXP IMMUNO, V10, P30.
   Flanagan TW, 2018, INT REV PSYCHIATR, V30, P363, DOI 10.1080/09540261.2018.1481827.
   Garcia-Romeu A, 2020, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00955.
   Gardner E A, 2022, Forensic Sci Rev, V34, P43.
   Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580.
   Glue P, 2016, CLIN PHARM DRUG DEV, V5, P460, DOI 10.1002/cpdd.254.
   Green JM, 2022, NEUROSCI BIOBEHAV R, V135, DOI 10.1016/j.neubiorev.2022.104544.
   GROF S, 1973, INT PHARMACOPSYCHIAT, V8, P129, DOI 10.1159/000467984.
   Hahn J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1009950.
   Hamill J, 2019, CURR NEUROPHARMACOL, V17, P108, DOI 10.2174/1570159X16666180125095902.
   Hardy J, 2012, J CLIN ONCOL, V30, P3611, DOI 10.1200/JCO.2012.42.1081.
   Higgins C, 2019, BRIT J ANAESTH, V122, pE114, DOI 10.1016/j.bja.2018.09.019.
   Hooten WM, 2015, ADDICT BEHAV, V42, P69, DOI 10.1016/j.addbeh.2014.11.007.
   Hoyt MR, 2018, INT J OBSTET ANESTH, V34, P67, DOI 10.1016/j.ijoa.2018.01.001.
   Hser YI, 2017, J SUBST ABUSE TREAT, V77, P26, DOI 10.1016/j.jsat.2017.03.006.
   Hurd YL, 2019, AM J PSYCHIAT, V176, P911, DOI 10.1176/appi.ajp.2019.18101191.
   IsHak WW, 2018, HARVARD REV PSYCHIAT, V26, P352, DOI 10.1097/HRP.0000000000000198.
   Jensen KP, 2018, CNS DRUGS, V32, P981, DOI 10.1007/s40263-018-0572-y.
   Jiang S, 2021, PAIN MED, V22, P1010, DOI 10.1093/pm/pnaa184.
   Jones JL, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00277.
   Kane CM, 2018, PALLIATIVE MED, V32, P276, DOI 10.1177/0269216317711826.
   Kapural L, 2010, PAIN PHYSICIAN, V13, P389.
   Karmali RN, 2020, PHARMACOEPIDEM DR S, V29, P252, DOI 10.1002/pds.4929.
   Kast E, 1966, Chic Med Sch Q, V26, P80.
   KAST EC, 1964, ANESTH ANALG, V43, P285.
   Keizer BM, 2020, PSYCHOTHER PSYCHOSOM, V89, P326, DOI 10.1159/000507095.
   Knuijver T, 2022, ADDICTION, V117, P118, DOI 10.1111/add.15448.
   Kooijman NI, 2023, PAIN PRACT, V23, P447, DOI 10.1111/papr.13203.
   Koopmans JR, 1997, ALCOHOL CLIN EXP RES, V21, P537, DOI 10.1111/j.1530-0277.1997.tb03800.x.
   Krupitsky E, 2002, J SUBST ABUSE TREAT, V23, P273, DOI 10.1016/S0740-5472(02)00275-1.
   Krupitsky EM, 2007, J PSYCHOACTIVE DRUGS, V39, P13, DOI 10.1080/02791072.2007.10399860.
   Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y.
   KUROMARU S, 1967, J LANCET, V87, P22.
   Latif ZEH, 2021, AM J ADDICTION, V30, P366, DOI 10.1111/ajad.13153.
   Lau BK, 2014, CURR OPIN NEUROBIOL, V29, P159, DOI 10.1016/j.conb.2014.07.010.
   Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040.
   Lauretti GR, 1999, J CLIN ANESTH, V11, P663, DOI 10.1016/S0952-8180(99)00122-1.
   Lauretti GR, 1999, ANESTHESIOLOGY, V90, P1528, DOI 10.1097/00000542-199906000-00005.
   LaVigne Justin E, 2022, Neurobiol Pain, V11, P100092, DOI 10.1016/j.ynpai.2022.100092.
   Leal PC, 2015, J CLIN ANESTH, V27, P331, DOI 10.1016/j.jclinane.2015.02.002.
   Lee M, 2011, PAIN PHYSICIAN, V14, P145.
   Lilius TO, 2015, BRIT J PHARMACOL, V172, P2799, DOI 10.1111/bph.12974.
   Liu HJ, 2014, J PALLIAT MED, V17, P837, DOI 10.1089/jpm.2013.0544.
   Liu S, 2013, CNS DRUGS, V27, P1093, DOI 10.1007/s40263-013-0111-9.
   Lossignol DA, 2005, SUPPORT CARE CANCER, V13, P188, DOI 10.1007/s00520-004-0684-4.
   LSD Used As Analgesic, 1964, JAMA-J AM MED ASSOC, V187, pA33, DOI {[}10.1001/jama.1964.03060140099054, DOI 10.1001/JAMA.1964.03060140099054].
   LUDWIG AM, 1965, AM J PSYCHOTHER, V19, P417, DOI 10.1176/appi.psychotherapy.1965.19.3.417.
   Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18.
   Malcolm BJ, 2018, J PSYCHOACTIVE DRUGS, V50, P256, DOI 10.1080/02791072.2018.1447175.
   Mangnus TJP, 2021, PAIN PRACT, V21, P890, DOI 10.1111/papr.13056.
   Marel C, 2019, DRUG ALCOHOL DEPEN, V194, P136, DOI 10.1016/j.drugalcdep.2018.10.010.
   Mash D C, 2001, Alkaloids Chem Biol, V56, P155, DOI 10.1016/S0099-9598(01)56012-5.
   Mash DC, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00529.
   McCarson KE, 2014, NEUROCHEM RES, V39, P1948, DOI 10.1007/s11064-014-1254-x.
   McCleane GJ, 1998, ANESTH ANALG, V87, P1117, DOI 10.1097/00000539-199811000-00025.
   McCleane GJ, 2003, NEUROSCI LETT, V338, P151, DOI 10.1016/S0304-3940(02)01388-5.
   Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P246, DOI 10.1016/S0885-3924(00)00194-9.
   Mercadante S, 2019, CNS DRUGS, V33, P943, DOI 10.1007/s40263-019-00660-0.
   Metz VE, 2017, NEUROPSYCHOPHARMACOL, V42, P1825, DOI 10.1038/npp.2017.70.
   Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099.
   Mitchell JM, 2006, PHARMACOL BIOCHEM BE, V85, P787, DOI 10.1016/j.pbb.2006.11.014.
   Murnion BP, 2020, PAIN MED, V21, P1188, DOI 10.1093/pm/pnz178.
   Naef M, 2003, PAIN, V105, P79, DOI 10.1016/S0304-3959(03)00163-5.
   Narang S, 2008, J PAIN, V9, P254, DOI 10.1016/j.jpain.2007.10.018.
   Nau F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075426.
   Navratilova E, 2015, TRENDS NEUROSCI, V38, P741, DOI 10.1016/j.tins.2015.09.003.
   Nguyen JD, 2019, NEUROPHARMACOLOGY, V151, P127, DOI 10.1016/j.neuropharm.2019.04.010.
   Nielsen S, 2017, NEUROPSYCHOPHARMACOL, V42, P1752, DOI 10.1038/npp.2017.51.
   Noller GE, 2018, AM J DRUG ALCOHOL AB, V44, P37, DOI 10.1080/00952990.2017.1310218.
   Ocker AC, 2020, PAIN PRACT, V20, P95, DOI 10.1111/papr.12829.
   Pahnke W N, 1969, Curr Psychiatr Ther, V9, P144.
   Pauly V, 2012, DRUG ALCOHOL DEPEN, V126, P13, DOI 10.1016/j.drugalcdep.2012.03.009.
   Peek AL, 2020, NEUROIMAGE, V210, DOI 10.1016/j.neuroimage.2020.116532.
   Phillips WJ, 2007, J PAIN SYMPTOM MANAG, V34, P346, DOI 10.1016/j.jpainsymman.2007.07.001.
   Pisano VD, 2017, J PSYCHOPHARMACOL, V31, P606, DOI 10.1177/0269881117691453.
   Prochazka J., 2008, BOLEST, V11, P36.
   Ramaekers JG, 2021, J PSYCHOPHARMACOL, V35, P398, DOI 10.1177/0269881120940937.
   Rigo FK, 2017, PAIN PHYSICIAN, V20, P207.
   Roberts JD, 2006, EUR J PHARMACOL, V530, P54, DOI 10.1016/j.ejphar.2005.11.036.
   Rodriguez L, 2022, ACS OMEGA, V7, P12307, DOI 10.1021/acsomega.2c00795.
   Sanders JC, 2009, J CLIN ANESTH, V21, P486, DOI 10.1016/j.jclinane.2008.12.019.
   SAVAGE C, 1973, ARCH GEN PSYCHIAT, V28, P808.
   Schliessbach J, 2017, EUR J PAIN, V21, P1336, DOI 10.1002/ejp.1032.
   Schneider T, 2022, PAIN, V163, pE62, DOI 10.1097/j.pain.0000000000002310.
   Schwenk ES, 2018, REGION ANESTH PAIN M, V43, P456, DOI 10.1097/AAP.0000000000000806.
   Sebret A, 1999, J NEUROSCI, V19, P7230, DOI 10.1523/JNEUROSCI.19-16-07230.1999.
   SERRAO JM, 1992, PAIN, V48, P5, DOI 10.1016/0304-3959(92)90125-U.
   Sheehy KA, 2015, PAIN PRACT, V15, pE90, DOI 10.1111/papr.12336.
   Slatkin NE, 2001, J PAIN SYMPTOM MANAG, V21, P425, DOI 10.1016/S0885-3924(01)00270-6.
   Smallwood RF, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00174.
   Srivastava AB, 2020, LANCET, V395, P1938, DOI 10.1016/S0140-6736(20)30852-7.
   Staud R, 2005, J PAIN, V6, P323, DOI 10.1016/j.jpain.2005.01.357.
   Stoicea N, 2015, FRONT PHARMACOL, V6, DOI {[}10.3382/fphar.2015.00104, 10.3389/fphar.2015.00104].
   Subramaniam K, 2011, PAIN MED, V12, P1276, DOI 10.1111/j.1526-4637.2011.01144.x.
   Teixeira PJ, 2022, J PSYCHOPHARMACOL, V36, P12, DOI 10.1177/02698811211008554.
   Thomas Gerald, 2013, Curr Drug Abuse Rev, V6, P30.
   TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728.
   Tsui JI, 2011, PAIN, V152, P2640, DOI 10.1016/j.pain.2011.08.011.
   Usman MA, 2022, DISASTER MED PUBLIC, V16, P3, DOI 10.1017/dmp.2020.259.
   Verret M, 2020, ANESTHESIOLOGY, V133, P265, DOI 10.1097/ALN.0000000000003428.
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1.
   Walsh Z, 2021, BJPSYCH OPEN, V8, DOI 10.1192/bjo.2021.1061.
   Weinbroum AA, 2002, CANCER-AM CANCER SOC, V95, P1164, DOI 10.1002/cncr.10784.
   Whelan A, 2018, PAIN MANAG, V8, P217, DOI 10.2217/pmt-2017-0068.
   Yang CY, 1996, CAN J ANAESTH, V43, P379, DOI 10.1007/BF03011718.},
Number-of-Cited-References = {154},
Times-Cited = {0},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Int. Rev. Psych.},
Doc-Delivery-Number = {K7EU5},
Web-of-Science-Index = {Social Science Citation Index (SSCI)},
Unique-ID = {WOS:001018043300001},
DA = {2023-07-30},
}

@article{ WOS:000903668900001,
Author = {Williams, Monnica T. and Reed, Sara and George, Jamilah},
Title = {Culture and psychedelic psychotherapy: Ethnic and racial themes from
   three Black women therapists},
Journal = {JOURNAL OF PSYCHEDELIC STUDIES},
Year = {2020},
Volume = {4},
Number = {3},
Pages = {125-138},
Month = {NOV},
Abstract = {Psychedelic medicine is an emerging field of research and practice that
   examines the psychotherapeutic effects of substances classified as
   hallucinogens on the human mind, body, and spirit. Current research
   explores the safety and efficacy of these substances for mental health
   disorders including anxiety, depression, and posttraumatic stress
   disorder (PTSD). Although current studies explore psychotherapeutic
   effects from a biomedical perspective, gaps in awareness around cultural
   issues in the therapeutic process are prominent. African Americans have
   been absent from psychedelic research as both participants and
   researchers, and little attention has been paid to the potential of
   psychedelics to address traumas caused by racialization. This paper
   examines cultural themes and clinical applications from the one-time use
   of 3,4-methylenedioxymethamphetamine (MDMA) as part of an US Food and
   Drug Administration (FDA)-approved clinical trial and training exercise
   for three African American female therapists. The primary themes that
   emerged across the varied experiences centered on strength, safety,
   connection, and managing oppression/racialization. The participants'
   experiences were found to be personally meaningful and instructive for
   how Western models of psychedelic-assisted psychotherapy could be more
   effective and accessible to the Black community. Included is a
   discussion of the importance of facilitator training to make best use of
   emerging material when it includes cultural, racial, and spiritual
   themes. A lack of knowledge and epistemic humility can create barriers
   to treatment for underserved populations. Implications for future
   research and practice for marginalized cultural groups are also
   discussed, including consideration of Functional Analytic Psychotherapy
   (FAP) as an adjunct to the psychedelic-therapy approaches currently
   advanced. As women of color are among the most stigmatized groups of
   people, it is essential to incorporate their perspectives into the
   literature to expand conversations about health equity.},
Publisher = {AKADEMIAI KIADO ZRT},
Address = {BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY},
Type = {Article},
Language = {English},
Affiliation = {Williams, MT (Corresponding Author), Univ Connecticut, Dept Psychol Sci, Storrs, CT 06269 USA.
   Williams, MT (Corresponding Author), Behav Wellness Clin LLC, Tolland, CT 06084 USA.
   Williams, MT (Corresponding Author), Univ Ottawa, Sch Psychol, Ottawa, ON, Canada.
   Williams, Monnica T.; Reed, Sara; George, Jamilah, Univ Connecticut, Dept Psychol Sci, Storrs, CT 06269 USA.
   Williams, Monnica T.; Reed, Sara, Behav Wellness Clin LLC, Tolland, CT 06084 USA.
   Williams, Monnica T., Univ Ottawa, Sch Psychol, Ottawa, ON, Canada.},
DOI = {10.1556/2054.2020.00137},
EISSN = {2559-9283},
Keywords = {African Americans; hallucinogens; psychedelic medicine; MDMA;
   psychotherapy; education; race; culture},
Keywords-Plus = {NATIONAL EPIDEMIOLOGIC SURVEY; MENTAL-HEALTH; INTRAVENOUS KETAMINE;
   COMMITMENT THERAPY; ASSISTED THERAPY; SUBSTANCE-ABUSE; USE DISORDER;
   ACCEPTANCE; RELEVANCE; BEHAVIOR},
Research-Areas = {Pharmacology \& Pharmacy; Psychiatry; Psychology},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy; Psychiatry; Psychology, Multidisciplinary},
Author-Email = {monnica.williams@uottawa.ca},
Affiliations = {University of Connecticut; University of Ottawa},
ResearcherID-Numbers = {Williams, Monnica/O-8209-2017},
ORCID-Numbers = {Williams, Monnica/0000-0003-0095-3277},
Funding-Acknowledgement = {Multidisciplinary Association for Psychedelic Studies (MAPS)},
Funding-Text = {The authors wish to thank MarcelaOt'alora for her therapeutic support
   and guidance in these experiences. The author also wishes to thank the
   non-profit organization, Multidisciplinary Association for Psychedelic
   Studies (MAPS; www.maps.org), who sponsored and funded ``A Phase 1
   Placebo-Controlled, Double-Blind, Multi-Site Crossover Study to Assess
   Psychological Effects of MDMAwhen Administered to Healthy
   Volunteers{''}(MT-1; Clin-icalTrials.gov identifier: NCT01404754).},
Cited-References = {ABRAMSON HA, 1960, J MENT SCI, V106, P1120, DOI 10.1192/bjp.106.444.1120.
   Alexander JC, 2004, CULTURAL TRAUMA AND COLLECTIVE IDENTITY, P1, DOI 10.1525/california/9780520235946.003.0001.
   Anderson C., 2017, UNDERSTANDING PROBLE.
   {[}Anonymous], 2019, NEW JIM CROW MASS IN.
   Baker TA, 2015, GERONTOLOGIST, V55, P51, DOI 10.1093/geront/gnu105.
   Beckett K, 2006, CRIMINOLOGY, V44, P105, DOI 10.1111/j.1745-9125.2006.00044.x.
   Bogenschutz MP, 2017, J HUMANIST PSYCHOL, V57, P389, DOI 10.1177/0022167816673493.
   Bor J, 2018, LANCET, V392, P302, DOI {[}10.1016/S0140-6736(18)31130-9, 10.1016/s0140-6736(18)31130-9].
   Brackenridge P, 2010, DRUGS ALCOHOL TODAY, V10, P20, DOI 10.5042/daat.2010.0724.
   Brown TK, 2018, AM J DRUG ALCOHOL AB, V44, P24, DOI 10.1080/00952990.2017.1320802.
   Campbell N. D, 2017, REVIVAL ANALYTICAL P, P225.
   Campbell ND, 2008, NARCOTIC FARM RISE F.
   Ching T. H. W, 2018, 52 ANN CONVENTION AS.
   Chou T, 2012, CULT DIVERS ETHN MIN, V18, P74, DOI 10.1037/a0025432.
   COMASDIAZ L, 1991, AM J ORTHOPSYCHIAT, V61, P392, DOI 10.1037/h0079267.
   Costandi M, 2014, PSYCHOLOGIST, V27, P714.
   Dawson A, 2019, PSYCHEDELICS SEX CON.
   DeGruy J, 2007, POSTTRAUMATIC SLAVE.
   DiAngelo R., 2011, INT J CRITICAL PEDAG, V3, P54.
   Doffana ZD, 2017, COGENT FOOD AGR, V3, DOI 10.1080/23311932.2017.1365399.
   George JR, 2020, J PSYCHEDELIC STUD, V4, P4, DOI 10.1556/2054.2019.015.
   Grant BF, 2016, JAMA PSYCHIAT, V73, P39, DOI 10.1001/jamapsychiatry.2015.2132.
   Halberstadt N., 2014, MAPS B SPECIAL EDITI, V24, P4.
   Hayes SC, 2012, J CONTEXT BEHAV SCI, V1, P1, DOI 10.1016/j.jcbs.2012.09.004.
   Heart MYHB, 2003, J PSYCHOACTIVE DRUGS, V35, P7, DOI 10.1080/02791072.2003.10399988.
   Hinton E., 2018, UNJUST BURDEN DISPAR.
   Johansen PO, 2015, J PSYCHOPHARMACOL, V29, P270, DOI 10.1177/0269881114568039.
   Kanter J. W., 2019, ELIMINATING RACE BAS.
   Kanter JW, 2020, BMC MED EDUC, V20, DOI 10.1186/s12909-020-02004-9.
   Kemprai P, 2020, FLAVOUR FRAG J, V35, P5, DOI 10.1002/ffj.3521.
   Kirmayer Laurence J, 2007, Transcult Psychiatry, V44, P232, DOI 10.1177/1363461506070794.
   Kpanake L, 2018, TRANSCULT PSYCHIATRY, V55, P198, DOI 10.1177/1363461517749435.
   Labate B., 2014, JOURNEY FIND IBOGA.
   Lacey KK, 2016, SUBST USE MISUSE, V51, P1147, DOI 10.3109/10826084.2016.1160124.
   Luoma JB, 2019, J CONTEXT BEHAV SCI, V14, P136, DOI 10.1016/j.jcbs.2019.10.003.
   Michaels TI, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1824-6.
   Miller A., 2015, BEHAV THERAPIST, V38, P150.
   Mithoefer M.C., 2015, MANUAL MDMA ASSISTED.
   Mithoefer MC, 2018, LANCET PSYCHIAT, V5, P486, DOI 10.1016/S2215-0366(18)30135-4.
   National Institute on Drug Abuse (NIDA), 1978, ANN BIBL PAP ADD RES.
   Neitzke-spruill L, 2020, J PSYCHEDELIC STUD, V4, P51, DOI 10.1556/2054.2019.022.
   Nemu D., 2019, J PSYCHEDELIC STUD, V3, P117, DOI {[}10.1556/2054.2019.004, DOI 10.1556/2054.2019.004].
   Nielson E.M., 2018, J PSYCHEDELIC STUD, V2, P64, DOI {[}10.1556/ 2054.2018.009, DOI 10.1556/2054.2018.009, 10.1556/2054.2018.009].
   Ot'alora M, 2018, J PSYCHOPHARMACOL, V32, P1295, DOI 10.1177/0269881118806297.
   Palamar JJ, 2017, DRUG ALCOHOL DEPEN, V181, P20, DOI 10.1016/j.drugalcdep.2017.09.011.
   Papaseit E, 2018, EXPERT OPIN DRUG MET, V14, P183, DOI 10.1080/17425255.2018.1424832.
   Passie T, 2018, DRUG SCI POLICY LAW, V4, P1, DOI {[}10.1177/2050324518767442, DOI 10.1177/2050324518767442].
   Reed S., 2019, MAPS B, V29, P50.
   Rigg KK, 2018, SUBST USE MISUSE, V53, P1076, DOI 10.1080/10826084.2017.1392985.
   Rigg KK, 2017, J PSYCHOACTIVE DRUGS, V49, P192, DOI 10.1080/02791072.2017.1305518.
   Rodriguez CI, 2016, J CLIN PSYCHIAT, V77, P408, DOI 10.4088/JCP.15l10138.
   Ross S, 2016, J PSYCHOPHARMACOL, V30, P1165, DOI 10.1177/0269881116675512.
   Schultes R. E, 2010, PLANTS GODS THEIR SA.
   Shalit N, 2019, ADDICT BEHAV, V89, P35, DOI 10.1016/j.addbeh.2018.09.020.
   Sloshower J, 2020, J CONTEXT BEHAV SCI, V15, P12, DOI 10.1016/j.jcbs.2019.11.002.
   Sobiecki J. F., 2002, Transactions of the Royal Society of South Africa, V57, P1.
   Sobiecki JF, 2012, J PSYCHOACTIVE DRUGS, V44, P216, DOI 10.1080/02791072.2012.703101.
   Suite DH, 2007, J NATL MED ASSOC, V99, P879.
   Tsai M, 2009, GUIDE TO FUNCTIONAL ANALYTIC PSYCHOTHERAPY: AWARENESS, COURAGE, LOVE, AND BEHAVIORISM, P1, DOI 10.1007/978-0-387-09787-9.
   Turner KB, 2006, J CRIM JUSTICE EDUC, V17, P181, DOI 10.1080/10511250500335627.
   United States Department of Justice (DOJ), 2016, INV BALT CIT POL DEO.
   Vaismoradi M., 2016, J NURSING ED PRACTIC, V6, P100, DOI DOI 10.5430/JNEP.V6N5P100.
   Vandenberghe L, 2008, BEHAV ANALYST, V31, P67, DOI 10.1007/BF03392162.
   Wetterneck C. T., 2012, INT J BEHAV CONSULTA, V7, P167.
   Wilkinson ST, 2017, PSYCHOTHER PSYCHOSOM, V86, P162, DOI 10.1159/000457960.
   Williams A, 2018, WOMEN SPIRITUALITY P.
   Williams M., 2019, DIRECTIONS PSYCHIAT, V39, P265.
   Williams M. T., 2018, DIRECTIONS PSYCHIAT, V38, P179.
   Williams M. T., 2012, PSYCHOL CULTURE, P25.
   Williams M. T., 2020, J PSYCHEDELIC STUD, V4, P40, DOI {[}10.1556/2054.2019.016, DOI 10.1556/2054.2019.016].
   Williams M. T, 2016, MULTIDISCIPLINARY AS, V26, P32.
   Williams M. T., 2020, WHY BLACK PEOPLE SHO.
   Williams MT, 2020, J PSYCHEDELIC STUD, V4, P1, DOI 10.1556/2054.2019.032.
   Winkelman M. J, 2007, PSYCHEDELIC MED NEW, V2, P143.
   Wu LT, 2011, ARCH GEN PSYCHIAT, V68, P1176, DOI 10.1001/archgenpsychiatry.2011.120.
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856.},
Number-of-Cited-References = {76},
Times-Cited = {15},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Psychedelic Stud.},
Doc-Delivery-Number = {7I1QI},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000903668900001},
OA = {gold},
DA = {2023-07-30},
}
